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Summary
Recent developments in molecular biology have led to a greater understanding 
of signalling mechanisms which are overexpressed or distorted in the cancer 
cell, resulting in the identification of a number of new molecular targets for 
cancer chemotherapy. Protein Tyrosine Kinases (PTKs) are enzymes which 
play an important role in the signal transduction pathways leading to 
mitogenesis. Growth factors, such as epidermal growth factor (EGF) are 
responsible for stimulating cells to synthesise DNA prior to mitosis. The EGF 
receptor, which is present at elevated levels in certain cancer cells, has been 
shown to display PTK activity.
Tyrphostins are low molecular weight molecules which are structurally similar to 
tyrosine. These have been shown to display PTK inhibition activity. The earliest 
reported tyrphostins such as (a) were based upon a benzylidenemalononitile 
nucleus, but more recently a number of tyrphostins containing a 5-membered 
heterocyclic nucleus (b) have been reported.
Tyrphostins containing a nitrothiophene fragment (c) were prepared using 
standard methodology. These compounds were shown to display excellent in 
vitro growth inhibition in cells with a high EGF concentration. More detailed 
studies, later showed that a number of these compounds were not selective for 
the EGF receptor, and instead displayed wide-spectrum cytotoxicity by an 
unknown mechanism. The crystal structure of one tyrphostin was solved, 
showing that the aromatic and cyano groups are cis across the extra-annular 
double bond.
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(a) (b)
X= O, S, NH
(c)
R= CN,C(NH2)=C(CN)2, C 02R' 
CONH2) CSNH2> 2-thienyl
OoN
N
H
O
OH
OCH
(d) (e)
Previous studies had shown that analogues of misonidazole (d) which 
contained a nitrothiophene group (e) possessed the ability to become reduced 
to cytotoxic species in hypoxic tumour cells, which have a low oxygen 
saturation. The reduction potentials of a number of nitrothienyl tyrphostins were 
measured, and some of these fell within the parameters required for in vivo 
bioreduction.
NH2
(f) (g) (h)
Pyridyl and quinolyl tyrphostins such as (f) and (g) have been reported to 
display interesting biological profiles. In particular, 2- and 4-substituted 
quinolines were particularly active, and this may be perhaps due at least in part 
to substitution at these electropositive centres. Substitution at the 3-position 
gave rise to a series of inactive compounds. In order to extend the study of this 
structure-activity relationship, a series of 6-, 7- and 8-quinolyl tyrphostins (h) 
were synthesised.
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) is a sophisticated 
method to deliver cytotoxic agents at their preferred site of action. An antibody 
which recognises surface antigens on a cancer cell also possesses an enzyme 
which hydrolyses a prodrug molecule such as (i) and leads to the release of the 
drug molecule. A methodology to synthesise such a prodrug was investigated, 
but it was not possible to complete the urea linkage between L-glutamate and 
the benzene ring by attempting to generate an isocyanate at either of the amino 
groups in the starting materials.
0  COoH
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1. Introduction
Cancer (karnsai), si>.
Pathol. A  malignant growth or tumour in difler- 
ent parts of the body, that tends to spread indefin­
itely and to reproduce itself, as also to return after 
removal; it eats away or corrodes the part in 
which it is situated, and generally ends in death.
Oxford English Dictionary
1.1 Cancer
For a very long time, cancer was defined as a 'killer' disease for which there 
was little or no hope of cure. In the past century, however, our knowledge of the 
various types of cancer has increased dramatically, and many treatments have 
been developed to combat these diseases. More recently, in the last ten years 
or so, science has begun to understand that cancer is a genetic disorder,1- 2 
and we have started to understand the molecular mechanisms underpinning the 
carcinogenic process.3-4
Cancer is a disease of abnormal growth. Healthy cells undergo a number of 
structural and molecular changes which result in them escaping from the 
normal control mechanisms. If left untreated, they will continue to increase in 
number. They often form tumour masses which resemble the surrounding 
tissue less and less as the disease progresses. Local invasion occurs, and 
tumour cells may break off and enter the lymphatic system, becoming deposited 
at remote sites to form secondary growth or metastases. It is these invasive and 
metastatic properties which distinguishes malignant cancer cells from benign 
growths. Unlike bacterial infection, there is relatively little immune response by 
the body to cancer. When there is any, it soon becomes overwhelmed and is 
only weakly effective.
Whilst there have been some degrees of success in developing therapeutic 
agents to treat cancers, including lymphatic leukaemia of childhood, Hodgkin's 
disease, Burkitt's lymphoma, Wilm's tumour (a kidney cancer in children), 
choriocarcinoma (a malignancy of placental trophoblast), testicular cancer and 
certain ovarian cancers, these only account for a relatively small percentage of 
all malignant tumours. In other cases such as breast, lung, colon and prostate 
cancer (the most common types in adults), the most effective treatments remain
1
early diagnosis and surgery combined with radiotherapy. Most of these cancers 
cannot be treated effectively with the current range of relatively non-specific 
anticancer drugs, and whilst solid tumours show a limited response to these 
drugs, resistance usually develops and renders the treatment ineffective.
1.2 Cancer Epidemiology
Every 63 seconds, someone dies of cancer in the United States alone.5 Of the
500,000 cancer-related deaths in the USA in 1992, some 76,000 were children 
aged between 3 and 14 years; 46,000 were women suffering from breast 
cancer and 43,000 were men with prostate cancer. However, it is important to 
note that thanks to improved methods of diagnosis and treatment, the latter two 
figures represent 26% and 42% of the total number of diagnoses for the same 
year. The five-year survival rate for all cancers has increased from 20% in the 
1930s to almost 50% in the early 1990s.
1.3 Factors Leading to Cancer
It is extremely difficult to identify the various factors, be they chemical, viral, 
inherited or a result of exposure to radiation, which increase the likelihood of 
cancer.
Few would disagree with the observation that smoking is a key factor in causing 
30% of all cancers; as well as lung cancer, smoking has also been shown to 
contribute to cancers of the mouth, pharynx, larynx, oesophagus, urinary 
bladder, pancreas and kidney.6 Lifestyle is the next most common cause of 
cancer. Diet, alcohol use, reproduction and sexual behaviour and exposure to 
sunlight are some of the risk factors involved. Not surprisingly, exposure to 
chemicals, particularly in an industrial environment, has been linked to cancer.
Patients who have been infected by viruses such as hepatitis B have displayed 
a higher rate of liver cancer. There is little doubt that cancers may also arise 
from genetic predisposition. However, inherited malignancies account for only 
1 -2% of the total number of cancers.7 But a high percentage of certain tumours 
are genetically determined. Examples include 40% of retinoblastomas, 20-40% 
of Wilm's tumours and almost 80% of familial multiple polyposis of the large 
bowel.
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In certain cases specific chromosomal abnormalities have been identified. 
Some patients suffering from Wilm's tumour have been shown to have a 
deletion in band 13 of the short arm of chromosome 11.8 Other genetic 
abnormalities are only triggered by environmental factors. These include 
xeroderma pigmentosum, which is characterised by extreme sensitivity to 
sunlight and incidences of skin cancer approaching 100%, and Fanconi's 
anaemia, which is a haematological deficiency giving rise to anaemia and 
haemorrhaging and an increased risk for leukaemia.
1.4 Cancer Chemotherapy
If cancer is in fact many diseases which can be caused or triggered by one or 
more factors, how can we as scientists develop new therapeutic agents to treat 
these diseases? This question has been asked for a long time, and many 
treatments have been tested with varying degrees of success. In 1768, the 
natural historian Gilbert White wrote of "The wonderful method of curing cancer 
by means of toads".9 It is true to say that the drugs we use today to treat cancer 
are far-removed from the treatments of White's days; but too few drugs are 
available to treat effectively all but a handful of cancers.
Why has it taken so long? The reason is, at least in part, due to the inability of 
cancer researchers to understand fully the complex series of molecular events 
which occur in normal healthy cells, and to identify the stages at which these 
mechanisms fail or become disrupted to give rise to cancer. But dramatic 
breakthroughs in molecular biology and biochemistry have led to the 
identification and greater understanding of key processes which are 
overexpressed or initiated in the abnormal cell. Within the apparent chaos of the 
tumour cell genome lie the specific alterations to DNA which provide the genetic 
basis for the initiation of the tumour. We now know that tumour suppressor 
genes are rendered inactive by mutation, deletion or whole chromosomal 
loss.10- 11 Oncogenes, which encode for the expression or overexpression of 
key molecules in the cancer cell, are activated by translocation, point mutation 
or amplification in the chromosomes.
Ultimately, a clinically effective cancer drug should be one which can identify 
and kill malignant cells at a concentration which will allow survival of the 
patient's critical tissues (such as bone marrow and the gastrointestinal tract). 
This is difficult to achieve owing to the rapidity of cellular proliferation in all 
malignant tumour cells. Surgery, together with combinatorial treatments of 
radiotherapy and chemotherapy are still the most widely-used techniques.
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However, the low degree of specificity of these methods make them 
unfavourable owing to the debilitating effects which they have on the patient's 
health.
It is perhaps ironic that the first systemic cancer chemotherapy was originally 
developed as a war gas. This was nitrogen mustard, whose precursor, sulfur 
mustard, was used on the battlefield during World War I. In the 1930s, the 
nitrogen mustards were shown to have an antitumour effect in 
lymphosarcoma-bearing mice. These mustards entered clinical trials in 1942, 
but the results remained unpublished until 1946 after the war ended.12 The 
following year, Farber et al. treated children with acute leukaemia using 
aminopterin or its non-methylated derivative methotrexate, which are folic acid 
antagonists.13
1.4.1 Anticancer Agents in Use Today
There are currently around 40 anticancer agents in general clinical use today. 
These fall into 4 categories.
1. Alkylating Agents. These are highly reactive species which form covalent 
links with nucleophilic sites in nucleic acids, proteins, amino acids and 
nucleotides. The common property of all alkylating agents is that they can 
undergo transformation to produce reactive, electron-deficient species. 
Examples of drugs in this class include nitrogen mustard (1), chlorambucil (2), 
melphalan (3), and cyclophosphamide (4).
Cl Cl
H3C —N
Cl
N
Cl
H02C
(3)
(2)
H ^N O\ II
P -N
/
O
(4)
Cl
Cl
All of the alkylating agents shown are bifunctional, possessing two chloroethyl 
groups which form reactive aziridinium groups which are responsible for
4
alkylation of DNA. This is normally at the N-7 position of the base guanine. 
Scheme 1 shows the action of nitrogen mustard on a guanine base. Initial 
formation of a highly reactive positively-charged aziridine ring is followed by 
covalent binding with the electronegative N-7 group on guanine, resulting in 
alkylation. This may lead to mispairing of the alkylated guanine with thymine, or 
to strand break. Alternatively, the second chloroethyl side-chain may undergo a 
similar reaction with a guanine on the opposite DNA strand, causing 
cross-linking and thereby preventing DNA replication and mitosis. In this case, 
the result is cell death.
O
NH
DNA
HoC-N
Cl ,CH.
NH
DNA
Scheme 1
Nitrogen mustard is still used today as part of a cocktail of drugs in the 
treatment of Hodgkin's disease, but its reactivity and vesicant properties make it 
unfavourable for treatment of most cancers. On the other hand, 
cyclophosphamide is devoid of these properties until it undergoes metabolic 
activation, and is much more widely used.
Nitrosoureas such as BCNU (5) and CCNU (6) are lipid-soluble, and have the 
potential to penetrate into the central nervous system for treatment of 
intracranial tumours. Whilst they have been successfully used in the treatment 
of experimental tumours in mice, their clinical application has been limited 
owing to the fact that they cause prolonged myelosuppression.
5
Busulfan (7) has been used in the treatment of myeogeneous leukaemia. This 
compound generates electron-deficient sulfonates which can form covalent 
bonds to DNA, and may cause cross-linking.
OII O
H o C -S -O3 II
o
O -S -C H o  
II 3
o
II
A number of compounds containing aziridine rings, such as Thio-TEPA 
(triethylenethiophosphamide) (8) have been employed as anticancer drugs. 
Thio-TEPA is administered topically to treat papillary carcinoma of the bladder.
(2) Antimetabolites. These compounds interfere with nucleic acid production 
by one of two mechanisms. They may either inhibit production of the 
deoxyribonucleoside triphosphates which are the immediate precursors for DNA 
synthesis, or they may be sufficiently similar in structure to purines or 
pyrimidines to be substituted for them. A major clinical advantage of 
antimetabolites is that their toxicity is reversible. An example is methotrexate 
(MTX) (9), which is a folic acid antagonist or antifolate. Folic acid (10) is 
required in the biosynthetic pathway to purines.
V~7
N
N
ZA
(8)
h2n N ^ c h 3 
n ^ N
N
C02H
O C02H
(9) R = -NH2 
(10) R = -OH
Pyrimidine antagonists include 5-fluorouracil (11) and 5-fluorodeoxyuridine, 
which prevent thymine and uracil production in DNA and RNA respectively. 
Mercaptopurine and 6-thioguanine (12) inhibit purine biosynthesis.
(3) Natural Products. A number of anticancer agents have been isolated from 
natural sources. These include bleomycin, the anthracyclines (such as 
doxorubicin and daunorubicin), the vinca alkaloids, mitomycin C and taxol.
Oppenheimer et al. showed that the structure of bleomycin (13), isolated from 
Streptomyces verticullus, was a complex glycopeptide with two major 
domains.14 These constituted a bisthiazole ring moiety, which interacts with 
DNA by intercalation, and a large fragment containing primary amine, 
pyrimidine and imidazole nitrogens which function as ligands to form a metal 
co-ordination site. This domain essentially acts as a ferrous oxidase. Fe (II) 
bleomycin can be regenerated from Fe (III) bleomycin by an NADPH-dependent 
enzyme system in the nucleus, and this redox recycling of the iron-co-ordinated 
drug is accompanied by increased DNA cleavage preferentially at 
5'-guanine-cytosine-31 and 5-guanine-thymine-31 sequences.15-16
O S
H
(11) (12)
7
HoNOC NH?
2 ' H H I
N. .NHc
N N
CHo HN
CHo O
H H
O HO^ .N
N XHo HO CH3 
H H 3
NH N
HO. OH I
O
I I H / 0H
OH V O ^ O H
OH I 
O ^ N H 2
(13)
R = n ^ ^ ! > / C H 3
CH?
Doxorubicin (14) and daunorubicin (15) display broad spectrum antitumour 
activity. They have a wide range of clinical uses, and are particularly effective 
against solid tumours such as breast cancer (doxorubicin) and acute leukaemia 
(daunorubicin). Whilst these compounds display topoisomerase (TI)-2 
dependent DNA intercalation (TI-2 is an enzyme which recognises and cleaves 
on either side of species intercalated in DNA), an additional mode of action is 
via radical generation of superoxide (*02‘ ) (Scheme 2), which causes 
irreversible membrane damage.
OCHoO OH O
HO
[NHo 
OH
(14) R= -COCH2OH
(15) R=-CH3
8
reversible
Scheme 2
©e
0,0
Microtubule inhibitors include the vinca alkaloids (e.g. vindesine, (16)) and taxol 
(17). Microtubules are involved in a number of functions, including mitosis, 
transport of solutes, cell motility and maintenance of the cell's structural 
integrity. The vinca alkaloids act by binding to a site on tubulin and prevent 
polymerisation, which inhibits microtubule formation. Conversely, taxol 
enhances tubulin polymerisation. The net result of both of these mechanisms is 
the prevention of mitosis.
(16)
HXOCO
chA £ % 0H
c h J  \
r ' x  Z h
o h
HO
OCOCH
(17)
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Mitomycin C (22), derived from a species of Streptomyces, can be described as 
a bioreducible alkylating agent. Reductive activation of the quinone moiety by a 
variety of enzymes (including NADPH-cytochrome c reductase, xanthine 
reductase and quinone reductase) is followed by spontaneous elimination of the 
methoxy group attached to C-10. The protonated aziridine ring is then opened, 
and the semiquinone undergoes nucleophilic attack at C-10, most often by N-2 
on guanine. Subsequent intramolecular displacement of the carbamate group 
yields a cross-linked drug-DNA adduct (Scheme 3). Mitomycin C has been 
used in the treatment of cancers of the stomach, colon, pancreas, breast, lung 
and head and neck.
(4) Other Compounds. These include non-classical alkylating agents such as 
cisplatin (18) and carboplatin (19) and methylating agents such as dacarbazine 
(20) and procarbazine (21). Procarbazine is metabolised to produce a 
methyldiazonium cation, which methylates at N-7 of guanine.
h3i\  x ci
Pt 
/  \  
H3N Cl
o
h2n
(18)
c h 3
N ^ C H s
(19)
N ^ N H
(20)
CH
N -N
CH
(21)
1.5 Targets for New Anticancer Agents
New developments in biochemistry and molecular biology have led to a 
substantial increase in our knowledge of the processes which regulate cellular 
proliferation and differentiation, as well as the responses of cells to external 
signals such as hormones and growth factors. It is on this latter group which 
this thesis will concentrate.
10
NH
OCH
NH
(22)
3 ^ 0  NH
a
O NHo
t^ P T b
O NHo
OH
h 2n . X
H3C
OH
A A nh c o 2nh :
OH
H2N A
h 3c
OH
‘N
c h 2- dna
DNA
DNA
NH,
Scheme 3 (Adapted from Tomasz et a/.17).
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1.5.1 Growth Factors
Growth factors are small polypeptides with molecular weights in the region of 
6,000 to 25,000. They are responsible for stimulating cells in the Go phase to 
enter and proceed through the cell division cycle (Figure 1). The mitogenic 
response occurs in two distinct ways.18’ 19
(1) Quiescent cells are acted upon by "competence" factors, which allow entry 
and subsequent traversion of the Gi phase. Examples are Epidermal 
Growth Factor (EGF), Platelet-Derived Growth Factor (PDGF), and 
Fibroblast Growth Factor (FGF).
(2) Cells in the Gi phase are committed to DNA synthesis by the action of 
"progression" factors such as Insulin Growth Factor (IGF) and Insulin.
Figure 1 The Cell Division Cycle. Go, quiescent phase; G-i ,^ gap phases (normal cell function); 
M, mitosis; S, synthesis of DNA prior to mitosis. Adapted from Aaronson20
Transition through the Gi phase requires sustained growth factor stimulation 
over a period of several hours; if the signal is disrupted for a short period of 
time, the cell reverts back to Go- There is also a critical period in the Gi phase 
where simultaneous stimulation by both the competence and progression 
factors is required. Beyond this point of restriction, only the progression factor is 
required.
In some cell types, the absence of growth factor stimulation causes the rapid 
onset of apoptosis (programmed cell death).
Almost all of the genetic changes involved in the evolution of the cancer cell 
affect molecules involved in signal transduction pathways. Many malignant cells 
have been shown to have uncontrolled expression or mutation of growth 
factors, their receptors or components of their signal transduction pathways.
M ti
EGF
PDGF
FGF
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In the late 1970s, Collett and Erikson demonstrated that a number of retroviral 
oncogene products were similar to the protein kinase encoded by the product of 
v-src.21 Further studies of this oncogene revealed that the protein pp60src, 
which was encoded by v-s/c, phosphorylated the tyrosine residue of target 
protein substrates.22 Purification and sequencing of growth factors and their 
receptors revealed that the v-erbB product (and its equivalent rat viral 
oncogene, v-neu) was a truncated form of the EGF receptor.23 Subsequently, 
protein tyrosine kinase (PTK) activity has been shown to be associated with the 
cytoplasmic domains of several growth factor receptors.24
There are now known to be 3 types of growth factor receptor which possess 
PTK activity.25
(1) Those associated with the cytoplasmic domains of the growth factor 
receptor (e.g. EGF and PDGF).
(2) Those located in the cytoplasm, but often attached to the surface of a 
membrane (e.g. the products of the sue and lek oncogenes).
(3) Those located in the nucleus, at least one of which is the abl oncogene 
tyrosine kinase.
Further examples of PTKs are given in Table 1.
Oncogene Associated Protein Tyrosine Kinase
sre
yes
far ► Membrane-associated non-receptor PTKs
lek
fps/fes Non-receptor PTK
abl/bcr-abl Non-receptor PTK
ros Membrane-associated receptor-like PTK
erbB Truncated EGF PTK
neu Membrane-receptor PTK
fms Mutated CSF-1 receptor tyrosine kinase
met soluble truncated receptor-like PTK
trk Mutated NGF receptor PTK
kit Truncated stem cell receptor PTK
sea Membrane-associated truncated receptor-like
PTK
ret Truncated receptor-like PTK
Table 1 (taken from reference 25)
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1.5.2 Signalling Mechanisms of Growth Factors with Tyrosine Kinase 
Activity
Although our knowledge of the signal transduction mechanisms which lead to 
the activation of cytoplasmic and particularly membrane-bound tyrosine kinases 
is far from complete, we do have a reasonable understanding of the mode of 
action of the EGF and PDGF receptor kinases.26-28 In both these growth factor 
receptors, binding of substrate to its cognate receptor results in dimerisation 
and trans-autophosphorylation in the cytoplasmic domain. The resultant 
phosphorylated tyrosine induces a conformational change which allows the 
docking of signalling proteins such as GTPase Activating Protein (GAP), 
Phosphatidyl inositol 3'-kinase (PI3'-kinase) and phospholipase CY (PLC) (all 
binding by their src-homology (SH2) domains), and also the serine/threonine 
(ser/thr) kinase raM . Although our understanding of this molecular cascade is 
incomplete, effects on MAP kinase, S6 kinase, cyclin/cdc kinase and certain 
transcription factors have been implicated.
Many growth signalling pathways are activated in human tumours, including 
PDGF which is implicated in a high fraction of sarcomas and glially deprived 
neoplasms, and TGFa which occurs frequently in carcinomas expressing large 
amounts of EGF. Members of the EGF family of receptor kinases, especially 
erbB2 and erbB3 are most frequently implicated in human cancers, including 
adenosarcomas of the breast, stomach and ovary. Of particular importance is 
the observation that overexpression of these receptor kinases is correlated with 
cell survival.29
1.6 Protein Tyrosine Kinases as Targets for Drug Development
Clearly, the high PTK activity found in many cancer cells presents these 
enzymes and their corresponding genes as promising targets for new 
therapeutic agents. Recombinant DNA technology has shown that inactivation 
of kinase activity results in abolition of cellular transformation. It follows, then, 
that developing drugs which act as antagonists for the growth factor receptors 
would have the same antiproliferative, prodifferentiating effect.
One obvious problem is that PTKs are involved in a plethora of normal cell 
functions. It would be essential to develop tyrosine kinase inhibitors which have 
a high molecular specificity for one or more oncoproteins. Further therapeutic 
selectivity may also arise from the excessive dependence of certain tumours on
14
particular signalling pathways. A number of PTKs have been identified as viable 
targets for inhibition by new anticancer agents.30
1.6.1 The EGF Tyrosine Kinase
The EGF receptor (also called HER1) is a 170 kD plasma membrane protein 
possessing an extracellular ligand binding domain, a single transmembrane 
region and an intracellular domain possessing PTK activity.31 Fibroblasts which 
overexpress the EGF receptor have been shown to be tumourigenic,32- 33 whilst 
expression of the related growth factor TGFa in transgenic mice results in 
higher incidences of liver and breast cancer.34- 35 A very high percentage of 
primary tumours of the brain, bladder, thyroid, lung, ovary and oesophagus 
express significant levels of EGF. Antibodies raised against EGF or TGFa have 
been shown to inhibit tumour cell growth, implicating the involvement, at least in 
part, of EGF in the mitogenesis of these cells.36- 37
1.6.2 The erbB2 Tyrosine Kinase
Also known as HER2, the human erbB2 proto-oncogene is a 185 kD protein 
which has 44% structural affinity with the EGF receptor.38 It is a homologue of 
the nitrosourea-induced neuroblastoma rat oncogene neu. Breast tissue is 
particularly susceptible to overexpression of pp185e/]t?B2, which induces 
transformation and tumourigenicity. Antibodies to pp185er^ B2 inhibit growth of a 
number of breast and ovarian cell lines.39 Although structurally similar to the 
EGF receptor, erbB2 does not bind EGF.
1.6.3 The abl Tyrosine Kinase
This 145 kD non-receptor tyrosine kinase has been implicated in several 
leukaemic states since the discovery of the Philadelphia chromosome. It is 
understood that the abl proto -oncogene, which is located on chromosome nine 
in humans, becomes juxtaposed with the bcr gene from chromosome twenty to 
form two protein products, namely p‘\85bcr/abl and p2‘\0bcr/abl, which both 
possess tyrosine-specific kinase activity. The mechanisms of action of these 
fused proteins is poorly understood, although evidence exists to suggest that 
bcr is a ser/thr kinase which interferes with the regulation of abl.40’ 41
1.6.4 The FGF Tyrosine Kinases
The Fibroblast Growth Factor (FGF) family is a group of related proteins which 
has been created either as distinct gene products, or as the result of splicing of 
a number of genes. Several ligands are known to bind to these proteins, which 
are involved in growth regulation, embryogenesis and angiogenesis. Genes
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encoding analogues of FGF have been found in cancers of the stomach, and in 
Kaposi's sarcoma.42- 43 Overexpression of FGF results in transformation of 
cellular phenotype, and FGF has also been shown to stimulate new blood 
vessel growth in tumours 44
1.6.5 The PDGF Tyrosine Kinase
Platelet-Derived Growth Factor (PDGF) is an extremely abundant growth factor, 
and is a major mitogen for cells involved in connective tissue organs including 
smooth muscle tissue and fibroblasts. PDGF, which consists of two polypeptide 
chains labelled A and B, is assembled as two homodimers (PDGF-AA or 
PDGF-BB) or as a heterodimer (PDGF-AB). There are two PDGF receptors; the 
first, a 170 kD protein labelled a, binds both the homodimers as well as the 
heterodimer, whilst the second, p (180 kD), binds only PDGF-BB. Cells 
transformed by the simian sarcoma virus secrete a protein, p28s/s, which is 
encoded by the v-s/s viral oncogene. V-s/s is homologous to PDGF-B, and 
cellular transformation by v-s/s requires the presence of PDGF receptors.45- 46 
PDGF-B is ten times more efficient at cellular transformation than PDFG-A, and 
has been shown to be present in elevated amounts in the plasma or tissue of 
patients with breast cancer.47-49
1.6.6 The pp60c-src Tyrosine Kinase
The c-src proto-oncogene encodes for a 60 kD phosphoprotein which is 
homologous to v-s/c, a highly transforming oncogene found in the Rous 
sarcoma virus.50 Whilst the precise function of c-src is not known, it appears to 
be involved in the processes of mitogenic signal transduction, cell cycle 
progression and cell adhesion, as well as cytoskeletal activities. Elevated c-src 
activity has been observed in tumours of the breast, colon and bladder.51- 52>53 
In the case of the former, elevated tyrosine activity has been observed in 100% 
of all breast cancer cases; at least 70% of this activity is known to be caused by 
pp60c'src54> 55 In transgenic mice carrying a disrupted c-src gene, no tumours 
were observed to develop.56
1.6.7 Structure of The Active Site of a Tyrosine Kinase
To date the crystal structure of only one growth factor receptor possessing a 
tyrosine kinase domain has been reported.57 The Insulin receptor, refined to a 
resolution of 2.1 A, was shown to possess a tyrosine residue (Tyr 1,162) in the 
active site. It has been hypothesised that binding of ligand moves the kinase 
domains of the heterotetrameric receptor closer together, resulting in transient 
cross-phosphorylation of Tyr 1,162 and adjacent tyrosines on the activation
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loop. Tyr 1,162 is then probably displaced from the active site, and the resulting 
change in conformation allows ATP and exogenous substrate to bind.58 Whilst 
there is a degree of structural diversity throughout the family of tyrosine 
kinases, all are known to contain at least one tyrosine in the activation loop at a 
position corresponding to Tyr 1,162 in the Insulin receptor.
The structure of a catalytic subunit of a ser/thr kinase (which are known to have 
around 70% structural affinity with tyrosine kinases) has also been solved at 2.7 
A resolution.59 However, as yet no example of a PTK inhibitor designed using 
these data has been reported.
Considerable progress has been made in identifying a number of potent PTK 
inhibitors.25- 80 A number of these are natural products, which whilst displaying 
good PTK inhibition are often non-specific towards sub-classes of PTK and 
often show inhibition of ATP binding. It is in the development of a number of 
synthetic tyrosine kinase inhibitors that most progress has been made.
1.7 Tyrosine Kinase Inhibitors
1.7.1 Flavonoids
The flavone quercetin (23) (a natural product) is capable of growth inhibition in 
a number of human tumour cell lines.60-62 Quercetin has been shown to inhibit 
the tyrosine phosphorylation activity of pp60v'src both in vitro and in vivo.63 It 
has been shown, however, that quercetin is not a specific PTK inhibitor, but 
also inhibits other enzymes such as phospholipase A2 , phosphorylase kinase, 
phosphodiesterases and a number of ser/thr kinases, as well as being 
competitive with respect to ATP.
OH
OH
OH
OH O
HO
(23) (24)
The isoflavone genistein (24) is a more potent EGF inhibitor than quercetin at 
concentrations which have no effect on ser/thr kinases and phosphorylase 
kinase.64 Genistein is also a competitive inhibitor of ATP, and inhibits S6
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tyrosine phosphorylation65 and Tl I and II.66 It is unclear whether Tl inhibition by 
this compound involves competition with the ATP binding site.
A number of flavonoid analogues have been reported,67 although the 
antiproliferative and antitumour activity of these compounds have not yet been 
ascertained.
1.7.2 Benzoquinoid Ansamycin Antibiotics
A number of benzoquinoid ansamycin antibiotics, including herbimycin A (25), 
geldamycin and macbecin have been reported to have moderate antitumour 
activity.68- 69 Herbimycin A has also been shown to reverse the transformed 
morphologies of chicken and mammalian cells which have been transformed by 
the yes, fps, ros, abl, erbB and lek tyrosine kinase oncogenes, but not by raf, 
ras or myc.70- 71 Consequentially, in vitro studies have revealed inhibition of 
p60v_src, p2 10^cr"a^  and EGF autophosphorylation.
1.7.3 Peptide and Nucleotide Analogues
Analogues corresponding to Tyr419 (the residue phosphorylated by p60v_src) 
have been synthesised.72 A 21 non-phosphorylated residue was shown to 
inhibit both p60v_src and EGF autophosphorylation, but not ser/thr kinases.73 
Several other analogues have shown effective inhibition of the EGF, Insulin and 
p60v_src tyrosine kinases.74- 75
O
c h 3 c h 3 o c h 3
(25)
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Nucleot ide analogues such as the ATP analogue 
5'-[4-(fluorosulfonyl)benzoyl]adenosine (FSBA) (26) and Ciberon Blue have 
been reported as potent PTK inhibitors.76- 77
1.7.4 Anilinoquinazolines
Anilinoquinazolines such as compound (28) display high potency and selectivity 
for the EGF receptor. 78'82 Ward et al. showed that anilinoquinazolines are 
competitive with ATP, but their degree of selectivity remained high even in cells 
with high levels of ATP.81 Zeneca Pharmaceuticals have synthesised a series 
of anilinoquinazolines which inhibit growth function at concentrations in the 
micromolar range (unpublished data).
1.7.5 Multisubstrate Tyrosine Kinase Inhibitors
The majority of multisubstrate tyrosine kinase inhibitors possess a tyrosine 
mimic covalently linked to a triphosphate mimic. It is intended that these 
compounds will simultaneously inhibit both the tyrosine and ATP binding sites. 
The most potent compound (27) is an analogue of FSBA.
These compounds display limited specificity against various tyrosine kinases, 
and also inhibit serine-specific phosphorylation of phosphorylase b by 
phosphorylase kinase.83- 84
(28)
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The fermentation product lavendustin A (29) displays bisubstrate inhibition at 
the EGF receptor tyrosine kinase.85 Analogues of this compound which have 
had the core pharmacophore trimmed such as (30) show similar inhibition of 
EGF tyrosine kinase, and some have also been shown to distinguish between 
this and the p56lck receptor kinase. AG814 (31), a lavendustin analogue, is 
competitive with respect to growth factor and ATP.86-87
1.7.6 Erbstatin
Erbstatin (32) was isolated and characterised by Umezawa et al. from the 
medium of an actinomycete, and was shown to inhibit EGF receptor 
autophosphorylation in the membranes of A431 epidermoid carcinoma cells, 
which have a high concentration of the EGF receptor.88 Although erbstatin 
displays potent inhibition of a number of tyrosine kinases, it has recently been 
shown to be competitive both with substrate and ATP.86 Bishop and co-workers 
later showed that erbstatin also inhibits ser/thr kinases such as protein kinase C 
in the same range of concentrations.89 Other properties include observed 
inhibition of DNA Topoisomerase I and II.90 In vivo studies in EGF-positive 
mammary and oesophageal solid tumour xenografts revealed the necessity for 
feroxymithine (a ferric iron chelator) for antitumour activity. Feroxymithine was 
shown to suppress greatly the breakdown of erbstatin, which is unstable in 
serum.91
C02H
OH
(31)
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More stable analogues such as methyl 2,5-dihydroxycinnamate have been 
reported.92 This compound inhibits EGF receptor autophosphorylation in intact 
cells, as well as in a cell-free system with potency equal to erbstatin.
1.7.7 Tyrphostins
The striking similarity in structure between erbstatin and tyrosine led to a series 
of compounds based on the erbstatin nucleus, which had similar potencies.93 
This class of compounds was defined as tyrphostins, or tyrosine 
phosphorylation inhibitors. Several hundred tyrphostins have been reported in 
the literature in the last six years.
Tyrphostins have the general structure shown (Figure 2), and are normally 
prepared by Knoevenagel condensation of an aromatic aldehyde with a 
substituted malonate derivative in the presence of a catalytic amount of base, 
normally piperidine or pyridine (Scheme 4).94-96 The aromatic moiety may be 
phenyl, heteroaromatic or fused heteroaromatic. The group labelled R is 
normally an electron-withdrawing group such a -CN, -C(NH2)=C(CN)2 , -CO2R" 
-CONH2 , “CSNH2 or a heteroaromatic moiety. One or both of the aromatic or 
heteroaromatic moieties may also be substituted with functional groups such as 
hydroxy, methoxy or nitro, or with a halogen atom (labelled R').
NC R
R
Figure 2
R R
Ar-CHO
Scheme 4
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An extensive number of assays are available for the biological evaluation of 
tyrphostins. Whilst these give detailed insight into the modus operandi of these 
compounds, it makes direct comparison of drugs extremely difficult.
There are two main methods used for the primary screening of tyrosine kinase. 
The first involves measurement of the antiproliferative effect by in vitro 
exposure of cells expressing a high concentration of tyrosine kinase receptors, 
commonly for the Epidermal Growth Factor, to the compound. These include 
MCF-7 human breast adenocarcimona cells, HN5 human squamous carcinoma 
cells, A431 vulval carcinoma cells, SKOV-3 ovarian cancer cells, HT29 colon 
cancer cells or HER14 cells, which are a cloned form of NIH3T3 carcinoma 
cells transfected with the EGF receptor.
The second method gives a more accurate indication as to whether the 
compounds are inhibiting tyrosine kinase activity. The EGF receptor kinase 
activity is determined by measuring the EGF-dependant phosphorylation of a 
synthetic substrate, polyGAT (glutamine-alanine-tyrosine) in the presence of 
the drug. The system is exposed to 32P-ATP, and the uptake of the labelled 
ATP is directly proportional to tyrosine kinase activity.
In both groups of assay systems, potency is measured in terms of IC50 values, 
that is the concentration of drug required to inhibit 50% of the function being 
observed. Where possible the IC50 values quoted in this Chapter are for drugs 
tested in MCF-7 cells or for activity of the drugs at the EGF receptor in a 
cell-free system.
Further details of the MCF-7 cell and EGF receptor kinase assays are given in 
Chapters 6 and 7.
Tyrphostins may be considered as falling into two broad classes.
1. 'Classical' Tyrphostins. The first series of tyrphostins were derived from the 
benzylidenemalononitile (BMN) nucleus. The direction of the amide bond in 
erbstatin was inverted and dehydrated to the cyano group in BMN. The nitrile 
group on BMN was reported to increase the biological activity of these 
compounds.97 Similar to erbstatin, the presence of hydroxyl groups in the 
phenyl ring was associated with increased biological activity. In particular, 
compounds containing two or more hydroxyl groups (33-35) showed increased 
activities (Figure 3).
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(33) (34)
IC50 375 (iM IC50 35 |iM
HO CN
CN
HO
OH
(35)
IC50 6 pM
Figure 3 1C50  values are for inhibition of phosphorylation of a 
poly(GAT) substrate (see section 6.2.2 for further details)
Coplanarity of the sidearm with the aromatic ring is extremely important, having 
a dramatic effect on the biological activity. This was shown when Gazit et al. 
synthesised a series of conformationally constrained tyrphostins.98 By fixing the 
dicyanoethylene moiety to a bicyclic structure, it was determined that optimal 
potency was achieved with tyrphostins having a coplanar catechol ring with the 
3-hydroxy and cyano group "syn" (Figure 4).
HO HO
CN
HO HO "anti’"syn"
NC
OH
HO HO— 1 — 1
HO
NC NC
OH
HO HO
HO
NCNC
AG765
R= CN 
IC50 7|iM
Figure 4
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In contrast, when the rigidity of these tyrphostins was decreased by 
incorporating the dicyanoethylene moiety exo to a more flexible 6 -membered 
ring (36), or when the sidearm was saturated (37), the tyrosine kinase inhibitory 
activity was lost.
Tyrphostins containing a-keto and a-amido moieties in the sidearm generally 
showed good results both in biochemical and biological screens. A number of 
aromatic ketones were also included in the study, including (38) which contains 
a 2 -thienyl moiety, and displayed IC50 values of 31 pM and 35 pM in the EGF 
receptor autophosphorylation and erbB2/neu autophosphorylation assays 
respectively.
Tyrphostins containing a-amido moieties also displayed good biological profiles, 
although no correlation between chain length and activity was apparent. This is 
in contrast to tyrphostins with ester moieties, where a substantial decrease in 
activity was observed when the ester chain was lengthened.93
In 1993, Gazit et al. reported a further series of tyrphostins, which contained a 
5-S-aryl moiety with the general structure shown in Figure 5 ."  Many of these 
compounds inhibited autophosphorylation of the EGF receptor and erbB2/neu 
receptors at least one order of magnitude less than erbstatin. Moreover, these 
showed greater selectivity between the two receptor types, acting preferentially 
at erbB2/neu. The best results were observed for compounds where R1 = 
substituted phenyl or benzyl, R2 = -CONH2 and R3 = -CH3 or -H. This is in 
contrast to other BMN tyrphostins, where a marked difference in activity was 
observed for compounds containing hydroxy as opposed to methoxy residues 
on the aromatic ring.
N C . X N
OH
(36) (37) (38)
S -R 1 
Figure 5
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2. Tyrphostins Containing Heteroaromatic Moieties. A few tyrphostins 
containing heteroaromatic moieties in the sidearm have been reported to inhibit 
EGF kinase activity. RG13022 (39) and RG14620 (40) also inhibit the growth of 
human squamous cell carcinoma (which over-expresses the EGF receptor) 
when implanted in nude mice. 100
Subsequent studies in which the BMN nucleus was replaced with indole101- 102 
or quinoline103 gave a number of compounds which displayed similar biological 
profiles to the lead compounds. Several tyrphostins containing an isoquinoline 
ring were also prepared such as (41). These may be considered as cyclic 
BMNs, and have been shown to inhibit the EGF receptor tyrosine kinase as 
opposed to p56lck in vitro.104>105
HoCO
H3CO
(39) (40)
O
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NH,
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Robins and co-workers recently reported a series of tyrphostins containing 
pyridyl (42), imidazyl (43) and thienyl (44) moieties. 106 These showed moderate 
activities in vitro when tested in MCF-7 human breast carcinoma cells (which 
over-express the EGF receptor). Whilst these initial results were very promising 
and contradicted the results reported earlier by Gazit et a!., further studies in a 
cell-free system measuring EGF-dependent phosphorylation indicated that the 
activity of these compounds was not due to inhibition of the EGF receptor 
kinase.
CSNH
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Tyrphostins were originally proposed to be competitive inhibitors with respect to 
substrate at the binding site, and non-competitive with respect to ATP. It was 
subsequently shown that a greater degree of selectivity by some tyrphostins 
was apparent, particularly in the cases of AG494 (45), which was selective for 
EGF receptor, and AG825 (46), an erbB2lneu -selective tyrphostin.107
Subsequent and more detailed studies suggested that the mode of inhibition 
was more complicated.86- 108 Many tyrphostins are competitive both with 
substrate and ATP.
Several tyrphostins containing S-aryl moieties have also been shown to be 
potent antiproliferative agents. 86 Interestingly, tyrphostins in this series which 
could discriminate between erbBI and the erbBl -2 chimera in vitro did not 
show the same effect when assayed in NIH3T3 cells which expressed either 
erbB\ or erbB‘1 -2. A number of possible explanations accounting for this 
discrepancy included the suggestion that the agents must overcome high 
intracellular concentrations of ATP, which masked their differential ability. 
However it is more likely that alternatively, or even additionally, tyrphostins do 
not act solely at the level of erbBI and erbB1-2 kinases, but also at a signal 
transduction element further downstream in the pathway. To date, the nature or 
location of this other binding site is not known.
It has become increasingly apparent that although many tyrphostins are more 
selective than genistein, lavendustin A and herbimycin A, each group inhibits 
several tyrosine kinases to some degree, either competitively with respect to 
substrate, or ATP, or both. The improvement of selectivity remains a continuing 
learning process. Of particular interest are tyrphostins containing a 
heteroaromatic moiety, since synthesis of compounds of this type would allow 
comparison of the potency of electron-rich and electron-deficient systems, as 
well as the investigation of 5-membered and fused ring systems. Drugs such as 
RG13022 (39) and RG14620 (40) show promising results both in vitro and in 
vivo and act as interesting leads for new compounds. The mode of action of the 
tyrphostins reported by Robins and co-workers may not yet be fully understood, 
but these compounds are worth further exploitation since few tyrphostins
CONH,
(45) (46)
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containing heteroaromatic moieties have been reported in the literature, and 
they fall outwith existing patents. 104- 10°-118
There are clearly a number of potent tyrphostins currently available, but their 
limited selectivity and stability may prevent them from ever becoming viable 
anticancer agents. There have been a number of new developments in the 
methodology available for identifying cancer cells by their environment and 
expression of surface antigens, and these are discussed in Chapter 2 .
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2. New Targets for Cancer 
 Chemotherapy
2.1 Tumour Hypoxia
Cancer cells are identified by their rapid proliferation and lack of differentiation. 
Since solid tumours grow at a rate which far exceeds that of the surrounding 
tissue, the intercapillary distance increases and results in areas of the tumour 
being deprived of essential materials such as oxygen, which is supplied through 
the vascular structure.119 Hypoxic cells, therefore, exist at an oxygen 
concentration which is suboptimal for cell growth and metabolism, but is 
sufficient to maintain viability. These cells can be around 3 times more resistant 
to ionising radiation, since molecular oxygen is a potent radiosensitiser. When 
oxic cells are exposed to radiation from X-ray or y-ray sources, only a small 
amount of lethal damage results as a direct interaction between DNA and the 
radiation source. Secondary damage occurs as a result of the action of 
high-energy electrons expulsed from atoms through the action of this radiation. 
These produce a track of short-lived ion pairs, which may react with each other 
and nearby molecules, producing a wide selection of free radicals and reactive 
species, which in turn may react with DNA or other important biological 
molecules. The result of this can be mutations or cell death. Reaction of 
molecular oxygen (the 'oxygen effect' ) 120 with these electron-affinic molecules 
can result in a significant amount of cell damage. Conversely, there is little 
damage by radiation to hypoxic cells.
Hypoxic cells also show a reduced response to various chemotherapeutic 
agents, since they may be too far removed from blood vessels to allow 
significant concentrations of the drugs to reach the cells. The cells may also be 
moving much more slowly through the cell cycle, or the cycle may be totally 
blocked.
In order to overcome this very real problem, methods have been developed in 
which the tumour is re-oxygenated between treatments of radiotherapy. The
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specificity of this method is extremely limited, and a number of other ways to 
improve oxygen delivery have been explored.121
It is in the development of agents which in a sense substitute for oxygen by 
radiosensitising hypoxic cells that the greatest progress has been made. These 
compounds, called electron -aftin ic radiosensitisers, take the place of oxygen by 
accepting an electron from the initially-formed DNA radicals. The drugs can 
reach the interior of solid tumours because they are less actively metabolised.
An alternative approach is in the development of compounds which display 
hypoxic cytotoxicity, which involves metabolic reduction of a functional group on 
the molecule to a toxic species in a hypoxic cell. An example of these are nitro 
compounds, which undergo a series of 1 -electron and 2 -electron reductions, 
giving rise to several toxic intermediates (Scheme 5). Initial addition of an 
electron gives rise to a cytotoxic free radical (47). This can occur via radical 
transfer from radiation-induced CO2 '* radicals, or by enzymic reduction under 
hypoxic conditions. This NO2"  radical may be either oxidised back to the initial 
nitro species, in which case a toxic superoxide radical is formed, or may be 
further reduced to a nitroso compound (48). Two subsequent 1-electron 
reductions give rise to a hydroxylamine (49), which is reduced via a 2-electron 
mechanism to an amine (50).
1- ^ - R -  N O -^-^R — NOH ■ ^► R - n h o h ^ » - r -  nh 2
(48) (49) (50)
r - n o 2
Scheme 5
A prerequisite of electron-affinic radiosensitisers is that at least their first 
reduction potential (Ej) must fall within physiological limits. This represents a 
value of between -200 and -500 mV vs. the Normal Hydrogen Electrode (NHE).
2.1.1 Nitroimidazole Radiosensitisers
Misonidazole (51) has received a great deal of clinical study as an 
electron-affinic radiosensitiser.122 Unfortunately due to neurotoxicity it was 
found to be impossible to administer this compound at a sufficient dose to 
achieve radiosensitisation of tumours.123 The second generation of agents to be 
the subject of clinical trials include etanidazole (SR2058, (52)),124> 125 
pimonidazole (Ro 03-8799, (53))126- 127 and RSU1069 (54) 128> 129> 130 which 
can be considered as a 'dual-function' agent, possessing electrophilic and
29
f = \
j^ n" r
n o 2
Bioreduction
H
wO-H
P = \
H N / ^ *
OH
(56)
-H©
H©
£JH
©
r ? ( '
N v N
h T  r
V NH
H
H
NH
(59)
(57)
H -0
HN
NH
(60)
R
Scheme 6
H
N N.
nh2
(58)
Isolated
O -H
R
o  0  
(61)
h2n . ^ n h r
T
NH
(62)
2.1.2 Other Nitroheterocyclic Radiosensitisers
A series of azole compounds containing either one or three nitrogen atoms 
based upon the nitroimidazole nucleus has been reported. 134 The triazole 
derivative (63) displayed a high degree of selectivity for hypoxic cells, whereas 
the pyrrole (64) showed no specificity. Both groups of compounds displayed 
similar E) values to RSU1069, whose first one-electron reduction potential is 
-389 mV vs. NHE.
OoN
N ^ N
(63)
OH
(64)
N
A s im i la r  se r ies  of 2-nitrofuran-4-carboxamides and
2 -nitrofuran-5 -carboxamides was shown to have E) values between -210 to
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-350 mV vs. NHE. 135 These are much better radiosensitisers than RSU1069, 
with their degree of sensitisation being dependent upon their reduction potential 
and structure.
Threadgill etal. later showed that a series of 2-nitrothiophene-5-carboxamides 
and 2-methyl-3-nitrothiophene-5-carboxamides such as (65) and (6 6 ), had E) 
values between -240 and -540mV vs. NHE.136 Once again, these compounds 
proved to be more potent radiosensitisers than predicted137- 138 and were toxic 
with respect to hypoxic V79 cancer cells at concentrations equal to or one order 
of magnitude lower than misonidazole. However, their general toxicity under 
aerobic conditions implies that they are unsuitable for use as bioreducible 
anticancer agents.
More recently, Hay et al. synthesised a number of bis(nitroimidazoles) .139 
These compounds displayed increased solubility and hypoxia selectivity 
compared to a previously-published bis(imidazole) (67).140 Symmetrical 
bis(nitroimidazoles) such as (6 8 ) were up to nine times more potent than (67), 
having much more rapid kinetics of cell kill under hypoxic conditions.
(65) (66)
2.2 Antibody Directed Enzyme Prodrug Therapy
Since the advent of monoclonal technology, attempts have been made to attach 
anticancer agents to antibodies which have been raised against surface 
proteins (antigens) unique to cancer cells.141- 142 Once the antibody-drug 
conjugate is bound to the cancer cell, the drug or toxin can be released and is 
taken up by the cell. The earliest methods involved attaching a nitrogen 
mustard such as A/-acetylmelphalan to an antibody, but a major drawback of 
this strategy was that the antibody-drug conjugate failed to gain sufficient 
tumour access. Another disadvantage is that every molecule of the cytotoxic 
agent of choice would have to be bound to a separate antibody.
One other approach relies upon the ligation of a radioactive element such as 
indium 111 or yttrium 90 to an antibody, a process known as 
radioimmunology. 143 The element would only be released once the antibody 
was bound to the cancer cell. Whilst the limited success of this method has 
been reported,144 it is severely limited by the poor attachment of the antibody 
conjugate to tumours. Indeed, it has been shown that only between 0.0001 to 
0.01% of the administered conjugate is present per gram of tumour.145 This 
could be explained by the crude method of attachment of the multidentate 
ligand to the antibody, a process which involved stirring an anhydride of the 
ligand with the antibody. The anhydride may have been attacked by the portion 
of the antibody which recognises the antigen, thus rendering the antibody 
inactive.
A third approach would be to encapsulate the cytotoxic drug into a liposome, 
and to attach antibodies to the liposome's external surface. Once bound to the 
surface of a cancer cell, the immunoliposome is engulfed within endosomes, so 
releasing its contents into the cancer cell (Figure 6).146 Studies have confirmed 
the viability of this approach, with 84% of the immunoliposomes binding to 
tumour cells within 2  hours.147
In order to overcome the problems relating to the stability and delivery of an 
antibody-enzyme conjugate, it has been proposed that it may be advantageous 
to separate the two functions.148 Antibody-directed enzyme prodrug therapy 
(ADEPT) 149 separates the targeting function from the cytotoxic function by 
adopting a two-phase approach. An antibody-enzyme conjugate (AEC) is first 
administered to the patient, and after sufficient time is allowed to optimise 
localisation of the AEC at the tumour and clearance from the blood and normal 
tissue (a period of between 3-7 days), the patient is then given a prodrug. 150- 151 
Upon exposure of the prodrug to the AEC, the prodrug is converted into a toxic 
drug close to the cell membrane, which is then taken up by the cell or by a
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neighbouring cell (the 'bystander' effect) and so causes cell death (Figure 7). A 
major advantage of this approach is that the AEC may act upon several prodrug 
molecules, and it is free to bind to another cancer cell after acting upon the 
prodrug.
Antibody fragment
Im m unoliposom e
Drug/cytotoxin
Phospholipid bilayer
Surface antigen
Cancer Cell
Figure 6
Phospholipid bilayer
Cancer
Cell
Drug
Surface antigen
Enzyme
Antibody
Figure 7
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Whilst the nature of the antibody and antigen are outwith the scope of this 
thesis, it is important to review the possible target prodrugs and enzymes which 
may act upon them.
2.2.1 Nature of the Enzyme
It would be desirable for the enzyme of choice to be non-mammalian, since this 
will ensure that lysis of the prodrug does not occur as a result of the action of 
the host's enzymes. A disadvantage of this approach, however, is that this 
increases the likelihood of an immune response by the host. The enzyme must 
also be easily conjugated to the antibody, either by chemical means, or perhaps 
through the development of genetically engineered antibodies possessing 
enzymatic domains.152
2.2.2 Nature of the Prodrug
Ideally, the prodrug should be a compound possessing high water solubility, low 
toxicity and a relatively long half-life, and should only be converted into the 
active form by the action of the AEC. The active drug by comparison would be a 
small, lipid-soluble molecule which could easily traverse the cell membrane, 
such as a mustard. Its half-life would be of the order of seconds rather than 
minutes (but long enough to allow the 'bystander' effect to occur), helping to 
minimise any toxic effects with respect to healthy tissue surrounding the 
tumour.
2.2.3 Enzymes and Prodrugs used in ADEPT
There are several enzymes which have been identified as possible targets for 
action upon ADEPT prodrugs.
(1) Carboxypeptidase G2. This zinc metalloenzyme, which was isolated from a 
Pseudomonas strain153 catalyses the hydrolytic cleavage of reduced and 
non-reduced folates to pteroates and L-glutamates (Scheme 7). The enzyme 
has been linked to a monoclonal antibody raised to human chorionic 
gonadotrophin.154- 155 A number of prodrugs which are acted upon by an AEC 
containing carboxypeptidase G2 (CPG2) have been reported.156-158 Many of 
these are based on a para-A/-bis(dischloroethyl)aminobenzoyl glutamic acid 
skeleton which incorporates a nitrogen mustard moiety (Figure 8).
35
h2n n n
HO
OH
N
Carboxypeptidase G2
OH
N
HoN N
O
OH
N
Pteroic Acid
H O ^ O
H,N \''*'
OH
O
L-Glutamic Acid
Scheme 7
COoH
O CO2H
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These prodrugs fill the criterion of having a longer half-life compared with their 
equivalent active drugs. By exchanging one of the chloroethyl moieties for a 
mesyloxyethyl group, which reacts more quickly with DNA, the authors were 
able to increase the biological activity of the free drug by a factor of 70. In 
addition, it was shown that incorporating a 2 -fluoro substituent in the aromatic 
ring had a deactivating effect on the alkylating moieties, whereas a 
3-substituted fluorine activated the alkylation of DNA, although generally the 
non-fluorinated drugs showed a stronger binding affinity for CPG2 .158 This 
clearly indicates the requirement for non-substituted benzenoid prodrugs by this 
enzyme.
36
Carboxypeptidase G2
O
OH
N
Pteroic Acid
HOOH
OH
O
L-Glutamic Acid
Scheme 7
C02H
O CO2H
Figure 8 : X, Y, -Cl or -SO3 CH3
These prodrugs fill the criterion of having a longer half-life compared with their 
equivalent active drugs. By exchanging one of the chloroethyl moieties for a 
mesyloxyethyl group, which reacts more quickly with DNA, the authors were 
able to increase the biological activity of the free drug by a factor of 70. In 
addition, it was shown that incorporating a 2 -fluoro substituent in the aromatic 
ring had a deactivating effect on the alkylating moieties, whereas a
3-substituted fluorine activated the alkylation of DNA, although generally the 
non-fluorinated drugs showed a stronger binding affinity for CPG2 .158 This 
clearly indicates the requirement for non-substituted benzenoid prodrugs by this 
enzyme.
36
In vitro experiments showed that the prodrugs of this type exert minimal 
cytotoxicity both in normal and cancerous cells.156 It is anticipated that this will 
be reflected in vivo, although clinical trials are incomplete.159
(2) Carboxypeptidase A. This enzyme has been used in the breakdown of a 
methotrexate-phenylalanine conjugate (69) (Scheme 8) by an AEC.160 By 
breaking the amide bond between the MTX subunit and the peptide, the AEC 
generates free MTX (9). In vitro studies have shown this conjugate to display 
similar cytotoxicity with respect to cancer cells as MTX; in vivo data have not 
yet been reported.
However, since MTX is an antimetabolite which is dependent upon the cell 
being in the S-phase of the cell cycle for its action, the question remains as to 
the feasibility of using this drug and its analogues in ADEPT. It may be more 
desirable to choose cytotoxic agents whose activities are independent of the 
cell cycle.
COoH
O
CHpPh
CH
N (69)
Carboxypeptidase A OH
O
NH
NI
CH
COpH
MTX (9)
Scheme 8
(3) P Lactamases This class of enzymes not only hydrolyses penicillins, but 
also cephalosporins via a mechanism which involves expulsion of a 3'-leaving 
group (Scheme 9). The enzyme is also tolerant of a wide variety of substituents 
at this position,161 making it a good candidate for ADEPT.
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A number of prodrugs of this type containing nitrogen mustards attached via a 
carbamate linkage have been reported. 162 In addition, MTX has been 
conjugated to the cepham sulfoxide nucleus via nucleophilic displacement of 
the cepham alkyl iodide by the terminal carboxyl group of MTX. 163 The 
vinblastine analogue, DAVLB (70) has been similarly attached to the cepham 
moiety. 164
Whilst the MTX prodrug and free drug showed similar toxicities, the DAVLB 
conjugate (71) was five times less active compared to the free drug, and also 
induced tumour regression in mice xenografts which had been previously 
exposed to the p-lactamase AEC.165 This conjugate has also been shown to be 
a good substrate for the AEC.166
(4) (3-Glucuronides. These enzymes are present at low concentrations in the 
blood, but due to their high polarity they have poor cell membrane permeability.
OH
HO
(70)
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A series of prodrugs which are acted upon by a p-glucuronide has been 
recently reported, an example of which is (72).167 Of particular interest is the 
fact that these drugs contain a spacer unit. The reasons for this are two-fold. 
Firstly, the spacer provides added stability to the prodrug, and it secondly also 
separates the 'specifier' fragment, i.e. the p-glucuronide, from the drug 
fragment, in this case daunomycin. This helps to reduce the steric crowding 
around the specifier, and should, in theory, increase the binding affinity of the 
prodrug with the AEC.
0CH30  OH O
I M U
Na02C
(72)
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2.2.4 Possible New Targets for ADEPT
Carboxypeptidase G2 is, at present, perhaps the most promising enzyme for 
new ADEPT chemotherapy treatment. Prodrugs possessing nitrogen mustard 
moieties have been shown to be less toxic compared to the corresponding free 
drug, and studies have confirmed the hydrolysis of these compounds by the 
AEC in vitro. Traditionally, the approach has been to attach a 'hit and run' drug, 
such as a mustard or one which may induce apoptosis, since these do not rely 
on an extensive exposure time to exert a toxic effect. However, the relative 
non-specificity of these types of drug remains an area of concern. It would be 
perhaps more desirable to design a series of prodrugs which would release an 
extremely specific anticancer agent, such as one which would interfere with a 
key signalling mechanism in the cancer cell, but would also be sufficiently toxic 
to display an effect within a relatively short timescale. It is for this reason that 
tyrosine kinase inhibitors, and tyrphostins in particular, are interesting targets 
for new ADEPT drugs.
2.3 Conclusions
Cancer, unlike many other diseases, is not peculiar to race, or climate. It is a 
disease which is universally widespread. The first generation of anticancer 
agents such as the nitrogen mustards made an enormous impact in reducing 
the numbers of deaths from this affliction. These drugs, and the current 
second-generation compounds including the antimetabolites, anthracyclines 
and microtubule inhibitors are much more specific and potent substances, and 
their discovery and synthesis remain one of the most important contributions to 
medical science in the twentieth century.
The almost exponential increase in our understanding of molecular biology in 
the past twenty years has led to the development of a third generation of cancer 
treatments. By appreciating how cellular signalling mechanisms function, we 
have been able to identify new targets such as growth factor receptors which 
can be acted upon to inhibit the function of abnormal cells. By preventing the 
phosphorylation of signal transduction proteins, it may be possible to halt 
completely the proliferation of these cells.
The problem of the specificity of new agents remains. In particular, it is 
apparent that many current treatments display suboptimal potency at hypoxic 
centres in solid tumours. The development of electron-affinic radiosensitisers 
which owe their activity, at least in part, to their ability to become bioreduced
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under anaerobic conditions may help to overcome this dilemma. By 
synthesising new prodrugs for ADEPT, it may be possible to achieve new 
chemotherapeutic treatments which are so subtle, yet so precise in their 
targeting, that the enormous side-effects of so many of the current drug 
treatments may become a thing of the past.
There is clearly an enormous amount of scope for developing new anticancer 
agents, which will present many new challenges for the medicinal chemist.
2.4 Outline of the Following Chapters
This thesis will concentrate on the development of a number of new compounds 
based on those discussed in this and the preceding Chapter.
In Chapter 3, a series of tyrphostins containing a thienyl nucleus will be 
discussed. These were chosen to extend the earlier work of Robins and 
co-workers, 106 which showed that compounds of this type containing a 
5-membered heterocycle performed well in vitro. The thiophene ring also 
contained a nitro group, as it was considered necessary to investigate the 
biological potential of tyrphostins which might be active under hypoxic 
conditions. Threadgill and co-workers had already shown that a number of 
nitrothiophenes have first 1 -electron reduction potentials which fall within 
physiological parameters, and are effective anticancer agents. 136 It was also of 
interest to investigate the effect of an electron-withdrawing group, attached to 
the thiophene ring at various positions, on the biological activity of these 
compounds. The planarity of the sidearm with the aromatic ring was confirmed 
when the crystal structure of one nitrothienyl tyrphostin was solved.
Chapter 4 considers the synthesis of tyrphostins containing a 6 -,7- or 
8 -substituted quinolyl moiety. Previous work carried out in this department 
(unpublished) showed that 2 and 4-substituted quinolyl tyrphostins displayed 
promising in vitro activity, whereas 3-substituted quinolines did not. The 
Chapter concludes with the synthesis of two 8-nitro-2-quinolyl tyrphostins.
In Chapter 5, the identification of a target prodrug containing a tyrphostin for 
use in ADEPT is discussed. This tripartate molecule would be acted upon by an 
AEC incorporating the CPG2 enzyme. Of particular note are the methods used 
in the unsuccessful attempts to link the L-glutamic acid specifier to the spacer 
unit via a urea linkage.
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Chapter 6 details some of the methods used in the biological and biochemical 
evaluation of the compounds synthesised in Chapters 4 and 5, and draws 
attention to data which suggest that some of these compounds may not be 
tyrosine kinase inhibitors, but exhibit their cytotoxicity by causing DNA strand 
breaks. The Chapter contains electrochemical data for the nitrothiophene and 
nitroquinoline tyrphostins synthesised, which confirm that some of these 
compounds possess the requisite reduction potentials to allow bioreduction 
under hypoxic conditions, although no clear pattern for the nature of these 
reductions was observed.
Finally, Chapter 7 gives details of the experimental procedures used in the 
synthesis of the compounds discussed in Chapters 3 to 5.
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3. Synthesis of 
Nitrothienyl Tyrphostins
3.1 Introduction
Tyrphostins containing a thienyl moiety have been made, and one of those 
prepared displayed considerable in vitro tyrosine kinase inhibition. 106 Whilst a 
significant number of tyrphostins based on the BMN nucleus have been 
reported in the literature,93- 97> 98> 99 only a few containing 5-membered 
heterocycles have been synthesised.
Nitrothiophenes generally undergo nucleophilic attack at the 2- or 5-position 
depending on the position of the nitro moiety. The deactivating effect of the nitro 
group generates electropositive centres at ring positions either 'ortho' or 'para' 
to it.
(73)
Threadgill and co-workers have shown that the substitution pattern had little 
effect on the ability of nitrothiophene radiosensitisers to display potent in vitro 
activity in hypoxic cells.136 However, substantial differences in the first 
1-electron reduction potentials were reported. In 2-substituted
4-nitrothiophenes, this value was around -510 mV vs. NHE, whereas in 
compounds based upon the 5-nitro-2-thiophene nucleus a much more positive 
value of between -240 and -275 mV was recorded, the lowest values 
corresponding to compounds in which the sidearm contained a group such as 
an amide (e.g. (73)). These findings have clear implications for the synthesis of 
other anticancer agents which may be reduced under hypoxic conditions.
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3.2 General Route to Tyrphostins- The Knoevenagel Condensation
The majority of tyrphostins which have been reported in the literature were 
prepared by Knoevenagel Condensation of an aromatic aldehyde (74) with a 
substituted malonate derivative (75) in the presence of a catalytic amount of 
base (Scheme 10). Whilst the nature of the base can vary, it is generally a 
secondary amine such as piperidine (76) or a tertiary amine such as pyridine. 
Two mechanisms have been proposed, depending upon the nature of the base.
o (76)
R N' R
Ar-CHO + (  ____ □______^  / = <
CN (cat) Ar CN 
(74) (75) (77)
Scheme 10
It is generally accepted that the extra-annular double bond in each tyrphostin 
has the aromatic and nitrile moieties cis (as drawn above) although there is little 
supporting evidence in the literature. The crystal structure of one thienyl 
tyrphostin (100) was solved (see Section 3.9), and this geometry (77) was 
observed for this compound.
3.2.1 'Classical1 Mechanism
Condensation of the aldehyde with a primary or secondary amine gives rise to 
an iminium salt (78). Nucleophilic attack by a preformed malonate carbanion 
(79) gives rise to an intermediate amine (80), which undergoes anti-elimination 
of HNR2 to give the Knoevenagel product (81) and results in regeneration of the 
base (Scheme 11).
3.2.2 Hann-Lapworth Mechanism
Deprotonation of the malonate derivative by the base gives rise to a carbanion 
(79) which attacks at the electrophilic carbonyl carbon of the aldehyde (74). The 
(3-hydroxycarbonyl compound (82) normally spontaneously dehydrates to give 
the Knoevenagel product (81) (Scheme 12). This mechanism hold true when 
tertiary amines such as pyridines are used, although it is possible to isolate a 
(3-hydroxycarbonyl species when other bases are used.
Many other bases, including the ammonium salts of primary, secondary or 
tertiary amines, Lewis acids such as TiCU and K2 CO3 , or potassium fluoride 
have been employed as catalysts for this reaction. It is widely held that the 
reaction follows the Hann-Lapworth mechanism when these catalysts are used.
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3.3 Synthetic Targets
There are six possible sites for the nitro and aldehyde groups around the 
thiophene ring (Figure 9). 5-Nitro-2- and 2-nitro-4-thiophenecarbaldehyde (85 
and 84) are commercially available, whilst 2-nitro-3- and 4-nitro-2- 
thiophenecarbaldehyde (83 and 87) can be easily prepared from readily 
available starting materials. Extensive literature searches were unable to 
identify feasible routes to the two other nitrothiophenecarbaldehydes.
Our initial targets were tyrphostins in which the nitro group and sidearm were 
'ortho' or 'para'. 2 , 5-Substituted nitrothienyl compounds had already been 
shown to possess 1-electron reductions of around -255 mV vs. NHE,136 and so 
a series of 5-nitro-2-thienyl tyrphostins was prepared. Compounds containing a
3-nitro-2-thiophene moiety were then prepared.
For comparison, a second group of tyrphostins in which the nitro group and 
sidearm were meta was then prepared. Compounds based upon the 2-nitro-4- 
and 4-nitro-2-thiophene nucleus are discussed in Sections 3.6 and 3.7.
A general procedure was employed in the synthesis of the tyrphostins reported 
in this thesis.93 The aromatic aldehyde was dissolved in a minimal amount of 
solvent, and to this was added the malonate derivative, either neat in the case 
of the methyl, ethyl, ^butyl or toutyl ester derivatives, or as a solution in the 
same solvent for all the other malonate derivatives. This mixture was stirred for 
several minutes at room temperature until the product precipitated. If no 
reaction occurred after about one hour, piperidine or some other base was 
added until the product formed. Further details are given in Sections 7.2 and
(83) (84) (85)
(86) (87) 
Figure 9
(88)
7.3.
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3.4 2-(5-Nitrothienyl) Tyrphostins
A procedure involving reaction of 5-nitro-2-thiophene carbaldehyde (85) with a 
series of malonate derivatives (89 to 98) in the presence of a catalytic amount 
of base gave rise to ten tyrphostins (Scheme 13 and Table 2). Most of these 
compounds were isolated as powders which could not be crystallised due to 
their insolubility in an extensive range of solvent systems. The compounds were 
characterised by NMR, IR and mass spectrometry, gave acceptable 
microanalytical data and were submitted for biological evaluation.
(85) (89-98) (99-108) NC
Scheme 13
R
R
<
CN
No. Base
NC
No. Yield (%)
CN (89) piperidine (99) 38
C(NH2)=C(CN) 2 (90) piperidine (100) 40
CO 2 Me (91) dilute piperidine (101) 94
C02Et (92) piperidine (102) 49
C0 2 nBu (93) dilute piperidine (103) 65
C02*Bu (94) piperidine (104) 61
C02 (TEG)0Met (95) piperidine (105) 89
c o n h 2 (96) piperidine (106) 15
c s n h 2 (97) diethylamine (107) 44
2 -thienyl (98) piperidine (108) 15
t  Discussed in Section 3.8.3
Table 2
The relatively low yield of compound (99) (38 %) may be explained in part by 
the fact that a spot with Rp 0.71 was observed by TLC, corresponding to an 
acetal which had formed as a result of the reaction of the starting aldehyde with 
the solvent (propan-2 -ol). The reaction was also carried out at 0 °C after 
previous attempts at room temperature resulted in polymerisation. The 1H NMR 
spectrum consisted of three signals of equal intensity. The most deshielded 
signal, a broad singlet at 8 8.79 was assigned to the olefinic proton on the 
sidearm, whilst signals consisting of an AB system at 8 8.23 and 7.89 with a 
coupling of 4.4 Hz were from the aromatic protons. The more downfield signal 
of these two corresponds to the proton a to the nitro group. These data were
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consistent with previously published values. 168 The 13C NMR spectrum showed 
two extremely deshielded signals in the aromatic region at 5 155.9 and 139.2, 
corresponding to the carbons bearing the nitro group and the sidearm 
respectively. The aromatic C-H carbons appeared at 5 152.5 and 137.9, the 
more deshielded signal corresponding to the carbon in the 4-position on the 
thiophene ring. A signal at 8 129.6 for the olefinic C-H and signals at 8 114.9 
and 112.9 for the two nitriles were also observed. In the IR spectrum, 
characteristic signals were observed at 2240 cm-1 (nitrile), 1590 cm-1 (extended 
conjugation to the aromatic system) and 3050 and 815 cm-1 (aromatic-H). The 
mass spectrum showed signals at m/z 205 and 159, for the molecular ion and 
for loss of the nitro group. Accurate mass spectrometry and microanalytic data 
were consistent with the proposed product.
Compound (100) was crystallised from 1:1 acetone/chloroform, giving crystals 
of sufficient size and purity to be submitted for X-ray crystallography (see 
Section 3.8). The 1H NMR spectrum of (100) contained by a broad singlet at 8 
9.17, corresponding to the -NH2 protons. The aromatic protons consisted of an 
AB system at 8 8.23 and 8 7.88, with a coupling of 4.4 Hz. The aromatic signal 
at 8 7.88 was further split by the olefinic proton at 8 8.41, with a long range 
coupling of 0.4 Hz. The 13C NMR spectrum included signals at 8 115.5, 115.2 
and 114.4 corresponding to three nitrile groups, which were observed as a 
weak signal at 2222  cm-1 in the IR spectrum. Signals at m/z 271 and 153 in the 
mass spectrum were assigned to the molecular ion and loss of the 
NC-C(NH2)=C(CN)2 fragment of the sidearm from the parent molecule.
The tyrphostins containing methyl (101),168 ethyl (102), nbutyl (103) and toutyl 
(104) ester groups in the sidearm were prepared by reaction of the aromatic 
aldehyde with the corresponding alkyl cyanoacetate (91-94). All products gave 
good microanalytical and accurate mass spectrometric data. The 1 H NMR 
spectra showed characteristic deshielded signals for the olefinic proton around 
8 8.60 and the aromatic protons around 8 8 .2 0 -8 .0 0 , with signals upfield 
corresponding to the methyl, ethyl, ^butyl and fbu\y\ protons. The carbonyl 
carbon was observed as a singlet at around 8 160 in the 13C NMR spectra, with 
four signals in the aromatic region between 8 155-137. The olefinic carbons 
came around 8 130 (CH) and at about 8 104. IR spectra included weak signals 
between 2 2 2 0 -2 1 2 0  cm-1 for the nitrile group, and sharp signals around 
1715 cm-1 corresponding to an ocp-unsaturated carbonyl. Signals for the 
molecular ion and loss of the nitro and ester moieties were observed in the 
mass spectra of these compounds.
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The IR spectrum of 2-cyano-3[5-(2-nitrothienyl)]propenamide (106) contained 
distinguishing signals at 3350 and 3250 cm-1, corresponding to the amide N-H 
stretch, a weak signal at 2 2 0 0  cm-1 for the nitrile and a sharp signal at 
1690 cm-1 for an alkene in conjugation to an aromatic species. The most 
distinctive signals in the 1H NMR spectrum were two broad singlets at 8 8.03 
and 8 7.96. These very deshielded signals were lost after D2O exchange, and 
were assigned to the -NH2 protons. The reason for the observation of these two 
separate line-broadened signals for these chemically equivalent protons arises 
from the delocalisation of the nitrogen lone pair into the n system, which slows 
down rotation around the C-N bond. When the sample was heated in the NMR 
probe, the singlets broadened further and eventually coalesced. The 13C NMR 
spectrum displayed a signal at 8 161.5 corresponding to the amide carbonyl 
carbon, and other signals which were consistent with previously published 
data. 169 Signals for the molecular ion and for loss of the nitro and amide groups 
from this ion were observed in the mass spectrum.
Compound (107) was prepared from 2 -cyanothioacetamide (97) and 
5-nitro-2-thiophenecarbaldehyde using diethylamine as the base since 
polymerisation of starting materials was observed when piperidine was used. 
The product was a dark brown solid which was very insoluble and could not be 
recrystallised. However, microanalysis and accurate mass spectrometry 
confirmed the purity and the presence of a molecular ion consistent with the 
molecular formula. Two broad singlets in the 1H NMR spectrum at 8 7.98 and 
8 7.95 correspond to the thioamide protons, whilst a quaternary carbon at 
8 162.4 was assigned to the thiocarbonyl carbon in the 13C NMR spectrum. The 
IR spectrum contained relevant signals for an aromatic system (3145 cm-1), a 
nitrile group (2190 cm-1), a C-NO2 stretch (1470 cm-1) and a broad peak at 
1460 cm-1 which was assigned to the thioamide N-H stretch.
Gazit et a i had previously reported a benzylidene tyrphostin which contained a 
2-substituted thiophene on the sidearm.93 This had been prepared by the 
reaction of 2 -thiopheneacetonitrile with the appropriate aromatic aldehyde using 
Knoevenagel methodology. In an attempt to develop this work further to include 
tyrphostins based on a nitrothienyl nucleus, 2-cyano-3-[5-(2- 
nitrothienyl)]-1 -(2-thienyl)propene (108) was synthesised (Scheme 14). 5-Nitro- 
2-thiophenecarbaldehyde (85) was stirred in ethanol in the presence of 
2-thiopheneacetonitrile (98) and piperidine for eight days; however the yield 
was very low at only 15 %. When the reaction time was extended, no significant 
increase in yield was observed, and when the base was changed to pyridine, 
diethylamine or potassium carbonate, a black tar formed. The 1H NMR 
spectrum of the product was dominated by a complex multiplet in the aromatic
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region between 8 8.30-7.45 with a relative intensity of five, with a singlet further 
downfield at 8 8.43 with a relative intensity of one for the olefinic proton. Signals 
in the 13C NMR spectrum were assigned to the thiophene rings, and the nitrile 
group came as a singlet at 8 116.4. The IR spectrum showed a very sharp 
signal at 1615 cm-1, corresponding to a C=C bond in conjugation with an 
aromatic system, and the mass spectrum showed signals for the molecular ion 
accompanied by signals at m/z 216 and 179 for loss of the nitro and thiophene 
moieties respectively.
5-Nitro-2-thiophenecarbaldehyde (85) was treated with 3-thiopheneacetonitrile 
(109) in the presence of a number of bases (Scheme 14). In each case 
however, a mixture of up to seven products was observed by TLC and could not 
be separated by column chromatography.
' - QNC s
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Piperidine
OoN CHO (199)
OoN
NC
(108)
S
(85)
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3.5 3-(2-Nitrothienyl) Tyrphostins
We then turned our attention to the synthesis of a series of nitrothienyl 
tyrphostins in which the sidearm and nitro group were 'ortho1 to each other. 
M^kosza and Owczarozyk had previously reported170 a method involving the 
nucleophilic substitution of hydrogen by a dichloromethyl carbanion and the 
subsequent hydrolysis of the dichloromethyl group to a formyl moiety at the a 
position in a nitroaromatic system. We treated a solution of 2-nitrothiophene
(111) and chloroform in THF with a slight excess of potassium toutoxide. The 
base generates a trichloromethyl carbanion, which attacks exclusively at the 
a-position (Scheme 15). Subsequent |3-elimination of HCI and rapid quenching
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of the reaction by a 1:1 mixture of formic acid and methanol results in 
restoration of aromaticity and formation of 3-dichloromethyl-2-nitrothiophene 
(112). Upon neutralisation of excess acid using sodium bicarbonate, the product 
was extracted into diethyl ether and the solvent was removed under reduced 
pressure to give a very viscous black tar. This was easily purified by column 
chromatography over silica gel to give the product. The 1H NMR spectrum of
(112) showed two doublets at 8 8.04 and 7.70 with a coupling of 5.7 Hz 
corresponding to the protons in the 5- and 4-positions on the thiophene ring, 
with a singlet at 8 7.75 for the dichloromethyl group. The 13C NMR spectrum 
contained five signals, consisting of quaternary carbons at 8 140.9 and 125.0 
for the ring carbons attached to the nitro and dichloromethyl moieties 
respectively, and CH groups at 8 130.0 and 8 128.9 for the aromatic carbons in 
the 5- and 4-positions. A CH group at 8 63.9 corresponded to the 
dichloromethyl group.
CCI
CIX
CHCU 
KOtBu * ^=NI
IOI
- ©
H
7 / - x  Cl>
(111)
-HCI
NO-
(112)—0  94% from (111)
H
° J
CH — Cl CHO
C ^ N 0 2 ---------------------------------NO;
S 28% from (112) S
27 % overall (83)
Scheme 15
The next step involved heating (112) with aqueous formic acid to reflux for 
22  hours. TLC showed the absence of the spot at Rp 0.75 for the starting 
material which was replaced by a new spot at Rf 0.58. The reaction mixture 
was allowed to cool to room temperature and the excess acid was neutralised 
using aqueous sodium bicarbonate solution, and extraction into diethyl ether
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using aqueous sodium bicarbonate solution, and extraction into diethyl ether 
was followed by purification using flash column chromatography over silica to 
give 2-nitro-3-thiophenecarbaldehyde (83) in moderate overall yield. The IR 
spectrum contained strong signals at 3096 and 3080 cm"1 for the aromatic C-H 
stretch, a sharp signal at 1694 cm-1 for an aromatic aldehyde and a signal at 
1534 cm-1 corresponding to a C-NO2 stretch. The 1H NMR spectrum showed a 
very deshielded aldehydic proton at 8 10.61, and two aromatic doublets at 
8 7.95 and 7.78 with a coupling of 5.4 Hz, assigned to the protons on the 5- and 
4-positions on the thiophene ring. These values were consistent with those 
which were reported in the original paper. 170 The 13C NMR spectrum had a CH 
group at 8 183.9 (-CHO), a quaternary carbon at 8 133.0 for the aromatic 
carbon attached to the nitro group, another signal at 8 126.0 for the aromatic 
carbon attached to the aldehyde, and two CH groups at 8 131.0 and 126.7 for 
the 5- and 4-carbons on the ring. The mass spectrum possessed a minor peak 
for the molecular ion and a significantly larger signal at m/z 111 corresponding 
to loss of the nitro group from the parent compound.
Compound (83) was then treated with a series of malonate derivatives in the 
usual manner to yield a series of tyrphostins (Scheme 16 and Table 3).
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f X  CN
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No. Yield (%)
CN (89) - (113) 77
C(NH2)=C(CN) 2 (90) dilute piperidine (114) 75
C02Me (91) piperidine (115) 77
C02Et (92) dilute piperidine (116) 45
C02nBu (93) piperidine (117) 33
C02 *Bu (94) piperidine (118) 80
C02 (TEG)OMet (95) dilute piperidine (119) 62
CONH2 (96) piperidine (120) 31
c s n h 2 (97) - (121) 85
t  Discussed in Section 3.8.3
Table 3
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The first tyrphostin to be synthesised containing this nucleus was (113), which 
was produced from the reaction of 2-nitro-3-thiophenecarbaldehyde (83) with 
malononitrile (89) without the addition of base. The product was isolated as a 
brown precipitate which was filtered and washed to give the product in 77 % 
yield.
In the 1H NMR spectrum a singlet at 5 8.72 was assigned to the olefinic proton, 
and doublets with a coupling of 5.7 Hz at 8 8.22 and 7.76 corresponding to the 
protons in the 5- and 4-positions on the thiophene ring were observed. The 
13C NMR spectrum contained a CH group at 8 152.2 for the olefinic CH=C, with 
the corresponding CH=C coming at 8 88.3. In the aromatic region, signals at 
8 134.3, 131.6, 131.5 and 125.7 were assigned to the carbons in the 5-, 2-, 3- 
and 4-positions. The nitrile groups were observed as two quaternary carbons at 
8 113.3 and 112.2. IR spectroscopy of the product showed the presence of an 
aromatic system, with signals at 3038 cm-1 (Ar-H), 1580 cm-1 (aromatic C=C), 
and weak signals at 870 and 834 cm-1 for two o/t/?o-substituted Ar-H stretches. 
Other signals at 2230 and 1522 cm-1 confirmed the presence of a nitrile group 
and nitro moiety. In the mass spectrum, the molecular ion was observed at 
m/z 205, and a signal at m/z 159 corresponded to loss of the nitro group from 
the parent compound.
The tyrphostin formed from the reaction of 2-nitro-3-thiophenecarbaldehyde (83) 
with malononitrile dimer (90), compound (114), was prepared in the usual 
manner in the presence of a catalytic amount of piperidine. In the 1 H NMR 
spectrum, a broad singlet at 8 9.27 was seen for the -NH2 protons. The olefinic 
proton came as a singlet at 8 8.40, and the aromatic protons were doublets at 
8 8.23 and 7.78 with a coupling of 5.6 Hz. The 13C NMR spectrum included 
signals at 8 164.0 (aromatic C-NO2), and three quaternary carbons for the nitrile 
groups at 8 115.1, 114.4 and 114.0. In the IR spectrum, a sharp signal at 
3052 cm-1 and a weak signal at 820 cm-1 were assigned to an aromatic C-H 
stretch, and a sharp signal at 2726 cm-1 corresponded to an N-H stretch. 
Medium bands at 2223 and 2209 cm-1 were assigned to nitrile groups, and a 
sharp signal at 1647 cm-1 corresponded to a C=C bond conjugated to an 
aromatic system. In the mass spectrum, a small signal at m/z 270 was 
observed for the molecular ion, with other signals at m/z 245 and 225 
corresponding to loss of the cyano and nitro groups from the parent molecule 
respectively.
Tyrphostins which contained methyl (115), ethyl (116), nbutyl (117) and toutyl 
(118) ester groups in the sidearm were then prepared, using piperidine as the 
base. Again, the low yield (33 %) of the ^butyl ester may be attributed to the fact
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was produced from the reaction of 2-nitro-3-thiophenecarbaldehyde (83) with 
malononitrile (89) without the addition of base. The product was isolated as a 
brown precipitate which was filtered and washed to give the product in 77 % 
yield.
In the 1H NMR spectrum a singlet at 8 8.72 was assigned to the olefinic proton, 
and doublets with a coupling of 5.7 Hz at 8 8.22 and 7.76 corresponding to the 
protons in the 5- and 4-positions on the thiophene ring were observed. The 
13C NMR spectrum contained a CH group at 8 152.2 for the olefinic CH=C, with 
the corresponding CH=C coming at 8 88.3. In the aromatic region, signals at 
8 134.3, 131.6, 131.5 and 125.7 were assigned to the carbons in the 5-, 2-, 3- 
and 4-positions. The nitrile groups were observed as two quaternary carbons at 
8 113.3 and 112.2. IR spectroscopy of the product showed the presence of an 
aromatic system, with signals at 3038 cm-i (Ar-H), 1580 cm-i (aromatic C=C), 
and weak signals at 870 and 834 cm-i for two o/t/70-substituted Ar-H stretches. 
Other signals at 2230 and 1522 cm-i confirmed the presence of a nitrile group 
and nitro moiety. In the mass spectrum, the molecular ion was observed at 
m/z 205, and a signal at m/z 159 corresponded to loss of the nitro group from 
the parent compound.
The tyrphostin formed from the reaction of 2-nitro-3-thiophenecarbaldehyde (83) 
with malononitrile dimer (90), compound (114), was prepared in the usual 
manner in the presence of a catalytic amount of piperidine. In the 1 H NMR 
spectrum, a broad singlet at 8 9.27 was seen for the -NH2 protons. The olefinic 
proton came as a singlet at 8 8.40, and the aromatic protons were doublets at 
8 8.23 and 7.78 with a coupling of 5.6 Hz. The 13C NMR spectrum included 
signals at 8 164.0 (aromatic C-NO2), and three quaternary carbons for the nitrile 
groups at 8 115.1, 114.4 and 114.0. In the IR spectrum, a sharp signal at 
3052 cm_i and a weak signal at 820 cm-i were assigned to an aromatic C-H 
stretch, and a sharp signal at 2726 cm-i corresponded to an N-H stretch. 
Medium bands at 2223 and 2209 cm-i were assigned to nitrile groups, and a 
sharp signal at 1647 cm-1 corresponded to a C=C bond conjugated to an 
aromatic system. In the mass spectrum, a small signal at m/z 270 was 
observed for the molecular ion, with other signals at m/z 245 and 225 
corresponding to loss of the cyano and nitro groups from the parent molecule 
respectively.
Tyrphostins which contained methyl (115), ethyl (116), nbutyl (117) and toutyl
(118) ester groups in the sidearm were then prepared, using piperidine as the 
base. Again, the low yield (33 %) of the '’butyl ester may be attributed to the fact
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that ethanol was used as the solvent for this reaction, perhaps resulting in ester 
exchange with nbutyl cyanoacetate. This was not observed in the case of the 
toutyl ester derivative, where propan-2-ol was used as the solvent. In the 
1H NMR spectra of these products, signals for the olefinic proton were observed 
as singlets between 8 9.00-8.72. The aromatic protons came as doublets with 
couplings of 5.6-5.7 Hz at 8 8.82-7.83. Characteristic signals for the methyl, 
ethyl, nbutyl and *butyl moieties were seen further upfield. In the 13C NMR 
spectra, the ester carbonyls were observed at about 8 162. Two quaternary 
carbons and two CH groups were observed in the aromatic region between 
8 145-126, and olefinic C-H groups were observed at about 8 127. The nitrile 
groups came at ca. 8 115. In the IR spectra, sharp absorptions at around 
1720 cm-1 were assigned to an ap-unsaturated carbonyl stretch. Weak signals 
at ca. 2220-2250 cm_1 and signals of medium intensity at 1530-1540 cm-1 
corresponded to a nitrile group and a C-NO2 stretch respectively. Broad signals 
of weak to medium intensity for an aromatic C-H stretch came at about 
3120 cm-1. The mass spectra of the products contained signals corresponding 
to the molecular ions, accompanied by other signals for loss of the nitro moiety. 
All the mass spectra contained a signal at m/z 179 for loss of CO2 R from the 
parent compound.
2-Cyano-3-[3-(2-nitrothienyl)]propenamide (120) was then prepared in the usual 
manner over an extended time of 50 hours until TLC showed the presence of a 
spot at Rp 0.56 and the absence of unreacted aldehyde. After filtration, the 
product was isolated as a brown precipitate which could not be crystallised but 
was analytically pure for biological evaluation. In the 1H NMR spectrum, a 
singlet at 8 8.20 was assigned to the olefinic proton, with doublets at 8 8.19 and 
7.79 for the aromatic protons, with a coupling of 5.6 Hz. The NH2 protons came 
as a broad singlet at 8 8.08. In the 13C NMR spectrum, a quaternary carbon at 
8 161.3 for the carbonyl carbon was accompanied by two CH groups and two 
quaternary carbons in the aromatic region at 8 141.9, 139.5, 133.8 and 131.7 
were assigned to the ring carbons in the 5-, 2-, 4- and 3-positions. The olefinic 
carbons came as a CH group and a quaternary carbon at 8 127.7 and 112.3. 
The nitrile group came at 8 115.3. The IR spectrum contained characteristic 
signals at 3077, 1495 and 824 cm-1 for aromatic C-H and C=C stretches, with 
the lower signal corresponding to two ort/70-substituted aromatic C-H stretches. 
Amide N-H stretches were observed as sharp absorptions at 3455 and 
3380 cm-1, accompanied by a weak amide N-H stretch at 1516cnrr1, and a 
weak absorption at 2200 cm-1 for the nitrile group. In the mass spectrum a 
signal at m/z 223 for the molecular ion was accompanied by signals at m/z 179 
and 177 for loss if the -CONH2 and nitro moieties from the parent molecule.
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Finally, 2-cyano-3-[2-nitrothienyl)]propenethioamide (121) was prepared from 
2-cyanothioacetamide and the appropriate nitrothiophenecarbaldehyde without 
the need for base. In the 1H NMR spectrum, two broad singlets at 8 9.84 and 
9.55 were assigned to the -NH2 protons, with the olefinic proton coming at 
8 7.73. The aromatic protons in the 5- and 4-positions were seen as doublets 
with a coupling of 5.6 Hz at 8 8.05 and 8 7.62 respectively. The 13C NMR 
spectrum showed a characteristically deshielded quaternary signal at 8 168.2 
for the thiocarbonyl carbon, and the aromatic carbons were seen as two 
quaternary signals and two CH groups between 8 143.1 and 134.2. A CH group 
at 8 128.4 corresponded to the olefinic carbon (3 to the thiocarbonyl, with the a 
olefinic carbon at 8 111.8. The nitrile group came at 8 116.1. In the IR spectrum, 
a sharp signal at 3096 cm-1 and a weak signal at 818 cm_i were assigned to 
aromatic C-H stretches; the nitrile group showed a medium absorption at 
2188 cm-1. A sharp absorption at 1625 cm-1 resulted from a C=C conjugated to 
an aromatic system. A thioamide N-H stretch came as a sharp signal at 
1459 cm-1, and a sharp signal corresponding to a C-NO2 stretch was observed 
at 1507 cm-1. In the mass spectrum, the molecular ion was observed at m/z 
239.
3.6 4-(2-Nitrothienyl) Tyrphostins
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CN (89) - (122) 63
C(NH2)=C(CN)2 (90) piperidine (123) 75
C02Me (91) dilute piperidine (124) 86
C02Et (92) dilute piperidine (125) 95
C02nBu (93) dilute piperidine (126) 57
C02*Bu (94) piperidine (127) 62
C02(TEG)0Me+ (95) piperidine (128) 11
CONH2 (96) - (129) 69
c s n h 2 (97) - (130) 62
t  Discussed in Section 3.8.3
Table 4
55
These compounds were prepared in the usual manner outlined in Section 3.2. A 
total of nine compounds were made (Scheme 17 and Table 4).
The 1H NMR spectrum of compound (122) (detail shown in Figure 10) showed 
three deshielded doublets of doublets. The furthest downfield signal at 
8 8.76-8.74 corresponds to the olefinic proton on the sidearm, and signals at 
8 8.48-8.44 were assigned to the aromatic protons in the 3- and 5-positions on 
the thiophene ring. The olefinic methine carbon was observed in the 13C NMR 
spectrum at 8 153.4 (Figure 11). Aromatic singlets at 8 152.8 and 132.0 were 
accompanied by CH groups at 8 143.5 and 127.5. The nitrile carbons came at 
8 113.6 and 112.9, with the quaternary olefinic carbon at 8 82.0. This compound 
has been reported as an agent which could be used in the treatment of diabetic 
complications such as retinopathy, nephropathy and neuropathy,116» 118 
although no analytical data were given.
In the IR spectrum, signals were observed for an Ar-H stretch at 3103 cm-1, a 
nitrile group (2233 cm-1), a sharp signal at 1597 cm-1 for a diene conjugated to 
an aromatic system and a sharp signal at 819 cm*1 for an out-of-plane bending 
by an isolated aromatic C-H. The signal for the molecular ion at m/z 205 was 
accompanied by one for loss of the nitro group from the parent compound at 
m/z 159.
56
89 01m rsQD<d 01
f*4
K1N ca
a:. in m tn tnu i rv rs rs P'*
5? r i
w
to J1 aK1in K1rs niCO 01* i 01
rs fN*U)to rJ ca
010)0)01010)01
09090910091009
r-i r i iH
w
J  V V .
,CN
(122)
Figure 10
’T "
8.80
' ' J ' "  ‘ ‘ 1 ' ' ' J ' ' 
8.70 8.60 8.50
57
160 1^0 140 1^0 1&  v/o 100 90 80 70 60 ' 50 40 30 20 10 0
Figure 11
Compound (123) was isolated in 75 % yield as large brown crystals after an 
extended reaction time of eight days. The 1H NMR spectrum displayed a broad 
signal at 5 9.10 for the -NH2 protons, whilst the aromatic protons were seen as 
doublets with a coupling of 2.3 Hz at 5 8.70 and 8.58. The olefinic proton came 
as a singlet at 8 8.15. Quaternary carbons at 8 132.4, 102.6 and 50.1 were 
assigned to the quaternary olefinic carbons in the 13C NMR spectrum, and 
three signals corresponding to the nitrile groups were observed at 8 115.4,
114.7 and 114.6. A signal at 1636 cm-1 in the IR spectrum showed the 
presence of extended conjugation to an aromatic system, and the molecular ion 
was observed at m/z 271 in the mass spectrum.
Syntheses of the tyrphostins which contained either methyl (124), ethyl (125), 
nbutyl (126) or toutyl (127) ester groups then followed. Whilst the methyl and 
ethyl esters were isolated in >85 % yields, the reactions to produce the two 
butyl esters only gave yields of around 60 %, which may be a result of 
transesterification of the starting materials (the cyanoacetates) with the solvents 
used for these reactions (propan-2-ol and ethanol). This was incidental since 
purity of the products (confirmed by microanalysis) and not efficiency of their 
synthesis was considered important. The 1H and 13C NMR spectra showed 
characteristic upfield signals corresponding to the alkyl portions of the esters
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accompanied by signals in the aromatic region. In all cases no signal was 
observed for the aldehydic group. In the IR spectra, signals corresponding to 
ap-unsaturated carbonyls, extended conjugation to an aromatic system and 
isolated aryl-H stretches were observed at about 1720, 1610 and 860-820 cm-1. 
The molecular ions were observed in the mass spectra, and the methyl and 
ethyl derivatives possessed a signal at m/z 179 corresponding to the loss of 
C02 R.
2-Cyano-3-[4-(2-nitrothienyl)]propenamide (129) was quickly prepared and 
isolated as a brown crystalline solid when the aldehyde was treated with 
2-cyanoacetamide (97) without the addition of base. The 1H NMR spectrum 
showed two broad signals at 6 7.86 and 7.80 for the -NH2 protons, which were 
further upfield from the aromatic protons (doublets at 8 8.63 and 8.50, 4J 1.7 
Hz) and the olefinic proton (a singlet at 8 8.13). The 13C NMR spectrum 
contained a deshielded signal at 8 162.0 (C=0), a CH group at 8 128.0 and a 
signal at 8 106.9 (olefinic carbons). In the IR spectrum, three weak signals at 
3422, 3335 and 3289 cm_l were assigned to a primary amide N-H stretch, with 
another N-H stretch at 2849 cm-1. An amide carbonyl stretch was seen as a 
sharp peak at 1597 cm'1. Signals at m/z 223 and 179 were assigned to the 
molecular ion and for loss of -CONH2 from the parent compound.
The equivalent thioamide derivative (130) was also prepared without the use of 
a catalyst in acceptable yield. The signals in the 1H NMR spectrum for the -NH2 
protons were further downfield this time at 8 8.69 and 8.61, whilst the aromatic 
protons with a coupling of 1.9 Hz were observed as doublets at 8 8.17 and 8.10. 
A singlet at 8 8.11 was assigned to the olefinic proton. In the 13C NMR 
spectrum, a signal for the thiocarbonyl carbon was seen at 8 156.8, and the 
olefinic carbons were seen at 8 128.2 (CH) and 8 112.8, with the nitrile carbon 
coming at 8 116.2. The mass spectrum showed the molecular ion at m/z 239, 
and a smaller signal at m/z 82 was assigned to the thiophene ring having lost 
the nitro group and sidearm.
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3.7 2-(4-Nitrothienyl) Tyrphostins
0 2N
Major
product
o -S
(131)
(87)
+
o2n - O - C H O
s
(85)
Scheme 18
4-Nitro-2-thiophenecarbaldehyde (87) was p re p a re d  from  
2 -thiophenecarbaldehyde (131) using standard nitration conditions 
(Scheme 18).171 Other approaches, such as the use of acetic acid with HNO3 
to generate the nitronium ion were not pursued owing to the acceptable yield 
that this approach gave. The reaction required extremely careful addition of a 
nitrating solution consisting of fuming nitric acid and concentrated sulfuric acid 
to a pre-cooled solution of 2 -thiophenecarbaldeyde in concentrated sulfuric 
acid. After several attempts, it was established that the best method for this 
addition required the use of a syringe pump to ensure that the reaction 
temperature did not exceed 5 °C. The addition took around two hours to 
complete, and gave a black, turbid solution. The excess acid was then 
neutralised by careful addition of aqueous sodium bicarbonate solution, and the 
mixture was poured onto a slurry of ice and water and was slowly warmed to 
room temperature. Extraction of the products into ethyl acetate and removal of 
the solvent in vacuo gave a brown oil which was purified by column 
chromatography and recrystallisation from ethyl acetate gave the major product, 
4-nitro-2-thiophenecarbaldehyde, as large orange crystals in 80 % yield. The 
1H NMR spectrum of the product showed a characteristic aldehydic proton at 
8 9.26, accompanied by a singlet at 8 8.65 for the proton in the 5-position and a 
broader singlet between 88.29-8.12 for the proton on ring position 3. This 
broadening may be as a result of a long range coupling with the aldehydic 
proton. The IR spectrum contained sharp absorptions at 1508 and 1366 cm-1, 
corresponding to asymmetric and symmetric stretches of the nitro N-0 bonds. A 
sharp signal at 1734 cm-1 was assigned to the aldehydic carbonyl stretch. In the 
mass spectrum the molecular ion was seen as the largest signal in the 
spectrum at nn/z 157, and was accompanied by a signal at m/z 111 
corresponding to loss of the nitro group from the parent molecule.
60
Subsequent Knoevenagel condensation of compound (87) with a series of 
malonate derivatives in the usual manner (Scheme 19 and Table 5) generated 
the final series of nitrothienyl tyrphostins.
OoN
Base (cat.)
CHO+ (
CN
NC
(87) (89-94) (132-139)
and
(96-97)
Scheme 19
NC
R No. Base No. Yield (%)
CN (89) dilute piperidine (132) 70
C(NH2)=C(CN) 2 (90) dilute piperidine (133) 55
C02Me (91) dilute piperidine (134) 86
C02Et (92) dilute piperidine (135) 40
C0 2 nBu (93) dilute piperidine (136) 30
C02 *Bu (94) dilute piperidine (137) 40
CONH2 (96) dilute piperidine (138) 15
c s n h 2 (97) dilute piperidine (139) 10
Table 5
Preparation of 2-cyano-3-[2-(4-nitrothienyl)]propenonitrile (132) followed the 
normal procedure using piperidine as the base. In the 1H NMR spectrum, the 
olefinic proton came as a singlet at 5 8.72, with the aromatic protons in the 5- 
and 3-positions as doublets with a coupling of 5.7 Hz at 8 8 .22  and 7.76. The 
13C NMR spectrum contained signals at 8 151.9 (CH) and 8 117.3 for the 
olefinic carbons, whilst the quaternary carbon bearing the nitro group came at 
8 149.2 and the ring carbon bearing the sidearm was at 8 135.8. The two 
tertiary ring carbons came at 8 136.1 and 132.1. The nitrile groups were 
observed at 8 112.6 and 113.0. In the IR spectrum a sharp signal for an 
aromatic C-H stretch was observed at 3038 cm-1, with weak signals at 870 and 
834 cm-1 from two isolated aromatic C-H stretches. A signal corresponding to a 
nitrile group came at 2230 cm-1, and a C-NO2 stretch gave rise to a sharp 
absorption at 1522 cm-1. A sharp absorption at 1636 cm-1 was assigned to a
61
C=C conjugated to an aromatic system. The mass spectrum contained a signal 
at m/z 205 for the molecular ion, and loss of a nitro group from this ion was 
signified by a peak at m/z 159.
The next compound to be prepared was ( 1 3 3 ) ,  from
4-nitro-2-thiophenecarbaldehyde (87) and 2-aminopropene-1,1,3-tricarbonitrile 
(90) using a catalytic amount of piperidine. In the 1H NMR spectrum of the 
product, two broad singlets corresponding to the -NH2 protons was observed at 
the characteristically downfield values of 5 9.19 and 9.17. The olefinic proton 
was a singlet at 5 9.18. In the 13C NMR spectrum, the quaternary olefinic 
carbons came at 5 164.3, 101.2  and 50.2. Three nitrile signals were observed at 
5 115.4, 114.6 and 114.5. The IR spectrum contained distinctive peaks at 3052, 
1607 and 820 cm-1 for aromatic C-H and C=C stretches, and a sharp signal at 
1647 cm-1 corresponded to a C=C conjugated to an aromatic system. A sharp 
absorption at 2726 cm-1 was assigned to an N-H stretch. The molecular ion was 
seen in the mass spectrum, and a signal at m/z 225 corresponded to loss of the 
nitro moiety from the parent molecule.
Reaction of 4-nitro-2-thiophenecarbaldehyde (87) with compounds (91 to 94) 
gave the corresponding products (134 to 137). Yields for these reactions were 
low at around 30-40 %, although microanalysis of the products confirmed their 
purity. In the 1 H NMR spectra, the olefinic protons came as characteristic 
singlets at around 6 8.7, whilst the aromatic protons often showed a long range 
coupling of between 0.8-1.7 Hz. The 13C NMR spectra all possessed a 
quaternary carbon at around 6 162, and a nitrile signal at 5 115. All of the NMR 
spectra showed signals for the alkyl fragments of the ester chain. In the IR 
spectra, signals corresponding to aromatic C-H stretches, nitrile moieties, 
ap-unsaturated carbonyls and C-NO2 stretches were observed. Mass spectra 
all contained signals corresponding to the molecular ion, and a signal at m/z 
179 for loss of -CO2R from the parent molecule.
2-Cyano-3-[2-(4-nitrothienyl)]propenamide (138) was prepared from 
2-cyanoacetamide and 4-nitro-2-thiophenecarbaldehyde (87) in the presence of 
piperidine. A brown precipitate formed after only five minutes, and despite 
attempts to react all of the starting materials by heating to reflux temperature, 
only 15 % of the product was obtained, which was easily separated from the 
starting materials by filtration. The 1H NMR spectrum of the product contained a 
very broad singlet centred at 6 7.92 for the -NH2 protons, and the aromatic 
protons were also observed as broad singlets at 5 9.16 and 8.41. In the 
13C NMR spectrum, a signal at 5 161.7 resulted from an amide carbonyl, and 
the olefinic carbons came at 5 142.6 (CH) and 105.6. The IR spectrum had two
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absorptions of medium intensity at 3423 and 3181 cm-1 for primary amide N-H 
stretches, and a sharp amide C=0 stretch at 1690 cm-1. Aromatic C=C 
vibrations gave rise to signals at 1599 and 1542 cm-1. In the mass spectrum, a 
signal at m/z 223 corresponding to the molecular ion was accompanied by 
another signal at m/z 179 for loss of the amide from the parent molecule.
The final tyrphostin in this series to be prepared was compound (139). This was 
prepared in the usual manner, using one equivalent of 2 -cyanothioacetamide in 
the presence of piperidine. As in the case of the amide derivative, the yield for 
this reaction was particularly low at only 10 %. The NH2 protons were observed 
in the 1H NMR spectrum as two broad singlets at 5 10.22 and 9.66, and the 
olefinic proton came at 6 8.36. In the 13C NMR spectrum, signals were 
observed at 6 191.0 for the thiocarbonyl carbon, at 8 147.9 (CH) and 111.3 for 
the olefinic carbons and at 8 116.1 for the nitrile. In the IR spectrum, signals at 
3277 and 3170 cm-1 resulted from a thioamide N-H stretch, and a thiocarbonyl 
stretch came as a sharp absorption at 1628 cm-1. Aromatic C=C vibrations 
gave rise to absorptions at 1596 and 1541 cm-1. The mass spectrum showed a 
peak at m/z 239 for the molecular ion.
3.8 Attempts to Overcome the Problems of Solubility
The compounds discussed thus far were extremely insoluble in water and 
common organic solvents, and only displayed an acceptable level of solubility 
when DMSO was used as the solvent. Dimethylsulfoxide is itself toxic and may 
therefore mask any inherent biological activity. We therefore considered it 
necessary to investigate a number of methods which could be employed to 
increase the solubility of these compounds.
3.8.1 HCI Salt of 2-cyano-3[5-(2-nitrothienyl)]propenoic acid (100)
A procedure involving the stirring of an acetone solution of
2-cyano-3[5-(2-nitrothienyl)]propenoic acid (100) with 1.0 M hydrochloric acid 
was carried out at room temperature (Scheme 20), but only starting material 
was observed by TLC after three hours. The same result was observed when 
the procedure was repeated using dry ethereal HCI and a suspension of (100) 
in dry diethyl ether. The failure of these routes can be accounted for by the 
reduced basicity of the lone pair on the amino nitrogen, whose electrons have 
been delocalised into the molecule's extended n system.
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3.8.2 Sodium Salts of Acid Derivatives
The procedure outlined in Scheme 21 was employed, and involved reaction of 
toutyl 2-cyano-3-[2-(5-nitrothienyl)]-propenoate (104) with formic acid to 
hydrolyse the ester. The product (141) was identified from its 1 H NMR 
spectrum, which showed a very broad signal for the acid proton along the 
baseline between 8 7.8-7.0, and a sharp signal in the IR spectrum at 1694 cm-1 
for an a|3-unsaturated carboxylic acid C=0 stretch.
Subsequent treatment of (141) with one molar equivalent of aqueous sodium 
bicarbonate solution yielded a yellow solid which was freeze-dried for 24 hours 
to give the pentahydrated sodium salt (142) (determined by microanalysis) in 
44 % overall yield. No signal for the acid proton in the 1H NMR spectrum was 
observed, and the IR spectrum did not posses a peak which could be assigned 
to the unsaturated acid. The pentahydrate was completely soluble in water, and 
was converted back into the deuterated acid (143) by stirring in a mixture of DCI 
and D2O.
0 2N \£ ^C (VB u
T  >  T  HCOpH >
S CN
(104) 5-NO 2 2-substituted 
(127) 5-NO 2 3-substituted
© ©
o2N \^
----------------------------------$  I  j> i
NaHC03 (aq.) X SX  CN DCI/ X S CN
,5H20  D20
(142) or (145) (143) or (146)
Scheme 21
The above procedure was repeated using ^butyl 2-cyano-3- 
[4-(2-nitrothienyl)]propenoate (127) to give compound (144) in quantitative yield.
0 2N\£ ^ C 0 2H
^  >  T
CN
(141) or (144)
c o 2h
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In the 1H NMR spectrum of this compound, a broad signal between 8 8.0-7.0 
was assigned to the acidic proton, and a signal at 8 163.1 in the 13C NMR 
spectrum corresponded to the carbonyl carbon in the acid, compared to 8 160.3 
for the toutyl ester. No signals for the toutyl moiety were observed in these 
spectra. A significant absorption in the IR spectrum at 3098 cm-1 was assigned 
to an O-H stretch, and was accompanied by a signal for an ap-unsaturated acid 
C=0 stretch at 1750 cm-1. A fairly strong signal in the mass spectrum at m/z 
224 corresponded to the molecular ion.
Compound (144) was then stirred with a slight excess of aqueous sodium 
bicarbonate solution until fully dissolved, and after freeze-drying, the sodium 
salt of (144) was isolated as the dihydrate (145). No signal for the acidic proton 
was observed in the 1H NMR spectrum of the product, nor was the absorption 
at -3100 cm-1 in the IR spectrum. A signal at m/z 223 corresponded to the 
anion of this salt. The salt was converted back into the deutero acid in the 
manner outlined in Scheme 21 to give (146) in quantitative yield.
3.8.3 Tri(ethyleneglycol) Ester Derivatives
Currently, a great deal of interest has been shown in the attachment of drugs to 
tri- and poly(ethyleneglycol) units (TEG and PEG) as a means of increasing the 
duration of activity through slow release of the compound, and to increase drug 
solubility. Ethyleneglycols are know to be non-toxic, non-antigenic and 
biocompatible, are soluble in water and organic solvents and have solubilising 
properties when attached to other organic compounds.172
A variety of drugs, such as procaine173 and atropine174 have been attached to 
TEG and PEG. The trimer/polymer-drug conjugates showed longer durations of 
activity due to slow release. Insulin has been attached to PEG to give a product 
which retained its biological activity.175
Attachment of a drug to ethyleneglycols is carried out via the terminal hydroxyl 
group of TEG or PEG. Monomethyl ethers of TEG or PEG are often employed 
to prevent bifunctionalisation of the trimer/polymer.
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Scheme 22 and Table 6
Our synthetic route, outlined in Scheme 22, involved the preparation of an 
ethyleneglycol malonate ester such as compound (95) and its subsequent 
reaction with nitrothiophenecarbaldehydes (83-85) to produce compounds (105)
(119) and (128). Treatment of 2-cyanoacetic acid (147) with a slight excess of 
tri(ethyleneglycol) monomethyl ether (148) using Dean-Stark conditions for 
24 hours gave a yellow solution which was concentrated to a light brown oil. 
TLC showed the presence of two very broad spots, the lower of which (R f 0.15) 
corresponding to unreacted (148). These were easily separated by positive 
pressure column chromatography, giving the product as an amber oil in 64 % 
yield. The 1H NMR spectrum of this oil was dominated by a complex multiplet at 
6 3.42-3.29, corresponding to six sets of methylene protons. Signals at 6 4.01 
(multiplet) and 6 3.03 (singlet) were also observed, and were assigned to the 
methylene protons a to the nitrile group and to the terminal methyl group, 
respectively. The 13C NMR spectrum consisted of a downfield signal at 6 162.9 
(corresponding to the carbonyl carbon), a quaternary carbon at 6 113.0 for the 
nitrile carbon, seven signals between 6 70.6-57.4 for the methylene carbons 
and the methyl carbon at 8 23.2. Signals for the nitrile group, a carbonyl stretch 
and a C-O-C stretch were seen in the IR spectrum, whilst the mass spectrum 
showed a very small peak for the molecular ion and larger signals
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corresponding to loss of fragments of the tri(ethyleneglycol) portion of the 
molecule. Microanalytical and accurate mass data were consistent with the 
structure shown.
Compound (95) was then reacted with 5-nitro-2-thiophenecarbaldehyde in the 
presence of piperidine to give (105) as an orange solid in 89 % yield after a 
short reaction time of ten minutes. In the 1H NMR spectrum (Figure 12), three 
signals of equal intensity were observed in the aromatic region. These 
consisted of a singlet at 8 8.29 corresponding to the olefinic proton, and two AB 
systems with a coupling of 4.4 Hz at 8 7.97 and 8 7.76 for the ring protons (3 and 
a to the sidearm. A large multiplet at 8 3.86-3.39 with an intensity of 12 for the 
methylene protons was accompanied by a singlet at 8 3.37 with an intensity of 
three for the terminal methyl group. In the 13C NMR spectrum (Figure 13), a 
very deshielded signal at 8 161.2 was assigned to the carbonyl carbon. Signals 
at 8 156.0 and 145.2 were assigned to the ring carbons bearing the nitro group 
and the sidearm respectively, whilst two CH signals corresponding to the 
aromatic carbons in the 3- and 4- positions came at 8 128.2 and 135.0. The 
olefinic methine carbon was a signal at 8 145.2, and the quaternary olefinic 
carbon was at 8 104.8. The nitrile came as a singlet at 8 114.2. The six 
methylene carbons on the sidearm were observed between 8 71.9-66.2, and 
the terminal methyl group came at 8 59.0. The IR spectrum of (105) contained a 
signal of medium intensity at 2892 cm-1 corresponding to an ether C-H stretch. 
A weak absorption at 2222 cm-1 was assigned to a nitrile moiety, and a C-NO2 
stretch came as an absorption of medium intensity at 1504 cm-1. Signals at 
1725 cm-1, and at 1338 and 1271 cm-1 could be assigned to an ap-unsaturated 
carbonyl and ester C-0 stretch, respectively. In the mass spectrum, a signal at 
m/z 355 corresponding to loss of a methyl group from the molecular ion was 
accompanied by other signals at m/z 252 and 235 for loss of fragments of the 
ester chain from the parent molecule.
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A second tri(ethyleneglycol) ester, (119), was prepared next, from the 
corresponding cyanoacetate using piperidine as the base. After a reaction time 
of 14 hours, the product was isolated as a peach solid in 62 % yield. The 
olefinic proton was observed as a singlet in the 1H NMR spectrum at 6 9.21. 
The aromatic protons came as broad singlets at 6 8.71 and 8.62. The six 
groups of methylene protons were seen as a broad multiplet at 8 4.71 -3.38, and 
the terminal methyl group was a singlet at 8 3.26. In the 13C NMR spectrum, the 
carbonyl carbon observed at 8 161.4. In the aromatic region, a quaternary 
carbon at 8 148.2 was assigned to the aromatic C-NO2 , and another signal at 
8 146.6 corresponded to the ring carbon bearing the sidearm. Two CH signals 
at 8 147.9 and 136.0 corresponded to the ring carbons in the 5- and 4-positions. 
The methylene carbons came between 8 71.4-65.8, and the terminal methyl 
group was seen at 8 58.2. The IR spectrum had a medium signal at 2878 cm-1, 
corresponding to a C-O-CH3 bend. A weak signal at 2224 cm-i was assigned to 
a nitrile group, and a sharp absorption at 1716 cm-1 corresponding to an 
ap-unsaturated carbonyl was accompanied by signals at 1350 and 1272 cm-1 
for an ester C-0 stretch. There was a medium absorption at 1610 cm-1 for a 
C=C bond conjugated to an aromatic system, and a sharp absorption at 
1536 cm-1 was assigned to a C-NO2 stretch. A signal for the molecular ion at 
m/z 370 was seen in the mass spectrum. Other signals at m/z 295, 267 and 251 
corresponded to fragmentation of the tri(ethyleneglycol) moiety.
The 2-nitro-4-thienyl tri(ethyleneglycol) ester derivative compound (128), was 
prepared from  2-nitro-4-thiophenecarbaldehyde ( 8  4 ) and 
tri(ethyleneglycol)cyanoacetate methyl ether (95) using piperidine as the base. 
The reaction gave a dark precipitate upon stirring at room temperature for ten 
minutes, and TLC showed the presence of three compounds with Rf values 
0-0.17, 0.47 and 0.65. The two upper spots corresponded to unreacted 
aldehyde and 2-nitro-4-thiophenemethanol-1,2-diethyl ether, but as these spots 
were very faint it was decided to terminate the reaction and to purify the product 
by column chromatography. Despite careful collection of small fractions and 
after flushing the column with methanol to remove any residual amounts of 
product, only 10.5 % of (128) was isolated after crystallisation from ethanol. 
Purity was confirmed by accurate mass spectrometry and microanalysis, and 
the IR spectrum showed 2 sharp signals at 1730 and 1270 cm-1, corresponding 
to the carbonyl and C-0 stretches of an ap-unsaturated ester. Other signals at 
2826 and 2228 cm-1, both weak in intensity, could be assigned to an O-CH3 
stretch and a CN group. Three downfield signals of equal intensity in the 
1H NMR spectrum consisting of two doublets at 8 8.54 and 8.39 with a coupling 
of 1.93 Hz , and a singlet at 8 8.16 were assigned to the aromatic protons and 
the olefinic proton respectively. A multiplet at 8 4.50-3.53 with a relative intensity
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of 12 corresponded to the six groups of methylene protons, and the protons of 
the terminal methyl group were observed as a singlet of intensity three at 
8 3.37. In the 13C NMR spectrum, a signal for the carbonyl carbon was seen at 
8 161.6, whilst the aromatic carbons came as two quaternary carbons and two 
CH groups between 8 153.2-133.0. The olefinic methine carbon was at 8 128.0, 
and the nitrile carbon and quaternary olefinic carbon were observed at 8 114.0 
and 104.0. Six methylene groups were observed between 8 71.9-66.0, and the 
methyl carbon was seen at 8 59.0. The molecular ion and signals corresponding 
to fragmentation of the tri(ethyleneglycol) portion of the parent compound were 
observed in the mass spectrum.
3.8.4 Attempted Syntheses of Poly(ethyleneglycol) Ester Derivatives
A similar approach to the first step shown in Scheme 22 was adopted to 
synthesise the poly(ethyleneglycol) monomethyl ether (149). The product was 
isolated as a yellow waxy solid which was characterised by NMR spectroscopy. 
Both the 1H and 13C NMR spectra were dominated by a broad multiplet at 
8 3.57 and 8 77.9-58.9 respectively, which were assigned to the 
poly(ethyleneglycol) groups. In the IR spectrum, sharp signals at 2950 and 
2914 cm-1 were assigned to multiple methylene groups. Since the product had 
a molecular weight in excess of 2 0 0 0 , it was not feasible to characterise it by 
mass spectrometric methods, and microanalytical data were unhelpful owing to 
the wide range of molecular weights in the product mixture. We decided to treat 
(149) with 5-nitro-2-thiophenecarbaldehyde in the presence of a catalytic 
amount of piperidine in ethanol. Upon addition of the piperidine, the solution 
immediately turned black, and TLC showed the presence of the aldehyde with 
R f 0.53 and a black spot on the baseline. This spot may represent the product 
of a nucleophilic addition reaction of the cyanoacetate to the carbonyl or nitrile 
carbons of another molecule of (149) (Scheme 23).
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When the reaction was repeated in the presence of dilute piperidine solution 
both at 25 °C and at 0 °C, the same effect was observed. In the absence of 
base, only starting materials were recovered. Had this preparation succeeded, it 
might have been difficult to purify the product as it would consist of a number of 
species of differing masses, which would also result in a fairly substantial 
margin of error when calculating the molarities of solutions of the product to be 
used for biological evaluation. With this in mind, it was decided not to pursue 
this route further.
3.9 Crystal Structure of a Nitrothienyl Tyrphostin
2,4-Dicyano-3-amino-5-[2-(5-nitrothienyl)]-penta-2,4-dienonitrile (100) was 
recrystallised in a flat-bottomed flask from a 1:1 mixture of acetone/chloroform 
to give brown needles of about 5 mm length. These were submitted to 
Dr K.W. Muir (University of Glasgow) for X-ray crystallographic analysis.
The displacement ellipsoid structure of this compound is shown overleaf 
(Figure 14). Several important structural features were confirmed from the 
analysis. Of particular importance is the trans-configuration of the large groups 
across the C(4)-C(5) double bond. The molecule is essentially planar, with the 
C(7)-C(4)-C(5)-C(1') torsion angle, co, at -1.4 °. A slight distortion from the plane
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of the molecule by the second extraanullar double bond was observed, and the 
C(6)-C(2)-C(3)-C(4) torsion angle was 7.3 °. In addition, a substantial out-of- 
plane distortion of the C(3)-C(4) bond [N(3)-C(3)-C(4)-C(5) torsion angle 
G) = 29.4 °)] may arise from the repulsive effects of the nitrile groups [C(6 )-N(6 ) 
and C(7)-N(7)]. The combined effects of the sidearm and nitro group had little 
effect on the C-C and C-S bond lengths in the aromatic ring compared to values 
obtained from microwave studies of 2-nitrothiophene176 (Table 7).
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Parameter Observed Length (A) Reported Length (A)176
C(2')-C(3') 1.377 1.359
C(3')-C(4') 1.390 1.424
C(4,)-C(5') 1.348 1.370
C(5')-S 1.712 1.689
Table 7
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3.10 Synthesis of 'Hydrated' Tyrphostins
The Hann-Lapworth Mechanism for the Knoevenagel condensation proposes 
that an intermediate (3-hydroxy compound is formed which undergoes anti- 
elimination of H2O to form the Knoevenagel product. It has been suggested that 
this mechanism holds true when a tertiary amine is used to deprotonate the 
malonate derivative, although it is perfectly feasible for a reaction to proceed in 
this way when other bases are employed.
As part of our synthetic route to tyrphostins containing a heteroaromatic moiety 
on the sidearm, we treated 5-nitro-2-thiophenecarbaldehyde (85) with
3-pyridylacetonitrile (150). The earlier attempts at this reaction involving the 
treatment of the reactants with a catalytic amount of piperidine or potassium 
carbonate104 using ethanol as the solvent at room temperature failed to give 
any product, and only starting materials were recovered. However, when the 
reaction was performed at reflux temperature without the addition of base, a 
brown solid appeared after about 2.5 hours; TLC revealed this to be a polar 
material with R f 0.17. The reaction was continued for a further 15 hours to give 
more brown solid, which was filtered off and washed using a little diethyl ether, 
and was dried under vacuum in a drying pistol for several hours. The 1H NMR 
spectrum of the product was complicated (Figure 15), but clearly showed that a 
mixture of two diastereoisomers was present in a 3:1 ratio. Of particular note 
were two doublets of doublets at 5 5.56 and 5.34, accompanied by doublets at 
8 4.91 and 4.82. A very broad signal at 8 3.42 was also observed, which did not 
arise from water impurities in the sample since fresh DMSO had been used and 
an NMR spectrum of the solvent confirmed the absence of water. The doublets 
of doublets became two doublets upon D2O exchange, and the broad singlet 
disappeared. The signals at 8 5.56, 5.34, 4.91 and 4.82 clearly corresponded to 
non-aromatic protons which were nonetheless in a deshielded environment. 
The aromatic region of this spectrum also appeared to be considerably more 
complicated than would be expected for the Knoevanagel product, and a 
doubling-up of the signals in this region (Figure 16) was clearly apparent.
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This led us to consider the possibility of either an intermediate of the reaction or 
a completely different product having been isolated (Figure 17). Since no base 
had been employed, it was not possible for the reaction to have proceeded via 
the classical mechanism, and no signals for the diethyl ether (151) had been 
observed in the 1H NMR spectrum, nor had a spot at Rp 0.71 been noted by 
TLC.
NO-NO.
NO.
CNNC N
HO
CN
EtO OEt
(151) (152) (153)
Figure 17
Another possibility was that a Michael addition to the expected Knoevenagel 
product had taken place to give (152). This was overruled by the fact that a 2:1 
ratio of the pyridyl and thienyl protons was not observed in the 1H and 13C NMR 
spectra, nor were three deshielded methine groups observed. In addition, the IR 
spectrum of the product showed absorptions at 3431 cm -1 and 1294 cm-1 
corresponding to OH stretches and bends. A C-0 stretch at 1161 cm -1 was also 
observed, suggesting that compound (153) was in fact the product. Further 
evidence from microanalytical and accurate mass data confirmed that the 
compound had a molecular formula of C12H10N3O3S, consistent with that of 
compound (153). Detailed evaluation of the 1H and 13C spectra confirmed 
these findings (Table 8).
Compound (153) does not appear to decompose, nor does it dehydrate to the 
Knoevenagel product. This was confirmed when (153) was dissolved in ethanol 
and heated to reflux temperature, either in the presence of piperidine or K2CO3 
for extensive times of up to 72 hours. Only (153) was observed by TLC and 
NMR spectroscopy. NMR spectra of samples of (153) which were up to six 
months old showed no additional signals.
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Compound (154) was prepared by dissolving 2-nitro-4-thiophenecarbaldehyde 
(84) in ethanol and one drop of piperidine. 3-Pyridylacetonitrile was then added, 
as a solid, over a period of around five minutes. The mixture was stirred at room 
temperature for 6.5 hours until a yellow precipitate was observed. TLC revealed 
this to be a fairly polar compound with Rf 0.23. The precipitate was filtered off 
the liquors, and was washed and dried with a little diethyl ether, then placed in a 
drying pistol and heated under vacuum for several hours to remove traces of 
solvent and/or water. The 1H NMR spectrum of this solid was similar to that for 
compound (153) in that two sets of deshielded doublets were observed at 
6 5.61 and 4.96, and at 8 5.38 and 4.88, in a 3:2 ratio. These were 
accompanied by a complex set of broad multiplets in the aromatic region, and a 
very broad signal at 8 3.79 corresponding to the alcohol proton. DEPT analysis 
of the 13C NMR spectrum allowed complete assignment of the signals. Details 
of the NMR spectra are given in Table 9.
We then considered it necessary to attempt a synthesis of a hydrated form of a 
nitrothienyl tyrphostin containing a 2- or 3-thienyl moiety (compounds 155 and 
156). 5-Nitro-2-thiophenecarbaldehyde (85) was treated with 2- and 
3-thiopheneacetonitrile in the absence or presence of piperidine or pyridine, 
both at room temperature and under reflux conditions. Either a black tar formed 
or starting material was recovered in most of these cases (the exception being 
the reaction of 5-nitro-2-thiophenecarbaldehyde with 2-thiopheneacetonitrile 
(98) in the presence of piperidine at room temperature for eight days, which 
gave compound (108) as before). When K2CO3 was used, a very complex 
mixture of about ten products was observed by TLC, which could not be 
separated.
OH
OoN
NC
OH
OoN
NC
(155) (156)
An alternative strategy involves the reaction of the aromatic aldehyde with a 
Grignard reagent as outlined in Scheme 24.
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Scheme 24
A suitable malonate derivative is treated with bromine to generate an a-bromo 
compound. Subsequent treatment of this compound with magnesium in an inert 
atmosphere should give the Grignard reagent (157), which is reacted in situ 
with the aromatic compound to generate the p -hydroxy- p-thienyl malonate
A number of test reactions were performed to check the validity of this route. 
Malononitrile was successfully brominated in this manner to give 
2-bromomalononitrile (159).177 This was then treated with magnesium turnings 
and then with 5-nitro-2-thiophenecarba!dehyde at a variety of temperatures, but 
only starting materials were recovered (Scheme 25). Attempts to synthesise 
a-bromothiopheneacetonitrile and a-bromopyridylacetonitrile were 
unsuccessful.
(89) (159) (160)
An alternative approach would be to generate a lithium salt of the malonate 
derivative and to react it in situ with an aromatic aldehyde. This method was not 
attempted.
3.11 Attempted Synthesis of a p-Methyl Nitrothienyl Tyrphostin
It is possible to perform a variant of the Knoevenagel condensation on ketones 
using a strong Lewis acid such as TiCU (161), which co-ordinates with the 
carbonyl and therefore increases the 5+ at the carbon. A strong base is then 
employed to deprotonate the malonate derivative, and reaction at the 
electropositive centre of the ketone then results (Scheme 26). When an earlier 
attempt to react 2-acetylthiophene (162) with malononitrile using piperidine 
failed, we decided to attempt this synthesis using the methodology of
(158).
Scheme 25
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Lehnert.178 2-Acetylthiophene and malononitrile were dissolved in dry THF, and 
cooled to 0 °C before TiCU was slowly added. The addition was extremely 
exothermic, and the mixture was not allowed to heat above 5 °C. After about 
two hours, pyridine was added to the mixture, giving a deep red solution 
instantly, and a beige oil separated from the solution. This solution solidified, 
giving a complex mixture of products (Rf 0.86-0.29, several spots). Attempts to 
crystallise the mixture from a range of solvent systems were unsuccessful, and 
the 1H NMR spectrum did not show a signal corresponding to a deshielded 
methyl group.
Ck
T i" ^C\ /  \  (161)
Cl
O - fs 
(162)
*
CHo Base
CH
CN
NC
NC
(163)
CN
Scheme 26
The same result was observed using a procedure in which TiCU and
2-acetylthiophene were stirred at 0 °C for two hours before pyridine and 
malononitrile were added.
3.12 Conclusion
A total of 40 tyrphostins based upon different nitrothienyl moieties were 
prepared. In addition, two 'hydrated' tyrphostins were isolated. These were 
presented for biological evaluation, and the first 1-electron reduction potentials 
of a number of these compounds were measured (see Chapter 6). These data 
have been submitted for publication in the scientific press.179
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4. Synthesis of Quinolyl Tyrphostins
4.1 Introduction
Only a few tyrphostins based upon a six-membered heteroaromatic nucleus 
have been reported in the literature.98- 106 Of these, some tyrphostins based 
upon a 3-substituted pyridyl nucleus have shown a degree of inhibition of 
function of EGF receptor kinase activity. It may be possible that the electron- 
deficient character of the pyridine ring may, at least in part, contribute to the 
biological activity of these compounds compared with that of tyrphostins based 
upon the BMN nucleus (see Chapter 1). Tyrphostins such as RG13022 (39) and 
RG14620 (40) which contain pyridyl moieties in the sidearm have been shown 
to inhibit human squamous cell carcinoma in vivo.10°
In order to investigate other electron-deficient systems, our group synthesised a 
series of tyrphostins containing a quinoline nucleus, and recent data180- 181 
have shown that quinolyl tyrphostins display a varied degree of antiproliferative 
and tyrosine kinase inhibition activity. In particular, 2,4-dicyano-3-amino-5-(2- 
quinolyl)-penta-2,4-dienonitrile (165) and 2,4-dicyano-3-amino-5-(4-quinolyl)- 
penta-2,4-dienonitrile (183) were the most potent compounds in the EGF 
receptor kinase assay, whereas the equivalent 3-substituted compound (174) 
had an activity at least 15 times lower than the other two. A number of other 2-,
3- and 4-substituted quinolyl tyrphostins prepared by Lear and McKeown180 
possessed moderate antiproliferative activity in an MCF-7 cancer cell assay 
(details given in Chapters 6 and 7) (Table 8).
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1C50 (nM )
Structure No. EGFRK MCF-7
CN
(164) CN 58 >100
(165) C(NH2)=C(CN)2 1.7 77
(166) C02Me 200 59
(167) C02Et 240 17
(168) C02nBu 60 57
(169) C02fBu 145 14
(170) 2-Pyridyl >500 5
(171) 3-Pyridyl >500 8
(172) 3-Thienyl >500 28
(173) CN 400 76
(174) C(NH2)=C(CN)2 27 52
(175) C02Me 450 >100
(176) C02Et >500 >100
(177) C02/7Bu >500 >100
(178) C02*Bii >500 61
(179) c o n h 2 >500 n.d.
(180) c s n h 2 300 >100
(181) c o 2h 350 >100
(182) CN 170 78
(183) C(NH2)=C(CN)2 4.7 55
(184) C02Me 250 16
(185) C02Et 330 n.d.
(186) C02a?Bu 275 22
(187) C02 B^u 325 1.6
(188) c o n h2 140 49
(189) c s n h 2 38 41
(190) c o 2h 380 >100
Table 10 Details of the assays are given in Chapter 7 
(reproduced by kind permission of the authors of reference 180).
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Quinolines undergo nucleophilic attack at positions 2- and 4-, which are the 
most electropositive centres on the ring (Figure 18). Taylor used a method 
involving the pyrolysis of 1-(x-quinolyl)ethyl acetate to obtain direct 
measurements of the electrophilic reactivity at position x.182 He concluded that 
the order of reactivity to electrophilic attack was
N > 5 > 8  = 6 > 3 > 7 » 2 > 4
Figure 18
4-Substituted quinolyl tyrphostins are significantly more potent than the 2- or 3- 
substituted drugs. There is a clear structure-activity relationship (SAR) between 
the position of the sidearm relative to the ring and the electronegativity at that 
position.
In order to extend the evidence for the SAR, we considered it essential to 
synthesise a series of quinolyl tyrphostins. These were prepared from the 
appropriate methyl quinoline using the method outlined in Section 4.2. We 
would expect the 7-substituted compounds to have a slightly greater biological 
activity than the equivalent 3-substituted derivatives. The 6- and 8-substituted 
derivatives would be expected to have similar activities to each other, but 
should be substantially less active than the other compounds.
4.2 Synthesis of 6-, 7- and 8-quinolinecarbaldehyde
There have been many publications concerning the oxidation by selenium (IV) 
oxide (191) of aromatic methyl groups, and several reviews are devoted to this 
subject.183-185 In 1972, the mechanism of these oxidations was clarified186 and 
improvements to the experimental procedure have since been possible.
^OH 0  © ^X
0 = S e = 0  + R -O H  *-0=Se =  0=Se ► 0~Sex
OR Y Y
(191) (192)
Scheme 27
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In the presence of a hydroxylated solvent such as water, alcohol or carboxylic 
acid, the reagent is in fact the selenious acid, an alkyl selenite or a mixed 
anhydride (192) (Scheme 27). It is understood that the oxidation is in fact a 
three-step process. Owing to the basic character of the oxygen atom linked to 
the selenium atom, the reagent undergoes an ene reaction with the substrate 
(193) to give (194). A [2,3]-sigmatropic rearrangement leads to a Se (II) ester
(195) which is either hydrolysed, as a selenenate, to give the allylic alcohol
(196), or decomposes to give the enone (197) (Scheme 28).
H^L-FT
' W ( T
® S e ( ^ V  
X Y
(193)
ene
reaction
OHi
Se, 
X ' '
Y
R> R
XSe
(194)
H2 O or 
ROH
(195)
-HY
R = H 
-Se, -HX
© -  R.
x & >
[2,3] 
sigmatropic 
rearrangement
HO. P,R R
(196) (197)
Scheme 28
Tadros et al reported the syntheses of 5-, 6-, 7- and 8-chloro- and 5-, 6-, 7- and 
8-nitroquinolinacrylic acids from the corresponding aldehydes.187 These had 
been prepared from the corresponding methylquinoline in moderate yields using 
Se02 as the oxidant.188 Similarly, Johnson and Hamilton189 had earlier reported 
the synthesis of 8-nitro-4-quinolinecarbaldehyde using this methodology.
There are, of course, other reagents which may be employed for the oxidation 
of methylaromatics. The use of chromic acid,190 alkaline permanganate,191 
potassium hydrogen persulfate,192 ruthenium tetroxide193 and other reagents 
has been widely reported. The advantage of Se02 over these reagents is that 
the position of the methyl group and the additional presence of other functional 
groups appears to have little effect upon the yield of the reaction. The products 
of the reaction are also easily isolated by filtration followed by recrystallisation.
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4.2.1 Synthesis of 6-Quinolinecarbaldehyde (198)
This was prepared by treating 6-methylquinoline neat with Se02 at reflux for 90 
minutes. As an added precaution, the reaction vessel was covered with 
aluminium foil since the starting material was light-sensitive. Initiation of the 
reaction was indicated by an exotherm, which raised the temperature to 210 °C. 
The evolution of heat was allowed to subside before heating at reflux (140 °C) 
was continued. Thin layer chromatography was employed to check for the 
presence of the starting material, which had an Rp value of 0.60 compared to 
0.38 for the product. After 90 minutes, no starting material was present; 
however some polymerisation was noted by the presence of some dark 
baseline material on the TLC. The most effective method for removing the 
product from selenium metal residues was by filtration through Celite, which 
also had the added advantage of making the toxic metal residues easier to 
handle for disposal. The product was then purified by column chromatography 
followed by recrystallisation.
The 1H NMR spectrum of (198) (Figure 19) possessed a deshielded singlet at 
6 10.09 arising from the aldehydic proton, and a set of signals in the aromatic 
region between 6 8.95-7.42. Some of these signals could be assigned (Table 
11) whilst the remaining signals for the protons on C-4, C-5, C-7 and C-8 came 
as a multiplet in the middle of this group at 5 8.25-8.04. In the 13C NMR 
spectrum, each signal was easily assigned. No signal for a methyl group at 
8 19.2 in the 13C NMR spectrum or at 8 1.19 in the 1H NMR spectrum was 
observed.
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(198)
Ring Position 8h 8c
2 8.95, d, 3j  4.28 Hz 153.0
3 7.42, dd, 3J 8.34, 4.28 Hz 122.1
4 8.25-8.04, m 133.6
5 8.25-8.04, m 130.7
6 - 134.2
7 8.25-8.04, m 126.6
8 8.25-8.04, m 137.4
9 - 127.6
10 - 150.7
CHO 10.09, s 191.4
Table 11
The IR spectrum of (198) contained absorbances for the main functional 
groups, namely a carbonyl stretch at 1692 cm-1, signals arising from aromatic 
bonds at 1623, 1575 and 1501 cm'1 and two sharp absorbances at 838 and 
801 cm-1 from out-of-plane aromatic C-H bends. In the mass spectrum, the 
molecular ion came as the largest peak at m/z 157, with a signal corresponding 
to loss of the aldehyde group at m/z 128.
4.2.2 Synthesis of 7-Quinolinecarbaldehyde (199)
The starting material was commercially available from Lancaster as a mixture of
5- and 7-methylquinoline in a 30:70 ratio. Since the boiling points and R f 
values of these compounds were very similar, we decided to treat the mixture 
with selenium (IV) oxide and then purify the oxidation products. Using the 
procedure outlined in Section 4.2.1, heating the methylquinolines with Se02 at 
70 °C resulted in a strong exotherm which raised the temperature to ca. 120 °C. 
When this had subsided, heating at 70 °C was continued for 5 hours until TLC 
showed the absence of starting materials. Extraction of the products and 
concentration gave an orange oil, which was purified by column 
chromatography to give 7-quinolinecarbaldehyde (199) as the major product. A 
minor impurity was tentatively assigned to 5-quinolinecarbaldehyde from similar 
Rf value to (199).
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CHO
(199) (200)
The 1H NMR spectrum of (199) showed a very deshielded singlet at 8 10.16 for 
the aldehydic proton. The carbonyl carbon in the 13C NMR spectrum was not 
observed even when the experiment was run overnight, although a signal for an 
aldehydic carbonyl stretch was observed as a strong absorption at 1690 cm-1 in 
the IR spectrum. Other signals at 3022, 840 and 807 cm-1 arose from aromatic 
C-H bond vibrations, and were accompanied by a set of three signals of 
medium intensity corresponding to an aromatic system at 1623, 1572 and 1502 
cm-1. The largest signal in the mass spectrum corresponded to the molecular 
ion at m/z 157, with a signal at m/z 128 for loss of the aldehyde from the parent 
molecule.
4.2.3 Synthesis of 8-Quinolinecarbaldehyde (200)
8-Methylquinoline and Se02 were reacted in much the same manner as 
previously, although the reaction time was extended to 22 hours, after which 
there still remained a considerable quantity of starting material. When the 
reaction was repeated with up to two equivalents of Se0 2 , the same effect was 
observed. Although the Se02 appeared to be pure (an off-white crystalline 
solid), it was purified by sublimation194 and the reaction was repeated using one 
equivalent over the same period of time as before, but this did not give a 
marked increase in the yield (13%, as opposed to 11% before sublimation). The 
product (200) was isolated from the starting material by filtration and purification 
by column chromatography.
The most distinguishing features in the 1H and 13C NMR spectra were the 
signals corresponding to the aldehyde moiety. The presence of this functional 
group was further confirmed by IR spectroscopy, where a sharp absorption at 
1709 cm-1 was observed. Unlike the mass spectra of the other two quinoline 
carbaldehydes, only a very small signal was observed for the molecular ion, 
although larger signals corresponding to fragmentation of the parent molecule 
were present.
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4.2.4 Use of Oxidants to Regenerate Se02
We were concerned about the generation of highly toxic selenium metal 
residues from these reactions. Sharpless reported195 that such reactions can 
also be accomplished using toutyl hydroperoxide to oxidise Se(OH)2  or 
selenium metal, which need only be present in catalytic amounts. However, 
significant amounts of side-products are formed when the double bond is in a 
ring system.196 An alternative oxidant is 4-methylmorpholine-A/-oxide, but when 
we attempted to repeat the above reactions using this reagent in the presence 
of a catalytic amount of Se02, the yields fell dramatically (from 57% to 15% in 
the case of 7-quinoline carbaldehyde (199)).
4.3 Synthesis of 6-Quinolyl Tyrphostins
These were prepared in the usual manner by Knoevenagel condensation of
6-quinolinecarbaldehyde (198) with a number of malonate derivatives (Scheme 
29 and Table 12). As with these and other quinolyl tyrphostins, solubility 
problems prevented recrystallisation from organic solvents, but the products, 
which were normally powders, were pure by microanalysis and accurate mass 
spectrometry.
OHC
(198)
<
R
CN
(89-93)
and
(95-97)
Base (cat.)
(201-208)
Scheme 29
R No. Base No. Yield (%)
CN (89) - (201) 90
C(NH2)=C(CN)2 (90) dilute piperidine (202) 89
C02Me (91) - (203) 61
C02Et (92) - (204) 47
C02nBu (93) piperidine (205) 45
C02(TEG)0Me (95) piperidine (206) 63
c o n h 2 (96) piperidine (207) 58
c s n h 2 (97) - (208) 88
Table 12
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Compound (201) was previously reported in a patent for electrophotographic 
photoreceptors,197 although no characterisation of this compound was noted. In 
the 1H NMR spectrum (Figure 20), the most deshielded signal came at 8 9.09 
as a broad doublet of doublets with couplings of 4.21 and 1.47 Hz. This signal 
corresponded to the proton in the 2-position on the quinoline ring. The 
couplings arose from an interaction with the protons in the 3- and 4-positions, 
which came as another doublet of doublets at 8 7.70 and a very broad signal at 
8 8.54, respectively. The protons in the 5- and 7-positions came as very broad 
doublets at 8 8.21 and 8.32; the broadening of these signals may be a result of 
additional coupling with the proton in the 8-position, which was assigned to a 
very broad signal at 8 8.57. These data are summarised in Table 13.
The 13C NMR spectrum (Figure 21) consisted of a signal at 8 160.7 (CH) and 
one at 8 82.6 for the olefinic carbons, accompanied by 9 signals between 8 154 
and 8 123 for the aromatic carbons and two singlets at 8 114.3 and 112.2 for 
the nitrile groups. The IR spectrum contained the expected signals at 1617, 
1577 and 1500 crrr1 for the aromatic ring, accompanied by other signals at 
3034 cm-1 (aryl C-H), 2224 cm-1 (CN) and at 833 and 794 cm-1 (2 adjacent and 
3 adjacent out-of-plane aryl C-H bends). The molecular ion was observed in the 
mass spectrum and signals corresponding to loss of fragments of the sidearm 
from the parent molecule were also present.
The derivative formed from malononitrile dimer, (202), displayed two broad 
singlets at 8 9.28 and 8 9.18 in its 1H NMR spectrum corresponding to the -NH2 
protons. The olefinic proton came at 8 8.26, whilst signals for the nitrile carbons 
were observed at 8 115.6, 114.9 and 114.7 in the 13C NMR spectrum. In the IR 
spectrum, signals for out-of-plane aromatic C-H bends came at 826 and 
794 cm-1, with a vibration resulting from a C=C bond at 1656 cm-1. The 
molecular ion came at m/z 271 in the mass spectrum.
Tyrphostins possessing an ester group in the sidearm, (203-206), all displayed 
characteristic signals in the 1H and 13C NMR spectra. The IR spectra contained 
characteristically sharp absorptions around 1720 cm-1 arising from carbonyl 
stretches in an ap-unsaturated system, accompanied by signals corresponding 
to aryl C-H stretches and bends. In all cases the molecular ion and signals 
corresponding to loss of fragments of the ester moiety were observed in the 
mass spectra.
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Figure 20
(201)
Position 8h Multiplicity Coupled to
3 8.73 s -
2 9.09 br dd 3' and 4'
3 7.70 dd 2' and 4’
4' 8.54 v. br 2' (and 3?)
S 8.21 v. br d T  (and 87)
7 8.32 v. br d 8' (and 77)
8' 8.57 v. br T  (and 57)
Table 13
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Compounds (207) and (208) were then synthesised. No catalytic amount of 
base was required in the preparation of the latter, and the products precipitated 
from solution within 15 minutes. Attempts to recrystallise the products from ethyl 
acetate were unsuccessful, although microanalysis confirmed their purity. 
Broadening of most of the signals in the aromatic region of the 1H NMR spectra 
was observed, although doublets of doublets at 5 8.39 (207) and 7.65 (208) 
were assigned to the protons in position 3 of the quinoline rings. Two singlets 
around 5 7.8 for the amide and 5 9.8 for the thioamide were assigned to the 
-NH2 protons. A singlet corresponding to the carbonyl or thiocarbonyl carbon 
was not observed in the 13C NMR spectra, although sharp absorptions at 1699 
cm-1 were assigned to a C=0 stretch for (207). Other signals in the 13C NMR 
spectra could be assigned to the remaining carbons in the compounds. The 
molecular ions were accompanied by signals at m/z 179 for loss of -CXNH2 
from the parent molecules.
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4.4 Synthesis of 7-Quinolyl Tyrphostins
These were all prepared in moderate to good yield in the usual manner 
(Scheme 30 and Table 14).
OHC
(199)
<
R Base (cat.)
CN
(89-93)
and
(95-97)
(209-216)
Scheme 30
R No. Base No. Yield (%)
CN (89) - (209) 79
C(NH2)=C(CN)2 (90) - (210) 86
C02Me (91) piperidine (211) 46
C02Et (92) piperidine (212) 67
C02nBu (93) piperidine (213) 42
C02(TEG)OMe (95) piperidine (214) 78
CONH2 (96) piperidine (215) 73
c s n h 2 (97) - (216) 45
Table 14
2-Cyano-3-(7-quinolyl)propenonitrile (209) was the first tyrphostin to be 
prepared in this series. The starting materials reacted within one minute and 
without the addition of base to give the product as a beige solid in good yield. In 
the 1H NMR spectrum a total of three doublets of doublets, two doublets and 
two singlets were observed. The three dds corresponded to the protons in the 
2-, 3- and 6-positions on the ring, coming at 6 9.06, 7.73 and 8.11 respectively. 
The doublets at 5 8.49 and 8.21 were from the protons in positions 4 and 5, 
whilst singlets at 5 8.63 and 8.75 corresponded to the proton on position 8 and 
the olefinic proton. The 13C NMR contained signals at 8 161.0 (CH) and 83.3 for 
the olefinic carbons and two singlets at 5 114.2 and 113.2 for the nitrile groups. 
The IR spectrum did not give a great deal of information, although a sharp peak 
at 2228 cm-1 arose from two nitrile groups and signals were also observed for 
aromatic bonds and for aromatic C-H stretches and bends. The molecular ion 
was the largest signal in the mass spectrum, and was observed at m/z 205.
The 1H NMR spectrum of (210) did not differ substantially from that of (209) 
except for the presence of two singlets at 8 9.30 and 9.25 for the -NH2 protons.
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Three signals for the nitrile carbons came at 8 115.6, 114.9 and 114.7 in the 
13C NMR spectrum, and additional signals at 8 165.4 and 103.6 were assigned 
to quaternary olefinic carbons. The more deshielded of these two corresponded 
to the terminal olefinic carbon bearing two nitrile groups. More information was 
obtained from the IR spectrum, since signals at 2366 and 1667 cm-1 were 
attributed to an N-H bend and a C=C in conjugation with an aromatic system. 
Absorptions arising from a nitrile group, and from aromatic C-C and C-H bonds 
were also observed. The molecular ion was accompanied by signals at m/z 245 
for loss of one nitrile and at m/z 206 for loss of two nitriles and one carbon from 
the parent molecule in the mass spectrum.
Methyl 2-cyano-3-(7-quinolyl)propenoate (211) was then prepared. A yellow 
precipitate formed after one minute, and TLC showed the formation of a polar 
material with R f 0.23. The yield for this reaction was fairly low at 46 % and 
despite repeated attempts at various temperatures and using other bases such 
as pyridine, this yield could not be increased. The 13C NMR spectrum 
contained a deshielded signal at 8 159.3 for the carbonyl carbon, whilst the 
methyl group on the ester came at 8 54.0 (and at 8 3.95 in the 1H NMR 
spectrum, which also contained a singlet at 8 8.76 from the olefinic methine 
proton). The IR spectrum had a sharp absorption at 1727 cm-1 arising from an 
ap-unsatu rated carbonyl stretch, a weak signal at 2219 cm-1 from a nitrile 
group, and weak signals at 833 and 780 cm'1 from two and three adjacent 
aromatic C-H out-of-plane bends. The largest signal in the mass spectrum 
corresponded to the molecular ion, and signals at m/z 223, 207 and 179 arose 
from loss of a methyl, a methoxy and a methyl ester moiety, respectively.
The NMR spectra of the ethyl (212) and ^butyl (213) esters differed only in 
respect to the signals for the alkyl groups, which were observed as signals with 
the chemical shifts and multiplicity consistent with those expected. 
ap-Unsaturated carbonyl stretches at around 1720 cm'1 and signals around 
1600 cm-1 for an aromatic system were observed in the IR spectra. Additional 
signals arising from out-of plane aryl C-H bends came at -830 and -770 cm-1. 
Both compounds gave signals for the molecular ion in their mass spectra.
Preparation of the tri(ethyleneglycol) ester derivative (214) required a slightly 
longer reaction time of one hour to give the product, which was a brown oil at 
room temperature. The aromatic region of the 1H NMR spectrum was very 
similar to that of the other ester derivatives, and a broad multiplet of relative 
intensity 12 between 8 3.62-2.92 was assigned to the six groups of methylene 
protons. The 13C NMR spectrum had six signals between 8 71.8-57.7 for these 
groups, and the terminal methyl group was at 8 1.09 in the 1H spectrum and at
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8 18.3 in the 13C NMR spectrum. In the IR spectrum, signals consistent with 
functional groups in this molecule were assigned. Of particular note were two 
signals at 1452 and 730 cm-1 arising from C-H deformations and a -CH2- 
rocking, and another at 2878 cm-1 from an O-CH3 vibration. The molecular ion 
came as a signal at m/z 371 in the mass spectrum. A signal at m/z 251 
corresponded to loss of (OCH2CH2)2 0 CH3 , whilst one at m/z 207 arose from 
the loss of (0 CH2CH2 )3 0 CH3 and a hydrogen from the molecular ion.
The synthesis of 2-cyano-3-(7-quinolyl)propenamide (215) required the 
presence of piperidine, whereas 2-cyano-3-(7-quinolyl)propenthioamide (216) 
did not. Signals arising from the -NH2 protons were seen between 8 10.13 and 
9.81 in the 1H NMR spectra of the products, and the olefinic proton was seen at 
8 8.73 in the spectrum of (216). A complex multiplet in the 1H NMR spectrum of 
(215) was assigned to the aromatic and olefinic protons. In the 13C NMR 
spectra, the carbonyl and thiocarbonyl carbons came at 8 168.8 and 172.1. 
Signals for the olefinic carbons were observed in both these spectra. Amide and 
thioamide N-H stretches were observed in the IR spectra, whilst C=0 and C=S 
vibrations came as sharp absorptions at 1690 and 1123 cm'1. The molecular 
ions were observed in the mass spectra at m/z 222 and 239, respectively.
4.5 Synthesis of 8 -Quinolyl Tyrphostins
The final set of quinolyl tyrphostins was prepared as before (Scheme 31 and 
Table 15).
R Base (cat.)
CN
CHO
(89-93)
Rand
(200) (96-97) (217-223)
Scheme 31
95
CN NC —^
R
R No. Base No. Yield (%)
CN (89) piperidine (217) 28
C(NH2)=C(CN)2 (90) (218) 78
C02Me (91) piperidine (219) 60
C02Et (92) piperidine (220) 27
C02nBu (93) piperidine (221) 28
c o n h 2 (96) dilute piperidine (222) 92
c s n h 2 (97) dilute piperidine (223) 49
Table 15
The derivatives (217 and 218) made from malononitrile monomer (89) and its 
dimer (90) were the first to be prepared. The 1H NMR spectra contained 
singlets corresponding to the olefinic proton at ca 8 8.5, with two additional 
singlets at 8 9.31 and 9.25 for the -NH2 protons on (218). Signals 
corresponding to the nitrile moieties came at -8 115 in the 13C NMR spectra. 
The IR spectra each contained absorptions corresponding to aromatic C-H 
stretches at -3050 cm-1, out-of-plane C-H bends around 800 cm_i and a C=C 
bond conjugated to an aromatic system at 1620 cnrr1. The IR spectrum of (218) 
contained an additional sharp signal at 2208 cm_i which was attributed to the 
three nitrile groups. Molecular ions were observed in the mass spectra.
Tyrphostins containing methyl (219), ethyl (220) and nbutyl (221) ester groups 
on the sidearm were then synthesised. Each required the addition of a catalytic 
amount of piperidine, and the methyl and ethyl esters were isolated as yellow 
solids within one hour, whereas the nbutyl ester product took almost a full day to 
precipitate from solution, and even after this time the yield was low. However, 
microanalysis of the products confirmed their purity. The aromatic regions of the 
1H and 13C NMR spectra were similar, and the alkyl fragments of the ester 
gave characteristic upfield signals and multiplicities. The IR spectra contained 
the usual signals consistent with this type of compound, namely carbonyl 
stretches at -1710 cm-1 (indicative of an ap-unsaturated C=0), aromatic C-C 
vibrations at 1580 and 1520 cm-1, C=C conjugated to an aromatic system at 
-1620 cm-1 and aromatic C-H stretches and bends coming at 3064 and 
804-802 cm-1. Although no signal around 2220 cm-1 from a nitrile stretch was 
observed in any of these spectra, all of the 13C NMR spectra possessed
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singlets around 8115 corresponding to this moiety. Mass spectra contained 
somewhat small signals corresponding to the molecular ions.
We then attempted a synthesis of the tri(ethyleneglycol) ester derivative using 
standard conditions. Tri(ethylene glycol) cyanoacetate methyl ether (95) was 
treated with 8 -quinolinecarbaldehyde (200) and piperidine, but no product was 
noted after several hours mixing. Sequential addition of pyridine, K2 CO3 and 
triethylamine to the reaction failed to give any product, and when KF was 
added, a black tar formed instantly. It is clear that the choice of base is of 
extreme importance for this reaction, but we were unable to identify an 
appropriate base to be used for the synthesis of this compound.
The series was completed with the syntheses of the amide and thioamide 
derivatives (222 and 223). Extended reaction times of up to 24 hours and the 
use of piperidine was required, and the products were isolated in good yields. 
The -NH2 protons were observed in each 1H NMR spectrum, and the carbonyl 
and thiocarbonyl carbons came at 8 168.2 and 170.1 respectively in the 13C 
NMR spectra. Aromatic C-H stretches and bends (-3060 and 800 cm’1), nitrile 
stretches (-2200 cm'1), C=C conjugated to an aromatic system 
(1618-1606 cm-1) and N-H stretches at 3400-3300 cm-1 were observed in both 
IR spectra, and the IR spectrum of (222) also contained an absorption of 
medium intensity at 3058 cm-1 for an amide N-H stretch. The molecular ion was 
observed in both the mass spectra.
4.6 Nitroquinolinecarbaldehydes
As a continuation of our investigation of potential bioreducible tyrphostins, we 
considered it desirable to undertake a synthesis of a 
nitroquinolinecarbaldehyde. Earlier synthetic methods involving the oxidation of 
2- or 4-methylquinolines which had a nitro substituent in the 5-, 6 -, 7- or 
8 -position had been reported, 187,189 anc| we wished to develop this work 
further to investigate similar systems.
NO-
H,C
CH
(224) (225)
" Y ^ n ^ c h 3 
n o 2
(226)
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Several methylnitroquinolines such as (224-226) are commercially available. 
Following existing methodology, we attempted to oxidise the methyl group on 
these compounds using Se02-188 Each compound is a solid at room 
temperature, so these compounds were dissolved in dioxan before addition of 
SeC>2 . Despite repeated attempts, no reaction was observed after several 
hours. We then tried using toluene or xylene as solvent to allow an increase in 
the reaction temperature, but again no reaction was observed except for 
8-nitro-2-methylquinoline, where the product (227) was isolated in 53 % yield 
when toluene was used. The 1H NMR spectrum contained a deshielded signal 
at 5 10.11 for the aldehyde, which was also seen in the 13C NMR spectrum at 
5 192.8. No signals corresponding to the methyl group were observed in either 
of these spectra. The IR spectrum had a sharp signal from a carbonyl stretch at 
1716 cm-1.
A second method involving the route shown in Scheme 32 was also attempted 
to introduce an aldehyde moiety a to the nitro group.198 Reaction of the 
nitroquinoline with the nitromethane anion generates the a-nitromethyl species 
such as (229), which can then be oxidised using Nef methodology.199 The 
overall process can be considered as a nucleophilic formylation of the 
nitroquinoline in which the nitromethyl anion serves as a formyl anion 
equivalent.
N02
(227)
. CH3 NO2 , NaOH _
DMSO, -78 to 25 °C OoN
n o 2 n o 2
(228) (229)
Base, KMnO* 
Borate Buffer
NO
(230)
Scheme 32
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We attempted the first step using the methods employed by Danikiewicz and 
M^kosza198 when they introduced a nitromethyl group onto 1-nitronaphthalene 
or 8-nitroquinoline. When a solution of 8-nitroquinoline (228) in DMSO was 
treated with a solution of nitromethane and sodium hydroxide (two equivalents) 
in DMSO at 0 °C, a red colouration of the mixture occurred instantly, and TLC 
revealed the presence of two very faint new spots (visible only by UV) with Rf 
0.38 and 0.32 accompanied by spots corresponding to starting material at Rf 
0.53 and baseline material, and even after several hours the intensity of these 
new spots did not increase. It was assumed that these corresponded to the 
ortho-product and some of the para-isomer, and so the reaction was 
terminated, and the excess NaOH was neutralised using acetic acid. 
Purification of the products by column chromatography over silica was 
attempted, but the only material to be isolated was starting material 
accompanied by a substantial amount of baseline material. We then repeated 
the reaction at a variety of temperatures (between -78 °C and room 
temperature), but the same result was observed.
Normally the rate-determining step of this reaction is the addition of the 
nitromethyl anion to the aromatic species, forming a pseudo Meisenheimer salt 
such as (231). These are generally stable and some have been isolated, and a 
number of studies have been performed on these salts which have shown that 
the presence of additional nitro moieties on the aromatic system is generally 
associated with increased stability.200 Whilst no reports of Meisenheimer salts 
based upon a quinoline moiety have been reported, Terrier showed that for 
nitronaphthyl and nitropyridyl Meisenheimer salts, stability was increased with 
additional nitro moieties irrespective of their position relative to the first nitro 
group 200
OoN
Scheme 33
OoN- CH
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In this case, it appears that the presence of a second extra-annular nitro group 
confers stability to the intermediate. This would account for the presence of 
baseline material. In this instance, the first step may not be rate-limiting, and the 
second step could be slower, accounting for the fact that no product was 
observed.
4.7 Aminoquinolinecarbaldehydes
In order to improve water solubility of our compounds, we decided to attempt to 
synthesise a number of quinolinecarbaldehydes which possessed an amino 
group. Compounds (232) and (233) were reduced using hydrazine 
monohydrate (Scheme 34) in the presence of a catalytic amount of graphite 
powder.201 It has been proposed that under these conditions, molecular 
hydrogen is adsorbed onto the surface of the graphite,202 although it is 
generally accepted that reductions of nitro groups by Sn/HCI involves an 
electron transfer process. Signals arising from the -NH2 moieties were observed 
in the 1H NMR and IR spectra of these products. We then treated either of the 
amines (234 or 235) or its HCI salt (236 or 237) with SeC>2 in the usual manner, 
but in each case no reaction was observed.
OoN h3 h 2n
H2 NNH2 .1 H2 Q  rf 
graphite 
A
CHO
Ethereal HCI
n h 3+ ch3
(236) 6- 2-
(237) 5- 6-
Scheme 34
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4.8 Synthesis of 8-Nitro-2-Quinolyl Tyrphostins
8-Nitro-2-quinoline carbaldehyde (227) was the only nitroquinolinecarbaldehyde 
that we could prepare. For comparison with the most active 2-quinolyl 
tyrphostins which were previously reported,180 we decided to prepare the 
derivatives (238) and (239) from malononitrile (89) and its dimer (90) (Scheme 
35 and Table 16).
Base (cat.)  ► CN
CNCHO
(227) (88-89) (238-239)
Scheme 35
R/ / V N  cn
<
CN
n o 2
R No. Base No. Yield (%)
CN
C(NH2)=C(CN) 2
(89)
(90)
dilute piperidine
00 
O
) 
CO 
CO 
CM 
CM
69
30
Table 16
Both products were identified firstly from their 1H NMR spectra, which differed 
from the starting material by the presence of a deshielded singlet at ~8 8.3 for 
the olefinic proton, whilst the spectrum of (239) also contained two slightly 
broad singlets at 8 8.36 and 8.31 from the NH2 protons. Nitrile signals came 
between 8 116 and 113 in the 13C NMR spectra. C-NO2 and nitrile stretches 
were observed in the IR spectra, and were accompanied by signals 
corresponding to aromatic C-H stretches and bends.
4.9 Conclusions
We have been able to develop a synthetic route to give series of 6 -, 7- and 
8 -substituted quinolyl tyrphostins which involves oxidation of the equivalent 
methylquinoline using Se0 2 - We were unable to modify the reactions by adding 
an oxidant to reoxidise the selenium and thereby reduce the production of 
highly toxic selenium metal residues, but recovery of the metal was complete 
and therefore could be reoxidised separately for repeated use. When the 
aromatic ring was modified by including either a nitro group or an amino moiety,
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this methodology failed except for one instance, where a quantity of 
8 -nitro-2 -quinolinecarbaldehyde was isolated and was subsequently treated 
with monomeric or dimeric malononitrile to give two nitroquinolyl tyrphostins.
The 25 quinolyl tyrphostins synthesised have been submitted for biological 
testing in cancer cells which have a high concentration of the EGF receptor. 
The measurement of the reduction potentials of compounds (238) and (239) are 
discussed in Chapter 6 .
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5. Attempted Synthesis of 
 an ADEPT Prodrug
5.1 Introduction
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) is a new approach which 
delivers potent anticancer agents to cancer cells. The patient is exposed to a 
monoclonal antibody-enzyme conjugate (AEC) which recognises surface 
antigens unique to the cancer cells before a prodrug is administered. The 
prodrug is hydrolysed by the AEC, and decomposes to release the active drug. 
The advantages of this approach are numerous (see Chapter 2 ).
A prodrug (240) containing an L-glutamate moiety was chosen since a suitable 
antibody-enzyme conjugate containing carboxypeptidase G2 (CPG2 ) was 
available. This enzyme hydrolyses amide bonds adjacent to an L-glutamic acid 
residue154- 155 (see Scheme 7 in Chapter 2). We intended to link a tyrphostin 
through an aromatic spacer to the glutamate, which is essential for recognition 
by the enzyme. It was anticipated that the prodrug would also act to increase 
the solubility of the tyrphostin fragment. Cleavage of the amide bond by the 
enzyme would result in the release of a free electron pair which would assist in 
the breakdown of the compound, and would subsequently release the drug 
(Scheme 35). Sutherland203 had previously reported the synthesis of an 
ADEPT prodrug fragment consisting of a glutamic acid attached to the aromatic 
spacer by a carbamate linkage, but we decided to attempt to join these groups 
via a urea linkage. This was chosen because of its stability and apparent ease 
of synthesis. It was also vital for us to choose tyrphostins which showed an 
acceptable degree of growth and/or tyrosine kinase inhibition (see Chapter 6 ), 
and which possessed functional groups which could be easily adapted to attach 
the drug to the spacer unit in the ADEPT prodrug. We therefore chose 
compounds (141) and (144), in which the carboxylic acid moiety could be 
utilised to form either an ester or amide bond with the spacer group. However, 
as will be seen in Chapter 6 , the biological activity of these compounds was 
much lower compared to other tyrphostins which had been synthesised. This
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may be attributed to the low lipid solubility of carboxylate anions. The strategies 
discussed in this Chapter were therefore employed to develop the chemistry of 
synthesising prodrugs for ADEPT rather than to make a viable prodrug for use 
in this therapeutic approach.
When the glutamic acid is cleaved from the parent molecule (240) which has 
the tyrphostin moiety attached by an ester linkage, electrons should be donated 
from the resulting carbamate (241) to assist in the release of the drug. The 
breakdown products would be the tyrphostin carboxylate anion (243), an 
iminoquinone methide (244) which may itself display toxicity by reacting with 
cellular nucleophiles such as glutathione,204 and one mole of carbon dioxide.
CN
COoH
HN
(242)
(241)
CN
HN COpH
O C 02H
O
0 t V o N° 2 +
+ COc
CN S' 
(243)
NH
(244)
Scheme 35
5.2 Retrosynthetic Analysis of the Prodrug
Disconnection of compound (240) at the urea linkage with the glutamate portion 
and at the ester linkage with the tyrphostin gives the drug fragment as an acid 
chloride (245), 4-aminobenzyl alcohol (246) and L-glutamic acid (242) (Scheme 
36). General methods were sought which could be utilised to produce either the 
carbamate or ester linkages between these subunits. One possibility is the
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reaction of an acid chloride (247) with an alcohol (248) to generate an ester 
(249), and the treatment of an amine (250) with an isocyanate (251) to form a 
urea (252) (Scheme 37).
CN
a I /  jl
.o. ^ n o 2
o  c o 2h
(240)
c o 2h
COCI
CN
(245)
OH
(246) 
Scheme 36
R -C O C I + H O -R '
(247) (248)
H2N - R  + R-NCO 
(250) (251)
- R -C 02- R  + HCI
(249)
o
- r - n ^ n - r
H H (252)
Scheme 37
5.3 Synthesis of the Specifier Fragment
Protection of L-glutamic acid (242) as its di-^butyl ester (255) was carried out in 
the manner shown in Scheme 38. A/-Benzyloxycarbonyl-L-glutamic acid (253) 
was treated with isobutylene and a few drops of concentrated H2SO4 in DCM in 
a sealed vessel using standard procedures.205 The progress of the reaction
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could be easily monitored since the product was much more soluble in DCM 
compared to the starting material, and after 96 hours all of the starting material 
had disappeared. The product was isolated as an amber oil in good yield, but a 
considerable amount of polymeric material was also observed. When the 
procedure was repeated using a single drop of conc. H2 SO4 , the reaction time 
had to be extended (10  days) and no noticeable increase in yield was observed.
Cbz
COoH
>=
C02H c. H2 S0 4  (cat)
DCM, 25 °C 
69%
54 % overall yield
Cbz
C02'Bu
C02'Bu
(254)
h2
Pd\C
MeOH
78%
HoN
C02 Bu
C02fBu
Scheme 38
In the 1 H NMR spectrum of the Cbz-protected diester (254), a broad singlet 
corresponding to the two toutyl groups was observed. The presence of these 
groups was corroborated in the 13C NMR spectrum by signals for two fbutyl 
groups in magnetically distinct environments. No signals corresponding to an 
OH stretch or bend from the starting material was observed in the IR spectrum. 
The mass spectrum of (254) contained a signal for the molecular ion at m/z 
393, and the product also gave acceptable microanalytical data.
Hydrogenolysis of the protected amine was carried out using palladium on 
carbon.206 Contrary to Sutherland's findings,203 we did not experience any 
difficulties when the reaction was carried out in methanol, and the product (255) 
was isolated as a yellow oil after a reaction time of 24 hours at room 
temperature. The product was characterised by 1H and 13C NMR spectroscopy, 
which did not show downfield signals in the aromatic region corresponding to 
the Cbz group. The signals associated with the aromatic ring of (254) were 
absent in the IR spectrum of (255).
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5.4 Synthesis of the Spacer Section
Our initial target molecule (240) contained a spacer unit derived from 
4-aminobenzyl alcohol (246). Since we were unsure as to whether the spacer 
or glutamic acid would be converted into an isocyanate, it was necessary to 
protect the alcohol group on (246) as a tertiarybutyldimethylsilyl (TBDMS) ether 
(256) using standard procedures (Scheme 39).207 Other protecting groups, 
such as trimethylsilyl ethers were discounted owing to their instability under 
basic conditions,208 and Sutherland had unsuccessfully attempted to protect 
using triisopropylsilyl (TIPS) triflate and lutidine to generate the TIPS ether203 
4-Aminobenzyl alcohol (246) was treated with TBDMSCI and imidazole in a 
solution of dry DCM, to give the product (256) as a clear oil in high yield after 
distillation. The 13C NMR spectrum of (256) contained a very highfield signal 
(8 -5.0) corresponding to the methyl groups directly attached to the silicon. Si-0 
stretches were observed at 1110 cnr1 in the IR spectrum, and the molecular ion 
and a signal corresponding to loss of OTBDMS from the parent molecule were 
observed in the mass spectrum.
OTBDMSOH
TBDMSCI,
imidazole
DCM, 25 °C 
85%
(246) (256)
Scheme 39
5.5 Coupling the Spacer Subunit to the Drug
It would be possible to attach a tyrphostin such as (141) via an ester linkage to 
the spacer unit, or by an amide bond. When the glutamate residue is 
hydrolysed by CPG2 , an intermediate such as (241) would be formed, and this 
would decompose in the manner shown (Scheme 35) to release the drug.
5.5.1 Ester Linkage
Carbonyldiimidazole (CDI) (257) has been employed as a coupling agent in the 
formation of esters from benzoic acid or ap-unsaturated carboxylic acids which 
had an aromatic or heteroaromatic group in the p position 209 When 2-cyano-3- 
[2-(5-nitrothienyl)]propenoic acid (141) was dissolved in dry DMF and was then
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treated with CDI (257), we observed an immediate colour change which implied 
formation of an A/-acylimidazole intermediate (258). Addition of benzyl alcohol 
(259) and DBU (which was previously shown to accelerate the reaction rate of 
this type of reaction209) and stirring at room temperature for an extended period 
of 43 hours gave a brown solid which was shown to consist of a mixture of 
starting materials by NMR spectroscopy. The procedure was repeated either at 
80 °C, 120  °C or at reflux temperature, but in each case the same result was 
observed.
O
j ^ N ^ I
(257)
OoNOoN
COoH
NCNC
(141)
(258)
DBU
NC
(259)
(260)
Scheme 40
We then attempted to treat benzyl alcohol with the acid chloride (261) of (141) 
which had been formed in situ using standard methodology. Again, no product 
was isolated, and starting materials (i.e. the carboxylic acid and benzyl alcohol) 
were recovered.
5.5.2 Amide Linkage
The tyrphostin fragment may alternatively be attached to the spacer subunit via 
an amide linkage. Hydrolysis of this bond would generate the carboxylate anion 
(262) which would decompose as before (Scheme 41; compare with Scheme 
35).
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oCN
(263)
CN
(262)
Scheme 41
We carried out a series of test reactions involving the treatment of 2-cyano-3-[2- 
(5-nitrothienyl)]propenoic acid (141) with thionyl chloride. This was then reacted 
in situ with either ethylamine or 4-bromobenzylamine to give the corresponding 
amides (Scheme 42 and Table 17).
The latter reaction with 4-bromobenzylamine gave the product (265) in 69 % 
yield. In the 1H NMR spectrum, a broad singlet at 6 6.80-6.60 was assigned to 
the NH proton; an AA'BB' and an AB system in a 2:1 ratio between 6 8.29-7.00 
arose from the phenyl and thienyl protons. The carbonyl stretch for an a(3- 
unsaturated carboxylic acid was replaced by an amide carbonyl stretch at 1700 
cm'1 in the IR spectrum, together with an amide N-H stretch at 3448 cm-1. The 
intensity of signals for aromatic C-H stretches and bends were substantially 
greater compared to the IR spectrum of (141). Microanalytical and accurate 
mass spectrometric data confirmed the purity of (265).
Product
c o2h CONHR
(261)
Scheme 42
(264-265)
(264)
(265)
Et
Br
Table 17
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5.6 Coupling the Spacer Subunit with Glutamic Acid
A method to generate isocyanates involves the treatment of an acid chloride 
(247) with sodium azide in the presence of a catalytic amount of 
tetrabutylammonium iodide to generate an acyl azide (266), which undergoes 
Curtius rearrangement to give an isocyanate (267) in good yield,210 since no 
water is present to hydrolyse the product to the amine (Scheme 43).
R -C O C I— nR3NM *• R -C -N = N ? N ° — 2 »- @ -C i-N — ► 0 = C = N ~ R"BU4NI || -  || O *
o  o
(247) (266) (267)
Scheme 43
We performed a test reaction using 4-chlorobenzoic acid (268) as the substrate. 
This was treated for several hours with thionyl chloride to generate an acid 
chloride (269), which was either quenched with methylamine to give an amide 
(270) in 78 % yield, or was treated sequentially in situ with sodium azide and 
nBu4NI followed by methylamine in an effort to form the A/-methylurea (271). 
The expected product was not isolated, and instead again the methylamide 
(270) was produced, clearly indicating that acyl azide formation had not 
occurred. Given the dangers associated with azide chemistry, we decided not to 
repeat the reaction at elevated temperature and this route was abandoned.
O
HN NHMeCOCI
SOCI
Cl
CONHMe(269) (271)
Cl
(270)
Scheme 44
One of the most common methods for the preparation of isocyanates is the 
reaction of aliphatic and aromatic primary amines (272) with phosgene (273) to
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form chloroformates (274) or amine hydrochlorides (275), which lose HCI upon 
heating to give isocyanates (267) in good yield (Scheme 45) .211 As the reaction 
involves the use of highly toxic phosgene gas, alternative methods involving the 
use of triphosgene,212 bis(trichloromethyl)carbonate (276) which is a solid at 
room temperature, or carbonyldiimidazole213 (257) have been developed to 
transform amines into isocyanates in good yields. Modification of the reactions 
involving the use of phosgene or triphosgene by adding excess triethylamine 
results in the removal of the HCI produced as triethylamine hydrochloride.
25 °C~ RNHCOCI 50 °C»- RNCO + HCI
2 RNH2 + COCI2 — C (274> C0Cl2 (267)
(272) (273) 25 °C RNH2.HCI iqqoq1 RNCO + 3HCI
(275) (267)
Scheme 45
We were then faced with the problem as to which amine, either the protected 
glutamic acid (255) or the protected aniline (256) was to be treated with 
phosgene (or a phosgene equivalent) to give an isocyanate in good yield 
(Scheme 46). Neither compound is a particularly strong base, given that the 
amino groups have similar pKa values.214-215 A literature search had generated 
a greater number of publications on the synthesis of phenylisocyanates. In 
either case, sensitivity of isocyanates to moisture necessitated a strategy which 
would involve generation of the isocyanate and reaction with an amine to give 
the urea (278) in a one-pot reaction.
Di-toutyl-L-glutamate (255) was heated with CDI (257) in dry THF until TLC 
showed the absence of starting material. 4-Hydroxymethylaniline 
toutyldimethylsilyl ether (256) dissolved in dry THF was then added, followed by 
4-dimethylaminopyridine (DMAP, a coupling reagent). Heating at reflux for 24 
hours gave a complex mixture, but none of these could be identified as the 
expected product. A substantial quantity of (255) and (256) were recovered by 
column chromatography.
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NCO
OTBDMS r
Route 1
NH2 — h 
(256) Route 2
H2N \  / C 0 2fBu
C02fBu
(255)
OTBDMS
fBu02C
NH2 C02'Bu
(276)
OTBDMS
fBu02C
NHr
OTBDMS
OHN
HN
(278) \ |
C02fBu
C02'Bu
Scheme 46
Alternative methods using triphosgene to generate an isocyanate or dibutyltin 
diacetate as the coupling agent under the same conditions were investigated 
(Scheme 47). In each of these cases, complex mixtures were produced, and 
various amounts of starting materials were recovered.
h 2 N \ ^ \ ^ C 0 2'Bu 
C02'Bu (255)
OTBDMS
NH2
(256)
TBDMSO
Method (a) (b)
1 CDI DMAP
2 CDI (Bu)2 Sn(OAc)2
3 triphosgene DMAP
4 triphosgene (Bu)2 Sn(OAc)2
COo'Bu
C02'Bu
(278)
Scheme 47
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A second strategy would be to generate an isocyanate from (256) using the 
above technique and to react it with (255). In a test reaction, 4-bromoaniline 
was treated with CDI (257) in dry THF for 46 hours until TLC showed the 
absence of starting material. Diethylamine was then added, and gentle heating 
gave the diethylcarbamate (279) in moderate yield as large brown crystals. The 
1H NMR spectrum of (279) contained a very broad singlet at 6 12.21 (NH), an 
AA'BB' system between 8 7.81-7.13 and a triplet and quartet at 8 1.11 and 3.36 
respectively arising from the ethyl groups. These were also observed in the 13C 
NMR spectrum at around 8 13 and 41. Signals in the IR spectrum included an 
N-H stretching mode at 3264 cm-1 and a carbonyl stretch at 1633 cm-1.
This procedure was repeated using 4-hydroxymethylaniline toutyldimethylsilyl 
ether (256) and CDI (257) (Scheme 48). Precipitation of a white solid which 
was identified as imidazole by 1H NMR spectroscopy occurred within six hours, 
and a new spot with Rf 0.19 which was assumed to be the A/-acylimidazole 
(280) was observed by TLC. Stirring was continued for a further four hours, but 
this spot did not disappear, and although the isocyanate may perhaps not have 
formed, di-rbutyl-L-glutamate (255) and dibutyltin diacetate were added, and 
stirring was continued at an elevated temperature (70 °C) for three days, by 
which time the presence of a beige crystalline solid was apparent. TLC and 1H 
NMR spectroscopy showed this to consist of a mixture of (255) and (256), 
although the spot with Rp 0.19 was no longer present.
We attempted to modify the procedure in the same manner as before using 
DMAP as the coupling reagent, but this gave the same result. CDI was then 
replaced with triphosgene, and the procedure was repeated using dibutyltin 
diacetate or DMAP, but again the product was not observed and starting 
materials were recovered.
We were unable to generate the diethylurea by trapping with diethylamine when 
either CDI or triphosgene was used.
O
(279)
113
oN N NW  \ = /
(257)
25 °C. 5.5 h
OTBDMS
HN.
(280)
COs'Bu
CQ j'Bu
(255)
(Bu)2 Sn(OAc) 2  or DMAP 
65 °C, 72 h
O C02fBu
°  a ; '
B HN N C02fBu
I 1.CI3CO OCCI3.DCM.NEt3 1 H
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NH<
X
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C 0 2'Bu
2. J ^  (255)
H jN  COz'Bu
OTBDMS (Bu)2 Sn(OAc) 2  or DMAP 
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OTBDMS
(278)
5.7 Conclusions
Whilst the logic behind this synthetic route is sound, there appears to be little 
chance of its success. It is clearly apparent that the formation of a urea linkage 
between the spacer and specifier subunits is prevented by steric hindrance 
arising from the bulky 'butyl groups. Sutherland unsuccessfully investigated the 
possibility of generating a urea from diphenyl L-glutamate and the protected 
spacer unit (256) using triphosgene.203
Considerably more success was apparently achieved to generate a specifier- 
spacer unit which contained a carbamate linkage (282) (Scheme 49) 203 This 
was synthesised from 4-hydroxybenzyl alcohol and compound (281), which was 
generated from di-'butyl glutamate (254) and triphosgene. This particular route 
is worthy of further investigation, and so the author would like to propose some 
other synthetic routes which may be useful in developing ADEPT prodrugs 
containing tyrphostins in the future.
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DCM/Triethylamine
OH
(281)
DCM/
Triethylamine/
Triphosgene
OCN
(255)
HO
62%
overall
(282)
Scheme 49
5.8 Future Work
O COoH
o - V -
(NH) H
C02H
Figure 22
It is now clear that the preferred target is of the type shown in Figure 22. This 
consists of a tyrphostin linked to a spacer unit via an amide bond, and a 
specifier attached either through a urea or carbamate linkage, which may be 
achieved in the manner shown (Scheme 50).
NH,
1. DCM, Triethylamine
2. Di-butyl glutamate, DCM, 
Triethylamine, Triphosgene
3. Tyrphostin (as acid chloride)
4. H2, Pd\C
OH
(246) 0 2N \^
(283)
Scheme 50
O C02H 
H
C02H
It would, however, be preferable to synthesise an ADEPT prodrug whereby the 
specifier was attached to the spacer unit by a urea linkage. Since benzylamine
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is a stronger base compared to aniline (pKa 4.62 vs. pKa 9.3),216 the aliphatic 
amino group of 4-aminobenzylamine (284) would react more rapidly with 
benzylchloroformate to give the monoprotected species (285) (Scheme 51)217 
The Cbz protecting group also has the advantage of being easily removed later 
by hydrogenolysis.206* 218 Compound (285) could then be treated with either 
CDI (257) or triphosgene (276) to generate an isocyanate (286), which could 
react with an L-glutamate such as (287) to give a urea (288). This step may 
require the use of a coupling agent. It is likely that this reaction would proceed 
more readily than before, since earlier failures may be attributed to a steric 
effect caused by the bulky toutyl groups which were used to protect the glutamic 
acid, and in this case the straight-chain MEM groups (methoxyethoxymethyl 
ester)219 would reduce the steric bulk around the amino moiety. Deprotection of 
the aliphatic amino group206 and reaction with the acid chloride derivative of the 
tyrphostin of choice, followed by deprotection of the acid moieties under very 
mild conditions206 would generate the target molecule (283).
NHCbz
CDI or
Triphosgene
NHCbz
NCO
NH
PhCH2OCOCI
(284) (285) (286)
(287)
NHa o 2n<t ^ ^ , c o c i  
s CN
2. 3M HCI, THF, 
40 °C, 12 h
NHCbz
Pd\C
HN HN
COoMEM
CN O
H
N (288)
(283)
Scheme 51
H
NHN
O C02H
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6. Biological Evaluation and 
Electrochemical Data
6.1 Biology
The compounds discussed in Chapters 3 and 4 were presented for biological 
evaluation to the CRC Beatson Laboratories, Department of Medical Oncology, 
University of Glasgow, or to the Paterson Institute for Cancer Research, 
Christie Hospital, Manchester. Additional testing was carried out by the Drug 
Development Section at the Institute of Cancer Research (ICR), Sutton, Surrey.
IC50 values for growth inhibition in MCF-7 human breast adenocarcinoma cells 
were measured by myself (unless otherwise indicated) under the supervision of 
Dr Valerie Brunton at the Department of Medical Oncology, or by Dr Alan 
McGown and co-workers at the Paterson Institute. Dr Brunton carried out or 
supervised the assays which were used to determine the antiproliferative effect 
of the tyrphostins in HER14 fibroblasts which had been transfected with the 
human EGF receptor, the cytotoxicity assays in a number of squamous cell 
carcinoma cells, and the measurement of EGF receptor kinase activity in a cell- 
free system.
Alkaline elution studies to measure DNA single-strand breaks caused by 
compounds (100), (102), (123) and (125) were carried out by Dr Lloyd Kelland 
and co-workers at ICR Sutton.
6.2 Biological Data
6.2.1 Antiproliferative Assays
MCF-7 and MCF-7ADR breast adenocarcinoma cells. The growth stimulation 
of the MCF-7 breast cancer cell line is EGF-dependent, and antibodies to the 
EGF receptor have been shown to inhibit growth of breast cancer cells in 
vitro,220’ 221 suggesting that signalling via the EGF receptor plays an important
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role in the proliferation of this tumour type. MCF-7ADR cells have a higher 
concentration of the EGF receptor.
HER14 Fibroblasts. Additionally, several compounds were tested in HER14 
fibroblasts which had been transfected with the human EGF receptor. When 
quiescent, these cells undergo a further cycle of DNA synthesis after stimulation 
with EGF or 10 % Donor Calf Serum (DCS). Sequential exposure of these cells 
to either DCS or EGF followed by the compounds was carried out to determine 
whether the inhibition was EGF-dependant.
6.2.2 Measurement of EGF Receptor Kinase Activity
Other mitogens such as oestrogen and the insulin-like growth factors are also 
involved in the growth control mechanisms of cancer cells,222 and it was 
important to determine whether the ability of these compounds to inhibit 
proliferation was a result of control of the EGF receptor function, or was through 
some other mechanism. To this end, compounds were also tested in a cell-free 
system.
EGF receptor tyrosine kinase activity was measured in membrane fractions 
from the HN5 cell line, which is derived from a human squamous cell carcinoma 
of the tongue.223 These cells overexpress the EGF receptor, having 4.5 x 106 
binding sites / cell (V.G. Brunton, unpublished observation). The EGF receptor 
kinase activity in the membrane fractions was determined by measuring the 
EGF-dependent phosphorylation of a synthetic substrate, poly(Glu, Ala, Tyr).
6.2.3 Cytotoxicity Assay
Compounds which displayed good activity in the cell-free assay were then 
screened against a panel of four squamous cell carcinoma cell lines derived 
from tumours of the vulva, tongue, cervix and uterus. These cell lines have 
varying levels of EGF receptor concentration (Table 18), with the HN5 and 
A431 lines having high levels of receptor, and the SiHa cells having levels of 
EGF receptor similar to that found in normal keratinocyctes. Low IC50 values in 
the A431, HN5 and CaSki cell lines, accompanied by a considerably higher (i.e. 
several orders of magnitude) figure for the SiHa cells would imply that the 
compound was exerting toxicity upon the cancer cells through inhibition of EGF 
receptor function.
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HN5 A431 CaSki SiHa
Tumour Type tongue vulval cervix uterus
EGF Number (x 106 /cell) 5.195 1.544 0.785 0.114
Table 18
6.2.4 Alkaline Elution
Bioreduction of nitroaromatic species via a 1-electron mechanism gives rise to a 
cytotoxic free radical (47), which may induce radical-induced DNA single strand 
breaks. Compounds (100), (102), (107), (122) and (125) are reducible by a 1- 
electron mechanism, and some of the reduction potential values for these 
[compounds (100) and (102)] fell within the range of -200 to -500 mV, which are 
required if they were to be reduced within a biological system (see Section 
6.5.). By assaying for DNA strand-breaks in vitro, it is possible to infer whether 
the compound or its reduced species contributes to inhibition of DNA synthesis 
and thus prevents cellular proliferation.
6.2.5 General
This multi-stage screening process was designed to enable us to achieve early 
identification of compounds which either possessed potent EGF inhibition 
activity, or displayed a strong ability to inhibit cellular proliferation. By assaying 
for EGF receptor kinase activity and assessing the response of MCF-7 cells to 
the compounds, we were able to choose compounds which showed promising 
TK inhibition activity. We were then able to present these for further evaluation 
in the cytotoxicity and subsequently the alkaline elution studies.
6.3 Biological Activity of Nitrothienyl Tyrphostins
Tables 19-24 show the results from the screening of the 40 nitrothienyl 
tyrphostins synthesised. For the MCF-7 assay, all but those containing 
tri(ethyleneglycol) ester groups on their sidearm [compounds (GJM194), (119) 
and (128)] were tested at the Department of Medical Oncology by Dr Brunton 
and her colleagues. The remaining compounds were submitted for testing at the 
Paterson Institute, and the data from these sets of studies are dealt with 
separately. The data collected from all of these assays are discussed in Section 
6.6.
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RNC
I C 5 0  ( j i M )
Compound
Number R MCF-7 EGF-R
HER14 
DCS EGF HN5 A431 CaSki SiHa
(99) CN 18.4 50 20.70 28.00 25.80 25.40
(100) C(NH2)=C(CN)2 12.0 12.25 18.9 18.1 8.40 6.07 9.24 13.40
(101) C02Me >100 >500
(102) C02Et <1 34.00 29.8 26.5 5.40 4.60 6.94 4.59
(103) C02nBu 17.8 >500
(104) C02*Bu n.d. 75.00
(106) c o n h 2 1.9 >500
(107) c sn h 2 <1 37.50 82.1 85.3 66.90 71.60 82.93 82.10
(108) 2-Thienyl <0.001 >500
(141) c o 2h n.d. 150.00
(142) C02Na. 5H20 >100 >500
Table 19
R
G
L  CNn o2
IC90 0*M)
Compound
Number R MCF-7 EGF-R HN5 A431 CaSki SiHa
(113) CN <0.001 15.33
(114) C(NH2)=C(CN)2 0.025 14.63 5.10 4.73 4.70 7.80
(115) C02Me 6 .0 50.00
(116) C02Et <0.001 100
(117) COj/Bu <0.001 >500
(118) C02B u n.d. 9.00
(120) c o n h 2 <0.001 400
(121) c s n h 2 0.8 22.67 0.27 0.11 0.32 0.35
Table 20
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RS
IC50 (pM)
Compound
Number R MCF-7H EGF-R
HER14 
DCS EGF HN5 A431 CaSki SiHa
(1 2 2 ) CN <0 .0 0 1 23.00 82.9 71.5 40.40 28.41 40.00 44.56
(123) C(NH2 )=C(CN) 2 <0 .0 0 1 7.00 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0
(124) C02Me > 2 0 >500
(125) C02Et <0 .0 0 1 9.00 > 1 0 0 > 1 0 0
(126) COj/Bu > 2 0 >500
(127) C02*Bu n.d. 150
(129) c o n h 2 0.9 >500
(130) c s n h 2 <0 .0 0 1 10.50 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0
(144) c o 2h n.d. >500
(145) CQ2 Na. 5H20 > 1 0 0 >500
H Tested by Miss Jillian Queen
Table 21
OoN
NC
IC50 (pM)
Compound
Number R MCF-7H EGF-R
(132) CN 0.91 2 . 0 0
(133) C(NH2 )=C(CN) 2 <0 .0 0 1 160
(134) C02Me <0 .0 0 1 18.00
(135) C02Et <0 .0 0 1 >500
(136) c x v b u <0 .0 0 1 >500
(137) C02 ,Bu <0 .0 0 1
(138) c o n h 2 <0 .0 0 1 47.00
(139) c s n h 2 <0 .0 0 1 >500
H Tested by Martin Lear
Table 22
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1C so
Compound
Number Structure MCF-7 MCF-7ADR
OoN
(105) CO(OCH2CH2)3OMe i.76t 2.27+
(119)
(128)
,CO(OCH2CH2)3OMe
NO-
rCO(OCH2CH2)3OMe
OoN
20.79+ n.t.H
42.12t 54.81 +
+ Tested by Dr Alan McGown, Paterson Institute. 
H Not toxic.
Table 23
Compound
Number
IC50 (|iM)
Structure MCF-7 EGF-R
OH
OoN
NC
(153) °  )----- (v /> <0.001 >500
OH
(154) <0.001 >500
NC
Table 24
6.4 Biological Activity of Quinolyl and Nitroquinolyl Tyrphostins
After the departure of Professor Workman, the facilities at the Beatson Institute 
were unavailable for the biological evaluation of the 25 quinolyl and nitroquinolyl 
tyrphostins synthesised (Chapter 4). Provisions were made for these 
compounds to be tested in MCF-7 and MCF-7ADR cell lines (the latter has a 
higher concentration of the EGF receptor) at the Paterson Institute for Cancer 
Research, Manchester. These compounds have been submitted for testing, and 
results are eagerly awaited.
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6.5 Reduction Potentials
6.5.1 Cyclic Voltammetry
Cyclic voltammetry is a well-established technique which has been employed to 
measure the value and nature of the reduction and oxidation of compounds in 
solution. In cyclic voltammetry, a wide variety of electrodes and solvents may 
be used, and the ionic conductivity of a solvent may be enhanced by the 
addition of a supporting electrolyte.
RE- Reference Electrode 
WE- Working Electrode 
CE- Counter Electrode
RE CE
Scan
Generator Potentiostat
Plotter
Figure 23 Modified from reference 224.
A schematic representation of the instrumental set-up for cyclic voltammetric 
experiments is given in Figure 23. Three electrodes are attached to the cell 
containing the redox species in solution. A scan generator controls the voltage 
applied to the cell, which is scanned linearly to the working electrode, W, from 
an initial level, Ei to a predetermined level E2 , when the direction of the scan is 
reversed. The current response is plotted as a function of the applied potential. 
Figure X shows a typical CV obtained from the reversible electron transfer of an 
oxidisable material, R, for the reaction
R + n e *^  - ■■ ^  O
In order to validate measurements obtained by cyclic voltammetry, it is 
necessary to repeat scans and to vary the scan rate, which also helps to 
identify the nature of the redox process. In cases where the reduction is 
completely reversible (such as the first 1-electron reduction of a nitro group, see 
Scheme 5 in Chapter 2), there is usually little difference between the values 
recorded for different scans or scan rates.
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Reversible electron transfer processes are diffusion-controlled. A schematic 
representation of a cyclic voltammogram (CV) of a wholly reversible redox 
couple is shown in Figure 24. When one of the redox species is a radical [such 
as (47)], it is often the case that this species will give an intense colour at the 
working electrode. Removal of these radicals from the surface of the working 
electrode is achieved between scans by means of bubbling nitrogen through the 
solution, which also removes air bubbles (which may affect the readings) from 
the surface of the electrode.
^ 2. ^pa *pc
Figure 24 Adapted from references 225 and 226.
The wave for a reversible 1-electron transfer exhibits the following 
characteristics.
1. The cathodic (Epc) and anodic (E pa) peak potentials are 
independent of scan rate.
2. The separation (AEp) between Epc and E pa is constant 
irrespective of scan rate.
3. The cathodic (/pc) and anodic (/pa) peak currents are such that
4. The square root of the scan rate is directly proportional to /pa.
Irreversible or quasi-reversible electrochemical reactions may occur when 
electron transfer and diffusion of the reactants occur at similar rates, or when 
the rate of electron transfer is much slower than diffusion. In such cases, at
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least some of the properties listed above may not hold true. The CVs of such 
processes are more complicated, but essentially the return signal is not a mirror 
image of the forward peak, and is, instead, normally a horizontal line.
It is common practice to report the average value of the forward and reverse 
peaks [(Epc + Epa)/2] as the formal reduction potential for the redox couple. This 
approximation is most accurate when the process is a reversible one where the 
diffusion co-efficients for the oxidised and reduced species are the same.
6.5.2 Experimental Conditions
Details of the general conditions for measuring the reduction potentials are 
given in Chapter 7. Atmospheric humidity had a noticeable effect on the values 
of AEP, which increased when humidity was high. CVs were obtained on three 
separate dates, and on each occasion the reduction potential of ferrocene was 
measured as an internal standard. Whilst the value of AEP fluctuated 
substantially (see Table 25), the reduction potential remained constant at 
around -10 mV. Measurements were carried out by myself under the 
supervision of Dr Robert D. Peacock and Dr Stephen M. Lacy (University of 
Glasgow).
6.5.3 Reduction Potentials of Selected Nitrothienyl and Nitroquinolyl 
Tyrphostins
Compounds which displayed good biological activities in the assays noted in 
Section 6.4 were tested. The results are given in Table 25. The observed 
reduction potential (E ^ ) was corrected by +580 mV (a value which represents 
the difference in potential between the Ag/AgN0 3  reference electrode and the 
Normal Hydrogen Electrode, NHE)227 to give the reduction potential (E j)  with 
respect to NHE, to which these values are normally referred.
Samples were scanned at 20, 50, 200 and 500 mVs-1, and in some cases the 
margins of error of the measurements were quite high. This was attributed to 
internal resistance in the equipment. Figure 25 is the cyclic voltammogram for
(99). which shows the reduction of this compound to be a reversible process. 
As can be seen, two one-electron reductions occurred within the parameters of 
the scan; only the values of the first reduction are recorded in Table 25. The 
cyclic voltammogram of an irreversible electron transfer involving compound 
(132) is shown in Figure 26. Both CVs also possess a large signal around +150 
mV corresponding to oxidation of the solvent.
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20 mVs
50 mVs1
200 mVs
500 mVs'1 \ J
-2500 -2000 -1500 -1000 -500 500
mV 
Figure 25
50 mVs /
200 mVs
500 mVs'1
I I I I I I I
-2500 -2000 -1500 -1000 -500 0 500
mV
Figure 26
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Nature of Reduction
Run E ols ^7
Ar R No. No. (mV) (mV) (mV) Reversible Irreversible
R
CN
NOc
OoN
R
NC
NO2
1
Fe
ce !g>
CN (99) 1 -1050 100 -470 ± 50 X
C(NH2)=C(CN)2 (100) 1 -1000 70 -420 ± 20 X
C02Me (101) 1 -950 120 -370 ± 60 X
C02Et (102) 2 -910 227 -330 ± 50 X
CONH2 (106) 1 -1140 116 -560 ±20 X
CSNH2 (107) 1 -1340 -760 ±10 X
C(NH2)=C(CN)2 (114) 3 -960 121 -380 ±10 X
C02Et (116) 3 -930 120 -350 ± 50 X
c s n h 2 (121) 3 -1090 -510 ±30 X
CN (122) 2 -1260 . -680 ± 20 X
C(NH2)=C(CN)2 (123) 2 -1790 - -1210 ±30 X
C02Et (125) 2 -1300 - -720 ±10 X
c s n h 2 (130) 2 -1380 -800 ± 30 X
:N
CN (132) 3 -1120 -540 ± 20 X
C02Me (134) 3 -1220 -760 ± 20 X
CN (238) 3 -1120 -540 ±30 X
C(NH2)=C(CN)2 (239) 3 -1227 -643 ± 20 X
1 100 -10 ± 5 X
Ferrocene - 2 220 -8 ± 6 X
■ 3 120 -12 ± 4 X
Table 25
127
6.6 Discussion
A total of 40 nitrothienyl tyrphostins have been synthesised, 36 of which are 
novel, as well as 25 quinolyl tyrphostins, of which only one has been reported in 
the existing literature (this information was obtained by means of a Chemical 
Abstracts System on-line substructure search). It was anticipated that these 
compounds would selectively inhibit the growth of cancer cells which possessed 
a high concentration of the EGF receptor by inhibiting a key stage in the 
molecular cascade leading to cellular proliferation. It has been proposed that 
some tyrphostins are selective inhibitors of specific TKs, but the precise mode 
of inhibition of these compounds is as yet unknown. Indeed, evidence is 
emerging which suggests that tyrphostins do not inhibit TKs at all, but perhaps 
act upon some other key molecule in the signalling pathway.
To this end, we considered it important to test the compounds both in vitro in 
intact cells and in a cell free system which specifically measures 
EGF-dependent phosphorylation of a known substrate. A good correlation 
between both these data sets would suggest that a compound's antiproliferative 
effect arose through inhibition of the EGF receptor.
A number of compounds tested in this manner displayed biological activities in 
the nanomolar range in the MCF-7 cell assay, which is several orders of 
magnitude better than previously reported tyrphostins.93- 97> 98- 99 In particular,
(99), (113), (122) and (132) which contained two nitrile groups in the sidearm 
were extremely active in both test systems. Similarly, when the conjugation was 
extended by the inclusion of a 2-aminoethene-1,1-dinitrile moiety [compounds
(100), (114) and (123)] the activity remained extremely high.
In the case of all the ester derivatives, activity generally decreased with ester 
chain length or bulk, and almost without exception the ethyl esters were the 
most active in all series, although the low measured activity of the methyl ester 
derivatives may be related to the fact that these compounds were often so 
insoluble that they would precipitate out of solution whilst they were being 
prepared for administration to the biological system. The two carboxylic acid 
derivatives (141) and (144) were inactive in the cell-free assays. A similar result 
was observed for their sodium salts (142) and (145), which were also inactive in 
vitro. This is probably due to the fact that anions are extremely lipophobic, and 
are not readily taken up by the cell.
No clear structure-activity relationship has emerged from our studies. Indeed, it 
may be true to say that the data contradicts earlier predictions regarding the 
effect of the substitution pattern of the sidearm and nitro groups around the
128
aromatic ring with respect to the observed biological activity.93 Activity seems to 
arise solely from the nature of the substituents on the sidearm.
A substantial difference in the activities of many of the compounds across both 
assays was observed. (117), (135) and (136) all exerted antiproliferative effects 
at nM concentration, but failed to display any inhibition at the EGF receptor.
If nitrothienyl tyrphostins are not necessarily inhibitors of EGF receptor kinase 
function, what is their mode of action? Testing of selected compounds in 
HER14 fibroblasts showed that the inhibition was not EGF-dependent, and 
suggests that these compounds may be antiproliferative agents. Testing of 
compounds in squamous cells showed that cytotoxicity was independent of 
EGF receptor concentration.
Further evidence for cytotoxicity came from testing carried out at the US 
National Cancer Institute (NCI), where selected compounds were screened 
against an extensive panel of 60 human tumour cell lines (Figures 27 and 28). 
Compounds (100) and (122) appeared to show a very narrow range of GI50 
values (50 % growth inhibition) in different cell lines, indicating no selectivity 
against particular cell types. However, compound (102) showed significant 
variation in the sensitivity of cell types, with leukaemic tumour cells being 
particularly sensitive, as well as the majority of colon cancer, melanoma and 
breast cancer cell lines. Conversely, the CNS-derived and non-small cell lung 
cancer lines showed a degree of resistance to these compounds. A 
computerised analysis called COMPARE indicated that these three compounds 
had unique sensitivity profiles in the 60 cell lines compared to a panel of agents 
whose mechanism of action is well understood.
Investigation of compound (102) in vivo against leukaemic, renal tumour and 
melanoma xenografts was then carried out at NCI. This compound had no 
significant antitumour activity within the treatment schedule, and did not prolong 
the lives of the test animals.
Alkaline elution studies of compounds (100), (102), (123) and (125) showed that 
(102) and (100) exerted significant damage to DNA at 50 pM concentration, 
whereas compounds (123) and (125) were less effective. These data are 
extremely significant given that the first one-electron reduction potentials of 
(102) and (100) are both reversible and also fall within the limits required for 
reduction to occur within a biological system. The other two compounds had 
much more negative reduction potential values, which were also irreversible.
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LEUKEMIA LEUKEMIA
CCRF-CEM -5.36 CCRF-CEM •4.63 1
K-662 •5.41 ■ ■ HL-60(TB) •4.37 1
MOLT-4 •5.23 ■ K-662 •4.56
RPM4226 •5.30 ■1 MOLT-4 •4 J I 1
SR •4.02 RPNM226 •4.50
NON-SMALL CELL LUNG CANCER SR -4.52
A549/ATCC NON-SMALL CELL LUNG CANCER
BOOt •4.71 1 A54WATCC »-4.00 BS
HOP-62 •4.71 1 B(VX »-4.00 m
HOP-82 HOP-62 •4M 1
NCI-H226 -4.75 1 HOP-82 -4.51
NCI-H23 •4.76 NCLH226 >•4.00 tsss
N&-H322M -4.55 G NCI-H23 •4.52
NCFH460 •4.63 E NCFH322M •4.13 tz
NCLHS22 •4.06 NC4-H460 •4.26 E
COLON CANCER NCFH522 •4.62 3
COLO 205 -4.62 COLON CANCER
HCC-2008 •4.60 COLO 205 •4.56
HCT-116 •5.47 ■5 HCC-2996 -4.57
HCT-15 -4.75 1 HCT-116 •4.70 ■
HT29 -4.00 1 HCT-16 •4.47
KM12 •4.74 1 HT20 -4.66 1
SW-620 •5.40 ■1 KM12 •4.45 1
CHS CANCER SW-620 -4.36 1
SF-268 •4.65 C CNS CANCER
SF-295 -4.76 I SF-266 •4.41 I
SF-639 •4.63 c SF-205
SNB-19 -4.75 t SF-530 •4.36 C
SNB-75 •4.63 SNB-19 •4.22 c
U251 •4.73 c SNB-75 •4.60 J
MELANOMA U251
LOX IMVI -4.04 MELANOMA
MALME-3M •4.64 E LOX IMVI •4.51
M14 •4.02 MALME-3M •4.47
SK-MEL-2 -4.71 C M14 •4.75 3
SK-MEL-2B -4.77 1 SK-MEL-2 -4.57
SK-MEL-6 -5.12 3 SK-MEL-28 •4.70 □
UACC-257 -4.06 3 SK-Ma-6 •4.60 m
UACC-62 -5.10 3 UACC-257 •4.72 3
OVARIAN CANCER UACC-62 -4.75 □
tGROVI -5.14 3 OVARIAN CANCER
OVCAR-3 •4.61 IGROV1 -4.62 1
OVCAR-4 •4.61 OVCAR-3 •4.66 1
OVCAR-5 -4.57 e OVCAR-4 •4.54
OVCAR-8 -4.00 OVCAR-5 -4.23 ■
SK-OV-3 •4.75 1 OVCAR-8 -4.71 1
RENAL CANCER SK-OV-3 -4.23 ■
766-0 -4.70 e RENAL CANCER
ACHN •4.70 G 786-0 -4.47
CAKI-1 -4.74 E ACHN -4.71 3
RXF-303 •5.03 3 CAKI-1 -4.61 1
SN12C -4.67 RXF-303 -4.76 3
TK-10 •4.74 1 SN12C -4.46 1
UO-31 -4.74 t TK-10 •4.34 E
PROSTRATE CANCER UO-31 -4.75 3
PC-3 •4.70 1 PROSTRATE CANCER
DU-145 •4.63 PC-3 •4.42 1
BREAST CANCER DU-145 •4.62 ■
MCF7 •4.06 3 BREAST CANCER
MCF7/ADR-RES -4.67 C MCF7 •4.36 IMO A-MB-231 /AT CC •4.77 1 MCF7/ADR-RES •4.43 1
HS578T -4.73 t MD A-MB-231/ATCC •4.56
MDA-MS-435 •4.01 HS67BT •4.55
MOA-N •5.34 Z l MOA-MB-435 •4.66 3
BT-549 •4.60 MDA-N ■4.70 3
T-47D -5.16 3 BT-640 •4.56
T-47D •4.64 3
MG MID •4.66
DELTA 0.61 ■■ MG MID -4.52
RANGE 0.02 DELTA 0.30 ■
RANGE 0.62 n a
+3 4-2 +1 0 -1 -2 +3 +2 +1 0 *1
- i  1-------- 1-------- 1-------- 1--------1—   J_____i - i » i
NH,OoN
CNNC
NC
CN
(100) (122)
Figure 27 NCI Test Data. For each graph, the vertical line represents the log of the 
mean Gl5 0  value based on all the 60 cell lines. Bars to the right represent activity 
greater than the mean [lower log (Gl50)] whilst bars to the left represent activity 
lower than the mean [higher log (GI5 0 )].
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Our reduction potential data show that for nitrothienyl tyrphostins which have 
the sidearm and the nitro group ortho or 'para', the reduction is both within the 
desired parameters and is normally reversible (the only exception being 
compounds (107) and (121), which have a thioamide moiety on the sidearm). 
Conversely, mefa-substituted nitrothienyl tyrphostins are irreversibly reduced by 
a 1-electron mechanism at values which are much more negative. Clearly, a 
number of the compounds under investigation have reduction potentials of the 
order which would allow them to be reduced in vivo to an extremely toxic 
cytotoxic free radical, but to date none of the compounds reported in this thesis
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have been tested under hypoxic conditions, nor have they been tested in 
normal cells to determine whether or not the cytotoxicity is universal or is only 
with respect to cancer cells.
The three tri(ethyleneglycol) ester derivatives, (105) (119) and (128) gave IC50 
values in the micromolar region, and all but one compound displayed very good 
activities in MCF-7ADR cells, which have a higher concentration of the EGF 
receptor (IC50 2.27 |liM ). These are extremely promising results.
It is not possible to comment upon the biological activity of the quinolyl and 
nitroquinolyl tyrphostins synthesised since they are still undergoing evaluation. 
We would expect that the most active series would be based upon the 
7-substituted quinoline nucleus, and that the 6 - and 8 -substituted quinolines 
would have a relatively low biological activity. The two nitroquinolyl tyrphostins 
which were synthesised displayed extremely negative 1-electron reductions, 
which were irreversible.
The mode of action of tyrphostins is still unknown. We have shown that some 
tyrphostins based upon a nitrothienyl nucleus appear to inhibit EGF receptor 
tyrosine kinase activity in a cell-free assay, but little evidence exists for specific 
inhibition of EGF receptor function in intact cells. Nevertheless, a number of 
compounds do show interesting antiproliferative and cytotoxic effects, and, in 
particular, compound (102) displayed a significant degree of tumour type 
selectivity in the US NCI in vitro panel of human cell lines, although this effect 
was not repeated in vivo. This may simply be due to a problem of solubility, 
given that this compound (and nearly all of the others reported) are only soluble 
in polar aprotic solvents such as DMSO, which is itself highly toxic. 
Nonetheless, these are still highly potent compounds which may yet be further 
developed, either as free drugs, or, more likely, utilising new technologies such 
as ADEPT as a method of increasing specificity and solubility. Further 
investigation, particularly of the method of action of these compounds, is 
required if they are to be exploited as anticancer agents.
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7. Experimental
7.1 Instrumentation
All chemicals were purchased from Aldrich or MTM Chemicals. Organic 
solvents were dried with anhydrous Na2 S0 4  or MgS0 4  and concentrated under 
reduced pressure using a rotary evaporator. Unless otherwise stated, ether 
refers to diethyl ether and petroleum ether refers to the fraction which distils 
between 40-60 °C. Rf values were obtained by performing qualitative thin-layer 
chromatography (TLC) using Merck GF254 silica gel plates of 0.25 mm 
thickness. Compounds were detected by viewing under UV.
Melting points (m.p.) were determined on a Reichert-Kofler hot stage apparatus 
and are uncorrected. IR spectra were recorded as KBr discs or Nujol Mulls on a 
Philips PU9800 Fourier Transform IR spectrometer. IR frequencies, v, are given 
in wave numbers (crrr1) and the relative intensities (weak, medium and strong) 
are denoted by w, m and s respectively. Ultraviolet spectra were recorded as 
solutions in dimethylsulfoxide using a Perkin-Elmer Lambda 9 UVA/isible/Near 
IR spectrometer. Nuclear magnetic resonance spectra were recorded on 
Brucker AM200SY or WP200SY instruments operating at 200 MHz ( 5 h ) and 5 0  
MHz (5c). The multiplicities of the 13C NMR spectra were determined using 
DEPT spectra with pulse angles of <|)=90o and (|)=135°. Multiplicities (singlet, 
doublet, triplet, quartet, multiplet and broad) are denoted by s, d, t, q, m and br 
respectively. The numbering systems refer to the appropriate structures. Mass 
Spectra (MS) were performed on an AEI/Kratos MS12 (low resolution) and an 
AEI/Kratos MS902S (high resolution) instrument. Elemental compositions for C, 
H, N and S were determined on a Carlo Erba Strumentazione Elemental 
Analyzer-MOD1106 with a Hewlett-Packard 3394A Integrator.
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7.2 General Procedures
General Procedure A. A round-bottomed flask was charged with a magnetic 
stirring bar and 1-6 mmol of aryl carbaldehyde in absolute ethanol (1-5 ml). The 
solution was gently heated to obtain a clear liquid. To this was added an 
equimolar amount of malonate derivative dissolved in absolute ethanol (1-5 ml) 
and piperidine (1-5 drops from a pasteur pipette). The mixture was stirred at 
room temperature until precipitation of the product had occurred (10 min - 24 h) 
or until TLC (silica gel/1:1 ethyl acetate/petroleum ether unless otherwise 
stated) showed completion. The precipitate was filtered, washed (hexane) and 
dried (diethyl ether) under suction and needed no further purification.
General Procedure B. A round-bottomed flask was charged with a magnetic 
stirring bar and 1-6 mmol of aryl carbaldehyde in absolute ethanol (1-5 ml). The 
solution was gently heated to obtain a clear liquid. To this was added an 
equimolar amount of malonate derivative dissolved in absolute ethanol (1-5 ml) 
and piperidine (1-5 drops of an approx. 1:100 v/v solution of piperidine in 
absolute ethanol from a pasteur pipette; referred to as dilute piperidine solution 
in the text). The mixture was stirred at room temperature until precipitation of 
the product had occurred (10 min - 24 h) or until TLC (silica gel/1:1 ethyl 
acetate/petroleum ether unless otherwise stated) showed completion. The 
precipitate was filtered, washed (hexane) and dried (diethyl ether) under suction 
and needed no further purification.
General Procedure C. A round-bottomed flask was charged with a magnetic 
stirring bar and 1-6 mmol of aryl carbaldehyde in absolute ethanol (1-5 ml). The 
solution was gently heated to obtain a clear liquid. To this was added an 
equimolar amount of malonate derivative dissolved in absolute ethanol (1-5 ml). 
The mixture was stirred at room temperature until precipitation of the product 
had occurred (10 min - 24 h) or until TLC (silica gel/1:1 ethyl acetate/petroleum 
ether unless otherwise stated) showed completion. The precipitate was filtered, 
washed (hexane) and dried (diethyl ether) under suction and needed no further 
purification.
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7.3 Experimental Procedures for Chapter 3
2-Cyano-3-[2-(5-nitrothienyl)]propenonitrile (99)168> 228-230
4 ' 3 '
CN
NC
Using General Procedure A, 5-nitro-2-thiophenecarbaldehyde (0.5002 g,
3.2 mmol) was treated with malononitrile (0.2986 g, 4.5 mmol) in ethanol 
(15 ml) and piperidine (5 drops) at 0  °C to give a precipitate after 10 min which 
was dissolved in propan-2-ol and slowly formed brown crystals (0.2512 g, 
38%), m.p. 146-148 [lit.: 147-148]230 °C. RF 0.54 (ethyl acetate); (Found: 
C 47.02; H 1.59; N 20.52 %; M+, 204.9949. C8H3N3O2S requires C 46.83; 
H 1.47; N 20.48 %; M, 204.9946); Vmax/cm-1 (KBr disc) 3050s (Ar-H), 2240w 
(CN), 1590s (extended conjugation to aromatic system), 1485s (C-NO2), 815w 
(Ar-H); 6H (200  MHz, DMSO-d6) 8.79 (br s, 1H, 3-H), 8.23 (d, 3J  4.4 Hz, 1H, 
4'-H), 7.89 (d, 3 j  4 .4  Hz, 1H, 3'-H); 6 C (50 MHz, DMSO-d6) [lit.: 25 MHz, 
DMSO-de]168 155.9 [155.8] (s, 5'-C), 152.5 [152.3] (d, 3-CH), 139.2 [139.1] (s, 
2'-C), 137.9 [137.8] (d, 3'-CH), 129.6 [129.3] (d, 4'-CH), 114.9 and 112.9 [113.0 
and 112.5] (2 x s, 2  x CN), 102.8 [82.4] (s, 2-C); m/z 205 (M+, 67 %), 159 (M+ 
- N02).
2,4-Dicyano-3-amino-5-[2-(5-nitrothienyl)]penta-2,4-dienonitrile (100)
4 1 3 '
NH
NC CN
NC
5-Nitro-2-thiophenecarbaldehyde (0.7949 g, 5.06 mmol) was treated with
2-aminopropene-1,1,3-tricarbonitrile (1.0946 g, 8.28 mmol) in ethanol (20 ml) 
and piperidine (1 drop) using General Procedure A, to give brown crystals after 
10 min (0.5459 g, 40 %), m.p. 212-214 °C (1:1 acetone:chloroform). RF 0.50 
(ethyl acetate); (Found: C 48.52; H 1.91; N 25.96; S 12.06 %; M+, 271.0164. 
C11H5N5O2S requires C 48.71; H 1.86; N 25.82 S 11.82 %; M, 271.0170); 
V m a x /c m -1  (KBr disc) 3092w (Ar-H), 2250w (NH2), 2222w (CN), 1637s (C=C), 
1518s (C-NO2); 5H (200  MHz, DMSO-d6) 9.17 (s, 2 H, -NH2), 8.41 (d, 4J0A  Hz, 
1H, 5 -H), 8.23 (d, 3J 4.4 Hz, 1H, 4'-H), 7.88 (dd, 3J 4.4 Hz, 4J0A  Hz, Hz, 1H,
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3 -H); 6 C (50 MHz, DMSO-d6) 163.8 (s, 5'-C), 154.9 (s, 2 '-C), 145.3 (d, 4'-CH),
139.9 (d, 3'-CH), 136.7 (d, 5-CH), 129.7 (s, 2-C), 115.5 (s, 7-CN), 115.2 (s,
6 -CN), 114.4 (s, 1 -CN), 103.0 (s, 4-C), 50.4 (s, 3-C); m/z 271 (M+, 34 %), 225 
(M+ - N 02), 153 (M+ - [NC-C(NH2)=C(CN)2]), 92 ([C(NH2)=C(CN)2]+).
Methyl 2-cyano-3-[2-(5-nitrothienyl)]propenoate (101)168
4 ' 3 '
OoN
NC
Using General Procedure B, 5-nitro-2-thiophenecarbaldehyde (0.4646 g, 
2.96 mmol) was treated with methyl cyanoacetate (0.50 ml, 5.68 mmol) and 
dilute piperidine solution (1 drop) to give yellow crystals after 10 min (0.6440 g, 
94 %), m.p. 170-172 [lit.: 136-137]168 °C. RF 0.60 (ethyl acetate); (Found: 
C 45.54; H 2.50; N 11.81; S 13.66 %; M+, 238.0088. C9H6N20 4S requires 
C 45.38; H 2.54; N 11.76; S 13.44 %; M, 238.0048); vmax/cm-i (KBr disc) 3100s 
(Ar-H), 2950s (CHX), 1720s (ap-unsaturated carbonyl), 1500s (C-N02), 1340b 
(-OCOR), 835s and 815s (2 x Ar-H); 6H (200 MHz, DMSO-d6) [lit.: 80 MHz, 
CDCI3] 8.67 [8.56] (s, 1H, 4-H), 8 .22  [8 .12] (d, 3 j4.5 Hz, 1H, 3'-H), 8.02  [8.04] 
(d, 3J 4.5 Hz, 1H, 4'-H), 3.85 (s, 3H, CH3); 6 C (50 MHz, DMSO-d6) 161.5 (s, 
C=0), 155.2 (s, 5'-C), 146.4 (d, 4'-CH), 140.2 (s, 2'-C), 138.1 (d, 3'-CH), 129.6 
(d, 4-CH), 115.1 (s, CN), 103.2 (s, 3-C), 53.4 (t, CH3); m/z (M+, 38 %), 192 (M+ 
-N 0 2), 179 (M +-C 02Me).
Ethyl 2-cyano-3-[2-(5-nitrothienyl)]propenoate (102)
4 ' 3 '
OpN
NC
Using General Procedure A, 5-nitro-2-thiophenecarbaldehyde (0.50 g,
3.2 mmol) was treated with ethyl cyanoacetate (0.40 g, 4.5 mmol) in ethanol 
(15 ml) and piperidine (5 drops) to give yellow crystals after 30 min (0.40252. g, 
49 %), m.p. 170-172 °C. R f 0.52 (ethyl acetate); (Found: C 47.48; H 3.14; 
N 11.02 %; M+, 252.0211. C i0H8N2O4S requires C 47.62; H 3.20; N 11.11 %;
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M, 252.0205); Vmax/cnr1 (KBr disc) 3100s (Ar-H), 2220w (CN), 1710s 
(ap-unsaturated carbonyl), 1600s (extended conjugation to aromatic system), 
1500s (C-N02); Xmax (DMSO)/nm 368; 5H (200  MHz, DMSO-d6) 8.64 (s, 1H, 
5-H), 8.22 (d, 3J 4 .3  Hz, 1H, 3'-H), 8.03 (d, 3J 4.3 Hz, 1H, 4'-H), 4.35 (q, 
3J7.1 Hz, 2H, CH2), 1.33 (t, 3J 7.1 Hz, 3H, CH3); 8c (50 MHz, DMSO-de)
161.0 (s, C=0), 155.2 (s, 5'-C), 146.3 (d, 4'-CH), 140.34 (s, 2 '-C) 138.1 (d,
3-CH), 129.6 (d, 5 -CH), 115.0 (s, CN), 103.5 (s, 4-C), 62.9 (t, CH2), 14.0 (q, 
CH3); m/z252 (M+, 32 %), 206 (M+ - N02), 179 (M+ - C 02Et).
"Butyl 2-cyano-3-[2-(5-nitrothienyl)]propenoate (103)
4 ’ 3 '
5-Nitro-2-thiophenecarbaldehyde (0.48 g, 3.05 mmol) was treated with 
"butylcyanoacetate (1.0 ml, 7.08 mmol) in propan-2-ol (2.5 ml) and dilute 
piperidine solution (1 drop) using General Procedure B, to give a yellow 
precipitate after 10 min (0.56 g, 65 %), m.p. 1 1 0 -1 1 2  °C. R f 0.71 (ethyl 
acetate); (Found: C 51.45; H 4.30; N 9.96 %; M+, 280.0513. C i2H12N20 4S 
requires C 51.42; H 4.31; N 9.99 %; M, 280.0518); Vmax/crrr1 (KBr disc) 3100s 
(Ar-H), 2950s (CHX), 2 1 2 0w (CN), 1720s (ap-unsaturated carbonyl), 1500s 
(C-N02), 1340b (-OCOR),835s and 810s (2 x Ar-H); 8H (200  MHz, DMSO-d6) 
8.65 (brs, 1H, 7-H), 8.22 (d, 3J  4 .5  Hz, 1H, 4'-H), 8.03 (d, 3J  4.5 Hz, 1H, 3'-H), 
4.26 (t, 3J 6.4 Hz, 2H, 4-H2), 1.72-1.58 (tt, 3J  7.2 Hz, 3J 6.4 Hz, 2H, 3-H2), 
1.48-1.29 (tq, 3J  7.2 Hz, 3J 7.2 Hz, 2H, 2-H2), 0.91 (t, 3J  7.2 Hz, 3H, CH3); 
8C (50 MHz, DMSO-d6) 161.0 (s, C=0), 155.1 (d, 4'-C), 146.4 (s, 5'-C), 140.3 
(s, 2'-C), 138.1 (d, 3'-C), 129.6 (d, 7-CH), 115.0 (s, CN), 103.4 (s, 6 -C), 66.3 (t,
4-CH2), 30.0 (t, 3-CH2), 16.6 (t, 2-CH2), 13.6 (q, CH3); m/z280 (M+, 18 %), 234 
(M+ - N 02), 179 (M+ - C 02nBu).
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'Butyl 2-cyano-3-[2-(5-nitrothienyl)]propenoate (104)
4 ' 3 '
OoN
NC
5-Nitro-2-thiophenecarbaldehyde (0.4513 g, 2.87 mmol) was treated with *butyl 
cyanoacetate (0.4155 g, 2.94 mmol) in ethanol (7.5 ml) and piperidine (2 drops) 
using General Procedure A, to give a beige precipitate after 1 h (0.4893 g, 
61 %), m.p. 167-170 °C. R f 0.73 (1:1 ethyl acetate/petroleum ether); (Found: 
C 51.21; H 4.35; N 9.96 %; M+, 280.0522. C12H12N2O4S requires C 51.42; 
H 4.31; N 9.99 %; M, 280.0518); vmax/cm-1 (KBr disc) 3105s (Ar-H), 2986s and 
2355s (CHX), 2225w (CN), 1728s (C=C), 1605s (extended conjugation to 
aromatic system), 1532s and 1343s (C-N02), 1396s and 1373s (C-H), 839s and 
824s (2 x Ar-H); 5H (200  MHz, DMSO-d6) 8.57 (s, 1H, 7-H), 8.23 (d, 3J 4.0 Hz, 
1H, 4'-H), 8.04 (d, 3J 4.0 Hz, 1H, 3'-H), 1.58 (s, 9H, lBu); 5C (50 MHz, 
DMSO-de, 333K) 159.6 (s, C=0), 154.7 (s, 5’-C), 145.5 (d, 4'-CH), 140.2 (s, 
2-C), 137.1 (d, 3'-CH), 129.4 (d, 7-CH), 115.0 (s, CN), 105.0 (s, 6 -C), 83.9 (s, 
C(CH3)3), 27.3 (s, 3 x CH3); m/z 280 (M+, 100  %), 234 (M+ - N 02), 224 (M+ 
- *Bu, + H), 191 (M+-C02'Bu), 57 ('Bu+).
2-Cyano-3-[2-(5-nitrothienyl)]propenamide (106)169
4 ' 3 '
NC
Using General Procedure A, 5-nitro-2-thiophenecarbaldehyde (0.50 g,
3.2 mmol) was treated with 2-cyanoacetamide (0.30 g, 3.5 mmol) in ethanol 
(15 ml) and 5 drops piperidine to give a brown precipitate after 30 min (4.8 g, 
15%), m.p. 230-232 °C. Rf 0.58 (ethyl acetate); (Found: C 43.26; H 2.43; 
N 18.66 %; M+, 223.0041. C8H5N30 3S requires C 43.05; H 2.25; N 18.82 %; M, 
223.0052); Vmax/cm'1 (KBr disc) 3350s and 3250m (-CONH2), 2920s (Ar-H), 
2 2 0 0 w (CN), 1690s (extended conjugation to aromatic system), 1500m 
(C-NO2), 821m (Ar-H); 5H (200  MHz, DMSO-d6) 8.46 (s, 1H, 3-H), 8.24 (d, 
3JAA  Hz, 1H, 4'-H), 8.03 and 7.96 (2 br s, 2H, NH2), 7.90 (d, 3J  4 .4  Hz, 1H, 
3T-H); 5c (50 MHz, DMSO-d6) [lit.: 25 MHz, DMSO-d6] 161.5 [161.3] (s, C=0),
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154.1 [153.9] (s, 5'-C), 142.6 [142.8] (d, 3-CH), 141.1 [141.0] (s, 2'-C), 136.7 
[135.8] (d, 3'-CH), 129.7 [129.5] (d, 4'-CH), 115.9 [115.7] (s, CN), 107.5 [107.4] 
(s, 2-C); m/z223 (M+, 11 %), 179 (M+ -CONH2), 177 (M+ - N 02).
2-Cyano-3-[2-(5-nitrothienyl)]propenethioamide (107)
4 ' 3 '
o2n s
NC NH2
A round-bottomed flask was charged with 5-nitro-2-thiophenecarbaldehyde 
(0.50 g, 3.2 mmol) in absolute ethanol (10 ml). The solution was cooled to 
-78 °C. To this was added 2 -cyanothioacetamide (0.40 g, 4.0 mmol) dissolved 
in absolute ethanol (5 ml) and diethylamine (5 drops from a pasteur pipette). 
The mixture was stirred at -78 °C for 30 min until precipitation of the product 
had occurred. The precipitate was filtered, washed (hexane) and dried (diethyl 
ether) under suction to give a dark brown product (0.33 g, 44 %) which needed 
no further purification, m.p. 134-137 °C. R f 0.47 (ethyl acetate); (Found: 
C 40.32; H 2.14; N 17.40 %; M+, 238.9849. C8 H5N30 2S2 requires C 40.16; 
H 2.10; N 17.56 %; M, 238.9823); Vmax/cm-1 (KBr disc) 3145s (Ar-H), 2190w 
(CN), 1470s (C-N02), 1460b (CSNH2); W  (DMSO)/nm 365; 6H (200 MHz, 
DMSO-de) 8.36 (s, 1H, 3-H), 8.22  (d, 3J 4.4 Hz, 1H, 4'-H), 7.98 and 7.95 (2 br 
s, 2 H, NH2), 7.90 (d, 3J 4 .4  Hz, 1H, 3'-H); 6 C (50 MHz, DMSO-d6) 162.4 (s, 
C=S), 148.8 (s, 5'-C), 141.8 (d, 4'-CH), 140.7 (s, 2'-C), 134.2 (s, 3'-C), 127.3 (d,
3-CH), 112.4 (s, CN), 104.3 (s, 2-C); m/z239 (M+, 24.0 %), 193 (M+ - N 02), 
179 (M+ -CSNH2).
2-Cyano-3-[4-(2-nitrothienyl)]-1-(2-thienyl)propene (108)
2-Nitro-4-thiophenecarbaldehyde (0.1984 g, 1.26 mmol) was treated with 
2-thiopheneacetonitrile (0.1678 g, 1.51 mmol) in ethanol (3 ml) and piperidine 
(5 drops) using General Procedure A to give dark crystals after 8 d (0.0469 g, 
15 %), m.p. 245 °C. R f 0.45 (1:1 ethyl acetate/petroleum ether); (Found:
4 ’ 3 ’
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C 50.40; H 2.28; N 10.65 %; M+, 261.9875. C11H6N2O2S2 requires C 50.37; 
H 2.30; N 10.68 %; M, 261.9871); Vmax/cm-1 (KBr disc) 2970s (Ar-H), 2220w 
(CN), 1615s (extended conjugation to aromatic system), 1500 (C-N02), 819m 
(Ar-H); 8H (200 MHz, DMSO-d6) 8.43 (s, 1H, 2-H), 8.30-7.45 (m, 5H, 2', 4', 3", 
4” and 5“-H); 6C (50 MHz, DMSO-d6) 152.1 (s, 5'-C), 147.2 (d, 4'-CH), 139.0 (d,
2-CH), 133.5 (s, 3'-C), 133.2 (s, 2"-C), 130.1 (d, 2-CH), 127.3 and 127.0 (2 x d, 
3" and 5"-CH), 125.6 (d, 4"-CH), 116.4 (s, CN), 106.2 (s, 1 -C); m/z 262 (M+, 15 
%), 216 (M+ -N02), 179 (M+ -thiophene + H), 82 (thiophene+).
3-Dichloromethy l-2-nitrothiophene (112)170
JcHCIj
A flame-dried, 3-necked round-bottom flask, equipped with a magnetic stirrer, 
low-temperature thermometer, nitrogen bubbler, pressure-equilibrated dropping 
funnel and acetone/dry ice bath was set up, containing a dispersion of 
potassium fbutoxide (11.5107 g, 102.6 mmol) in dry DMF (25 ml) and distilled 
THF (25 ml). 2-Nitrothiophene (4.4146 g, 34.18 mmol) dissolved in dry dimethyl 
formamide (6 ml) and chloroform (6 ml, 74.9 mmol) was added to the flask over 
a period of about 2 h. The temperature during addition was not allowed to 
exceed -50 °C. Upon completion of addition of this solution, the reaction mixture 
was immediately quenched with a 1:1 solution of acetic acid in methanol 
(22 ml). Excess acid was neutralised using aqueous NaHC0 3 , and the thick 
brown slurry which formed was allowed to warm to room temperature and was 
washed with water (101 ml) and extracted into ether (3 x 100 ml). The ethereal 
extracts were dried (MgS0 4 ) and concentrated in vacuo to a black viscous tar. 
Column chromatography over silica (5:1 hexane/ethyl acetate) yielded the 
product as large brown crystals upon recrystallisation from methanol. (6.8223 g, 
94 %), m.p. 70-72 °C, R f 0.75 (1:1 ethyl acetate/petroleum ether). 
6h (200 MHz, acetone-de) 8.04 (d, 3J 5.7 Hz, 1H, 5'-H), 7.75 (s, 1H, 1-H), 7.70 
(d, 3 j 5 .7  Hz, 4'-H) ;6 C (50 MHz, acetone-d6) 140.9 (s, 2'-C), 130.0 (d, 5'-CH),
128.9 (d, 4'-CH), 125.0 (s, 3'-C), 63.9 (d, CHCI3).
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2-Nitro-3-thiophenecarbaldehyde (83)170
CHO 
N02
3-Dichloromethyl-2-nitrothiophene (112) (6.8223 g, 32.17 mmol) and an 85 % 
w/v aqueous solution of formic acid (101 ml) were heated at reflux temperature 
under a nitrogen atmosphere for 22  h. The mixture was cooled to room 
temperature, and the excess formic acid was neutralised using aqueous sodium 
bicarbonate solution. The mixture was extracted with diethyl ether (5 x 100 ml), 
and the combined ethereal extracts were concentrated in vacuo. Flash column 
chromatography over Si0 2  using 3:1 hexane/ethyl acetate, followed by 
concentration in vacuo gave a brown oil, which solidified at room temperature. 
The product was recrystallised from ethyl acetate to give fine brown needles 
(1.4391 g, 28 %), m.p. 59 [lit.: 54]170 °C, Rf 0.58 (1:1 ethyl acetate/petroleum 
ether); (Found: C 38.06; H 1.87; N 11.12 %; M+, 156.9846. C5 H3NO3S requires 
C 38.21; H 1.92; N 11.22 %; M, 156.9834); V m a x /c n r r 1 (KBr disc) 3096s (Ar-H), 
3080s (Ar-H) 1694s (Ar-CHO), 1534 (C-NO2); 8h (2 0 0  MHz, DMSO-d6) 
[lit.: 90 MHz, DMSO-d6] 10.61 [10.70] (s, 1H, -CHO), 7.95 (d, 3J 5.4 Hz, 5'-H), 
7.78 (d, 3J 5.4 Hz, 4'-H); 8 C (50 MHz, DMSO-d6) 183.9 (d, -CHO), 133.0 (s, 
2-C), 131.0 (d, 5'-CH), 126.7 (d, 4'-CH), 126.0 (s, 3'-C); m/z 157 (M+, 2 %), 111 
(M +-N 02).
2-Cyano-3-[2-(3-nitrothienyl)]propenonitrile (113)
1
CN
CN
5
Using General Procedure C, 2-nitro-3-thiophenecarbaldehyde (83) (0.2295 g, 
1.46 mmol) was treated with malononitrile (0.1041 g, 1.57 mmol) in ethanol 
(7 ml) to give a brown precipitate after 12 h (0.2288 g, 77 %), m.p. 192-196 °C. 
Rf 0.67 (1:1 ethyl acetate/petroleum ether); (Found: C 46.67; H 1.48; 
N 20.69 %; M+, 204.9962. C8H3N3O2S requires C 46.83; H 1.47; N 20.48 %; 
M, 204.9946); vmax/crrv1 (KBr disc) 3038s (Ar-H), 2230w (CN), 1636s 
(extended conjugation to aromatic system), 1580s (aromatic C=C), 1522s 
(C-NOg), 870w and 834w (2 x Ar-H); 5H (200  MHz, DMSO-d6) 8.72 (s, 1H, 3-H), 
8.22 (d, 3J 5.7 Hz, 1H, 5'-H), 7.76 (d, 3j  5 .7  Hz, 1H, 4'-H); 8 C (50 MHz,
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DMSO-de) 152.2 (d, 3-CH), 134.3 (d, 5'-CH), 131.6 and 131.5 (2 x s, 2 '-C and 
3'-C), 127.3 (d, 3-CH), 125.7 (s, 5'-C), 113.3 and 112.2  (2 x s, 2 x CN), 88.3 (s, 
2 -C); m/z205 (M+, 46 %), 159 (M+ - N02), 82 (thiophene+).
2,4-Dicyano-3-amino-5-[3-(2-nitrothienyl)]penta-2,4-dienonitrile (114)
2-Nitro-3-thiophenecarbaldehyde (83) (0.1046 g, 0.67 mmol) was treated with 
2-aminopropene-1,1,3-tricarbonitrile (0.0914 g, 0.69 mmol) in ethanol (6 ml) and 
dilute piperidine solution (2 drops) using General Procedure B, to give brown 
crystals after 48 h (0.1351 g, 75 %), m.p. 209-211 °C. RF 0.58 (1:1 ethyl 
acetate/petroleum ether); (Found: C 48.86; H 1.91; N 25.91, S 11.84%; M+, 
271.0146. C11H5N5O2S requires C 48.71; H 1.82; N 25.82, S 11.81 %; M, 
271.0164); vmax/cm-l (KBr disc) 3052s (Ar-H), 2726s (NH2), 2223m and 2209m 
(2 x CN), 1647s (external conjugation to aromatic system), 1607 (aromatic 
C=C), 1489s (C-NO2), 820w (Ar-H); 6H (200  MHz, DMSO-d6) 9.27 (br s, 2 H, 
-NH2), 8.40 (s, 1H, 5-H), 8.23 (d, 3 j 5.6  Hz, 1H, 5'-H), 7.78 (d, 3J 5 .6 Hz, 1H, 
5'-H); 6 C (50 MHz, DMSO-d6) 164.0 (s, 2 ’-C), 151.2 (s, 3'-C), 144.5 (d, 5'-CH),
134.3 (d, 4'-CH), 132.2 (s, 3-C), 127.2 (d, 5-CH), 115.1, 114.4 and 114.0 (3 x s, 
3 x CN), 108.8 (d, 4-CH), 108.2 (s, 2-C); m/z 270 (M+, 2 %), 245 (M+ - CN), 
225 (M+ - N02), 82 (thiophene+), 92 (C(NH2 )=C(CN)2+).
Methyl 2-cyano-3-[3-(2-nitrothienyl)]propenoate (115)
Using General Procedure A, 2-nitro-3-thiophenecarbaldehyde (83) (0.1650 g,
1.05 mmol) was treated with methyl cyanoacetate (0.1164 g, 1.17 mmol) in 
methanol (1 ml) and piperidine (5 drops) to give brown crystals after 10 min 
(0.1921 g, 77 %), m.p. 119-121 °C. Rf 0.46 (1:1 ethyl acetate/petroleum ether);
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(Found: C 45.28; H 2.57; N 11.59 %; M+, 238.0056. C9 H6N2O4 S requires 
C 45.38; H 2.54; N 11.76 %; M, 238.0048); Vmax/cnr1 (KBr disc) 3125m (Ar-H), 
2250w (CN), 1717s (a(3-unsaturated carbonyl), 1530m (C-NO2) 820m (Ar-H); 
8h (200  MHz, DMSO-d6) 9.00 (s, 1H, 4-H), 8.28 (d, 3J5.7 Hz, 1H, 5'-H), 7.83 (d, 
3J 5.7 Hz, 1H, 4'-H), 3.86 (s, 3H, CH3); 8c (50 MHz, DMSO-d6) 161.6 (s, C=0),
145.7 (d, 5'-CH), 143.0 (s, 2'-C), 133.9 (d, 4'-CH), 132.5 (s, 3’-C), 127.5 (d,
4-CH), 114.6 (s, CN), 108.2 (s, 3-C), 53.9 (q, CH3); ^ 2 3 8  (M+, 9 %), 192 (M+ 
- N02), 179 (M+ - C 02Me), 59 (C02Me).
Ethyl 2-cyano-3-[3-(2-nitrothienyl)]propenoate (116)
CN
2-Nitro-3-thiophenecarbaldehyde (83) (0.2245 g, 1.43 mmol) was treated with 
ethyl cyanoacetate (0.1694 g, 1.49 mmol) in ethanol (7 ml) and dilute piperidine 
solution (1 drop) using General Procedure B to give a brown precipitate after 
10 min (0.1650 g, 45 %), m.p. 89 °C. Ftp 0.63 (1:1 ethyl acetate/petroleum 
ether); (Found: C 47.55; H 3.14; N 11.09 %; M+, 252.0221. C 10H8N2O4S 
requires C 47.62; H 3.20; N 11.11 %; M, 252.0205); vmax/cm-i (KBr disc) 
3115m (Ar-H), 1725s (a^-unsaturated carbonyl), 1607s (extended conjugation 
to aromatic system), 1532s (C-NO2), 1501s (aromatic C=C), 819m (Ar-H); 
8H (200  MHz, DMSO-d6) 8.72 (s, 1H, 5-H), 8 .20  (d, 3J5.6 Hz, 1H, 5'-H), 7.83 (d, 
3J 5 .6  Hz, 1H, 4'-H), 8.36 (q, 3J 7.1 Hz, 2H, CH2), 1.36 (t, 3J 7.1 Hz, 3 H, CH3); 
8C (50 MHz, DMSO-d6) 161.0 (s, C=0), 145.3 (d, 5'-CH), 142.7 (s, 2 '-C), 133.9 
(d, 4'-CH), 132.4 (s, 3'-C), 127.4 (d, 5 -CH), 114.6 (s, CN), 108.4 (s, 4-C), 63.0 (t, 
CH2), 14.0 (s, CH3); m/z252 (M+, 7 %), 206 (M+ - N 02), 179 (M+ - C 02Et).
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nButyl 2-cyano-3-[3-(2-nitrothienyl)]propenoate (117)
2-Nitro-3-thiophenecarbaldehyde (83) (0.2209 g, 1.41 mmol) was treated with 
nbutyl cyanoacetate (0.1992 g, 1.41 mmol) in ethanol (3 ml) and piperidine 
(1 drop) using General Procedure A, to give yellow crystals after 10 min 
(0.1328 g, 33 %), m.p. 67-69 °C. R f 0.53 (1:1 ethyl acetate/petroleum ether); 
(Found: C 51.36; H 4.35; N 9.87 %; M+, 280.0517. C12H12N2O4S requires 
C 51.42; H 4.31; N 9.99 %; M, 280.0518); v max/cm-i (KBr disc) 3120w (Ar-H), 
2250w (CN), 1725s (C=0), 1608s (extended conjugation to aromatic system), 
1530s (C-NO2), 1522s (aromatic C=C), 822s (Ar-H); 5h (200  MHz, DMSO-d6) 
8.82 (s, 1H, 7-H), 8.20 (d, 3J 5.6 Hz, 1H, 5'-H), 7.86 (d, 3J5.6  Hz, 1H, 4'-H), 
4.35 (t, 3J 6.4 Hz, 2 H, 4-H2), 1.80-1.66 (tt, 3J 7.8 Hz, 3J 6.4 Hz, 2 H, 3-H2), 
1.55-1.37 (tq, 3J 7.8 Hz, 3J 7.1 Hz, 2H, 2-H2), 0.93 (t, 3J 7.1 Hz, 3H, CH3); 
8C (50 MHz, DMSO-de) 161.0 (s, C=0), 145.4 (d, 5'-CH), 133.9 (d, 4'-CH),
132.4 (s, 2'-C), 127.4 (d, 7-CH), 125.7 (s, 3'-C), 114.6 (s, CN), 106.4 (s, 6 -C),
66.5 (t, 4 -CH2 ), 30.1 (t, 3-CH2), 18.7 (t, 2-CH2), 13.6 (q, CH3); m/z 280 (M+, 
4 %), 234 (M+ - N02), 181 (M+ - C 02nBu, - 2H).
'Butyl 2-cyano-3-[3-(2-nitrothienyl)]propenoate (118)
O
i  f  CN 
5 N02
2-Nitro-3-thiophenecarbaldehyde (83) (0.0757 g, 0.48 mmol) was treated with 
'butyl cyanoacetate (0.10 ml, 0.70 mmol) in propan-2-ol (2 ml) and piperidine 
(1 drop) using General Procedure A to give brown crystals after 24 h (0.1077 g, 
80 %), m.p. 171-173 °C. Rf 0.69 (1:1 ethyl acetate/petroleum ether); (Found: 
C 51.69; H 4.26; N 9.95%; M+, 280.0546. C i2H 12N20 4 S requires C 51.42; 
H 4.31; N 9.99 %; M, 280.0518); vmax/cm-1 (KBr disc) 3105s (Ar-H), 2222m 
(CN), 1724s (ap-unsaturated carbonyl), 1640s (ap-unsaturated ester), 1614s 
(extended conjugation to aromatic system), 1540m (C-N02), 886w and 860w
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8 86w and 860w (2 x Ar-H); 6H (200  MHz, DMSO-d6) 8.92 (s, 1H, 7-H), 7.92 (d, 
3J 5.6 Hz, 1H, 5'-H), 8.18 (d, 3J 5.6 Hz, 1H, 4'-H), 1.47 (s, 9H, *Bu); 8C (50 MHz, 
DMSO-de) 163.4 (s, C=0), 140.1 (s, 2 '-C), 134.1 (d, 5'-CH), 128.2 (d, 4'-CH),
126.4 (d, 7-CH), 125.5 (s, 6 -C), 115.4 (s, CN), 27.6 (q, 3 x CH3), 25.6 (s, 
0(CH3)3); m/z 280 (M+, 15%), 234 (M+ - N 02), 223 (M+ - *Bu), 179 (M+ 
-0 0 2 ^ 11), 57 (*Bu).
2-Cyano-3-[3-(2-nitrothienyl)] propenamide (120)
O
CN
2-Nitro-3-thiophenecarbaldehyde (83) (0.1586 g, 1.01 mmol) was treated with 
2-cyanoacetamide (0.0849 g, 1.01 mmol) in ethanol (4 ml) and piperidine 
(1 drop) using General Procedure A, to give a brown precipitate after 50 h 
(0.0718 g, 31 %), m.p. 216-217 °C. Rf 0.56 (1:1 ethyl acetate/petroleum ether); 
(Found: C 43.04; H 2.31; N 19.01 %; M+, 223.0059. C8 H5N30 3S requires 
C 43.05; H 2.25; N 18.82 %; M, 223.0052); Vmax/cm-1 (KBr disc) 3455s and 
3380s (-CONH2), 3077b (Ar-H), 2200m (CN), 1618s (extended conjugation to 
aromatic system), 1516w (-CONH2), 1495m (aromatic C=C), 824s (Ar-H); 
5h (200  MHz, DMSO-de) 8.20 (s, 1H, 3-H), 8.19 (d, 3J5.6 Hz, 1H, 5'-H), 8.08 (br 
s, 2 H, NH2), 7.79 (d, 3J 5.6 Hz, 1H, 4'-H); 6 C (50 MHz, DMSO-d6) 161.3 (s, 
C=0), 141.9 (d, 5'-CH), 139.5 (s, 2'-C), 133.8 (d, 4'-CH), 131.7 (s, 3'-C), 127.7 
(d, 3-CH), 115.3 (s, -CN), 112.3 (s, 2-C); m/z223 (M+, 5 %), 179 (M+ - CONH2), 
177 (M+ - N 02).
2-Cyano-3-[3-(2-nitrothienyl)]propenethioamide (121)
S
CN
5
Using General Procedure C, 2-nitro-3-thiophenecarbaldehyde (83) (0.1226 g, 
0.78 mmol) was treated with 2-cyanothioacetamide (0.0801 g, 0.80 mmol) in
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propan-2-ol (4 ml) to give beige crystals after 10 min (0.1594 g, 85 %), m.p. 
89-91 °C. R f 0.55 (1:1 ethyl acetate/petroleum ether); (Found: C 40.23; H 2.15; 
N 17.66 %; M+, 238.9787. C8 H5N3O2S2 requires C 40.16; H 2.10; N 17.56 %; 
M, 238.9823); v max/cnrl (KBr disc) 3096s (Ar-H), 2188m (CN), 1625s 
(extended conjugation to aromatic system), 1507s (C-NO2), 1459s (CSNH2), 
818w (Ar-H); 6 H (200 MHz, DMSO-d6) 9.84 and 9.55 (2 x br s, 2H, NH2), 8.05 
(d, 3J 5.6 Hz, 1H, 5'-H), 7.73 (s, 1H, 3-H), 7.62 (d, 3 j 5.6 Hz, 1H, 4'-H); 
6c (50 MHz, DMSO-d6) 168.2 (s, C=S), 143.1 (d, 5'-CH), 140.2 (s, 2'-C), 138.1 
(d, 4'-CH), 134.2 (s, 3'-C), 128.4 (d, 3-CH), 116.1 (s, CN), 111.8 (s, 2-C); m/z 
239 (M+, 8  %), 192 (M+ - N 02 - H), 178 (M+ - CSNH2 - H).
2-Cyano-3-[4-(2-nitrothienyl)]propenonitrile (122)116 118
1
CN
Using General Procedure C, 2-nitro-4-thiophenecarbaldehyde (0.4985 g, 
3.17 mmol) was treated with malononitrile (0.5680 g, 8.60 mmol) in ethanol 
(5 ml) to give a pink precipitate after 10 min (0.4096 g, 63 %), m.p. 104-106 °C. 
R f 0.60 (ethyl acetate); (Found: C 46.75; H 1.52; N 20.54; S 15.70 %; M+, 
204.9926. C8 H3N3O2S requires C 46.83; H 1.47; N 20.48; S 15.61 %; M, 
204.9946); Vmax/cm-1 (nujol) 3103s (Ar-H), 2233s (CN), 1597s (C=C), 1508s 
(C-NO2), 819s (isolated Ar-H); 6h (2 0 0  MHz, DMSO-d6) 8.76-8.74 (dd, 
4J  1.9 Hz, 4J 0.5 Hz, 1H, 3-H), 8.48-8.47 (dd, 4J 0.9 Hz, 4J0.5 Hz, 1H, 4'-H), 
8.46-8.44 (dd, 4J 1.9 Hz, 4JOS Hz, 1H, 2 '-H); 5C (50 MHz, DMSO-d6) 153.4 (d,
3-CH), 152.8 (s, 5'-C), 143.5 (d, 4'-CH), 132.0 (s, 3'-C), 127.5 (d, 2 '-CH), 113.6 
and 112.9 (2 x s, 2 x CN), 82.0 (s, 2-C); m/z 205 (M+, 67 %), 159 (M+ - N02).
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2,4-Dicyano-3-amino-5-[4-(2-nitrothienyl)]penta-2,4-dienonitrile (123)
H2N
o2n
Using General Procedure A, 2-nitro-4-thiophenecarbaldehyde (0.5205 g, 
3.32 mmol) was treated with 2-aminopropene-1,1,3-tricarbonitrile (0.4415 g,
3.34 mmol) in ethanol (15 ml) and piperidine (3 drops) to give large brown 
crystals after 8 d (0.6750 g, 75 %), m.p. 153-155 °C. R f 0.50 (1:1 ethyl 
acetate/petroleum ether); (Found: C 48.98; H 1.99; N 26.04 %; M+, 271.0168. 
C11H5N5O2S requires C 48.71; H 1.84; N 25.82 %; M, 271.0164); v m a x / c n r 1 
(KBr disc) 3038w (Ar-H), 2230s (CN), 1636s (extended conjugation to aromatic 
system), 1522s (C-N02), 870s and 834s (2 x Ar-H); 8h (200  MHz, DMSO-d6) 
9.10 (br, 2H, -NH2), 8.58 (d, 4J 2.3 Hz, 1H, 4'-H), 8.70 (d, 4J2.3 Hz, 1H, 2'-H),
8.15 (s, 1H, 5-H); 8C (50 MHz, DMSO-d6) 164.6 (s, 5'-C), 152.9 (s, 3'-C), 145.8 
(d, 4'-CH), 141.6 (d, 2'-CH), 132.4 (s, 4-C), 127.6 (d, 5-CH), 115.4, 114.7, 114.6 
(3x s, 3 x CN), 102.6 (s, 2-C), 50.1 (s, 3-C); m/z 271 (M+, 65 %), 225 (M+ 
- N02), 141 (M+ - [C(CN)-C(NH2)=C(CN)2]), 92 ([C(NH2)=C(CN)2]+).
Methyl 2-cyano-3-[4-(2-nitrothienyl)]propenoate (124)
Using General Procedure B, 2-nitro-4-thiophenecarbaldehyde (0.1361 g, 
0.86 mmol) was treated with methyl cyanoacetate (0.1248 g, 1.26 mmol) in 
methanol (2.5 ml) and dilute piperidine solution (20 drops) to give orange 
crystals after 10 min (0.1764 g, 86  %), m.p. 88  °C. R f 0.49 (1;1 ethyl 
acetate/petroleum ether); (Found: C 45.42; H 2.49; N 11.80 %; M+, 238.0026. 
C9H6N2O4S requires C 45.38; H 2.54; N 11.76 %; M, 238.0048); v max/cm' 1 
(nujol) 3100s (Ar-H), 2950s (CHX), 1720s (ap-unsaturated carbonyl), 1500s 
(C-NO2), 1340b (-OCOR), 835s and 815s (2 x Ar-H); 5H (200  MHz, DMSO-d6) 
8 .86  (d, 4J 0.5 Hz, 1H, 4'-H), 8.62 (d, 4J 0.5 Hz, 1H, 2’-H), 8.45 (s, 1H, 4-H),
3.85 (s, 3H, CH3); 8c (50 MHz, DMSO-d6) 207.4 (s, C=0), 162.0 (s, 5'-C), 152.6 
(d, 4'-CH), 147.2 (d, 2 '-CH), 142.9 (s, 3'-C), 132.5 (d, 4-CH), 115.5 (s, CN),
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102.3 (s, 3-C), 53.5 (q, CH3); m/z 238 (M+ 21 %), 192 (M+ - N 02), 179 (M+ 
- C02 Me), 59 (CQ2Me+).
Ethyl 2-cyano-3-[4-(2-nitrothienyl)]propenoate (125)
O 2
o2n
2-Nitro-4-thiophenecarbaldehyde (0.1651 g, 1.05 mmol) was treated with ethyl 
cyanoacetate (0.1831 g, 1.62 mmol) in methanol (2 ml) and dilute piperidine 
solution (20 drops) using General Procedure B to give orange crystals after 
10 min (0.2536 g, 95 %), m.p. 140-141 °C. Rf 0.45 (1:1 ethyl acetate/petroleum 
ether); (Found: C 47.49; H 3.20; N 10.94 %; M+, 252.0195. C i0H8N2O4S 
requires C 47.62; H 3.17; N 11.11 %; M, 252.0205); V m a x /c r r r 1 (KBr disc) 3100s 
(Ar-H), 2240s (CN), 1450s (C-N02), 1300s (-OCOR); 6H (200 MHz, DMSO-d6)
8 .86  (d, 4J 1.9 Hz, 1H, 4'-H), 8.63 (d, 4J 1.9 Hz, 1H, 2'-H), 8.42 (s, 1H, 5-H), 
4.30 (q, 3J 7.1 Hz, 2H, CH2), 1.29 (t, 3j y .1 Hz , 3H, CH3); 8C (50 MHz, 
DMSO-de) 161.5 (s, C=0 ) , 152.5 (s, 5'-C), 147.1 (d, 4'-CH), 142.8 (d, 2 '-CH),
132.6 (s, 3'-C), 128.3 (d, 5-CH), 115.5 (s, CN), 103.0 (s, 4-C), 62.6 (t, CH2),
14.0 (q, CH3); m/z252 (M+, 19 %), 206 (M+ - N02), 179 (M + - C02 Et).
nButyl 2-cyano-3-[4-(2-nitrothienyl)]pentanoate (126)
2-Nitro-4-thiophenecarbaldehyde (0.1713 g, 1.09 mmol) was treated with ^butyl 
cyanoacetate (0.22 ml , 1.61 mmol) in propan-2-ol (3 ml) and dilute piperidine 
solution (1 drop) using General Procedure B to give a pink crystalline solid after 
10 min (0.1733 g, 57 %), m.p. 142-144 °C. R f 0.70 (1:1 ethyl acetate/petroleum 
ether); (Found: C 51.28; H 4.32; N 9.97 %; M+, 280.0517. C i2H12N204S 
requires C 51.42; H 4.31; N 9.99 %; M, 280.0518); vmax/cm-1 (KBr disc) 3100s 
(Ar-H), 2200w (CN), 1718w (ap-unsaturated carbonyl), 1610w (external
148
conjugation to aromatic system), 1491s (C-NO2), 817w (isolated Ar-H); 
8h  (2 0 0  MHz, DMSO-d6) 8 .8 6  (m, 1H, 4'-H), 8.64 (m, 1H, 2 '-H), 8.42 (m, 1H,
7-H), 4.26 (t, 3J6.5 Hz, 2 H, 4-H2), 1.69-1.58 (tt, 3J6.4 Hz, 3J6.5 Hz, 2H, 3-H2), 
1.44-1.34 (tq, 3J 7 .2  Hz, 3J6.4 Hz, 2 H, 2 -H2), 0.94-0.87 (t, 3J 7.2 Hz, 3H, CH3); 
8C (50 MHz, DMSO-d6) 161.5 (s, C=0), 152.5 (s, 5'-C), 147.1 (d, 4'-CH), 142.7 
(d, 2 '-CH), 132.6 (s, 3'-C), 128.4 (d, 7-CH), 115.5 (s, CN), 103.0 (s, 6 -C), 66.1 (t,
4-CH2), 30.0 (t, 3 -CH2, 18.6 (t, 2-CH2), 13.6 (q, CH3); m/z 280 (M+, 8 %), 234 
(M+ - N 02), 69 ([C(CN)-C02nBu]2+), 57 (nBu+).
'Butyl 2-cyano-3-[4-(2-nitrothienyl)]propenoate (127)
CN
Using General Procedure A, 2-nitro-4-thiophenecarbaldehyde (0.4030 g, 
2.56 mmol) was treated with 'butyl cyanoacetate (0.36 ml, 2.56 mmol) in 
ethanol (6 ml) and piperidine (1 drop) to give a red precipitate after 2 0  min 
(0.4475 g, 62 %), m.p. 165-167 °C. Rf 0.60 (1:1 ethyl acetate/petroleum ether); 
(Found: C 51.39; H 4.03; N 10.00 %; M+, 280.0516. C i2H12N20 4S requires 
C 51.42; H 4.31; N 9.99 %; M, 280.0518); vmax/cm-1 (KBr disc) 2226m (CN), 
1772s (C=C), 1726s (ap-unsaturated carbonyl), 1636s (ap-unsaturated ester), 
1614s (extended conjugation to aromatic system), 1350m (C-N02), 8 8 6w and 
860w (2 x Ar-H); 8H (200  MHz, DMSO-d6) 8.87 (d, 4J 1 .9 Hz, 1H, 4'-H), 8.67 (d, 
4J 1.9 Hz, 1H, 2 '-H), 8.38 (s, 1H, 7-H), 1.57 (s, 9H, (Bu); 8c (50 MHz, DMSO-d6)
160.3 (S, C=0), 152.4 (s, 5'-C), 148.5 (d, 4'-CH), 142.3 (d, 2'-CH), 132.6 (s,
3-C), 128.3 (d, 7-CH), 115.5 (s, CN), 104.4 (s, 6 -C), 83.6 (s, C(CH3)3), 27.5 (s, 
3 x CH3); m/z280 (M+, 5 %), 234 (M+ - N 02), 223 (M+ - fBu).
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2-Cyano-3-[4-(2-nitrothienyl)]propenamide (129)
O
CNOoN
2-Nitro-4-thiophenecarbaldehyde (0.1997 g, 1.27 mmol) was treated with 
2 -cyanoacetamide (0.1241 g, 1.47 mmol) in ethanol (4 ml) using General 
Procedure C to give brown crystals after 10 min (0.1971 g, 69 %), m.p. 
223-225 °C. R f 0.44 (1:1 ethyl acetate/petroleum ether); (Found: C 43.02; 
H 2.22; N 18.90 %; M+, 223.0069. C8H5N3O3S requires C 43.05; H 2.25; 
N 18.82 %; M, 223.0052); vmax/cm-1 (KBr disc) 3422w, 3335w and 3289w 
(-CONH2 ), 3125s (Ar-H), 2849w (NH2), 2 2 0 0 w (CN), 1686s (external 
conjugation to aromatic system), 1597s (amide N-H), 1526s (C-NO2), 1491s 
(aromatic C=C); 6 h  (200  MHz, DMSO-d6) 8.63 (d, 4J 1.7 Hz, 1H, 4'-H),8.50 (d, 
4J 1.7 Hz, 1H, 2 '-H), 8.13 (s, 1H, 3-H), 7.84 and 7.80 (2 br s, 2H, -NH2); 
6C (50 MHz, DMSO-de) 162.0 (s, C=0), 152.5 (s, 5'-C), 143.2 (d, 4'-CH), 140.8 
(d, 2'-CH), 133.1 (s, 3'-C), 128.0 (d, 3-CH), 116.3 (s, CN), 106.9 (s, 2-C); m/z 
223 (M+, 25 %), 179 (M+ - CONH2), 177 (M+ - N02).
2-Cyano-3-[4-(2-nitrothienyl)]propenthioamide (130)
S
CNOoN
Using General Procedure C, 2-nitro-4-thiophenecarbaldehyde (0.2113 g,
1.34 mmol) was treated with 2-cyanothioacetamide (0.1687 g, 1.68 mmol) in 
ethanol (3 ml) to give brown crystals after 10 min (0.1989 g, 62 %), m.p. 
197-199 °C. R f 0.50 (1:1 ethyl acetate/petroleum ether); (Found: C 40.13; 
H 2.08; N 17.40 %; M+, 238.9813. C8H5N3O2S2 requires C 40.15;H 2.10; 
N 17.56 %; M, 238.9823); Vmax/cm' 1 (KBr disc) 3135s (Ar-H), 2215w (CN), 
1480b (CSNH2), 1470s (C-N02); §H (200  MHz, DMSO-d6) 8.69 and 8.61 (2 x s, 
2 H, NH2), 8.17 (d, 4J1.9 Hz, 1H, 4'-H), 8.11 (s, 1H, 3-H), 8.10 (d, 4J 1.9 Hz, 1H, 
2-H); 6 c (50 MHz, DMSO-d6) 156.8 (s, C=S), 152.5 (s, 5'-C), 140.9 (d, 4'-CH),
139.3 (d, 2 '-CH), 133.0 (s, 3'-C), 128.2 (d, 3-CH), 116.2 (s, CN), 112.8 (s, 2-C);
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m/z 239 (M+, 22  %), 192 (M+ - N02), 178 (M+ - CSNH2), 82 (thiophene+), 60 
(CSNH2+).
4-Nitro-2-thiophenecarbaldehyde (87)171
2-Thiophenecarbaldehyde (1.3236 g, 11.91 mmol) and concentrated sulfuric 
acid (23 ml, 0.43 mol) were placed in a conical flask, which was cooled to 
-15 °C by means of a salt/ice bath. To this was slowly added a mixture of 
concentrated sulfuric acid (17.5 ml, 0.33 mol) and fuming nitric acid (25.2 ml, 
0.63 mol) such that the temperature of the reaction mixture did not exceed 5 °C. 
The resulting black solution was neutralised using aqueous sodium bicarbonate 
solution, poured onto a slurry of ice and water and left to warm to room 
temperature overnight. The reaction was extracted with hot ethyl acetate (3 x 
1000  ml), and the organic fractions were dried (MgS0 4 ) and concentrated in 
vacuo to give a brown tar. Column chromatography (silica gel, 1:1 ethyl 
acetate/petroleum ether) gave the product, which was recrystallised from diethyl 
ether/methanol to give large orange crystals (1.4972 g, 80 %), m.p. 50 [lit.: 
35-37] °C. R f 0.73 (1:1 ethyl acetate/petroleum ether); Vmax/cnr1 (KBr disc) 
1734s (CHO), 1508s and 1366s (N02); 6 H (200  MHz, DMSO-d6) 9.26 (s, 1H, 
-CHO), 8.65 (s, 1H, 5'-H), 8.29-8.12 (br s, 1H, 3'-H); m/z 157 (M+, 100%), 111 
(M+ - N 02).
2-Cyano-3-[2-(4-nitrothienyl)]propenonitrile (132)
OoN
CN/  2
NC
4-Nitro-2-thiophenecarbaldehyde (87) (0.1005 g, 0.64 mmol) was treated with 
malononitrile (0.0430 g, 0.65 mmol) in ethanol (1.5 ml) and dilute piperidine 
solution (1 drop) using General Procedure B to give a red precipitate after 
20 min (0.0920 g, 70 %), m.p. 169-171 °C. R f 0.81 (diethyl ether); (Found: 
C 46.56; H 1.53; N 20.53 %; M+, 204.9938. C8 H3N30 2S requires C 46.83;
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H 1.47; N 20.48 %; M, 204.9946); vmax/cm-1 (KBr disc) 3038s (Ar-H), 2230w 
(CN), 1636s (extended conjugation to aromatic system), 1580s (aromatic C=C), 
1522s (C-N02), 870w and 834w (2 x Ar-H); 6H (200  MHz, DMSO-d6) 8.72 (s,
1H, 3-H), 8.22 (d, 4J 1.7 Hz, 1H, 5'-H), 7.76 (d, 4J 1.7 Hz, 1H, 3'-H); 
6C (50 MHz, DMSO-de) 151.9 (d, 3-CH), 149.2 (s, 4'-C), 136.1 (d, 5'-CH), 135.8 
(s, 2'-C), 132.1 (d, 3'-CH), 117.3 (s, 2-C), 112.6 and 113.0 (2 x s, 2 x CN); m/z 
205 (M+, 61 %), 159 (M+ - N02), 82 (thiophene+).
2,4-Dicyano-3-amino-5-[2-(4-nitrothienyl)]penta-2,4-dienonitrile (133)
NH
NC CN
NC
Using General Procedure B, 4-Nitro-2-thiophenecarbaldehyde (87) (0.2106 g,
1.34 mmol) was treated with 2-aminopropene-1,1,3-tricarbonitrile (0.1776 g,
1.34 mmol) in ethanol (3 ml) and dilute piperidine solution (2 drops) to give a 
yellow precipitate after 30 min (0.2005 g, 55 %), m.p. 271-272 °C. R f 0.16 
(diethyl ether); (Found: C 48.79; H 1.82; N 25.81 %; M+, 271.0169. 
C11H5N5O2S requires C 48.71; H 1.86; N 25.82 %; M, 271.0164); vmax/crrr1 
(KBr disc) 3052s (Ar-H), 2726s (NH2), 2223m and 2209m (2 x CN), 1647s 
(external conjugation to aromatic system), 1607m (aromatic C=C), 1489s 
(C-N02), 8 2 0 w  (Ar-H); 6H (200 MHz, DMSO-de) 9.19 and 9.17 (2 x br s, 2 H, 
NH2), 9.18 (s, 1H, 5'-H), 8.42 (s, 2 H, 5-H and 3'-H); 5C (50 MHz, DMSO-de)
164.3 (s, 3-C), 147.9 (s, 4'-C), 145.1 (d, 5-CH), 136.8 (d, 3’-CH), 130.9 (d, 
5'-CH), 130.7 (s, 2'-C), 115.4 (s, 7-CN), 114.6 and 114.5 (2 x s, 1-CN and
6 -CN), 101.2 (s, 4-C), 50.2 (s, 2-C); m/z 271 (M+, 28 %), 225 (M+ - N02), 245 
(M+ - CN), 82 (thiophene+), 92 (C(NH2)=C(CN)2+).
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Methyl 2-cyano-3-[2-(4-nitrothienyl)]propenoate (134)
0 2N
o
NC O—
4-Nitro-2-thiophenecarbaldehyde (87) (0.2164 g, 1.37 mmol) was treated with 
methyl cyanoacetate (0.12 ml, 1.37 mmol) in methanol (0.5 ml) and dilute 
piperidine solution (1 drop) using General Procedure B to give a brown 
precipitate after 20 min (0.2807 g, 86  %), m.p. 172-174 °C. R f 0.81 (diethyl 
ether); (Found: C 45.15; H 2.47; N 11.90 %; M+ 238.0031. C9H6N2O4S 
requires C 45.38; H 2.54; N 11.76 %; M, 238.0048); V m a x /c rT V 1 (KBr disc) 
3310m and 3025m (=C-H), 2958w and 2854m (CH3), 2225m (CN), 1716s 
(C=0), 1604s (Ar, C=C), 1533s (N02), 1266s (C-O), 762m and 742m (=C-H); 
6h (200  MHz, DMSO-de) 9.18 (d, 1H, 4J \ A  Hz, 5'-H), 8.69 (s, 1H, 4-H), 8.59 (d, 
4J \ A  Hz, 3'-H), 3.90 (s, 3H, CH3); 6C (50 MHz, DMSO-d6) 161.9 (s, C=0),
147.8 (s, 4'-C), 146.4 (d, 4-CH), 136.4 (d, 5'-CH), 136.0 (s, 2'-C), 132.3 (d, 
3'-CH), 115.3 (s, CN), 101.4 (s, 3-C), 53.6 (q, CH3); m/z 238 (M+, 40 %), 222 
(M+ -  CH3, - H), 207 (M+ -  OCH3), 191 (M+ -  N 02, -  H), 179 (M+ -  C 02CH3), 
160 (M+ -  N02, -  S), 133 (M+ -  N02, -  C 02CH3).
Ethyl 2-cyano-3-[2-(4-nitrothienyl)]propenoate (135)
Using General Procedure B, 4-Nitro-2-thiophenecarbaldehyde (87) (0.1833 g,
1.16 mmol) was treated with ethyl cyanoacetate (0.125 ml, 1.16 mmol) in 
ethanol (0.5 ml) and dilute piperidine solution (1 drop) to give brown crystals 
after 3 h (0.117 g, 40 %), m.p. 169-170 °C. R f 0.84 (diethyl ether); (Found: 
C 47.38; H 3.20; N 11.28 %; M+, 252.0221. C10H8N2O4S requires C 47.62; 
H 3.20; N 11.11 %; M, 252.0205); Vmax/cm' 1 (KBr disc) 3102m and 3026w 
(=C-H), 2991 w and 2942m (CH2CH3), 2225m (CN), 1718s (C=0), 1607s (Ar, 
C=C), 1539s (N02), 1 2 5 9 s  (C-O), 762m and 736m (=C-H); 8H (200 MHz, 
DMSO-de) 9.16 (d, 4J 0.8 Hz, 1H, 5'-H), 8.69 (s, 1H, 5-H), 8.61 (d, 4J 0.8 Hz,
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1H, 3'-H), 4.39 (q, 3J  7.11 Hz, 2 H, CH2), 1.38 (t, 3J  7.11 Hz, 3 H, CH3); 
5C (50 MHz, DMSO-d6 ) 161.2 (s, C=0), 148.0 (s, 4'-C), 145.8 (d, 5-CH), 136.1 
(s, 2'-C), 135.3 (d, 5 '-CH), 131.5 (d, 3'-CH), 114.9 (s, CN), 102.0 (s, 4-C), 62.4 
(t, CH2), 13.4 (q, CH3); m/z 252 (M+, 80 %), 236 (M+ -  CH3, - H), 207 (M+ 
-  OCH2CH3), 179 (M+ -  CO2CH2CH3), 133 (M+ -  N02, -  CO2CH2CH3).
nButyl 2-cyano-3-[2-(4-nitrothienyl)]propenoate (136)
OoN
NC
1
Using General Procedure B, 4-Nitro-2-thiophenecarbaldehyde (87) (0.1230 g,
7.8 mmol) was treated with nbutyl cyanoacetate (0.11 ml, 7.8 mmol) in 
propan-2-ol (0.5 ml) and dilute piperidine solution (1 drop) to give a purple 
precipitate after 20 min (0.0658 g, 30 %), m.p. 150-151 °C. R f 0.89 (diethyl 
ether); (Found: C 51.36; H 4.10; N 10.15 %; M+, 280.0519. C12H12N2O4S 
requires C 51.42; H 4.31; N 9.99 %; M, 280.0518); V m a x /c r r r 1 (KBr disc) 3097m 
and 3024w (=C-H), 2937m and 2875w (CH2CH3), 2223w (CN), 1713s (C=0), 
1608s (Ar, C=C), 1540s (N02), 1278s (C-O), 761m and 736s (=C-H); 
8h (200  MHz, DMSO-d6) 9.20 (q, 4J  1.7 Hz, 1H, 5'-H), 8.71 (s, 1H, 7-H), 8.63 
(dd, 4J  1.7 Hz, 4J 0.4 Hz, 1H, 3'-H), 4.31 (t, 3J 6.4 Hz, 2H, 4-H2), 1.71 (tt, 
3J 6.4 Hz, 3J6.8 Hz, 2H, 3-H2), 1.44 (tq, 3J  7.3 Hz 3J 6 .8  Hz, 2H, 2-H2), 0.97 
(t, 3J 7.3 Hz, 3H, CH3); 8c (50 MHz, DMSO-d6) 161.4 (s, C=0), 147.9 (s, 4'-C),
146.4 (d, 7-CH), 136.5 (5 '-CH), 136.1 (2'-C), 132.3 (d, 3 '-CH), 115.4 (s, CN),
101.7 (s, 6 -C), 6 6 .2  (t, 4 -CH2), 30.1 (t, 3-CH2), 18.6 (t, 2-CH2), 13.7 (q, CH3); 
m/z280 (M+, 20 %), 224 (M+ -  "Bu, +H), 207 (M+ -  OnBu), 180 (M+ -  C02nBu, 
+H), 133 (M+ -  N02, - C 0 2nBu).
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*Butyl 2-cyano-3-[2-(4-nitrothienyl)]propenoate (137)
OoN
4NC O
Using General Procedure B, 4-Nitro-2-thiophenecarbaldehyde (87) (0.3392 g,
2.16 mmol) was treated with toutyl cyanoacetate (0.31 ml, 2.16 mmol) in 
ethanol (4 ml) and dilute piperidine solution (1 drop) to give a brown precipitate 
after 2 0  min (0.2419 g, 40 %), m.p. 320-324 °C. R f 0.61 (1:1 ethyl 
acetate/petroleum ether); (Found: C 51.36; H 4.31; N 10.10 %; M+, 280.0516. 
C i2H12N20 4 S requires C 51.42; H 4.21; N 9.99 %; M, 280.0518); Vmax/cnr1 
(KBr disc) 3114s (Ar-H), 2224w (CN), 1730s (ap-unsaturated carbonyl), 1350m 
(C-N02); 8h (200  MHz, DMSO-d6) 9.30 (s, 1H, 5’-H), 8.82 (s, 1H, 7-H), 8.60 (s, 
1H, 3'-H), 1.62 (s, 9H, ?Bu); 8C (50 MHz, DMSO-d6) 162.1 (s, C=0), 148.2 (s, 
4'-C), 147.1 (d, 7-CH), 137.2 (s, 2'-C), 136.8 (d, 5'-CH), 133.4 (d, 3'-CH), 115.8 
(s, CN), 107.1 (s, 6 -C), 85.4 (s, 4-C), 28.4 (q, 3 x CH3); m/z 280 (M+, 18 %), 
234 (M+ - N 02), 223 (M+ - *Bu), 179 (M+ - C0 2 *Bu).
2-Cyano-3 -[2 -(4-nit rot hieny l)]propenamide (138)
OoN
NC
Using General Procedure B, 4-Nitro-2-thiophenecarbaldehyde (87) (0.2112 g,
1.34 mmol) was treated with 2-cyanoacetamide (0.1148 g, 1.36 mmol) in 
ethanol (3 ml) and dilute piperidine solution (1 drop) to give a brown precipitate 
after 5 min (0.0452g, 15 %), m.p. 201 -204 °C. R f 0.34 (diethyl ether); (Found: 
C 43.06; H 2.16; N 18.64 %; M+, 223.0096. C8 H5N3O3S requires C 43.05; 
H 2.25; N 18.82 %; M, 223.0072); Vmax/cnrr1 (KBr disc) 3423m and 3181m 
(NH2), 3 0 8 9 s  and 3048m (=C-H), 2216s (CN), 1690s (C=0), 1599s and 1542m 
(Ar), 1541s (N02), 781m and 738m (=C-H); 5H (200  MHz, DMSO-d6) 9.16 (br s, 
1H, 5'-H), 8.62 (s, 1H, 3-H), 8.41 (br s, 1H, 3’-H), 7.92 (v.br s, 2 H, NH2); 
8C (50 MHz, DMSO-de) 161.7 (s, C=0), 147.8 (s, 4'-C), 142.6 (d, 3-CH), 136.6 
(s, 2'-C), 134.9 (d, 5 '-CH), 130.0 (d, 3'-CH), 116.2 (s, CN), 105.6 (s, 2-C); m/z
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223 (M+, 5 %), 207 (M+ -  NH2), 193 (M+ -  H, -  H-N=0), 179 (M+ -  CONH2), 
176 (M+- N 0 2,-H ).
2-Cyano-3-[2-(4-nitrothienyl)]propenthioamide (139)
OoN
NC
4-Nitro-2-thiophenecarbaldehyde (87) (0.1463 g, 0.93 mmol) was treated with
2-cyanothioacetamide ( 0.0940g, 0.94 mmol) in ethanol (1 ml) and dilute 
piperidine solution (2 drops) using General Procedure B to give a brown 
precipitate after 15 min (0.0223 g, 10 %), m.p. 210 °C (decomp.). R f 0.62 
(diethyl ether); (Found: C 39.98; H 2.14; N 17.00 %; M+, 238.9810. 
C8H5N3O2S2 requires C 40.16; H 2.10; N 17.56 %; M, 238.9823); Vmax/cm-1 
(KBr disc) 3277m and 3170m (NH2), 3084s and 3012m (=C-H), 2209m (CN), 
1628s (C=S), 1596s and 1541m (Ar), 1540s (N02), 780m and 732m (=C-H); 
8h (200 MHz, DM SO-de) 10.22 and 9.66 (2 x br s, 2H, NH2), 9.15 (d, 4J^.2 Hz, 
1H, 5'-H), 8.40 (d, 4J1.2 Hz, 1H, 3'-H), 8.36 (s, 1H, 3-H); 6C (50 MHz, 
DMSO-de) 191.0 (s, C=S), 148.8 (s, 4'-C), 147.9 (d, 3-CH), 136.5 (s, 2'-C),
135.0 (d, 5'-CH), 130.0 (d, 3'-CH), 116.1 (s, CN), 111.3 (s, 2-C); m/z 239 (M+, 
72 %), 192 (M+ -N 0 2, -H), 161 (M+ -N 0 2, -S).
Attempted synthesis of 2,4-dicyano-3-amino-5-[2-(5-nitrothienyl)] 
penta-2,4-dienonitrile hydrochloride (140)
OoN
NC CN
NC
To a solution of 2,4-dicyano-3-amino-5-[2-(5-nitrothienyl)]penta-2,4-dienonitrile 
(100) in acetone (5 ml) was added 1.0 M hydrochloric acid (1 ml). The mixture 
was stirred at room temperature for 3 h. TLC showed only the presence of 
starting material. The procedure was repeated using ethereal hydrochloric acid 
to give the same result.
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2-Cyano-3-[2-(5-nitrothienyl)]propenoic acid (141)
4 ' 3 '
OoN
NC OH
*Butyl-2-cyano-3-[2-(5-nitrothienyl)]propenoate (104) (0.2181 g, 0.78 mmol) was 
dissolved in formic acid (10 ml) and stirred at room temperature for 3 h. The 
mixture was concentrated in vacuo and neutralised with 6 % w/v aqueous 
sodium bicarbonate solution. This was washed with ethyl acetate (4 x 50 ml) 
and the combined organic extracts were dried (MgS0 4 ), filtered and 
concentrated in vacuo to a green powder, which was recrystallised from ethyl 
acetate/hexane to give a green solid, 0.1099 g (63 %), m.p. 189-191 °C. Rf 0.0 
(1:1 ethyl acetate/petroleum ether); (Found: C 42.65; H 1.87; N 12.24 %; M+, 
223.9890. C8H4N2O4S requires C 42.86; H 1.78; N 12.50 %; M, 223.9892); 
V m a x /c r r r 1 (KBr disc) 3100m and 3048m (Ar-H), 2280w (CN), 1694s (C=0, 
ap-unsaturated acid), 1600s (extended conjugation to aromatic system), 1528s 
and 1339s (C-N02), 818m (Ar-H); 8H (200 MHz, DMSO-d6) 8.50 (s, 1H, 3-H), 
8.21 (d, 3J 4.0 Hz, 1H, 4'-H), 8.03 (d, 3 j 4 .0  Hz, 1H, 3'-H), signal for acidic 
proton observed along baseline between 6 7.80-7.00; 8c (50 MHz, DMSO-d6)
162.4 (s, C=0), 154.8 (s, 5'-C), 145.5 (d, 4'-CH), 140.8 (s, 2'-C), 137.3 (d,
3-CH), 129.7 (d, 3-CH), 115.8 (s, CN), 105.5 (s, 2-C); m/z224 (M+, 19 %), 177 
(M+ - N 02), 141 (M+ - NC-CH2C02H).
Sodium 2-cyano-3-[2-(5-nitrothienyl)]propenoate pentahydrate (142)
4 ’ 3 '
OoN
NC
To 2-cyano-3-[2-(5-nitrothienyl)]propenoic acid (141) (0.0587 g, 0.26 mmol) was 
added sodium bicarbonate (0.0207 g, 0.29 mmol) and water (5 ml). The mixture 
was stirred at 25 °C for 8 h until all of the starting material was fully dissolved. 
Freeze drying for 24 h gave yellow crystals which were identified as the 
pentahydrate (0.0613 g, 70 %), m.p. >300 °C. R f 0.0 (1:1 ethyl 
acetate/petroleum ether); (Found: C 28.50; H 3.76; N 8.48 %; M, 222.9812. 
C8H3N2O4S.5 H2O requires C 28.58; H 3.90; N 8.33 %; M, 2232.9814; 
V m a x /c n r 1 (KBr disc) 3164 (Ar-H), 2260w (CN), 1629s (extended conjugation to
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aromatic system), 1534s and 1399s (C-NO2), 819m (Ar-H); 8 jh (200  MHz, 
DMSO-de) 8.17 (d, 3J 4.4 Hz, 1H, 4'-H), 8.09 (s, 1H, 3-H), 7.74 (d,3J4.4 Hz, 
1H, 3'-H); m/z 223 (M, 20  %), 178 (M+ - N02).
Deutero 2-cyano-3-[2-(5-nitrothienyI)]propenoic acid (143)
4 ' 3 '
OoN
NC OD
Sodium 2-cyano-3-[2-(5-nitrothienyl)]propenoate pentahydrate (142) (0.0110 g, 
0.033 mmol) was dissolved in methanol (1 ml). Upon addition of 1 drop of 
deuterium chloride (1M in D20) a yellow precipitate formed which was insoluble 
in water (0.074 g, 100  %), m.p. >300 °C. R f 0 .0  (1:1 ethyl acetate/petroleum 
ether); 8 h (91 MHz, DMSO-d6) 8.5 (s, 1H, 3-H), 8.2  (d, 3J 4 Hz, 1H, 4'-H), 8.0  
(d, 3J 4 Hz, 1H,3'-H).
2-Cyano-3-[4-(2-nitrothienyl)]propenoic acid (144)
O
CNOoN
*Butyl 2-cyano-3-[4-(2-nitrothienyl)]propenoate (127) (0.1634 g, 0.58 mmol) was 
dissolved in formic acid (10 ml) and stirred at room temperature for 2.5 h. The 
mixture was concentrated in vacuo and neutralised with 6 % w/v aqueous 
sodium bicarbonate solution. This was washed with ethyl acetate (4 x 50 ml) 
and the combined organic extracts were dried (MgS0 4 ), filtered and 
concentrated in vacuo to a beige solid (0.1118 g, 100  %) which needed no 
further purification; m.p. 230-231 °C. R f 0 .0  (1:1 ethyl acetate/petroleum ether); 
(Found: C 42.85; H 1.57; N 12.25 %; M+, 223.9885. C8 H4 N20 4S requires 
C 42.86; H 1.78; N 12.50 %; M, 223.9892); Vmax/cm’1 (KBr disc) 3098m (OH), 
3060m (Ar-H), 2232m (CN), 1750s (-C02H, C=0 stretch), 1606s (extended 
conjugation to aromatic system), 1534m (N02), 1388s (C-N02); 5h (200 MHz, 
DMSO-de) 8.78 (d, 4J 1.5 Hz, 1H, 4'-H), 8.65 (d, 4J 1.5 Hz, 1H, 2 '-H), 8.22  (s, 
1H, 3-H), signal for acidic proton observed along baseline between 5 8.0-7.0;
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8C (50 MHz, DMSO-de) 163.1 (s, C=0), 152.3 (s, 5'-C), 143.5 (d, 4'-CH), 140.5 
(d, 2 '-CH), 133.6 (s, 3'-C), 128.2 (d, 3-CH), 116.4 (s, CN), 108.8 (s, 2-C); m/z 
224 (M+, 47 %), 177 (M+ - N 02), 57 (C-C02H).
Sodium 2-cyano-3-[4-(2-nitrothienyl)]propenoate dihydrate (145)
O
0 ©
O N a. 2H20
To 2-cyano-3-[4-(2-nitrothienyl)]propenoic acid (144) (0.1017 g, 0.45 mmol) was 
added sodium bicarbonate (0.0333 g, 0.46 mmol) and water (5 ml). The mixture 
was stirred for 2.5 h at 25 °C to give a clear yellow solution. Freeze drying for 
6 h gave yellow crystals which were identified as the dihydrate (0.0910 g, 
71 %), m.p. 71 °C. R f 0.0 (1:1 ethyl acetate/petroleum ether); (Found: C 37.38; 
H 2.47; N 10.83 %; M, 222.9808. C8H3N2O4S.2 H2O requires C 37.07; H 2.72; 
N 10.81 %; M , 222.9814; v m a x /c n r r i  (KBr disc) 3108s (Ar-H), 2214m (CN), 
1734s (C=C), 1542m (N02), 1378s (C-N02), 889w and 816w (2 x Ar-H); 
8H (200 MHz, DMSO-de) 8.69 (d, 4J 1.6 Hz, 1H, 4'-H), 8.59 (6,4J 1.6 Hz, 1H,
2 -H), 8.18 (s, 1H, 3-H); 8C (50 MHz, DMSO-de) 162.3 (s, C=0), 152.1 (s, 5 '-C),
139.4 (d, 4’-CH), 137.9 (d, 2 '-CH), 134.8 (s, 3'-C), 128.3 (d, 3-CH), 119.2 (s, 
CN), 114.9 (s, 2 -C);m/z223 (M, 1 0 %), 177 (M+ - N02).
Deutero 2-cyano-3-[4-(2-nitrothienyl)]propenoic acid (146)
O
CNOoN
To sodium 2-cyano-3-[4-(2-nitrothienyl)]propenoate dihydrate (145) (0.0104 g, 
0.037 mmol) in water (5 ml) was added 1 drop deuterium chloride (1M in D20). 
A white precipitate formed immediately, which was insoluble in water (0.0083 g, 
100 %), m.p. >300 °C. R f 0.0 (1:1 ethyl acetate/petroleum ether); 8 h (90 MHz, 
DMSO-de) 8.7 (d, 4J 1.6 Hz, 1H, 4'-H), 8 .6  (6,4J 1.6 Hz, 1H, 2 '-H), 8.2  (s, 1H,
3-H).
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Tri(ethylene glycol) cyanoacetate methyl ether (95)
O
To a 100 ml round bottom flask were added 2-cyanoacetic acid (147) (10.1319 
g, 119.1 mmol), tri(ethylene glycol) monomethyl ether (148) (20 ml, 125.0 
mmol), 4-toluenesulfonic acid (20 mg) and toluene (50 ml). The mixture was 
heated at reflux temperature under Dean-Stark conditions for 24 h. Upon 
allowing to cool to room temperature, the mixture was concentrated in vacuo, 
and column chromatography over silica (ethyl acetate) gave the product as an 
amber oil (17.5766 g, 64 %), d 1.117 g mM. R f 0.30 (1:1 ethyl 
acetate/petroleum ether); (Found: C 51.94; H 7.26; N 6.11 %; M+, 231.1205. 
C10H17NO5 requires C 51.94; H 7.41; N 6.06 %; M, 231.1205); vmax/cm-l (KBr 
disc) 2885m (C-O-CH3), 2262m (CN), 1750s (C=0), 1105s (C-O-C); 
6h (200 MHz, DMSO-de) 4.01 (m, 2H, 9-H2), 3.42-3.29 (m, 12H, 2, 3, 4, 5, 6,
7-H2), 3.03 (s, 3H, CH3); 6c (50 MHz, DMSO-d6) 162.9 (s, C=0), 113.0 (s, CN),
70.6 (t, 9 -CH2 ), 69.2 (t, 7-CH2), 69.1 (t, 6-CH2), 69.0 (t, 5-CH2), 67.2 (t, 4-CH2),
64.4 (t, 3-CH2), 57.4 (t, 2 -CH2 ), 23.2 (q, CH3); m/z 231 (M+, 1 %), 186 (M+ 
- CH2OCH3), 156 (M+ - OCH2CH2OCH3), 112 [M+ - (OCH2CH2)20CH3)].
Tri(ethylene glycol) 2-cyano-3-[2-(5-nitrothienyl)]propenoate methyl ether 
(105)
4'  3'
02N ^f o
NC O—\
Vo
5 \
o
5-Nitro-2-thiophenecarbaldehyde (0.6717 g, 4.27 mmol) was treated with 
tri(ethylene glycol) cyanoacetate methyl ether (149) (906.5 pi, 4.33 mmol) in 
ethanol (10 ml) and piperidine (1 drop) using General Procedure A to give an 
orange precipitate after 10 min (1.4060 g, 89 %), m.p. 84-87 °C. R f 0.13-0.24 
(1:1 ethyl acetate/petroleum ether); (Found: C 48.58; H 5.11; N 7.59 %; M+ 
- CH3, 355.0651. C i5H18N2C>7S requires C 48.64; H 4.90; N 7.56 %; M - CH3,
160
355.0835); vmax/crrr1 (KBr disc) 2892m (C-O-CH3 ), 2222w (CN), 1725m 
(ocp-unsaturated carbonyl), 1599m (extended conjugation to aromatic system), 
1504m (C-N02), 1338s and 1271s (ester, C -0 stretch); 8 h (200 MHz, 
DMSO-de) 8.29 (s, 1H, 1 0 -H), 7.97 (d, 3J  4 .4  Hz, 1H, 4'-H), 7.76 (d, 3J 4A  Hz, 
1H, 3'-H), 3.86-3.39 (m, 12H, 2, 3, 4, 5, 6, 7-H2), 3.37 (s, 3H, CH3); 8C (50 MHz, 
DMSO-de) 161.2 (s, C=0), 156.0 (s, 5'-C), 145.2 (d, 10-CH), 140.5 (s, 2'-C),
135.0 (d, 4'-CH), 128.2 (d, 3'-CH), 114.2 (s, CN), 104.8 (s, 9-C), 71.9 (t, 7-CH2),
70.8 (t, 6-CH2), 70.6 (t, 5-CH2), 70.5 (t, 4-CH2), 68.6 (t, 3-CH2), 66.2 (t, 2-CH2),
59.0 (q, CH3); m/z 355 (M+ - CH3, 5 %), 324 (M+ - N 02), 252 (M+ 
- [(OC2H4)20CH3], + H), 235 (M+ - [(OC2H4)2OCH3], - O).
Tri(ethylene glycol) 2-cyano-3-[3-(2-nitrothienyl)]propenoate methyl ether 
(119)
/  6 
o
2-Nitro-3-thiophenecarbaldehyde (83) (0.1317 g, 0.84 mmol) was treated with 
tri(ethylene glycol) cyanoacetate methyl ether (149) (173.5 pi, 0.84 mmol) in 
ethanol (1 ml) and dilute piperidine solution (1 drop) using General Procedure B 
to give a peach precipitate after 14 h (0.1933 g, 62 %), m.p. 67-69 °C. Rf 0.10 
(1:1 ethyl acetate/petroleum ether); (Found: C 48.69; H 5.05; N 7.50 %; 
M+, 370.0783. C i5H i8N20 7 S requires C 48.64; H 4.90; N 7.56 %; 
M, 370.0835); vmax/cnr1 (KBr disc) 2878m (C-0-CH3), 2224w (CN), 1716s 
(ocp-unsaturated carbonyl), 1610m (extended conjugation to aromatic system), 
1536s (C-N02), 1350m and 1272s (ester, C-0 stretch); 8h (200 MHz, 
DMSO-de) 9.21 (s, 1H, 10-H), 8.71 (br, 1H, 5'-H), 8.62 (br, 1H, 4'-H), 4.71-3.38 
(br m, 12H, 2, 3, 4, 5, 6, 7-H2), 3.26 (s, 3H, CH3); 8C (50 MHz, DMSO-de) 
161.4(s, C=0), 148.2 (s, 2'-C), 147.9 (d, 5'-CH), 146.6 (s, 3'-C), 136.0 (d, 
4'-CH), 132.4 (d, 10-CH), 115.3 (s, CN), 101.5 (s, 9-C), 71.4 (t, 7-CH2), 70.0 (t,
6-CH2), 69.9 (t, 5-CH2), 69.7 (t, 4-CH2), 68.1 (t, 3-CH2), 65.8 (t, 2-CH2), 58.2 
(q, CH3); m /z  370 (M+, 5 %), 295 (M+ - OC2H4OCH3), 267 (M+ 
- [(OC2H4)2OCH3],) 251 (M+ - [(OC2H4)2OCH3, -O).
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Tri(ethylene glycol) 2-cyano-3-[4-(2-nitrothienyl)]propenoate methyl ether
(128)
. 0 ^
OoN2IN
O 6
Using General Procedure A, 2-nitro-4-thiophenecarbaldehyde (0.2146 g, 
1.37 mmol) was treated with tri(ethylene glycol) cyanoacetate methyl ether 
(149) (290.0 jliI, 1.40 mmol) in ethanol (25 ml) and piperidine (1 drop) to give a 
dark precipitate after 10 min. Column chromatography (silica gel/1 :1 ethyl 
acetate/petroleum ether) gave the product which was recrystallised from 
ethanol to give small brown needles (0.0534 g, 10.5 %), m.p. 72-74 °C. 
R f  0-0.17 (1:1 ethyl acetate/petroleum ether); (Found: C 48.32; H 5.06; 
N 7.45 %; M+, 370.0861. C15H18N2O7S requires C 48.64; H 4.90; N 7.56 %; 
M, 370.0834); Vmax/cm'1 (KBr disc) 2826w (C-O-CH3 ), 2228w (CN), 1730s 
(ap-unsaturated carbonyl), 1616s (extended conjugation to aromatic system), 
1512s (C-NO2), 1270s (ester, C-0 stretch); 5H (200 MHz, DMSO-d6) 8.54 (d, 
4J 1.9 Hz, 1H, 4'-H), 8.39 (d, 4J 1.9 Hz, 1H, 2'-H), 8.16 (s, 1H, 10-H), 4.50-3.53 
(m, 12H, 2, 3, 4, 5, 6, 7-H2), 3.37 (s, 3H, CH3); 6C (50 MHz, DMSO-d6) 161.6 
(s, C=0), 153.2 (s, 5'-C), 146.0 (d, 4'-CH), 138.5 (d, 2'-CH), 133.0 (s, 3'-C),
128.0 (d, 10-CH), 114.0 (s, CN), 104.4 (s, 9-C), 71.9 (t, 7-CH2), 70.7 (t, 6-CH2),
70.6 (t, 5 -CH2 ), 70.5 (t, 4 -CH2 ), 68.6 (t, 3-CH2), 66.0 (t, 2-CH2), 59.0 (q, CH3); 
m/z 372 (M+, 6 %), 324 (M+ - N02), 297 (M+ - OC2H4OCH3 + 2H), 252 (M+ 
- [(OC2H4)2OCH3)], + H), 235 (M+ - [(OC2H4)2OCH3)], - O)..
Poly(ethylene glycol) cyanoacetate methyl ether (149)
NC ^ ~ ^ f (  ° ^ ) o /
O
To a round-bottomed flask was added cyanoacetic acid (0.5717 g, 6.72 mmol), 
poly(ethylene glycol) monomethyl ether (13.60 g, ca 6.80 mmol),
4-toluenesulfonic acid (101 mg) and toluene (50 ml). The mixture was refluxed 
under Dean-Stark conditions for 72 h. Upon cooling to room temperature, the 
solvent was removed in vacuo to leave a yellow liquid which solidified to give a 
waxy solid which needed no further purification (12.1789 g, ca 90 %), m.p.
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58-61 °C. R f 0 (1:1 ethyl acetate/petroleum ether); vmax/cnrr1 (KBr disc) 2888s 
(OCHx), 2230w (CN), 1750w (C=0), 2950s and 2914s (-CH2-); 8 H (200  MHz, 
DMSO-de) 4.28 (m, 2 H, 3-H), 3.57 (br, 140 H, poly [CH2CH2]), 3.30 (s, 3H, 
CH3 ) (1H NMR spectrum was dominated by large signal for PEG; relative 
intensities are only estimated); 5c (50 MHz, DMSO-de) 13.4 (s, C=0), 137.4 (t,
3-CH2), 108.0 (s, CN), 77.9-58.9 (multiplet, poly[CH2CH2]), 24.6 (t, CH3).
1-(3-Pyridyl)-1 -cyano-2-[2-(5-nitrothienyl)ethan-2-ol (153)
5-Nitro-2-thiophene carbaldehyde (2.0687 g, 13.16 mmol) was dissolved in 
ethanol (15 ml). To this was added 3-pyridylacetonitrile (1.5722 g, 13.31 mmol). 
The mixture was heated at reflux temperature for 17.5 h until a precipitate 
formed. Filtration followed by washing with diethyl ether gave the product as a 
brown solid which was observed to be a mixture of diastereoisomers in a 
1:3 ratio by NMR spectroscopy. (1.6619 g, 46 %), m.p. 170-172 °C. R f 0.18 
(1:1 ethyl acetate/petroleum ether); (Found: C 51.95; H 3.84; N 15.55 %; M+, 
276.0428. C i2H10N3O3S requires C 52.16; H 3.64; N 15.18 %; M, 276.0443); 
Vmax/crn' 1 (KBr disc) 3431m (OH), 3106 (aryl-H), 2223w (CN), 1537 (aromatic 
C=C), 1499s (C-N02), 1294m (OH bend), 1161m (C-0 stretch), 814m 
(2 adjacent Ar-H); 5h (2 0 0  MHz, DMSO-d6) Diastereoisomer 1 (relative 
intensity 3):- 8 .66  (d, s j i . g  Hz, 1H, 2"-H), 8.58 (dd, 3J 4.8 Hz, 4J 1.5 Hz, 1H, 
6"-H), 8.07 (d, 3J 4.3 Hz, 1H, 4'-H), 7.88 (dd, 3J 4.1 Hz, 5J 1.9 Hz, 1H, 4"-H), 
7.46 (dd, 3J 7.8 Hz, 3J 4.8 Hz, 1H, 5"-H), 7.23 (d, 3J 4.3 Hz, 1H, 3’-H), 5.34 (dd, 
3J 4.4 Hz, 3J 4.3 Hz, 1H, 2-H), 4.91 (d, 3J 3.9 Hz, 1H, 1-H), 3.42 (v. br s, 1H, 
OH); Diastereoisomer 2 (relative intensity 1):- 8.52 (dd, 3J 4.8 Hz, 4J 1.5 Hz, 
1H, 6 "-H), 8.40 (d, S j 1.9 Hz, 1H, 2"-H), 7.98 (d, 3J 4.3 Hz, 1H, 4'-H), 7.69 (dd, 
3J4A  Hz, 5J 1.9 Hz, 1H, 4"-H), 7.38 (dd, 3J 8.5 Hz, 3J 4.8 Hz, 1H, 5"-H), 7.00 
(d, 3J 4.3 Hz, 1H, 3'-H), 5.56 (dd, 3J 4.5 Hz, 3J 4.4 Hz, 1H, 2-H), 4.82 (d, 
3J 4.9 Hz, 1H, 1-H), 3.42 (v. br s, 1H, OH); 5C (50 MHz, DMSO-d6) 
Diastereoisomer 1 (relative intensity 3):- 156.5 (s, 5'-C), 149.8 (s, 2'-C),
149.5 (d, 2 M-CH), 149.1 (d, 4'-CH), 136.4 (d, 6 H-CH), 130.1 (d, 4"-CH), 129.2 (s, 
3"-C), 124.4 (d, 5"-CH), 123.7 (d, 3'-CH), 118.2 (s, CN), 70.0 (d, 1 -CH), 43.0 (d, 
2-CH); Diastereoisomer 2 (relative intensity 1):- 155.1 (s, 5'-C), 149,8 (s, 
2-C), 149.7 (d, 2"-CH), 148.9 (d, 4'-CH), 136.6 (d, 6 "-CH), 129.7 (d, 4n-CH),
4'  3
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127.8 (s, 3"-C), 124.8 (d, 5,,-CH)> 123.5 (d, 3'-CH), 118.9 (s, CN), 69.4 (d,
1-CH), 42.2 (d, 2-CH); m/z 259 (M+- OH, 2 %), 198 (M+ - [pyridine]*), 160 (M+ 
- [NC-C-pyridine]*), 128 ([0 2 N-thiophene]+).
1-(3-Pyridyl)-1 -cyano-2-[4-(2-nitrothienyl)ethan-2-ol (154)
To a solution of 2-nitro-4-thiophene carbaldehdye (0.5596 g, 3.56 mmol) in 
ethanol (20 ml) and piperidine (1 drop) was added 3-pyridylacetonitrile 
(0.3946 g, 3.34 mmol) over a period of 5 min. The mixture was stirred at room 
temperature for 6.5 h until precipitation of solid was observed. This was filtered, 
washed (hexane) and dried (diethyl ether) to yield the product as a yellow solid 
which was observed to be a mixture of diastereoisomers in a 2:3 ratio by NMR 
spectroscopy. (0.6211 g, 63 %), m.p. 175 °C. R f 0.23 (1:1 ethyl 
acetate/petroleum ether); (Found: C 52.06; H 3.35; N 15.18 %; M*, 276.0469. 
C12H10N3O3S requires C 52.16; H 3.64; N 15.20 %; M, 276.0443); vmax/cm-1 
(KBr disc) 3432m (OH), 2250w (CN), 684m (external conjugation to aromatic 
system), 1534s (C-NO2), 1484m (aromatic C=C), 1290s (O-H bend), 1134w 
(C-0 stretch), 820m (2 adjacent Ar-H); 8 h (200  MHz, DMSO-d6) Overlapping 
Signals:- 8.65-8.58 (br m, 2H, 2 " and 6 "-H), 8.24-7.81 (br m, 1H, 4"-H), 
7.49-7.42 (br m, 1H, 5"-H), 3.79 (v.br, 1H, OH); Diastereoisomer 1 (relative 
intensity 3):- 8.26 (s, 1H, 4'-H), 7.05 (s, 1H, 2'-H), 5.61 (d, 3J 3.6 Hz, 1H, 1-H),
4.96 (d, 3J3.6 Hz, 1H, 2-H); Diastereoisomer 2 (relative intensity 2):- 8.28 (s, 
1H, 4'-H), 7.03 (s, 1H, 2'-H), 5.38 (d, 3J 4.9 Hz, 1H, 1-H), 4.88 (d, 3J 4.9 Hz, 1H, 
2 -H); 8c (50 MHz, DMSO-de) Diastereoisomer 1 (relative intensity 3):- 156.6 
(s, 5'-C), 149.8 and 149.1 (2 x d, 2 " and 6 "-CH), 136.5 (d, 4"-CH), 135.7 (d, 
4'-CH), 130.1 (d, 5"-CH), 127.9 (s, 3'-C), 124.4 (d, 2 '-CH), 123.8 (s, 3"-C), 118.3 
(s, CN), 70.1 (d, 1-CH), 43.1 (d, 2 -CH); Diastereoisomer 2 (relative intensity 
2):- 155.2 (s, 5'-C), 149.9 and 149.5 (2 x d, 2 " and 6 "-CH), 136.7 (d, 4"-CH),
136.0 (d, 4'-CH), 129.8 (d, 5"-CH), 127.6 (s, 3'-C), 124.9 (d, 2 '-CH), 124.0 (s, 
3"-CH), 119.0 (s, CN), 69.5 (d, 1 -CH), 42.3 (d, 2 -CH); m/z 258 (M+ - OH, - H, 
2 %), 198 (M+ - [pyridine]), 160 (M+ - [NC-C-pyridine]), 127 ([0 2 N-thiophene]+, 
-H), 116([NC-C-pyridine]+).
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Attempted syntheses of 1-(2-thienyl)-1-cyano-2-[5-(2-nitrothienyl)]
ethan-2-ol (155)
OH
NC
Method 1. Using General Procedure A, 5-nitro-2-thiophenecarbaldehyde and
2 -thiopheneacetonitrile were mixed in ethanol. To this was added sequentially 
catalytic amounts of pyridine and piperidine. The reaction was monitored by 
TLC, which showed only starting materials 12 h after the addition of piperidine. 
At this point, 1 molar equivalent of piperidine was added, and the mixture was 
heated at reflux temperature. However, TLC showed only starting materials 
after 72 h.
Method 2. A round-bottomed flask was charged with a magnetic stirring bar 
and 5-nitro-2-thiophenecarbaldehyde (0.3460 g, 2.20 mmol) in absolute ethanol 
(5 ml). The solution was gently heated to obtain a clear liquid. To this was 
added 2-thiopheneacetonitrile (0.2777 g, 2.25 mmol) and potassium carbonate 
(10 mg) in absolute ethanol (5 ml). The mixture was heated at reflux 
temperature for 1 h to give a complex mixture of products which could not be 
separated by column chromatography.
Attempted synthesis of 1-(3-thienyl)-1-cyano-2-[5-(2-nitrothienyl)] 
ethan-2-ol (156)
OH
OoN
NC
Using General Procedure A, 5-nitro-2-thiophenecarbaldehyde and
3-thiopheneacetonitrile were mixed in ethanol. To this was added sequentially 
catalytic amounts of pyridine and piperidine. The reaction was monitored by 
TLC, which showed the presence of starting materials 12 h after the addition of 
piperidine. At this point, 1 molar equivalent of piperidine was added, and the 
mixture was heated at reflux temperature. However, TLC showed only starting 
materials after 72 h.
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Bromomalononitrile (159)177
CN
Br— (
CN
To a solution of malononitrile (1.9655 g, 29 mmol) in water (20  ml) at 0 °C was 
added bromine (1.50 ml, 29 mmol). After stirring at 0 °C for 3.5 h, a white 
precipitate was observed; neutralisation with aqueous sodium bicarbonate 
followed by extraction into ethyl acetate (4 x 100 ml) and drying (MgS0 4 ) gave 
a brown solution after filtration. This was concentrated to a brown oil, which 
slowly crystallised to give beige crystals (0.8520 g, 20 %), 
m.p. 55-57 [lit.: 64-65]177 °C, Rf 0 .0 . 6H (91 MHz, DMSO-d6) 3.0 (s, 1H); m/z 
145 (M+, 15 %), 79 (Br*), 66  (M+ - Br).
Attempted syntheses of 1,1 -dicyano-2-[2-(5-nitrothienyl)ethan-2-ol (160)
NC
To a solution of bromomalononitrile (160) (0.5072 g, 3.52 mmol) in dry ethanol 
(50 ml) was added magnesium (0.0840 g, 3.45 mmol). The mixture was stirred 
at -78 °C under an atmosphere of nitrogen for 2.5 h, then was allowed to warm 
to 25 °C. To this was added 5-nitro-2-thiophene carbaldehyde (0.4216 g, 
2.68 mmol) in dry ethanol (7 ml). The mixture was stirred at 25 °C for 48 h, then 
was heated at reflux temperature for 24 h. Filtration and concentration in vacuo 
gave a beige precipitate, which was shown to be starting material by NMR 
spectroscopy.
This procedure was repeated at various temperatures and gave the same 
result.
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Attempted syntheses of 2-Cyan o-3-methyl-3-[4-(2-nitrothienyl)]
propenonitrile (163)
Method 1. 2-Acetylthiophene (1.4558 g, 11.53 mmol) and malononitrile 
(0.7694 g, 11.65 mmol) were mixed in ethanol (2 ml) and piperidine (2 drops) 
under the conditions of General Procedure A, to give a complex mixture of 
products (R f 0.24-0.54) which could not be separated by column 
chromatography.
Method 2.178 To a flame-dried 3-necked round bottom flask, equipped with a 
low temperature thermometer, nitrogen balloon and septum cap, was added 
2-acetylthiophene (6.3129g 50.0 mmol) and malononitrile (3.3243 g, 
50.32 mmol) in dry THF (150 ml). The solution was cooled to 0 °C, and TiCU 
(11 ml, 100 mmol) was slowly added such that the temperature of the reaction 
mixture did not exceed 5 °C. The mixture was stirred at 0 °C for 2 h, and 
pyridine (16 ml, 197. 8 mmol) was added to give a red solution instantly. Stirring 
at room temperature for 20  min gave a very viscous beige oil which separated 
from the solution and solidified to give a complex mixture of products which 
could not be separated.
NC
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7.4 Experimental Procedures for Chapter 4
6-Quinolinecarbaldehyde (198)
This was prepared using the method of V.M. Rodionov and M.A Berkengefm.183 
A 3-necked round bottom flask, equipped with a water condenser and 
thermometer was charged with 6 -methylquinoline (5.40 g, 37 mmol) and 
selenium (IV) oxide (4.59 g, 41 mmol). The mixture was heated to 140 °C, 
whereupon an exothermic reaction occurred, raising the temperature to 210  °C. 
When the exotherm had subsided, the mixture was heated at reflux for 90 min. 
Upon cooling to room temperature, the mixture was filtered through Celite, 
washed with water (50 ml) and extracted with diethyl ether (4 x 50 ml). The 
combined ethereal extracts were dried (MgS0 4 ) and concentrated in vacuo to a 
yellow oil. Column chromatography over silica gel (1:1 ethyl acetate/petroleum 
ether) isolated the product, which was recrystallised from diethyl ether to give 
fine yellow needles (2.85 g, 49 %), m.p. 65-66 [lit.: 75-76]198 °C. RF 0.38 (1:1 
ethyl acetate/petroleum ether); (Found: C 76.32; H 4.49; N 8.82 %; M+, 
157.0516. C10H7NO requires C 76.42; H 4.49; N 8.91 %; M, 157.0528); 
v m a x /c m -1 (KBr disc) 3039m (Ar-H), 1692s (C=0, aromatic aldehyde), 1623m, 
1575m and 1501m (aromatic ring), 838s (2 adjacent Ar-H), 801s (3 adjacent Ar- 
H); 8 h (200 MHz, CDCI3) 10.09 (s, 1H, -CHO), 8.95 (d, 3J 4.3 Hz, 1H, 2'-H), 
8.25-8.04 (m, 4H, 4', 5', 7', 8 '-H), 7.42 (dd, 3J 8.3 Hz, 3J 4.3 Hz, 1H, 3'-H); 
8C (50 MHz, CDCI3 ) 191.4 (d, CHO), 153.0 (d, 2 ’-CH), 150.7 (s, 10'-C), 137.4 
(d, 8 '-CH), 134.2 (s, 6 '-C), 133.6 (d, 4'-CH), 130.7 (d, 5'-CH), 127.6 (s, 9'-C),
126.6 (d, 7'-CH), 122.1 (d, 3'-CH); m/z 157 (M+, 100 %), 128 (M+ - CHO), 115 
(M+ - CHO, -CH), 100 (M+ - CHO, - C2H2).
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7-Quinolinecarbaldehyde (199)
This was prepared using the method of V.M. Rodionov and M.A Berkengefm.183 
To a 3-necked round bottomed flask equipped with a water condenser and 
thermometer was added 7-methylquinoline (4 ml of a mixture consisting of 70 % 
7-methyl quinoline and 30 % 5-methyl quinoline, i.e. 20.92 mmol 
7-methylquinoline) and selenium (IV) oxide (3.3716 g, 30.39 mmol). Heating to 
ca. 70 °C resulted in an exothermic reaction; once this had subsided, the 
mixture was heated at 70 °C for 5 h. The reaction was allowed to cool to room 
temperature, and was partitioned between ethyl acetate (50 ml) and water 
(50 ml), then filtered through Celite to remove residual selenium. After 
extracting with a further quantity of ethyl acetate (3 x 100 ml), the combined 
organic extracts were dried (Na2S0 4 ), filtered and concentrated to an orange oil 
which solidified on standing at room temperature. Column chromatography over 
silica (1:1 ethyl acetate/petroleum ether) resulted in the isolation of 
7-quinolinecarbaldehyde, which was recrystallised from ethyl acetate to yield 
fine orange needles (1.8827 g, 57 %), m.p. 87-89 [lit.: 85-86]183 °C. RF 0.35 (1:1 
ethyl acetate/petroleum ether); (Found: C 76.27; H 4.61; N 8.87 %; M+, 
157.0519. C10H7NO requires C 76.42; H 4.49; N 8.91 %; M, 157.0528); 
V m a x /c rrr1 (KBr disc) 3022w (Ar-H), 1690s (aldehydic C=0), 1623m, 1572m and 
1502m (aromatic ring), 840s (2 adjacent Ar-H), 807w (3 adjacent Ar-H); 5h (200 
MHz, CDCI3 ) 10.16 (s, 1H, CHO), 8.95 (d, 3J 4.2 Hz, 7J 1.8 Hz, 1H, 2'-H), 8.49 
(d, 7J 1.0 Hz, 1H, 8 '-H), 8.16 (dd, 3J 8.3 Hz, 7J 1.0 Hz, 1H, 4'-H), 7.97 (dd, 
3J 8 .8  Hz, 7J 1.8 Hz, 1H, 6 '-H), 7.84 (d, 3J 8.8  Hz, 1H, 5'-H), 7.47 (d, 3J 8.3 Hz, 
3J 4.2 Hz, 1H, 3'-H); 8 C (50 MHz, CDCI3) 151.6 (d, 2'-CH), 147.7 (s, 10'-C),
136.9 (s, 7'-C), 136.1 (d, 8 '-CH), 135.5 (d, 4'-CH), 131.8 (s, 9'-C), 129.0 (d,
6 -CH), 123.4 (d, 5'-CH), 123.1 (d, 3'-CH), signal for C=0 not observed; m/z 157 
(M+, 100  %), 128 (M+ - CHO), 101 (M+ - CHO, -C2H2, + H).
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8-Quinolinecarbaldehyde (200)
5 '  4 '
6
7
CHO
This was prepared using the method of V.M. Rodionov and M.A Berkengefm.183 
A 3-necked round bottomed flask equipped with a water condenser and 
thermometer was charged with 8 -methylquinoline (10 ml, 73.5 mmol) and 
selenium (IV) oxide (14.0399 g, 126.5 mmol). The mixture was heated at reflux 
for 22  h, then the condenser was removed and heating was continued until all 
of the remaining 8 -methylquinoline had evaporated. The remaining brown solid 
was dissolved in ethyl acetate (50 ml) and water (50 ml) and was heated at 
reflux for 2  h. On cooling to room temperature this was filtered through Celite 
and extracted with ethyl acetate (3 x 50 ml). The combined organic extracts 
were dried (MgS0 4 ), filtered and concentrated in vacuo to a beige solid. 
Column chromatography over silica gel (1:1 ethyl acetate/petroleum ether) gave 
a product which was recrystallised from methanol/water to yield a yellow solid 
(1.4983 g, 13 %), m.p. 96-99 [lit.: 94-95] 183 °C. RF 0.13 (1:1 ethyl 
acetate/petroleum ether); (Found: C 76.58; H 4.92; N 8.57 %; M+, 157.0514. 
C10H7NO requires C 76.42; H 4.49; N 8.91 %; M, 157.0528); Vmax/crn-1 (KBr 
disc) 3064w (Ar-H), 1709s (C=0, aromatic aldehyde), 1617m , 1583s and 
1524s (aromatic ring), 842m (2 adjacent Ar-H), 804m (3 adjacent Ar-H); 5h (200 
MHz, DMSO-de) 11-26 (s, 1H, CHO), 9.04 (dd, 3J 3.9 Hz, 4J 1.0 Hz, 1H, 2 '-H), 
8.62 (d, 3J 8.0 Hz, 1H, 7'-H), 8.45 (dd, 3J 7.3 Hz, 3J 1.0 Hz, 1H, 4'-H), 7.63 (d, 
3J 7.8 Hz, 1H, 5'-H), 7.16 (m, 1H, 6 '-H), 7.10 (dd, 3J  7.3 Hz, 3J 3.9 Hz, 1H, 
3'-H); 5C (50 MHz, DMSO-de) 167.1 (s, CHO), 149.8 (d, 2 '-CH), 144.3 (s, 
10'-C), 139.1 (d, 4'-CH), 134.9 (s, 8 '-C), 133.7 (d, 5'-CH), 133.0 (d, 7'-CH),
128.1 (s, 9'-C), 127.0 (d, 6 '-CH), 122.2 (d, 3'-CH); m/z 157 (M+, 1%), 128 (M+ 
- CHO), 102 (M+ - CHO, -C2H2, + 2 H).
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2-Cyano-3-(6-quinolyl)propenonitrile (201)
NC 5 4
Using General Procedure C, 6 -quinolinecarbaldehyde (0.1419 g, 0.90 mmol) 
was treated with malononitrile (0.0606 g, 0.91 mmol) in ethanol (1 ml) to give a 
yellow precipitate after 12 h which was recrystallised from 5:1 acetone/methanol 
(0.1661 g, 90 %), m.p. 196-197 °C. R f 0.23 (1:1 ethyl acetate/petroleum ether); 
(Found: C 76.06; H 3.39; N 20.55 %; M+ 205.6405. C13H7N3 requires C 76.09; 
H 3.44; N 20.48 %; M, 205.6400); v m a x /c m '1 (KBr disc) 3034w (Ar-H), 2224m 
(CN), 1617w, 1577s and 1500w (aromatic ring), 833w (2 adjacent Ar-H), 794m 
(3 adjacent Ar-H); 5h (200 MHz, DMSO-d6 ) 9.09 (br dd, 3J 4.2 Hz, 4 J 1 .5 Hz, 
1H, 2'-H), 8.73 (s, 1H, 3-H), 8.57 (v.br, 1H, 8 '-H), 8.54 (v. br, 1H, 4'-H), 8.32 
(v.br d, 3J 9.0 Hz, 1H, 7'-H), 8.21 (v. br d, 3J 9.0 Hz, 1H, 5'-H), 7.70 (dd, 
3JQA Hz, 3 j  4.1 Hz, 1H, 3'-H); 6c (50 MHz, DMSO-d6) 160.7 (d, 3-CH), 153.9 
(d, 2'-CH), 149.4 (s, 10'-C), 137.7 (d, 8 '-CH), 134.2 (d, 4'-CH), 130.4 (d, 5'-CH),
129.4 (s, 6 '-C), 128.0 (s, 7'-CH), 127.5 (s, 9'-C), 123.1 (d, 3'-CH), 114.3 and
112.2 (2 x s, 2 x CN), 82.6 (s, 2-C); m/z 205 (M+, 100%), 178 (M+ - CN, - H), 
154 (M+ - 2 x CN, + H), 129 (M+ - [C=C(CN)2]).
2,4-Dicyano-3-amino-5-(6-quinolyl)penta-2,4-dienonitrile (202)
6 -Quinolinecarbaldehyde (0.1482 g, 0.94 mmol) and 2-aminopropene-1,1,3- 
tricarbonitrile (0.1269 g, 0.94 mmol) were treated with ethanol (1 ml) and dilute 
piperidine solution (1 drop) using General Procedure B to give a yellow solid 
after 2.5 h (0.2286 g, 89 %), m.p. 251-254 °C. RF 0.28 (1:1 ethyl 
acetate/petroleum ether); (Found: C 70.92; H 3.52; N 25.56 %; M+, 271.0837. 
C16H9N5 requires C 70.84; H 3.34; N 25.82 %; M 271.0858); Vmax/cm-1 (KBr 
disc) 3016w (Ar-H), 2225w (CN), 1656s (C=C), 1618m, 1579s and 1505m 
(aromatic ring), 1536s (C-N02), 826m (2 adjacent Ar-H), 794m (3 adjacent 
Ar-H); 6 H (200  MHz, DMSO-d6) 9.28 and 9.18 (2 x br s, 2 H, NH2), 9.05 (d, 
3J 4.2 Hz, 1H, 2'-H), 8.57-8.14 (m, 4H, 4', 5', 7', 8 '-H), 8.26 (s, 1H, 5-H), 7.68 
(dd, 3 j 8 .3  Hz, 3J 4.2 Hz, 3 '-H); 6C (50 MHz, DMSO-d6) 165.4 (s, 3-C), 153.2
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(d, 5 -CH), 152.8 (d, 2'-CH), 148.9 (s, 10'-C), 137.5 (d, 8 '-CH), 132.7 (d, 4'-CH), 
130.3 (d, 5'-CH), 129.8 (s, 6 '-C), 128.3 (d, 7'-CH), 127.7 (s, 9'-C), 122.9 (d, 
3'-CH), 115.6 and 114.9 (2xs, 1-CN and 6-CN),114.7 (s, 7-CN), 104.8 (s, 2-C),
103.2 (s, 4-C); m/z27^ (M+, 71 %), 245 (M+ - CN), 206 (M+ - C(CN)2, - H), 179 
(M+ -[C(NH2)=C(CN)2]).
Methyl 2-cyano-3-(6-quinolyl)propenoate (203)
O
CN
Using General Procedure C, 6 -quinolinecarbaldehyde (0.3052 g, 1 .94 mmol) 
and methyl cyanoacetate (0.20 m l, 2.27 mmol) were treated in methanol (2 ml) 
to give a yellow precipitate after 24 h (0.2987 g, 61 %), m.p. 144-146 °C. 
R f 0.25 (1:1 ethyl acetate/petroleum ether); (Found: C 70.64; H 4.37; N 11.79 
%; M+, 238.0741. C i4H i0N2O2 requires C 70.60; H 4.20; N 11.76 %; M, 
238.0743); vmax/cm-1 (KBr disc) 3034w (Ar-H), 2215w (CN), 1728s 
(ap-unsaturated C=0), 1601s and 1566w (aromatic ring), 842m (2 adjacent Ar- 
H), 779w (3 adjacent Ar-H); 8 h (200 MHz, DMSO-d6 , 40 °C) 9.08 (dd, 3J 4.1 Hz, 
4J 1.6 Hz, 1H, 2'-H), 8.60 (br, 1H, 8 '-H), 8.50 (s, 1H, 4-H), 8.47-8.35 (m, 2H, 
4'-H and 7'-H), 8.20 (br, 1H, 5'-H), 7.60 (dd, 3J 4.1 Hz, 3J 8.4 Hz, 1H, 3'-H), 0.95 
(s, 3H, CH3); 8c (50 MHz, DMSO-d6> 40 °C) 163.2 (s, C=0), 155.0 (d, 2 '-CH),
153.7 (s, 10'-C), 150.2 (d, 4-C), 137.6 (d, 8 '-CH), 135.0 (d, 4'-CH), 130.6 (d, 
5'-CH), 129.7 (s, 6 '-C), 129.5 (d, 7'-CH), 128.2 (s, 9'-C), 123.5 (d, 3'-CH), 118.2 
(s, CN), 103.8 (s, 3-C), 55.2 (q, CH3); m /z238 (M+, 100 %), 223 (M+ - CH3), 
207 (M+ - OCH3), 179 (M+ - C 02CH3), 152 (M+ - C 02CH3, - CN, + H+).
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Ethyl 2-cyano-3-(6-quinolyl)propenoate (204)
O
8
6 -Quinolinecarbaldehyde (0.1389 g, 0.88 mmol) was treated with ethyl 
cyanoacetate (0.1 ml, 0.94 mmol) in ethanol (1 ml) using General Procedure C 
for 12 h. Concentration in vacuo gave a solid which was recrystallised from 
acetone to give yellow crystals (0.1051 g, 47%), m.p. 138-140 °C. R f 0.32 (1:1 
ethyl acetate/petroleum ether); (Found: C 71.50; H 4.73; N 11.09%; M+, 
252.0889. C 15H12N2O2 requires C 71.44; H 4.80; N 11.11%; M, 252.0899); 
V m a x /c rrr1 (KBr disc) 3035w (aryl-H), 2221w (CN), 1720s (ap-unsaturated 
carbonyl), 1570m and 1496m (aromatic ring), 846m (2 adjacent Ar-H), 797w (3 
adjacent Ar-H); 8 h (200 MHz, DMSO-d6) 9.06 (dd, 3J 4.2 Hz, 4J 1.7 Hz, 1H,
2-H), 8.60 (d, 3J 2.0 Hz, 1H, 8 '-H), 8.54 (s, 1H, 5-H), 8.49-8.39 (m, 2H, 4'-H and 
7'-H), 8.18 (br d, 3J 8.8  Hz, 5'-H), 7.65 (dd, 3J 8.3 Hz, 4JA.2 Hz, 1H, 3'-H), 4.43- 
4.33 (q, 3J 7.1 Hz, 2 H, CH2), 1.38 (t, 3J 7.1 Hz, 3H, CH3); 5C (50 MHz, 
DMSO-de) 161.8 (s, C=0), 154.1 (d, 2 '-CH), 153.2 (s, 10 '-C), 149.1 (s, 4-C),
137.3 (d, 8 '-CH), 134.0 (d, 4'-CH), 130.1 (d, 5'-CH), 129.5 (s, 6 '-C), 128.5 (d,
7-CH), 127.6 (s, 9'-C), 122.7 (s, 3'-CH), 117.9 (s, CN), 103.6 (s, 5-C), 62.5 (t, 
CH2), 13.9 (q, CH3); m/z252 (M+, 100 %), 223 (M+ - C2H5), 207 (M+ - OC2 H5), 
179 (M+ - CO2C2H5), 153 (M+ -CO2C2H5 , - CN).
nButyl 2-cyano-3-(6-quinolyl)propenoate (205)
Using General Procedure A, 6 -quinolinecarbaldehyde (0.3112 g, 1.98 mmol) 
was treated with nbutyl cyanoacetate (0.28 ml, 1.97 mmol) in butan-1-ol (1 ml) 
and piperidine (10  drops) to give a yellow solid after 10 min which was filtered 
and washed (diethyl ether). After 24 h under oil pump vacuum, this yielded a 
yellow solid which needed no further purification (0.2666 g, 45 %), 
m.p. 71-72 °C. R f 0.33 (1:1 ethyl acetate/petroleum ether); (Found: C 72.56; H 
5.71; N 10.05 %; M+, 280.1202. C i7H 16N20 2  requires C 72.86; H 5.75; 
N 10.00%; M, 280.1212); vmax/cnr1 (KBr disc) 3075w (Ar-H), 2226w (CN),
O
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1720s (ap-unsaturated carbonyl), 1632m (extended conjugation to aromatic 
ring), 1580s and 1500m (aromatic ring), 1370m (CH3), 840m (2 adjacent Ar-H), 
800w (3 adjacent Ar-H); 8 h (200 MHz, DMSO-d6) 9.07 (dd, 3J 4.3 Hz, 
3J 1 .4 Hz, 1H, 2 '-H), 8.62 (d, 3J  2.0 Hz, 1H, 8 '-H), 8.63 (s, 1H, 7-H), 8.47-8.39 
(m, 2H, 4' and 7'-H), 8.20 (br, 1H, 5'-H), 7.64 (dd, 3J  8.2 Hz, 3J  4.3 Hz, 1H,
3-H), 4.30 (t, 3J  6.4 Hz, 2 H, 4-H2), 1.95-0.74 (m, 7H, 2 and 3-H2, 1-H3); 
8c (50 MHz, DMSO-d6) 162.4 (s, C=0), 154.2 (d, 2 '-CH), 153.4 (d, 7-CH), 149.2 
(s, 10'-C), 137.4 (s, 8 '-CH), 134.3 (d, 4'-CH), 130.2 (5 '-CH), 129.5 (s, 6 '-C),
128.5 (d, 7'-CH), 127.6 (s, 9'-C), 122.8 (d, 3'-CH), 115.6 (s, CN), 103.5 (s, 6 -C), 
66.1 (t, 4-CH2), 30.1 (t, 3-CH2), 18.5 (t, 2-CH2), 13.6 (q, CH3); m/z 280 (M+, 
75 %), 223 (M+ - nBu), 180 (M+ - C 02nBu, + H), 154 (M+ - C 02nBu, - CN, + H).
Tri(ethylene glycol) 2-cyano-3-(6-quinolyl)propenoate methyl ether (206)
Using General Procedure A, 6 -quinolinecarbaldehyde (0.0815 g, 0.52 mmol) 
was treated with tri(ethylene glycol) cyanoacetate methyl ether (52 pi, 
0.52 mmol) in ethanol (2.5 ml) and piperidine (1 drop) for 12 h. Filtration, 
followed by concentration of the mother liquors in vacuo gave the product as an 
orange oil (0.1264 g, 63 %). Rf 0-0.14 (1:1 ethyl acetate/petroleum ether); 
(Found: C 64.79; H 5.97; N 7.58 %; M+, 371.1505. C a jH ^ N ^ s  requires 
C 64.85; H 5.99; N 7.56 %; M, 371.1529); V m a x /c n r1 (thin film) 3048m (Ar-H), 
2884s and 1434s (-CH2-), 2224w (CN), 1716s (ap-unsaturated carbonyl), 
1620s (extended conjugation to aromatic system), 1586s, 1574s and 1504m 
(aromatic ring), 802w (3 adjacent Ar-H), 838m (2 adjacent Ar-H); 8h (200 MHz, 
DMSO-d6) 9.01 (dd, 3J 4.1 Hz, 4J  1.5 Hz, 1H, 2 '-H), 8.46 (m, 1H, 4'-H), 8.43 (s, 
1H, 10 H), 8.41 (m, 1H, 8 '-H), 8.32 (m, 1H, 5'-H), 8.23 (m, 1H, 7'-H), 7.51 (dd, 
3J 8.3 Hz, 3J 4.3 Hz, 1H, 3'-H), 3.84-3.38 (m, 12H, 2, 3, 4, 5, 6 , 7-H2), 1.42 (t, 
3J  7.1 Hz, CH3); 8 c  (50 MHz, DMSO-d6) 154.1 (d, 10-CH), 153.0 (d, 2'-H),
149.7 (s, 10'-C), 137.2 (d, 8 '-CH), 133.1 (d, 4'-CH), 132.9 (s, 6 '-C), 130.6 (d, 
5'-CH), 129.4 (d, 7'-CH), 127.8 (s, 9'-C), 115.0 (s, CN), 103.8 (s, 9-C), 70.4 (t, 
7-CH2), 70.3 (t, 6 -CH2), 70.1 (t, 5 -CH2), 66 .6  (t, 4-CH2), 65.8 (t, 3-CH2), 61.5 (t, 
2-CH2), 14.0 (q, CH3 ), signal for C=0 not observed ; m /z371 (M+, 43 %), 294 
(M+ -OCH2 CH2OCH3 - H), 268 (M+ - [(CH2CH20)2CH3 j), 224 (M+ 
- [(CH2CH20)3CH3 j), 179 (M+ - [CO(OCH2CH2 )3OCH3], -H).
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2-Cyano-3-(6-quinolyl)propenamide (207)
O
CN
10’ N
6 -Quinolinecarbaldehyde (0.1094 g, 0.70 mmol) was treated with 
2-cyanoacetamide (0.0650 g, 0.77 mmol) in ethanol (5 ml) and piperidine 
(1 drop) using General Procedure A to give an off-white precipitate after 40 min 
(0.0925 g, 58 %), m.p. 236-239 °C. R f 0.24 (1:1 ethyl acetate/petroleum ether); 
(Found: C 69.84; H 4.12; N 18.61 %; M+, 223.0726. C13H9N3O requires 
C 69.95; H 4.06; N 18.82 %; M, 223.0746); vmax/cnrri (KBr disc) 3054m (Ar-H), 
2214W (CN), 1699s (amide C=0), 1636m and 1603m (aromatic ring), 839m (2 
adjacent Ar-H), 790w (3 adjacent Ar-H); 8 h (200  MHz, DMSO-de) 9.05 (br, 1H, 
2'-H), 8.54 (s, 1H, 3-H), 8.41-8.06 (m, 4H, 4', 5', 7' and 8 '-H), 7.90 and 7.74 (2 x 
s, NH2), 8.39 (dd, 3 j 8.3 Hz, 3 j 4 .2  Hz, 1H, 3'-H); 5C (50 MHz, DMSO-de) 154.1 
(d, 3-CH), 152.3 (s, 2'-CH), 150.3 (s, 10'-C), 138.9 (d, 8 '-CH), 131.6 (d, 4'-CH),
130.8 (d, 5'-CH), 130.5 (s, 6 '-C), 127.9 (d, 7'-CH), 127.0 (s, 9'-C), 124.2 (d, 
3'-CH), 117.3 (s, CN), 112.9 (s, 2-C), signal for C=0 not observed; m/z223 (M+, 
71 %), 207 (M+ - NH2), 179 (M+ -CONH2), 153 (M+ - CONH2, - CN).
2-Cyano-3-(6-quinolyl)propenethioamide (208)
S
Using General Procedure C, 6 -quinolinecarbaldehyde (0.3104 g, 1.97 mmol) 
and 2 -cyanothioacetamide (0.2006 g, 2 .00  mmol) were treated in ethanol (6 ml) 
to give an orange precipitate after 5 min (0.4147 g, 88  %), m.p. 223-225 °C. 
R f  0.19 (1:1 ethyl acetate/petroleum ether); (Found: C 65.06; H 4.05; 
N 17.18 %; M+, 239.0500. C13H9N3S requires C 65.25; H 3.79; N 17.56 %; M,
239.0517); V m a x /c n r 1 (KBr disc) 2997m (Ar-H), 2211w (CN), 1602s (aromatic 
ring), 835m (2 adjacent Ar-H), 774w (3 adjacent Ar-H); 5h (200  MHz, DMSO-d6)
9.97 and 9.77 (2 x s, NH2), 9.09 (br, 1H, 2'-H), 8.52 (s, 1H, 3-H), 8.35 (br, 1H, 
8'-H), 8.30 (s, 1H, 5'-H), 8.20 (br, 1H, 4'-H), 8.16 (br, 1H, 7'-H), 7.65 (dd, 
3J 8.2 Hz, 3J  4 .2  Hz, 1H, 3'-H); 8C (50 MHz, DMSO-d6) 148.7 (s, 10'-H), 152.9 
(d, 3 -CH), 146.3 (d, 2 '-CH), 137.2 (d, 8 '-CH), 132.4 (d, 4'-CH), 130.2 (s, 6 '-C),
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130.0 (d, 5'-CH), 128.9 (d, 7'-CH), 126.7 (s, 9'-C), 122.7 (d, 3'-CH), 116.3 (s, 
CN), 113.4 (s, 2-C), signal for C=S was not observed; m/z 239 (M+, 84 %), 207 
(M+ - S), 179 (M+ - CSNH2), 152 (M+ - CSNH2, - CN, - H).
2-Cyano-3-(7-quinolyl)propenonitrile (209)
5 4'
NC 3 8
7-Quinolinecarbaldehyde (0.1775 g, 1.13 mmol) and malononitrile (0.0770 g, 
1.16 mmol) were treated with ethanol (1 ml) using General Procedure C to give 
a beige precipitate after 1 min (0.1825 g, 79 %), m.p. 116-118 °C. R f 0.25 (1:1 
ethyl acetate/petroleum ether); (Found: C 76.00; H 3.50; N 20.20 %; M+, 
205.6411. C13H7N3 requires C 76.09; H 3.44; N 20.48 %; M, 205.6400); 
Vmax/cnr1 (KBr disc) 3037m (Ar-H), 2228s (CN), 1617w, 1559m and 1507w 
(aromatic ring), 837s (2 adjacent Ar-H), 770m (3 adjacent Ar-H); 5h (200 MHz, 
DMSO-de) 9.06 (dd, 3J 4.2 Hz, 7J 1.7 Hz, 1H, 2 '-H), 8.75 (s, 1H, 3-H), 8.63 (s, 
1H, 8 '-H), 8.49 (d, 3J8 A  Hz, 1H, 4'-H), 8.21 (d, 3J 8 .6  Hz, 1H, 5'-H), 8.11 (dd, 
3J 8 .6  Hz, 7J 1.7 Hz, 1H, 6 '-H), 7.73 (dd, 3J 8.4 Hz, 3J 4.2 Hz, 1H, 3'-H); 
6C (50 MHz, DMSO-de) 161.0 (d 3-CH), 152.6 (d, 2 '-CH), 146.8 (s, 10 '-C),
136.3 (d, 8 '-CH), 133.4 (d, 4'-CH), 132.1 (s, 7'-C), 130.8 (s, 9'-C), 129.7 (d,
6 -CH), 125.5 (d, 5'-CH), 124.3 (d, 3'-CH), 114.2 and 113.3 (2 x s, 2 x CN), 83.3 
(s, 2-C); m/z205 (M+, 100 %), 179 (M+ - CN), 154 (M+ - 2 x CN, + H).
2,4-Dicyano-3-amino-5-(7-quinolyl)penta-2,4-dienonitrile (210)
Using General Procedure C, 7-quinolinecarbaldehyde (0.1604 g, 1 .02  mmol) 
was treated with 2-aminopropene-1,1,3-tricarbonitrile (0.1350 g, 1.02 mmol) in 
ethanol (1 ml) to give a yellow precipitate after 1 min (0.2402 g, 86  %), 
m.p. 202-204 °C. R f 0.05 (1:1 ethyl acetate/petroleum ether); (Found: C 70.79; 
H 3.73; N 25.55%; M+, 271.0854. C16H 9N5 requires C 70.84; H 3.34; 
N 25.82 %; M, 271.0858); vmax/cm-i (KBr disc) 2366w (NH2), 2219s (CN),
6 7 5'  4
nh 2
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1667s (C=C conjugated to aromatic system), 1595s and 1543s (aromatic ring), 
841m (2 adjacent Ar-H), 800w (3 adjacent Ar-H); 5h (200 MHz, DMSO-d6) 9.30 
and 9.25 (2 x s, NH2), 9.06 (m, 1H, 2 '-H), 8.63 (s, 1H, 5-H), 8.47 (d, 3J 8.3 Hz, 
1H, 4'-H), 8.38 (s, 1H, 8 '-H), 8.19-8.12 (m, 2H, 5'-H and 6 '-H), 7.70 (dd, 
3J 8.3 Hz, 3J 4.2 Hz, 1H, 3'-H); 5C (50 MHz, DMSO-d6) 165.4 (s, 3-C), 152.9 (d,
5-CH), 152.3 (d, 2 '-CH), 147.1 (s, 10'-C), 136.1 (d, 8 '-CH), 132.5 (d, 4'-CH),
130.5 (s, 9'-C), 130.1 (s, 7'-C), 129.6 (d, 6 '-CH), 125.6 (d, 5'-CH), 123.7 (d,
3-CH), 115.6 (s, 7-CN), 114.9 and 114.7 (2 x s, 1-CN and 6 -CN), 103.6 (s, 
2 -C), 50.2 (s, 4-C); m/z 271 (M+, 100 %), 245 (M+ - CN), 206 (M+ - [C(CN)2], 
- H), 179 (M+ - [C(NH2)=C(CN)2]).
Methyl 2-cyano-3-(7-quinolyl)propenoate (211)
5'  4
o
7-Quinolinecarbaldehyde (0.0895 g, 0.57 mmol) was treated with methyl 
cyanoacetate (52 pi, 0.57 mmol) in methanol (1 ml) and piperidine (1 drop) 
using General Procedure A to give a yellow precipitate after 1 min (0.0629 g, 
46 %), m.p. 208-209 °C. R f 0.23 (1:1 ethyl acetate/petroleum ether); (Found: 
C 70.59; H 4.26; N 11.73%; M+, 238.0731. C i4H10N2O2 requires C 70.60; 
H 4.20; N 11.76 %; M , 238.0742); Vmax/cnrr1 (KBr disc) 3030w (Ar-H), 2219w 
(CN), 1727s (ap-unsaturated carbonyl), 1599s (aromatic ring), 833m 
(2 adjacent Ar-H), 780w (3 adjacent Ar-H); 8 h (200 MHz, DMSO-d6 ) 9.06 (m, 
1H, 2'-H), 8.76 (s, 1H, 4-H), 8.67 (s, 1H, 8 '-H), 8.48 (d, 3 j  8.2 Hz, 1H, 4'-H), 
8.27-8.16 (m, 2H, 5’-H and 6 '-H), 7.21 (dd, 3 j8.2 Hz, 3 j 4.1 Hz, 1H, 3'-H), 3.95 
(s, 3H, CH3); 5c (50 MHz, DMSO-d6) 159.3 (s, C=0), 152.9 (d, 4-CH), 152.4 (d, 
2,-CH), 147.6 (s, 10'-C), 135.8 (d, 8 '-CH), 132.9 (d, 4'-CH), 131.2 (s, 9'-C),
130.8 (d, 6 '-CH), 130.2 (s, 7’-C), 125.8 (d, 5'-CH), 123.6 (d, 3'-CH), 116.2 (s, 
CN), 102.7 (s, 3-C), 54.0 (q, CH3); m/z 238 (M+, 100 %), 223 (M+ - CH3), 207 
(M+ - OCH3), 179 (M+ - C 02CH3), 152 (M+ - C 02CH3, - CN, + H).
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Ethyl 2-cyano-3-(7-quinolyl)propenoate (212)
5 '  4 '
o
7-Quinolinecarbaldehyde (0.1524 g, 0.97 mmol) and ethyl cyanoacetate 
(0 .1 2  ml, 1.12  mmol) were treated in ethanol (1 ml) and piperidine (1 drop) 
using General Procedure A to give a yellow precipitate after 1 min (0.1723 g, 
67 %), m.p. 162-164 °C. R f 0.27 (1:1 ethyl acetate/petroleum ether); (Found: 
C 71.16; H 4.85; N 11.03%; M+, 252.0887. CH5H-12N2O2 requires C 71.44; 
H 4.80; N 11.11 %; M, 252.0899); vmax/cm-l (KBr disc) 3047W (Ar-H), 2224w 
(CN), 1724s (ap-unsaturated C=0), 1635w, 1600s and 1534w (aromatic ring), 
836s (2 adjacent Ar-H), 784w (3 adjacent Ar-H); 8h (200 MHz, DMSO-d6) 9.06 
(m, 1H, 2'-H), 8.70 (s, 1H, 8 ’-H), 8.64 (s, 1H, 5-H), 8.48 (d, 3J  8.3 Hz, 1H, 4'-H), 
8.24-8.15 (m, 2H, 5' and 6 '-H), 7.72 (dd, 3J 8.3 Hz, 3J 4.1 Hz, 1H, 3'-H), 4.34 (q, 
3J 7.05 Hz, 2 H, CH2), 1.28 (t, 3J 7.0 Hz, 3H, CH3); 5c (50 MHz, DMSO-d6)
160.8 (s, C=0), 153.4 (d, 5-CH), 152.5 (d, 2 '-CH), 147.2 (s, 10'-C), 136.0 (d, 
8 '-CH), 133.3 (d, 4'-CH), 131.8 (s, 7'-C), 130.8 (s, 9’-C), 129.6 (d, 6 '-CH), 127.0 
(d, 5'-CH), 123.7 (d, 3'-CH), 115.8 (s, CN), 103.5 (s, 4-C), 63.4 (t, CH2), 15.2 (q, 
CH3); m/z 252 (M+, 100%), 223 (M+ - C2H5), 207 (M+ - OC2 H5), 180 (M+ 
- CO2C2H5 , + H), 152 (M+ - CO2C2H5 -CN, + H).
nButyl 2-cyano-3-(7-quinolyl)propenoate (213)
5' 4'
o
o
7-Quinolinecarbaldehyde (0.0812 g, 0.52 mmol) and nbutyl cyanoacetate (73 pi, 
0.52 mmol) were treated with butan-1-ol (2 ml) and piperidine (1 drop) using 
General Procedure A to give a beige precipitate after 1 min (0.0636 g, 42 %), 
m.p. 104-105 °C. Rf 0.38 (1:1 ethyl acetate/petroleum ether); (Found: C 72.66; 
H 5.65; N 9.96 %; M+, 280.1215. C i7H i6N202 requires C 72.86; H 5.75; 
N 10.00 %; M, 280.1212); vmax/cm-i (KBr disc) 3026w (Ar-H), 2222w (CN), 
1718s (ap-unsaturated C=0), 1600s (aromatic ring), 832m (2 adjacent Ar-H), 
760w (3 adjacent Ar-H); 8H (200 MHz, DMSO-d6) 9.05 (m, 1H, 2'-H), 8.72 (s, 
1H, 8'-H), 8.67 (s, 1H, 7-H), 8.48 (d, 3J 8.3 Hz, 1H, 4'-H), 8.23-8.16 (m, 2H, 5'-H
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a n d  6'-H), 7.21 (d d , 3 j  8.3 Hz, 3 j 4.2  Hz, 1H, 3'-H), 4.35 (t, 3 J & A  H z , 2H, 4-H2), 
1.74 (d d , 3J  7 .6  Hz, 3J6A  Hz, 2H, 3-H2), 1.46 (d d , 3 j  7 .6  Hz, 3J7.2 Hz, 2H, 
2-H2), 0.98 (t , 3 j 7 .2  Hz, 3H, CH3); 6C (50 MHz, DMSO-d6) 161.8 (s, C=0),
154.6 (d , 7-CH), 152.2 (d , 2'-CH), 147.1 (s, 10'-C), 136.0 (d , 8'-CH), 133.5 (d , 
4'-CH), 132.3 (s, 7'-C), 130.4 (s, 9'-C), 129.4 (d , 5'-CH), 126.3 (d , 6'-CH), 123.8 
(d , 3'-CH), 115.7 (s, CN), 104.2 (s, 6-C), 66.2 (t, 4-CH2), 30.2 (t, 3-CH2), 18.7 (t,
2-CH2), 13.7 (q, CH3); m/z 280 (M+, 10 %), 235 (M+ - nBu, + 2H), 180 (M+ 
- C02nBu, + H), 152 (M+ - C 02nBu, - CN, - H).
Tri(ethylene glycol) 2-cyano-3-(7-quinolyl)propenoate methyl ether (214)
cn «:
Using General Procedure A, 7-quinolinecarbaldehyde (0.1410 g, 0.90 mmol) 
was treated with tri(ethylene glycol) cyanoacetate methyl ether (186 \l\, 
0.90 mmol) in ethanol (2 ml) and piperidine (1 drop) for 1 h. Filtration and 
concentration in vacuo gave the product as a brown oil (0.2613 g, 78 %) 
R f  0-0.38 (1:1 ethyl acetate/petroleum ether); (Found: C 64.98; H 6.02; 
N 7.54 %; M+, 371.1534. C20H22N2O5 requires C 64.85; H 5.99; N 7.56 %; M, 
371.1529); vmax/cnrr1 (KBr disc) 3054m (Ar-H), 2878s, 1452s and 730w 
(-CH2-), 2 2 4 4 w  (CN), 1720s (ap-unsaturated carbonyl), 1626s (extended 
conjugation to aromatic system), 1598m, 1570m and 1502s (aromatic ring), 
808m (3 adjacent Ar-H), 842s (2 adjacent Ar-H), 896w (isolated Ar-H); 
8h (200 MHz, DMSO-de) 8.74 (m, 1H, 2'-H), 8.09-7.24 (m, 6H, 10, 3', 4', 5', 6', 
8'-H), 3.62-2.92 (m, 12H, 2, 3, 4, 5, 6, 7-H), 1.09 (s, CH3); 8C (50 MHz, 
DMSO-de) 151.1 (d, 10-CH), 150.7 (d, 2'-CH), 147.7 (s, 10'-C), 136.1 (d, 8'-CH),
128.9 (d, 4'-CH), 128.6 (s, 7'-C), 128.4 (s, 9'-C), 128.1 (d, 6'-CH), 127.9 (d, 
5'-CH), 121.5 (d, 3'-CH), 115.2 (s, CN), 105.2 (s, 9-C), 71.8 (t, 7-CH2), 70.4 (t,
6-CH2), 70.3 (t, 5-CH2), 70.1 (t, 4-CH2), 68.3 (t, 3-CH2), 57.7 (t, 2-CH2), 18.3 (q, 
CH3), signal for C=0 not observed; m/z 371 (M+, 35 %), 294 (M+ 
-OCH2CH2OCH3 - H), 268 (M+ - [(CH2CH20)2CH3]), 251 (M+
- [(OCH2CH2)20CH3], - H), 207 (M+ - [0(CH2CH2)30CH3], - H), 179 (M+
- [CO(OCH2CH2)3OCH3], - H).
179
2-Cyano-3-(7-quinolyl)propenamide (215)
5 '  4 '
o
Using General Procedure A, 7-quinolinecarbaldehyde (0.1651 g, 1.05 mmol) 
and 2-cyanoacetamide (0.0932 g, 1.11 mmol) were treated with ethanol (2 ml) 
and piperidine (1 drop) to give a pink powder after 10 min (0.1696 g, 73 %), 
m.p. 185-187 °C. R f 0.27 (1:1 ethyl acetate/petroleum ether); (Found: C 69.84; 
H 4.86; N 18.82%; M+ 223.0732. C13H9N3O requires C 69.95; H 4.06; 
N 18.82%; M, 223.0746); Vmax/cm'1 (KBr disc) 2681w and 1598m (amide 
NH2), 2253w (CN), 1579m (aromatic ring), 1690s (amide C=0), 840m (2  
adjacent Ar H), 777m (3 adjacent Ar-H); 5h (200  MHz, DMSO-d6 ) 10.13 (br s, 
2H, NH2), 8.91 (m, 6 H, 3, 2', 4', 5', 6 ' and 8 '-H), 7.54 (dd, 3 j 8.3 Hz, 3 j 4.2  Hz, 
1H, 3'-H); 8C (50 MHz, DMSO-d6) 168.8 (s, C=0), 152.1 (d, 3-C), 150.8 (d, 
2I-CH), 147.2 (s, 10'-C), 135.4 (d, 8 '-CH), 132.9 (d, 4'-CH), 130.6 (s, 7'-C),
129.8 (s, 9'-C), 128.9 d, 6 '-CH), 125.8 (d, 5'-CH), 124.2 (d, 3'-CH), 116.2 (s, 
CN), 102.8 (s, 2  C); m/z 222  (M+, 100 %), 205 (M+ - NH2 - 2 H), 179 (M+ 
- CONH2), 128 (M+ - [C=C(CN)CONH2] + H).
2-Cyano-3-(7-quinolyl)propenethioamide (216)
5' 4'
s
Using General Procedure C, 7-quinolinecarbaldehyde (0.1153 g, 0.73 mmol) 
was treated with 2-cyanothioacetamide (0.0763 g, 0.76 mmol) with ethanol 
(1 ml) to give an orange precipitate after 1 h (0.0779 g, 45 %), m.p. 194-196 °C. 
Rf 0.26 (1:1 ethyl acetate/petroleum ether); (Found: C 65.27; H 3.73; N 17.58 
%; M+, 239.0512. C13H9N3S requires C 65.25; H 3.79; N 17.56 %; M,
239.0517); vmax/cm_i (KBr disc) 3347s (thioamide NH2), 2211w (CN), 1587s 
and 1566m (aromatic ring), 1123s (C=S), 837s (2 adjacent Ar-H), 771m (3 
adjacent Ar-H); 8H (200  MHz, DMSO-d6) 9.96 and 9.81 (2 x s, 2 H, NH2), 9.07 
(m, 1H, 2'-H), 8.73 (s, 1H, 3-H), 8.63 (s, 1H, 8 ’-H), 8.48 (d, 1H, 3 j 8.3 Hz, 4'-H), 
8.32-8.17 (m, 2H, 5' and 6 '-H), 7.70 (dd, 3 j  8.3 Hz, 3 j  4 .2  Hz, 1H, 3'-H); 
8C (50 MHz, DMSO-de) 172.1 (s, C=S), 154.8 (d, 3-CH), 151.2 (d, 2 '-CH), 148.5
180
(s, 10 '-C), 135.8 (d, 8 '-CH), 133.2 (d, 4'-CH), 131.2 (s. 7'-C), 129.7 (s, 9'-C),
128.9 (d, 6 '-CH), 126.1 (d, 5'-CH), 124.8 (d, 3'-CH), 118.4 (s, CN), 101.5 (s,
2 -C); m/z239 (M+ 71 %), 223 (M+ - NH2), 211 (M+ - CNH2), 179 (M+ -CSNH2), 
154 (M+ -CSNH2, -CN + H).
2-Cyano-3-(8-quinolyl)propenonitrile (217)
5'  4'
NC
'CN
8 -Quinolinecarbaldehyde (0.1101 g, 0.70 mmol) was treated with malononitrile 
(0.0480 g, 0.73 mmol) in methanol (5 ml) and piperidine (1 drop) using General 
Procedure A to give a beige solid after 24 h (0.0460 g, 28 %), m.p. 175-176 °C. 
R f  0.17 (1:1 ethyl acetate/petroleum ether); (Found: C 76.14; H 3.49; N 20.68 
%; M+, 205.6408. C13H7N3 requires C 76.09; H 3.44; N 20.48%; M, 205.6400); 
Vmax/cm-1 (KBr disc) 3048w (Ar-H), 1620m (extended conjugation to aromatic 
system), 1580s and 1520s (aromatic ring), 805m (3 adjacent Ar-H); 5h (200 
MHz, DMSO-de) 9.06 (dd, 3 j  3 .9  Hz, 4J 1.0 Hz, 1H, 2 '-H), 8.71 (d, 3 J 8 . 1  Hz, 
1H, 7'-CH), 8.52 (s, 3-H), 8.51 (dd, 3 j  7.4 Hz, 4J 1.0 Hz, 1H, 4'-H), 7.72 (d, 
3J  7.8 Hz, 1H, 5'-H), 7.31 (m, 1H, 6 '-H), 7.25 (dd, 3J  7 .4  Hz, 3 j  3.9  Hz, 1H,
3-H); 5C (50 MHz, DMSO-d6) 158.3 (d, 3-C), 150.2 (d, 2 ’-CH), 143.1 (s, 10 '-C),
138.2 (d, 4'-CH), 134.2 (d, 7'-CH), 133.5 (d, 5'-CH), 132.8 (s, S’-C), 127.1 (s,
9-C), 126.8 (d, 6 '-CH), 122.1 (d, 3'-CH), 84.4 (s, 2-C), 114.8 and 115.6 (2 x s, 
2 x CN); m/z 205 (M+, 14 %), 179 (M+ - CN), 153 (M+ - 2 x CN).
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2,4-Dicyano-3-amino-5-(8-quinolyl)penta-2,4-dienonitrile (218)
5' 4'
NC
NH
Using General Procedure C, 8-quinolinecarbaldehyde (0.1987 g, 1.26 mmol) 
was treated with 2-aminopropene-1,1,3-tricarbonitrile (0.1677 g, 1.27 mmol) in 
ethanol (5 ml) to give a brown powder after 10 min (0.2671 g, 78 %), 
m.p. 107-110 °C. R f 0.20 (1:1 ethyl acetate/petroleum ether); (Found: C 70.56; 
H 3.39; N 25.68 %; M+, 271.0849. C i6H9N5 requires C; 70.84 H 3.34; 
N 25.82%; M, 271.0856); Vmax/cm-1 (KBr disc) 3056m (Ar-H), 2208s (CN), 
1620s (extended conjugation to aromatic ring), 798m (3 adjacent Ar-H); 
8h (200 MHz, DM SO -de) 9.31 and 9.25 (2 x s, NH2), 9.04 (dd, 3J 3.9 Hz, 
4J 1.0 Hz, 1H, 2'-H), 8.72-8.49 (m, 2H, 4' and 7'-H), 8.46 (s, 1H, 5-H), 7.75 (d, 
3J 7.9 Hz, 1H, 5'-H), 7.55 (m, 1H, 6'-H), 7.45 (dd, 3J 7.4 Hz, 3J 3.9 Hz, 1H, 
3'-H); 8C (50 MHz, DM SO-de) 163.1 (s, 3-C), 156.2 (d, 5-CH), 150.4 (d, 2'-CH),
145.2 (s, 10'-C), 136.9 (d, 4’-CH), 134.8 (d, 7'-CH), 133.6 (s, 8'-C), 132.9 (d, 
5'-CH), 127.6 (s, 4-C), 127.2 (d, 6'-CH), 122.4 (d, 3'-CH), 115.3, 114.9 and
114.6 (3 x s, 3 x CN), 104.3 (s, 2-C); m/z271 (M+, 10 %), 206 (M+ - [C(CN)2], 
- H), 180 (M+ - [C(NH2)=C(CN)2], + H).
Methyl 2-cyano-3-(8-quinolyl)propenoate (219)
Using General Procedure A, 8-quinolinecarbaldehyde (0.2011 g, 1.28 mmol) 
and methyl cyanoacetate (115 pi, 1.28 mmol) were treated in methanol (7.5 ml) 
and piperidine (1 drop) to give a yellow solid after 45 min (0.1836 g, 60 %), 
m.p. 122-124 °C. Rf 0.21 (1:1 ethyl acetate/petroleum ether); (Found: C 70.42;
182
H 4.31; N 11.84 %; M+, 238.0764. C14H10N2O2 requires C 70.60; H 4.20; 
N 11.76 %; M ,  238.0743); Vmax/cm-1 (KBr disc) 3064w (Ar-H), 1708s 
(ap-unsaturated carbonyl), 1616m (extended conjugation to aromatic ring), 
1582s and 1524s (aromatic system), 804m (3 adjacent Ar-H); 5h (200 MHz, 
DMSO-d6) 9.07 (dd, 3 j  3 .9  Hz, 4J  0.9 Hz, 1H, 2 '-H), 8.69 (d, 3J8.1 Hz, 1H,
7-H), 8.55 (dd, 3 j  7 .4  Hz, 4J  0.9 Hz, 1H, 4'-H), 8.51 (s, 1H, 4-H), 7.82 (d, 
3 j  7.9 Hz, 1H, 5'-H), 7.60 (m, 1H, 6 '-H), 7.55 (dd, 3 j  7 .4  Hz, 3 j  3 .9  Hz, 1H,
3-H), 3.41 (s, 3H, CH3); 8 c (50 MHz, DMSO-d6) 167.2 (s, C=0), 153.1 (d,
4-CH), 152.2 (d, 2'-CH), 146.3 (s, 10'-C), 138.2 (d, 4'-CH), 136.4 (d, 7'-CH),
135.2 (s, 8 '-C), 132.8 (d, 5 '-CH), 128.9 (s, 9'-C), 128.2 (d, 6 '-CH), 123.2 (d,
3-C), 117.1 (s, CN), 104.8 (s, 3-C), 53.6 (q, CH3); m/z 238 (M+, 6  %), 223 (M+ 
- CH3), 179 (M+ -C02CH3), 153 (M+ - C 0 2CH3, - CN).
Ethyl 2-cyano-3-(8-quinolyl)propenoate (220)
Using General Procedure A, 8 -quinolinecarbaldehyde (0.1722 g, 1.09 mmol) 
and ethyl cyanoacetate (117.6 |xl, 1.09 mmol) were treated in ethanol (5 ml) and 
piperidine (1 drop) to give a yellow solid after 23 h (0.0756 g, 27 %), 
m.p. 176-178 °C. Ftp 0.11 (1:1 ethyl acetate/petroleum ether); (Found: C 71.63; 
H 4.90; N 11.05 %; M+, 252.0888. C i5H i2N202 requires C 71.44; H 4.80; 
N 11.11%; M,  252.0899); vmax/cm-1 (KBr disc) 3064w (Ar-H), 2924w (C-H 
stretch), 1710s (ap-unsaturated carbonyl), 1618m (extended conjugation to 
aromatic system), 1582s and 1524s (aromatic ring), 804m (3 adjacent Ar-H); 
8h (200 MHz, DMSO-d6) 9.06 (dd, 3 J  3.9 Hz, 4J  0.9 Hz, 1H, 2'-H), 8.53 (dd, 
3J 7 A  Hz, 4 J 0.9 Hz, 1H, 4'-H), 8.50 (s, 1H, 5 -H), 8.32 (d, 3 j 8.0 Hz, 1H, 7'-H), 
7.79 (d, 3 j  7 .9  Hz, 1H, 5'-H), 7.32 (m, 1H, 6 '-H), 7.23 (dd, 3J  7.4 Hz, 3 j  3 .9  Hz, 
1H, 3'-H), 3.42 (q, 3 j  7.1 Hz, 2H, CH2), 1.28 (t, 3 j  7.1 Hz, 3H, CH3); 
8c (50 MHz, DMSO-d6) 166.8 (s, C=0), 154.0 (d, 5-CH), 152.8 (d, 2 '-CH),
148.2 (s, 10'-C), 138.6 (d, 4'-CH), 138.1 (d, 7'-CH), 136.2 (s, 8 '-C), 134.2 (d, 
5'-CH), 129.8 (d, 6 '-CH), 127.7 (s, 9'-C), 120.1 (d, 3 '-CH), 116.9 (s, CN), 103.9 
(s, 4-C), 62.8 (t, CH2), 15.2 (q, CH3); m/z252 (M+, 15 %), 223 (M+ - C2H5), 208 
(M+ -OC2 H5, + H), 179 (M+ - COC2 H5).
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"Butyl 2-cyano-3-(8-quinolyl)propenoate (221)
Using General Procedure A, 8 -quinolinecarbaldehyde (0.1421 g, 0.90 mmol) 
and "butyl cyanoacetate (300 pi, 2.11 mmol) were treated in butan-1-ol (5 ml) 
and piperidine (1 drop) to give a brown solid after 22.5 h (0.0695 g, 28 %), 
m.p. 180-182 °C. R f 0.11 (1:1 ethyl acetate/petroleum ether); (Found: C 72.64; 
H 5.85; N 10.04 %; M+, 280.1204. C17H 16N2O2 requires C 72.86; H 5.75; 
N 10.00 %; M, 280.1212); Vmax/cm'1 (KBr disc) 3064w (Ar-H), 2926w (C-H 
stretch), 1714s ( r x p -u n s a tu r a te d  carbonyl), 1618w (extended conjugation to 
aromatic ring), 1582s and 1522s (aromatic ring), 1462m (C-H deformations), 
1382m (-CH3 symmetric deformation), 802m (3 adjacent Ar-H); 
6h (200  MHz, DMSO-d6) 9.06 (d, 3J 3.9 Hz, 4J  0.9 Hz, 1H, 2 '-H), 8.53 (s, 1H,
7-H), 8.72-8.50 (m, 2H, 4' and 7'-H), 7.84 (d, 3J  8.0 Hz, 1H, 5'-H), 7.64 (m 1H, 
0-H), 7.47 (d, 3J 7.4 Hz, 3J 3.9 Hz, 1H, 3'-H), 4.32 (t, 3J 6.5 Hz, 2 H, 4-H2), 1.81 
(tt, 3J  7.6 Hz, 3J  6.5 Hz, 2 H, 3-H2), 1.51 (tt, 3J  7.6 Hz, 3J  7.2 Hz, 2 H, 2 -H2), 
0.95 (t, 3J 7.2 Hz, 3H, CH3); 6C (50 MHz, DMSO-d6) 165.8 (s, C=0), 155.7 (d,
7-CH), 155.2 (d, 2 -CH), 149.2 (s, 10'-C), 139.6 (d, 4'-CH), 137.2 (d, 7'-CH),
136.1 (s, 8 '-C), 134.1 (d, 5 '-CH), 128.4 (d, 6 '-CH), 128.2 (s, 9'-C), 124.8 (d,
3-CH), 116.1 (s, CN), 106.1 (s, 6 -C), 68.1 (t, 4-CH2), 34.3 (t, 3 -CH2), 18.2 (t, 
2-CH2), 15.6 (q, CH3); m/z 280 (M+, 6  %), 206 (M+ - 0"Bu, + H), 180 (M+ 
- C02 "Bu, + H), 151 (M+ - C 02"Bu, -CN, - 2H).
184
2-Cyano-3-(8-quinolyl)propenamide (222)
5 4 '
N C V 3
2
8 -Quinolinecarbaldehyde (0.1024 g, 0.65 mmol) and 2-cyanoacetamide 
(0.0555 g, 0.66 mmol) were treated with ethanol (7.5 ml) and dilute piperidine 
solution (1 drop) using General Procedure B to give a beige precipitate after 
24 h (0.1346 g, 92 %), m.p. 98-100 °C. R f 0.14 (1:1 ethyl acetate/petroleum 
ether); (Found: C 69.74; H 4.00; N 18.77 %; M+, 223.0724. C 13H9N3O requires 
C 69.95; H 4.06; N 18.82%; M, 223.0746); vmax/cnrrl (KBr disc) 3424w (NH2), 
3058m (Ar-H), 2230w (CN), 1606w (extended conjugation to aromatic ring), 
1584w (amide N-H stretch); 5h (200  MHz, DMSO-d6) 10.02  and 9.98 (2 x s, 
NH2), 9.07 (dd, 3J3.9 Hz, *J  0.9 Hz, 1H, 2 '-H), 8.53 (s, 1H, 3-H), 8.45-8.76 (m, 
2H, 4' and 7'-H), 7.89 (d, 3 j  8.0 Hz, 1H, 5'-H), 7.40 (m, 1H, 6 '-H), 7.24 (dd, 
3J7A  Hz, 3J3.9 Hz, 1H, 3'-H); 5C (50 MHz, DMSO-d6) 168.2 (s, C=0), 154.3 
(d, 2'-CH), 153.1 (d, 3-CH), 148.8 (s, 10'-C), 137.1 (d, 4'-CH), 136.3 and 136.2 
(2 x d, 5' and 7'-CH), 134.2 (s, 8 '-C), 129.4 (d, 6 '-CH), 126.2 (s, 9'-C), 123.6 (d, 
3'-CH), 118.2 (s, CN), 110.3 (s, 2-C); m/z223 (M+, 14%), 207 (M+ - NH2), 179 
(M+ - CONH2), 153 (M+ - CONH2, - CN).
2-Cyano-3-(8-quinolyl)propenethioamide (223)
8 -Quinolinecarbaldehyde (0 .1 0 2 2  g, 0.65 mmol) was treated with
2-cyanothioacetamide (0.0690 g, 0.68 mmol) in ethanol (5 ml) and dilute 
piperidine solution (1 drop) using General Procedure B to give an orange 
precipitate after 18.5 h (0.0767 g, 49 %), m.p. 139-142 °C. R f 0.14 (1:1 ethyl 
acetate/petroleum ether); (Found: C 64.97; H 3.82; N 17.48 %; M+, 239.0534.
5 4
2
185
C13H9N3S requires C 65.25; H 3.79; N 17.56 %; M, 239.0.517); v max/cm ' 1 (KBr 
disc) 3314m (NH2 ), 3066m (Ar-H), 2186w (CN), 1618m (extended conjugation 
to aromatic system), 800s (3 adjacent Ar-H); Sh (200  MHz, DMSO-d6 ) 10.09 
and 10.06 (2 x s, NH2), 9.06 (dd, 3J  3.9 Hz, 1.0 Hz, 1H, 2 '-H), 8.55 (s, 1H,
3-H), 8.50-8.77 (m, 2H, 4' and 7'-H), 7.92 (d, 3J8.1 Hz, 1H, 5'-H), 7.62 (m, 1H, 
6 '-H), 7.23 (dd, 3J  7.5 Hz, 3J 3.9 Hz, 1H, 3'-H); 8c (50 MHz, DMSO-d6) 170.1 (s, 
C=S), 155.3 (d, 2'-CH), 153.8 (d, 3 -CH), 149.6 (s, 10'-C), 137.4 (d, 4'-CH),
135.8 (d, 5'-CH), 134.2 (d, 7'-CH), 133.1 (s, 8 '-C), 128.0 (d, 6 '-CH), 126.3 (s, 
9P-C), 124.0 (d, 3'-CH), 118.2 (s, CN), 113.3 (s, 2-C); m/z 239 (M+, 18 %), 223 
(M+ - NH2), 211 (M+ - CNH2), 179 (M+ - CSNH2), 154 (M+ - CSNH2, - CN, + H).
8-Nitro-2-quinolinecarbaldehyde (227)
6
7 CHO
To a 3-necked round bottomed flask equipped with a water condenser was 
added 2-methyl-8-nitroquinoline (2.1482 g, 11.41 mmol) and toluene (10 ml). 
The mixture was heated to 50 °C until fully dissolved, and selenium (IV) oxide 
(1.3266 g, 11.96 mmol) was added. After the initial exotherm had subsided the 
reaction was heated at reflux temperature for 24 h. The mixture was then 
cooled and the solvent was removed in vacuo to give a solid which was 
washed with water (50 ml) and extracted with diethyl ether (3 x 100 ml). The 
combined ethereal extracts were dried (MgSO^, filtered and concentrated 
under reduced pressure to a red solid. Column chromatography over silica (1:1 
ethyl acetate/petroleum ether) gave the product as an orange solid which was 
recrystallised from methanol (1.2815 g, 53 %), m.p. 136-137 °C. Rf 0.26 (1:1 
ethyl acetate/petroleum ether); (Found: C 59.41; H 3.05; N 13.85%; M+, 
202.0364. CioH6N20 3  requires C 59.41; H 2.99; N 13.86%; M, 202.0378); 
V m a x /c n r1 (KBr disc) 3070w (Ar-H), 1716s (C=0, aromatic aldehyde), 1622m, 
1590w and 1530s (aromatic ring), 854m (2 adjacent Ar-H), 798m (3 adjacent 
Ar-H); 5H (200  MHz, DMSO-d6) 10.11 (s, 1H, CHO), 8.37 (d, 3J 7.9 Hz, 1H, 
4'-H), 8.18-8.04 (m, 3H, 5', 6 ' and 7'-H), 7.71 (d, 3J 7.9 Hz, 1H, 3'-H); 
5C (50 MHz, DMSO-de) 192.8 (d, CHO), 163.3 (s, 8 '-C), 153.8 (s, 2'-C), 148.6 
(s, 10'-C), 137.7 (d, r-CH), 131.8 (d, 4'-CH), 130.4 (s, 9'-C), 127.8 (d, 5'-CH),
124.4 (d, 6 '-CH), 118.9 (d, 3'-CH); m/z 202  (M+, 58 %), 174 (M+ - CO, + H), 157 
(M+ - N 02 + H), 127 (M+ - CHO, - N02), 101 (M+ - CHO, - N02, - C2H2 + 2 H).
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Attempted synthesis of 7-nitromethyl-8-nitroquinoline (238)
This experiment followed the procedure of Danikiewicz and M§kosza198. A 250 
ml 3-necked round bottom flask was cooled to 0 °C, and was charged with 
powdered sodium hydroxide (0.23 g, 5.75 mmol) dispersed in DMSO (7 ml). To 
this was added dropwise 8-nitroquinoline (228) (0.1745 g, 1.00 mmol) in DMSO 
(2 ml), followed by nitromethane (0.15 ml, 3.40 mmol). An immediate colour 
change, giving a red solution, was observed upon addition of the latter, and 
TLC showed that the spot at Rf 0.53 (8-nitroquinoline) was accompanied by 
two new spots (very faint) at Rf 0.38 and 0.32. The mixture was allowed to 
warm to room temperature, and was stirred at this temperature for 12 h, during 
which time the intensities of the three spots did not change. The excess NaOH 
was neutralised using aqueous HCI, and the mixture was washed with water 
(50 ml). The products were extracted (ethyl acetate, 3 x 50 ml), dried (MgS0 4 ), 
filtered and concentrated in vacuo. Column chromatography (Si02, 1:1 ethyl 
acetate/petroleum ether) was then attempted, but only 8-nitroquinoline 
(identified by TLC) and a considerable quantity of baseline material were 
recovered.
6-Amino-2-methylquinoline (234)
2-Methyl-6-nitroquinoline (0.9222 g, 4.90 mmol), hydrazine monohydrate (5 ml,
103.08 mmol), graphite (ca. 0.5 g) and ethanol (50 ml) were heated at reflux for 
24 h. The mixture was allowed to cool to room temperature and was filtered 
through Celite then concentrated in vacuo to a brown solid which needed no 
further purification (0.7167 g, 68 %), m.p. 182-184 °C. Rf 0.15-0.32 (1:1 ethyl 
acetate/petroleum ether); (Found: C 76.08; H 6.11; N 17.81 %; M+, 158.0841. 
C10H10N2 requires C 75.92; H 6.37; N 17.70 %; M, 158.0844); Vmax/cnr1 (KBr 
disc) 3468m (>N-H), 2918w (Ar-H), 1624s, 1560w & 1502s (aromatic ring), 
1380 (CH3), 8 3 6 s  (2 adjacent Ar-H); 6 H (200 MHz, DMSO-d6) 8.71 (br, 1H,
3-H), 8.52-8.16 (m, 3H, 5', 7' & 8'-H), 7.21-6.94 (br d, 2H, NH2), 7.42 (br, 1H,
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3'-H), 2.90 (s, 3H, CH3); 8c (50 MHz, DMSO-d6) 158.4 (s, 10 '-C), 150.8 (s, 
2,-C), 137.2 (d, 8 '-CH), 135.8 (s, 6 '-C), 132.4 (d, 4'-CH), 125.8 (s, 9'-C), 125.2 &
124.7 (2 x d, 5' & 6 '-CH), 121.9 (d, 3'-CH), 28.4 (q, CH3); m/z 158 (M+, 23 %), 
142 (M+ - CH3, - H), 112 (M+ - N02), 98 (M+ - CH3, - N02, + H).
5-Amino-6-methylquinoline (235)
NH2
h3c
8
To 6-methyl-5-nitroquinoline (1.0010 g, 5.37 mmol) was added hydrazine 
monohydrate (1.60 ml, 32.98 mmol), graphite powder (ca. 1 g) and ethanol 
(5 ml). The mixture was heated at reflux for 48 h. Upon cooling to room 
temperature, the solution was filtered through Celite and concentrated under 
reduced pressure to a brown solid. This was dissolved in ethyl acetate and was 
placed under water pump vacuum until a few yellow crystals were observed. 
The solution was then allowed to stand at room temperature and atmospheric 
pressure to yield 5-amino-6-methylquinoline as fine yellow crystals (0.3908 g, 
46 %), m.p. 179-180 °C. R f 0.18 (1:1 ethyl acetate/petroleum ether); (Found: 
C 75.74; H 6.26; N 18.00 %; M+, 158.0841. C i0H i0N2 requires C 75.92; H 6.37; 
N 17.70 %; M, 158.0844); V m a x /c n r1 (KBr disc) 3414m (N-H), 3020w (Ar-H), 
1574m & 1515m (aromatic ring), 802w (2 adjacent Ar-H); 8 h (200 MHz, 
DMSO-de) 8.81 (d, 3J 4.2 Hz, 1H, 2 '-H), 8.15 (d, 3J 8 .2  Hz, 1H, 8 '-H), 7.52 (d, 
3J 8 .6  Hz, 1H, 4'-H), 7.43 (d, 3J 8.2 Hz, 1H, 7'-H), 7.30 (dd, 3J 8 .6  Hz, 
3J 4.2 Hz, 1H, 3'-H), 4.16 (br s, 2H, NH2), 2.34 (s, 3H, CH3); 8 C (50 MHz, 
DMSO-de) 149.2 (d, 2 '-CH), 148.2 (s, 10 '-C), 139.0 (s, 9'-C), 133.0 (d, 8 -CH),
129.0 (d, 4’-CH), 119.5 (d, 7'-CH), 119.3 (d, 3'-CH), 118.2 (s, 6 '-C), 106.8 (s, 
5'-C); m/z 158 (M+, 15 %), 143 (M+ -CH3), 112 (M+ - N 02).
6-Amino-2-methylquinoline hydrochloride (236)
6-Amino-2-methylquinoline (0.4293 g, 2.71 mmol) was dissolved in diethyl ether 
(ca. 100 ml). To this was added ethereal hydrochloric acid (2 ml) to give a bright
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orange precipitate instantly (0.4055 g, 94 %), m.p. 251-253 °C. vmax/cnr1 (KBr 
disc) 3034m (Ar-H), 2928m and 1394m (CH3); 5H (200  MHz, DMSO-d6) 8.80 
(br, 1H, 3-H), 8.60-8.25 (m, 3H, 5', 7' and 8 '-H), 7.50 (br, 1H, 3'-H), 7.42-6.98 
(v br, 3H, NH3+); 8C (50 MHz, DMSO-d6) 159.2 (s, 10 '-C), 152.0 (s, 2 '-C),
137.5 (d, 8 '-CH), 136.2 (s, 6 '-C), 132.9 (d, 4'-CH), 126.4 (s, 9'-C), 125.9 and
125.2 (2 x d, 5' and 6 '-CH), 122.2 (d, 3'-CH), 30.1 (q, CH3).
5-Amino-6-methylquinoline hydrochloride (237)
5-Amino-6-methylquinoline (0.0797 g, 0.50 mmol) was dissolved in diethyl ether 
(5 ml). To this was added ethereal hydrochloric acid (ca. 2 ml), whereupon a 
precipitate formed immediately. This was filtered and washed (hexane) to give 
the title compound as an orange solid (0.7165 g, 90 %), m.p. 256-258 °C. 
Rf  0 .0  (ethyl acetate); 8H (200  MHz, DMSO-d6) 8.92 (d, 3J 4.3 Hz, 1H, 2 '-H),
8.19 (d, 3J 8.2 Hz, 1H, 8 ’-H), 7.62 (d, 3J 8.6 Hz, 1H, 4'-H), 7.48 (d, 3J 8.2 Hz, 
1H, 7'-H), 7.39 (dd, 3J 8 .6  Hz, 3J 4.3 Hz, 1H, 3'-H), 4.19 (br s, 3H, NH3), 2.40 
(s, 3H, CH3); 8c (50 MHz, DMSO-d6) 151.2 (d, 2 '-CH), 149.8 (s, 10 '-C), 141.0 
(s, 9'-C), 135.0 (d, 8 '-CH), 129.8 (d, 4'-CH), 120.5 (d, 7'-CH), 119.9 (d, 3'-CH),
119.2 (s, 6 '-C), 107.1 (s, 5'-C).
2-Cyano-3-[2-(8-nitroquinolyl)]propenonitrile (238)
CN6
7
8-Nitroquinoline-2-carbaldehyde (0.1200 g, 0.59 mmol) was treated with 
malononitrile (0.0413 g, 0.63 mmol) in ethanol (7 ml) and dilute piperidine 
solution (1 drop) using General Procedure B to give an orange solid after 3 h 
(0.1029 g, 69 %), m.p. 240-243 °C. R f 0.25 (1:1 ethyl acetate/petroleum ether); 
(Found: C 63.01; H 2.39; N 22.45%; M+, 250.0492. C i3H6N40 2 requires 
C 62.40; H 2.42; N 22.39%; M, 250.0491); V m a x /c n r1 (KBr disc) 3072w (Ar-H),
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2200w (CN), 1620m (extended conjugation to aromatic system), 1574s and 
1520s (aromatic ring), 822s (3 adjacent Ar-H), 1510s (C-NO2); 5h (200  MHz, 
DMSO-d6) 8.74 (2 x overlapping d, 3J 8.4 Hz, 3J 7.8 Hz, 2H, 4' and 7'-H), 8.39 
(d, 3J 8.0 Hz, 1H, 5’-H), 8.34 (s, 1H, 3-H), 7.97 (dd, 3JQA  Hz, 3J 8.0 Hz, 1H,
6 -H), 7.90 (d, 3J 7.8 Hz, 1H, 3'-H); 5C (50 MHz, DMSO-d6) 156.7 (d, 3-CH),
150.5 (s, 8 '-C), 147.5 (s, 2'-C), 138.0 (d, 7'-CH), 136.0 (s, 10'-C), 131.1 (d, 
4'-CH), 129.3 (s, 9'-C), 127.6 (d, 5'-CH), 125.1 (d, 6 '-CH), 124.0 (d, 3'-CH),
114.1 and 111.9 (2 x s, 2 x CN), 87.3 (s, 2-C); m /z250 (M+, 71 %), 204 (M+
- N02, -H), 174 (M+ - [CH=C(CN)2], + H).
2,4-Dicyano-3-amino-5-[2-(8-nitroquinolyl)]penta-2,4-dienonitrile (239)
5' 4'  7 6
6.r t ^ 3- CN CN
n o 2 NH2
Using General Procedure C, 8 -nitroquinoline-2 -carbaldehyde (0.1164 g,
0.57 mmol) and 2-aminopropene-1,1,3-tricarbonitrile (0.0760 g, 0.57 mmol) 
were treated with ethanol (1 ml) to give an orange precipitate after 30 min which 
was filtered, dried and recrystallised from diethyl ether to give brown crystals 
(0.0556 g, 30 %), m.p. 100 °C (decomp.). Rf 0.11 (1:1 ethyl acetate/petroleum 
ether); (Found: C 60.82; H 2.61; N 26.23%; M+, 316.0711. C i6H8 N60 2  requires 
C; 60.69 H 2.55; N 26.54 %; M, 316.0709); vmax/cm-1 (KBr disc) 2367w (NH2), 
2217m (CN), 1645s (extended conjugation to aromatic ring), 1533s (aromatic 
ring), 1505s (C-NO2 ), 847w (3 adjacent Ar-H), 797w (2  adjacent Ar-H); 
5h (200  MHz, DMSO-de) 8.36 and 8.31 (2 x s, 2 H, NH2), 8.86-8.78 (overlapping 
d, 3J8.45 Hz, 1H, 7-H and d, 3J 7.8 Hz, 1H, 4’-H), 8.40 (d, 3J 8.5 Hz, 1H, 5'-H), 
8.29 (s, 1H, 5-H), 8.03 (dd, 3J 8.5 Hz, 3J8 A  Hz, 1H, 6 '-H), 7.91 (d, 3J 7.8 Hz, 
1H, 3'-H); 5C (50 MHz, DMSO-d6) 165.5 (s, 3-C), 164.5 (s, 8 '-C), 151.4 (s, 2 '-C),
149.1 (d, 5-CH), 147.8 (s, 10'-C), 138.9 (d, 7'-CH), 131.9 (d, 4'-CH), 129.0 (s, 
9'-C), 128.0 (d, 5'-CH), 125.5 (d, 6 '-CH), 124.6 (d, 3'-CH), 115.5, 114.4 and
113.7 (3 x s, 3 x CN), 109.9 (s, 4-C), 108.2 (s, 2-C); m/z316 (M+, 5%), 251 (M+ 
- [C(CN)2], -H ), 174 (M+ - [CH=C(CN)-C(NH2 )=C(CN)2)], + H), 143 
([CH=C(CN)-C(NH2)=C(CN)2)]+), 128 ([quinoline]+).
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7.5 Experimental Procedures for Chapter 5
Di-toutyl Af-benzyloxycarbonyl-L-glutamate (254) 203<205*231
4
2
3
k JL
15 O 14 NH
In a cold finger equipped with a rotovap tap was placed A/-benzyloxycarbonyl-l_- 
glutamic acid (4.2167 g, 14.99 mmol), dichloromethane (30 ml) and fuming 
sulfuric acid (0.3 ml, ca. 2 eq.). The mixture was cooled to -78 °C, and 
isobutene (ca. 20 ml) was added. The mixture was slowly warmed to 25 °C and 
was then sealed and left standing at this temperature for 96 h until starting 
material was no longer visible. Upon cooling to -78 °C, the vessel was opened 
and allowed to come to atmospheric pressure, then allowed to warm to room 
temperature. The contents were poured into water (100 ml) and brought to pH 7 
by addition of aqueous NaHC0 3 . Extraction with dichloromethane (2 x 50 ml) 
and subsequent drying (MgS0 4 ), filtration and concentration under reduced 
pressure of the combined organic extracts gave the product as a clear brown oil 
(4.0854 g, 69 %). Rf 0.72 (1:2 ethyl acetate/petroleum ether); (Found: C 64.36; 
H 7.70; N 3.53 %; M+, 393.2158. C2iH 3iN 0 6 requires C 64.10; H 7.94; N 3.56 
%; M, 393.2151); Vmax/cm-1 (CHCI3) 3428w (CONH), 3030w (Ar-H), 1720s 
(ester and carbamate C=0), 766s and 698m (monosubstituted benzene); 
6h (200 MHz, DMSO-de) 8.60-8.50 (br s, 1H, NH), 7.29 (br s, 5H, 2', 3', 4’, 5' 
and 6'-H), 5.11 (s, 2H, 15-H), 2.37-2.22 (m, 1H, 6-H), 1.41 (s, 18H, 2 x *Bu), 
1.06-0.83 (m, 4H, 7 and 8-H); 6C (50 MHz, DMSO-d6) 171.8 and 171.2 (2 x s, 5 
and 9 C), 156.0 (s, 14-C), 145.0 (s, 1'-C), 128.3, 128.0 and 127.8 (3 x d, 2', 3', 
4', 5' and 6-CH), 53.8 (d, 6-CH), 32.0, 31.9, 31.8, 31.7, 31.6 and 31.5 (6 x q, 1, 
2, 3, 11, 12, I 3 -CH3), 27.9 and 27.8 (2 x s, 2 x C(CH3)3); m/z 393 (M+, 48 %), 
292 (M+ - C 0 2*Bu), 286 (M+ - PhCH2), 258 (M+ - PhCH2OCO), 192 (M+ - 2 x 
C02teu), 135 (PhCH2OCO+), 91 (PhCH2+), 58 (CH2OCO+).
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Di-*butyl L-glutamate (255)203- 205>231
NH2
A 3-necked round bottom flask, charged with di-*butyl A/-benzyloxycarbonyl-L- 
glutamate (4.0854 g, 10 mmol), Methanol (10 ml) and a catalytic amount of 
palladium on carbon (ca. 20  mg) was placed under an atmosphere of hydrogen 
and stirred at 25 °C for 24 h. This was then filtered through Celite, washed with 
methanol and concentrated under reduced pressure to yield the title compound 
as a yellow oil (1.9062 g, 78 %). R f 0.28 (1:4 ethyl acetate/petroleum ether); 
6h (200  MHz, DMSO-de) [lit.: 2 0 0  MHz, CDCI3]203 3.20-3.15 [3.33] (br, 1H,
6 -H), 1.60-2.10 [1.60-2.10] (brm, 4H, 7 and 8 -H2), 1.28 [1.47 and 1.44] (s, 18H, 
2 x 'Bu); 6C (50 MHz, DMSO-d6) 175.5 and 173.0 (2 x s, 2  x C=0), 81.0 and 
80.3 (2 x s, 4-C and 10 -C), 54.0 (d, 6 -CH), 32.1 and 2 2 .8  (2 x t, 7-CH2 and 
8 -CH2), 30.4 and 27.6 (2 x q, 2 x CH3).
4-Hydroxymethylaniline tertiarybutyldimethylsilyl ether (256)
Prepared using the method of Corey and Venkateswarlu 232A flask was charged 
with 4-aminobenzyl alcohol (2.6361 g, 21.40 mmol) and imidazole (2.1378 g, 
31.40 mmol). The system was placed under a nitrogen atmosphere and the 
solids were dissolved in distilled dichloromethane (7 ml). Addition of a solution 
of tertiarybutyldimethylsilylchloride (3.2368 g, 21.47 mmol) in distilled 
dichloromethane (5 ml) was added, and the reaction was stirred for 10 min until 
TLC showed the absence of starting materials. The mixture was then washed 
with water (3 x 30 ml), filtered and concentrated to give a pale yellow oil 
(7.5669 g). Purification by distillation gave a colourless oil (4.1998 g, 
20.06 mmol, 94%), (Found: C 65.58; H9.71; N 5.95 %; M+,237.1568. 
C i3H23NOSi requires C 65.77; H 9.76; N 5.90 %;M, 237.1549); RF 0.50 (1:2 
EtOAc/pet. ether); vmax/cm*1 (CHCI3) 3468 and 3390 (NH), 3015 (Ar-H), 2985
NH2
192
and 2965 (CH3), 2900 (CH), 1630 (NH), 1260 (C-O), 1100 (Si-O); 6 H (200 MHz, 
CDCI3) 7.12 (m, 2 H, 3'-H and 5'-H), 6.62 (m, 2H, 2'-H and 6 '-H), 3.54 (br s, 2 H, 
NH2), 4.58 (s, 2 H, CH2), 0.90 (s, 9 H, 'Bu), 0.05 (s, 6 H, Si(CH3)2); 8 C (50 MHz, 
CDCI3) 145.8 (s, 1'-C), 131.0 (s, 4'-C), 127.7 (d, 2 '-C and 6 '-C), 115.2 (d, CH, 
3'-C and 5'-C), 65.2 (t, CH2), 25.7 (q, C(CH3)3), 18.6 (s, C(CH3)3), -5.0 (q, 
Si(CH3)2); m/z 237 (M+, 15%), 222 (M+ -CH3), 180 (M+ -'Bu), 106 (M+ 
-OTBDMS).
Attempted synthesis of Benzyl 2-cyano-3-[2-(5-nitrothienyl)]propenoate 
(260)209
OpN
NC
A flame-dried 3-necked round bottom flask equipped with a nitrogen balloon 
was charged with a slurry of 2-cyano-3-[2-(5-nitrothienyl)] propenoic acid 
(0.1997 g, 0.88 mmol) in dry DMF (5 ml). To this was added carbonyl 
diimidazole (0.1472 g, 0.90 mmol) in dry DMF (5 ml). An immediate colour 
change giving a brown solution was observed. The mixture was stirred at room 
temperature for 1.5 h, before the addition of benzyl alcohol (0.09 ml, 0.87 mmol) 
in DBU (0.07 ml, 0.46 mmol). Stirring was continued at 25 °C for 43 h, then the 
mixture was washed with 10 % HCI (10 ml), 10 % NaHC03 (10 ml) and ethyl 
acetate (3 x 50 ml). The combined organic extracts were dried (MgSCU), filtered 
and concentrated in vacuo to a beige solid. NMR spectroscopy revealed the 
presence of starting materials.
/V-Ethyl-2-cyano-3-[2-(5-nitrothienyl)] propenamide (264)
OoN
NC N
2-Cyano-3-[2-(5-nitrothienyl)]propenoic acid (141) (0.3913 g, 2.03 mmol) and 
thionyl chloride (2 ml, 10.30 mmol) were heated at reflux temperature for 2.5 h.
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The excess thionyl chloride was removed in vacuo to give a green solid, which 
was dissolved in dry THF (100 ml), and the solution was flushed with nitrogen 
and cooled to 0 °C. To this was added ethylamine (0.25 ml, 3.74 mmol). 
Precipitation of a beige solid was observed after stirring at 0 °C for 2 h. The 
solvent was removed in vacuo, and the residue was recrystallised from ethanol 
to give beige crystals (0.0643 g, 13 %), m.p. 190-192 °C. R f 0 .0  (1:1 ethyl 
acetate/petroleum ether); (Found: C 47.46; H 3.64; N 16.78 %; M+, 251.0389. 
C10H9N3O3S requires C 47.77; H 3.61; N 16.78 %; M, 251.0365); vmax/cm-1 
(KBr disc) 3440m and 1670s (-CONHR), 2220w (-CN), 3106s (Ar-H), 1676m 
(external conjugation to aromatic system), 1534s (C-NO2 ), 1472m (aromatic 
C=C); 5h (200  MHz, DMSO-d6) 8 .66  (br. s, 1H, NH), 8.44 (s, 1H, 5-H), 8.26 (d, 
3J4A  Hz, 1H, 3-H), 7.95 (d, 3J4A  Hz, 1H, 2 '-H), 3.42 (q, 3J 7 .0  Hz, 2H, 2-H2),
1.05 (t, 3J 7.0 Hz, 3H, I-H3 ); 6 C (50 MHz, DMSO-d6) 162.1 (s, C=0), 153.7 (s, 
4'-C), 142.7 (d, 3'-CH), 142.0 (s, 1'-C), 135.8 (d, 2 '-CH), 129.8 (d, 5-CH), 117.1 
(s, CN), 110 .0  (s, 4-C), 40.4 (d, 2 -CH), 11.2 (s, 1-C); m/z 251 (M+, 3 %), 224 
(M+ - C2 H3), 208 (M+ - NC2H5), 179 (M+ - CONHC2H5 ,+ H).
A/-4-Bromobenzyl-2-cyano-3-[2-(5-nitrothienyl)]-propenamide (265)
To a solution of 2-cyano-3-[2-(5-nitrothienyl)]propenoyl chloride (0.4630 g,
2.19 mmol) in 10 ml dry THF was added 4-bromoaniline (0.3811 g, 2.20 mmol). 
The mixture was stirred at room temperature for 12 h to form a red precipitate. 
The solution was washed with water (25 ml) and ethyl acetate (2 x 25 ml) and 
the combined organic extracts were dried (MgSC>4), filtered and concentrated in 
vacuo to a brown crystalline solid (0.5123 g, 69 %), m.p. 169-170 °C. R f 0.46 
(1:1 ethyl acetate/petroleum ether); (Found: C 45.99; H 2.54; N 10.85 %; M+, 
390.9623. C i5HioN30 3SBr requires C 45.93; H 2.57; N 10.71 %; M, 390.9626); 
Vmax/cm-1 (KBr disc) 3448m (amide, NH stretch), 221 Ow (CN), 1700w (C=0), 
1632s (extended conjugation to aromatic system), 1590s (amide N-H), 828m (2 
adjacent Ar-H); 6H (200 MHz, DMSO-d6) 8 .66  (s, 1H, 4-H), 8.29 (d, 3J4 A  Hz, 
1H, 4'-H), 8.06 (d, 3J 4.4 Hz, 3'-H), 7.45 (d, 3J 8.7 Hz, 2H, 3"-H and 5"-H), 7.00 
(d, 2H, 3J 8.7 Hz, 2"-H and 6 "-H), 6.80-6.60 (br s, 1H, NH), 4.31 (br s, 2H, 1-
Br
NC O
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H2); Sc (50 MHz, DMSO-de) 162.4 (s, C=0 ), 154.9 (s, 4'-C), 145.9 (d, 3'-CH),
140.7 (s, 1'-C), 139.6 (s, 1M-C), 137.6 (d, 3'-CH), 132.1 (d, 3M-CH and 5"-CH),
129.8 (d, 4-CH), 121.0 (d, 6 H-CH and 2"-CH), 115.8 (s, CN), 113.8 (s, 4"-C),
105.0 (s, 3-C), 50.5 (t, 1-CH2); m/z391 (M+, 5 %), 264 (M+ - Br, - N 02, -H), 262 
(M+ - nitrothiophene), 237 (M+ - PhBr), 184 (M+ - [HC=C(CN)CONHPh).
4-Chloro-A/-methylbenzamide (270)
Cl
4-Chlorobenzoic acid (0.8194 g, 5.2 mmol) was reacted with thionyl chloride 
(0.39 ml, 5.3 mmol) at 0 °C using the method of Munch-Petersen.233 After 4 h, 
TLC showed the absence of starting materials. A 40 % w/v solution of 
methylamine in industrial methylated spirits (0.5 ml) was then added, and 
stirring was continued at 0 °C for 1 h until formation of a white precipitate. This 
was filtered, washed (hexane) and dried (diethyl ether) to give the title 
compound (0.6924 g, 78 %), m.p. 176-176 °C, Rp 0.42 (1:1 ethyl 
acetate/petroleum ether). 8 h (90 MHz, DMSO-d6) 8.1 (br s, 1H, NH), 7.6 (d, 
3J 6 Hz, 2H, 2' and 6 '-H), 7.4 (d, 3JQ Hz, 2H, 3' and 5 -H), 3.9 (s, 3H, CH3).
Attempted synthesis of /V-methyl-A/'-(4-chlorophenyl) urea (271)
Cl NH
NH
4-Chlorobenzoic acid (1.6074 g, 10.3 mmol) was reacted with thionyl chloride 
(3 ml, 41.1 mmol) in CCI4 (10 ml) at 0 °C for 4 h using the same procedure as 
above. To this was added tetrabutylammonium iodide (ca 10 mg), followed by 
the slow addition of sodium azide (1.0972 g, 16.8 mmol) in water (10 ml) to 
immediately give a pale pink solution. This was gently heated for 4 h, then 
cooled to -78 °C before the addition of a 40 % w/v solution of methylamine in 
industrial methylated spirits (0.8 ml). Upon stirring at -78 °C for 1.5 h, a white 
precipitate was observed, which was filtered, washed and dried. NMR 
spectroscopy showed this to be 4-chloro-A/-methylbenzamide (270).
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Attempted syntheses of A/-(di-*butyl-L-glutamate)carbonylamino-4- 
hydroxy methyl benzene foutyldimethylsilyl ether (278)
OTBDMS
Method 1. In a flame dried 3-necked round bottom flask equipped with a 
nitrogen balloon was placed a solution of 4-aminobenzyl alcohol (0.2462 g, 
1.99 mmol) in dry ethanol (5 ml). To this was slowly added carbonyldiimidazole 
(0.3244 g, 2.00 mmol) in dry ethanol (3 ml). The reaction was stirred at 25 °C 
until the precipitation of a white solid, whereupon di-fbutyl-L-glutamate 
(0.4962 g, 2.00 mmol) and dibutyltin diacetate (5 drops from a pasteur pipette) 
were added. The mixture was heated to 50 °C for 72 h until TLC showed the 
absence of the L-glutamate, and the presence of a yellow precipitate was 
observed. Filtration and drying (diethyl ether) gave a beige crystalline solid, 
which was shown by NMR spectroscopy to be a mixture of starting materials.
Method 2. To a flame-dried 3 necked flask, equipped with a water condenser 
and nitrogen balloon was added carbonyl diimidazole (0.1794 g, 1.11 mmol) in 
dry THF (5 ml) and di-toutyl-L-glutamate (0.3109 g, 1.19 mmol) in dry THF 
(5 ml). The mixture was heated to 50 °C for 26.5 h. 4-Aminobenzyl alcohol 
(0.1386 g, 1.15 mmol) in THF (5 ml) was added, followed by 4-dimethylamino 
pyridine (0.2002 g, 1.64 mmol) in dry THF (5 ml). The reaction was heated at 
reflux temperature for 24 h. Upon cooling to room temperature, the solvent was 
removed under reduced pressure, and a silica plug of the mixture was 
prepared. Column chromatography (silica, 1:1 ethyl acetate/petroleum ether) 
resulted in the complete recovery of starting materials.
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1,1-Diethyl-2-(4-bromophenyl) urea (279)213
5'  6'
To a flame-dried 3-necked round-bottom flask equipped with a nitrogen balloon 
and water condenser was added 4-bromoaniline (3.5652 g, 20.7 mmol) in dry 
THF (10 ml) and carbonyldiimidazole (3.3649 g, 20.6 mmol) in dry THF (50 ml). 
The mixture was gently heated, then stirred at 25 °C for 46 h. This was followed 
by addition of diethylamine (2.15 ml, 20.8 mmol) and gentle heating at 50 °C for 
1 h. The mixture was concentrated in vacuo to a brown solid, which was 
redissolved in 1:1 methanol/water and recrystallised to give the title compound 
as large brown crystals (3.7216 g, 66 %), m.p. 280 °C (decomp.), R f 0.48. (1:1 
ethyl acetate/petroleum ether); (Found: C 48.91; H 5.64; N 10.42%; M+, 
271.0354. C n H 15N2OBr requires C 48.72; H 5.58; N 10.33 %; M, 270.0368); 
V m a x /c n r1 (KBr disc) 3264m (N-H, secondary amide), 3060w (Ar-H), 1633m 
(C=0), 1600s and 1514m (benzene ring), 835s (2 adjacent Ar-H); 8h (200 MHz, 
DMSO-de) 12.21 (v br, 1H, NH), 7.81 (br, 2H, 3'-H and 5'-H), 7.13 (br, 2H, 2'-H 
and 6'-H), 3.36 (q, 3J 7 .1 Hz, 4H, 2-H2 and 4 H2), 1.11 (t, 3j  7.1 Hz, 6H, 1-H3 
and 3 -H3); 8C (50 MHz, DMSO-de) 154.6 (s, C=0), 140.3 (s, 1'-C), 131.6 and 
131.4 (2 x d, 3* and 5’-CH), 122.1 and 121.8 (2 x d, 2' and 6'-CH), 113.4 (s, 
4'-C), 42.4 and 40.7 (2 x t, 2 and 4-CH2), 13.8 and 12.9 (2 x q, 1 and 3 -CH3); 
m /z271 (M+, 38 %), 242 (M+ - CH2CH3), 198 (M+ - NEt2, -H), 191 (M+ - Br), 
171 (M+ - CONEt2), 143 (M+ - NHCONEt2, - H).
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7.6 Experimental Procedures for Chapter 6
Antiproliferative Assays
1. MCF-7 breast adenocarcinoma cells. MCF-7 cells (American Type Culture 
Collection, Rockville, MD) were maintained in RPMI 1640 supplemented with 
2 mM glutamine and 10 % (v/v) foetal calf serum (all obtained from Gibco BRL, 
Paisley, UK). [3H]-Thymidine (sp. act. 5 Ci / mmol; Amersham Ltd, Amersham, 
UK) incorporation was used as an indicator of DNA synthesis. Cells were plated 
at a concentration of 1 x 103 / well in 96 well plates and grown in a humidified 
atmosphere of 5 % (v/v) C02:air at 37 °C for 72 hours. A range of inhibitor 
concentrations (0.001-500 pM) was then added and after 24 hours 
[3H]-thymidine (0.25 pCi / well) was added to each well for a one hour pulse 
prior to harvesting. The medium was removed and the cell sheet was washed 
twice with ice-cold phosphate-buffered saline. The cells were harvested using 
trypsin / EDTA (0.25 % /1  mM) and transferred onto filter mats using an LKB 
Cell Harvester. They were then washed three times with distilled water, allowed 
to dry and 10 ml Ecoscint A (National Diagnostics) was added. The radioactivity 
was determined using a Packard Liquid Scintillation Analyser.
2. HER14 Fibroblasts. [3H]-Thymidine (sp. act. 5 Ci / mmol; Amersham Ltd, 
Amersham, UK) incorporation was used as an indicator of DNA synthesis. 
HER14 cells were plated at a concentration of 1 x 103 / well in 96 well plates 
and grown in a humidified atmosphere of 2 % (v/v) C02:air at 37 °C to 
confluence (72 hours). The medium was then replaced with fresh medium 
supplemented with 0.1 % (v/v) DCS. After a further 48 hours a range of inhibitor 
concentrations (0.01 pM - 50 pM) was added in either medium containing 10 % 
(v/v) DCS or medium containing 0.1 % (v/v) DCS plus 1 % bovine serum 
albumin and 10 ng / ml EGF. [3H]-Thymidine (0.25 pCi / well) incorporation was 
measured over a 16 hour exposure to the drugs. The medium was then 
removed and the cell sheet was washed twice with ice-cold phosphate buffered 
saline. The cells were harvested using trypsin / EDTA (0.25 % / 1 mM) and 
transferred onto filter mats using a LKB Cell Harvester. They were then washed 
three times with distilled water, allowed to dry and 10 ml Ecoscint A (National 
Diagnostics) added. The radioactivity was determined using a Packard Liquid 
Scintillation Analyser.
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Measurement of EGF Receptor Kinase Activity
The membrane fractions (0.5 pg protein) were incubated with kinase buffer 
[45 mM HEPES (pH 7.4), 100 pM sodium orthovanadate, 0.05 % Triton X-100, 
2 % glycerol], 25 mM MgCl2 , 2 mg / ml poly(Glu, Ala, Tyr) and inhibitors at a 
range of concentrations. Incubations were carried out in the presence or 
absence of 0.25 pM EGF. The inhibitors were prepared as stock solutions in 
DMSO and diluted in distilled water. The final concentration of DMSO in the 
incubations (1 %) had no effect on the reaction rate. The reaction was initiated 
by the addition of [y-32P]-ATP (0.5 pCi, 20 pM, sp. act. 3000 Ci / mmol; 
Amersham Ltd, Amersham, UK). After 20 min at 30 °C, the reaction was 
stopped by the addition of 1 mM ATP on ice. The products of the reaction were 
spotted onto Whatman 3MM paper and the peptide precipitated with 10 % 
trichloroacetic acid containing 0.01 M sodium pyrophosphate. The filters were 
then washed extensively with the trichloroacetic acid solution, dried and 
transferred to scintillation vials. Ten millilitres of Ecoscint A (National 
Diagnostics) were added and the radioactivity determined using a Packard 
Liquid Scintillation Analyser.
Cytotoxicity Assay
This was carried out using the method of Plumb and co-workers.234 Squamous 
cell carcinoma cells were seeded at the appropriate cell density in 96 well 
plates and grown for 72 hours in a humidified atmosphere of 2 % (v/v) C02:air 
at 37 °C before addition of a range of inhibitor concentrations in 200 pi of 
medium. Four replicate wells were used for each drug concentration. Cells 
alone were used as a control and medium alone was used as a blank. After 
24 hours the inhibitors were removed and fresh medium added. The medium 
was replaced every 24 hours for a further three days allowing the cells to pass 
through two to three doublings. This allows the assay to be used as a measure 
of cell kill. On the third day 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
(MTT) (5 pg / ml) was added to each well. The plates were then incubated in 
the dark at 37 °C for 4 hours. Medium and MTT were then removed and the 
formazan crystals (formed following reduction of MTT by live cells) were 
dissolved in 200 pi dimethylsulfoxide and 25 pi Sorensen's glycine buffer (0.1 M 
glycine plus 0.1 M NaCI adjusted to pH 10.5 with 0.1 M NaOH) then added. The 
absorbance was read at 570 nm in an enzyme-linked immunosorbent assay 
plate reader (Model 2550; Bio-Rad Laboratories). Log-concentration response 
curves were generated, from which IC50 values were determined as the dose to 
inhibit MTT absorbance by 50 %.
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Alkaline Elution
DNA single strand breaks were measured by alkaline filter elution as previously 
described.235 In brief DNA from control cells and cells treated for 2 hours with 
inhibitor was labelled with 0.03 pCi / ml [ 14C]-thymidine (sp. act. 51 mCi / mmol, 
Amersham Ltd, Amersham, UK) for 24 hours. Cells labelled with 0.17 jiCi / ml 
pH]-thymidine (sp. act. 5 Ci / mmol, Amersham Ltd, Amersham, UK) and 
y-irradiated were used as an internal control. Cells were loaded onto 2 |nm pore 
size polycarbonate filters and lysed. DNA was eluted at pH 12.2 with 0.1 M 
tetrapropylammonium hydroxide containing 0.1 % sodium dodecyl sulphate and
0.02 M EDTA over a 15 hour period at an elution rate of 0.011 ml / min. The 
radioactivity was determined in each fraction taken at 90 minute intervals and 
the results expressed as fraction of [14C] retained versus fraction [3H] (internal 
standard) retained.
Cyclic Voltammetry
CVs were recorded using an EG & G Parc model 175 Universal Programmer, 
model 173 Potentiostat/Galvanostat and model 176 Current Follower to 
generate the signal, and were plotted using a Lloyd PL3 Plotter. Compounds 
were dissolved at 1 mM concentration in dry, double-distilled DMSO which 
contained tetraethylammonium tetrafluoroborate at 100 mM concentration. The 
DMSO was stored over 4A molecular sieves under a nitrogen atmosphere for a 
maximum of 12 hours236 prior to use (storage for longer times generally 
resulted in additional signals in the CVs corresponding to reduction and 
oxidation of water which had been acquired by the solvent), and the solvent 
was filtered using Millex PTFE-F syringe filters (0.5 pM pore size; Aldrich) to 
remove residues of the sieves. The CVs were measured using a 0.5 cm2 gold 
working electrode, a platinum gauze counter electrode and a standard 
Ag/AgN0 3  reference electrode. The gold electrode was polished using Hyprez 
Five-Star Diamond Compound (Engis Ltd., England) before the reduction 
potential of each compound was measured. All samples were scanned between 
-2.5 V and +0.5 V , with scans commencing and terminating at 0 V.
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Appendix: Additional Biological Data
The biological evaluation of the quinolyl tyrphostins reported in the thesis has 
recently been completed, and the author wishes to record these values here. As 
can be seen, there are still a number of reasonably active compounds in these 
series, and, as predicted, the 7-substituted quinolines proved to be the most 
active, although a number of these compounds displayed no activity in the 
MCF-7ADR cytotoxicity assay. There was not quite such a dramatic difference 
in activities across these series compared to the case of the 2, 3 and 4- 
substituted compounds synthesised by Lear and McKeown.
The data does not give any clear evidence for the SAR of these compounds, 
and further biological evaluation will be necessary before any conclusions may 
be drawn.
ICg) (|lM)
Compound
Number R MCF-7H MCF-7ADRH
(201) CN >98 n.tT
(202) C(NH2 )=C(CN) 2 52 96
(203) C02Me 47 56
(204) C02Et 65 44
(205) COj/Bu 59 106
(206) C02TEG-OMe n.tT n.t.+
(207) c o n h 2 65 91
(208) c s n h 2 49 89
H Tested by Dr Alan McGown, Paterson Institute,
t  Not toxic.
Compound
Number R MCF-7 H MCF-7ADRU
(209) CN 17 23
(2 1 0 ) C(NH2 )=C(CN) 2 46 75
(2 1 1 ) C02Me 63 n.t.t
(2 1 2 ) C02Et 2 n.t.t
(213) COj/Bu 28 n.t.t
(214) C02TEG-0Me 13 70
(215) c o n h 2 81 2
(216) c s n h 2 6 8 79
11 Tested by Dr Alan McGown, Paterson Institute, 
t  Not toxic.
NC
R
1C90 (fiM)
Compound
Number R MCF-7H MCF-7ADRH
(217) CN n.t.t n.t.1-
(218) C(NH2 )=C(CN) 2 57 75
(219) C02Me 169 n.t.t
(2 2 0 ) C02Et n.t.t n.t.1'
(2 2 1 ) COj/Bu 146 n.t.t
(2 2 2 ) c o n h 2 n.t.l- n.t.t
(223) cs n h 2 19 136
H Tested by Dr Alan McGown, Paterson Institute,
t  Not toxic.
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